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Chapter 1
General introduction
Innate immunity is the body’s alarm system. Upon recognition of  invading pathogens 
such as bacteria and viruses, innate immune cells release inflammatory mediators 
signalling the presence of  danger which results in the recruitment of  inflammatory 
cells to the site of  infection. Furthermore, innate immune cells and inflammatory 
mediators play a pivotal role in the clearance of  pathogens. The innate immune 
system therefore represents the body’s first line of  defence and is vital to survival. 
However, excessive, inappropriate, or persistent activation of  the innate immune 
system, such as in sepsis or autoimmune diseases, can cause organ damage. In this 
respect, therapeutic measures aimed to limit the innate immune response could be 
beneficial. Classically, the innate immune response is thought to be self-governing, 
e.g. not regulated by another system. However, in the past few decades, strong 
links between the brain, in particular the autonomic nervous system (ANS), and 
the innate immune system have been established. Through the afferent arm of  the 
parasympathetic vagus nerve, the ANS can sense inflammation in the periphery and 
relay this information to the brain. The efferent sympathetic division of  the ANS 
has been shown to both stimulate and dampen the innate immune response, and 
more recently, a novel anti-inflammatory mechanism mediated by the efferent vagus 
nerve has been identified. This mechanism is called the cholinergic anti-inflammatory 
pathway, after acetylcholine, the neurotransmitter of  the vagus nerve.
This thesis describes interactions between the ANS and the innate immune system, 
focusing on the cholinergic anti-inflammatory pathway and the effects of  stimulation 
of  this pathway. In the remainder of  this introduction, some background on the 
ANS, the innate immune system and the links between these two systems is provided. 
Furthermore, the aim and outline of  this thesis is presented.
The autonomic nervous system
The ANS is called autonomic because it is regarded as a system that we cannot 
consciously influence. Descriptions of  the ANS go back to antiquity. Galen (A.D. 
130-200) described the sixth cranial nerve, which comprised what we call today the 
ninth (glossopharyngeal), tenth (vagus), and eleventh (accessory) cranial nerves, 
and the sympathetic chain1. Galen described that through this sixth cranial nerve, 
spirits go from one organ to another, producing the phenomenon of  ‘sympathy’: 
cooperation or coordination of  organs. It was not until 1563 that a distinction between 
the parasympathetic (vagus) and sympathetic nerve was made by Eustachius2. The 
medieval Latin word vagus literally means wandering; it ‘wanders’ from the brain stem 
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through organs in the neck, thorax, and abdomen. In the nineteenth century, Langley 
in Cambridge first developed the notion of  antagonism between the sympathetic and 
parasympathetic systems3, and one of  his disciples later showed that epinephrine has 
the same general effects as stimulation of  the sympathetic nerve. In 1921, German 
pharmacologist Otto Loewi discovered the release of  vagusstoff  (later identified as 
acetylcholine, the principal neurotransmitter of  the parasympathetic nervous system) 
from the vagus nerve upon electrical stimulation, providing the fist evidence of  
synaptic transmission and the birth of  the neurotransmitter4. In 1946, von Euler 
identified norepinephrine as the principal neurotransmitter of  the sympathetic 
nervous system5.  
Except for skeletal muscle, the ANS innervates every organ in the body. The 
sympathetic and parasympathetic parts of  the ANS typically have opposite effects on 
effector organs; the sympathetic part can be viewed as the body’s accelerator (‘fight 
or flight’ response) while the parasympathetic part represents the brake (‘rest and 
digest’). The most obvious example of  this opposite effect is the heart; sympathetic 
activity increases heart rate via noradrenergic stimulation of  beta-receptors while 
parasympathetic (vagus nerve) activity slows the heart down via stimulation of  
muscarinic acetylcholine receptors. In the 90s of  the previous century, effects of  the 
sympathetic nervous system on the innate immune response were established. Finally, 
in the year 2000, a novel pathway was discovered via which the vagus nerve can 
reflexively attenuate the innate immune response: the cholinergic anti-inflammatory 
pathway.
The innate immune system
Pattern recognition of  pathogen-derived and endogenous ligands
Cells of  the innate immune system, such as monocytes and macrophages, recognise 
conserved components of  pathogens, so-called pathogen-associated molecular 
patterns (PAMPs), via pattern recognition  receptors (PRRs)6. Upon ligation of  PRRs, 
an acute inflammatory response is orchestrated, characterized by production of  
proinflammatory cytokines such as tumour necrosis factor (TNF)-α, interleukin (IL)-
1β, and IL-6, and recruitment of  immune cells, including neutrophils and lymphocytes, 
to the site of  inflammation. Subsequently, pathogens are phagocytosed, leading to 
production of  inflammatory mediators  that result in the activation of  lymphocytes 
and more specific adaptive immune responses7, 8. In conjunction with this pronounced 
proinflammatory response, anti-inflammatory mediators such as IL-10 are released to 
counteract excessive inflammation. The most extensively studied family of  PRRs is 
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the Toll-like receptor (TLR) family. In 1997, the first human homolog of  Toll, TLR4, 
was identified9. The human TLR family currently consists of  10 members6. These 
different TLRs recognize different PAMPs; TLR2 is involved in the recognition of  
peptidoglycan, a cell wall component of  Gram positive bacteria, TLR3 recognizes 
viral double stranded RNA, TLR4 binds lipopolysaccharide (LPS), the major cell 
wall component of  Gram negative bacteria which is the most potent of  all PAMPs, 
TLR5 recognizes bacterial flagellin, TLR7 binds viral single stranded RNA, and TLR9 
recognizes bacterial and viral unmethylated CpG DNA6, 10. More recently, it has 
emerged that next to PAMPs, TLRs and other PRRs also recognize DAMPs (damage-
associated molecular patterns), endogenous molecules released upon tissue injury11, 12. 
Examples include binding of  hyaluronic acid, a major component of  the extracellular 
matrix, to TLR413, and recognition of  mitochondrial DNA by TLR914.  Ligation of  
DAMPs to PRRs results in generation of  a sterile inflammatory response11. 
Therapy aimed to limit the innate immune response
While an effective acute inflammatory response is essential in case of  invasion of  
microorganisms, it must be tightly regulated. Overactivation or persistent activation 
of  the innate immune system can result in a systemic cytokine storm as well as 
overproduction of  reactive oxygen production by neutrophils, leading to shock, 
tissue damage, and ultimately, multiple organ dysfunction syndrome (MODS) and 
death. This cascade of  events is commonly seen in the early phase of  sepsis and 
accounts for high mortality and morbidity; sepsis is still the leading cause of  death in 
the ICU15. As such, many therapies aimed to limit the innate immune response have 
been investigated in the past, of  which only few have proven to be effective. Anti-
cytokine therapies such as anti-TNF-α and anti-IL-1β that showed great promise in 
animal models of  sepsis, have yielded disappointing results in patients16, 17. Likewise, 
treatment with antibodies against LPS18, or a TLR4 antagonist19, has not resulted in 
improved outcome in septic shock. These results have led to the current opinion that 
there is not a single ‘magic bullet’ to be targeted in sepsis. Furthermore, these studies 
have signified that dampening the immune response too much may be detrimental; 
when pathogen clearance is seriously compromised, known as immune paralysis, the 
body is more vulnerable to secondary infections. This is especially harmful in the 
later phase of  sepsis, when the initial hyperinflammatory state has subsided and the 
immune system is already in a hyporeactive state20. The most compelling evidence for 
this phenomenon has emerged from the opposing effects of  trials employing high 
versus low doses of  corticosteroids; high doses of  these immune suppressing drugs 
resulted in increased mortality21, whereas low-dose treatment showed favourable 
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effects on outcome22. To date, the only pharmacological therapeutic interventions 
that have resulted in improved outcome in sepsis are activated protein C (APC) 
and the abovementioned low-dose corticosteroids22, 23. Although both APC- and 
corticosteroid-treatment is associated with accelerated resolution of  the excessive 
innate immune response in the early phase of  sepsis23, 24, these drugs exert various 
other effects that might account for the observed improved outcome. Still, these 
clinical studies indicate that appropriately-timed therapies aimed to reduce the initial 
overwhelming innate immune response in sepsis can be beneficial.
Another field where limiting the innate immune response could prove to be effective is 
excessive or inappropriate sterile inflammation. For instance, hyperinflammation similar 
to that observed in sepsis is known to occur following major trauma25. Furthermore, 
inflammatory processes play a deleterious role in the pathogenesis of  ventilator-induced 
lung injury (VILI), which is another major problem in the ICU26, 27. Lastly, in auto-
immune diseases such as rheumatoid arthritis, inappropriate and persistent activation 
of  the innate immune system causes major tissue damage28. Interestingly, many of  
the anti-cytokine therapies designed to attenuate the immune response in sepsis but 
have failed in terms of  outcome, have proved to be very effective in autoimmune 
diseases29.
Taken together, limiting excessive, inappropriate or persistent activation of  the 
innate immune system is a viable treatment option for a variety of  conditions. As 
described in the first part of  the introduction, the ANS can modulate the innate 
immune response, thereby representing a novel treatment opportunity to limit the 
innate immune response.
Links between the autonomic nervous system and the innate immune 
response
Immune-ANS signalling
It has long been known that inflammatory cytokines in an inflamed part of  the body 
signal the brain via the afferent vagus nerve, resulting in fever30, activation of  the 
stress response consisting of  the hypothalamic-pituitary-adrenal (HPA) axis30, and the 
sympathetic nervous system31. This signalling pathway was elegantly demonstrated in 
animal studies, where subdiaphragmatic vagotomy reduced the increase in temperature 
and cortisol response (the end-product of  the HPA axis) induced by intraperitoneal 
administration of  LPS32, IL-1β33, and TNF-α33. In addition, it has been proposed 
that increased afferent vagus nerve signalling results in increased efferent vagus nerve 
activity, thereby representing a vago-vagal reflex that may act as a negative feedback 
loop during infection or inflammation34, 35.
14
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ANS-immune signalling: sympathetic nervous system
The sympathetic nervous system exerts its effects on innate immunity via binding of  
cathecholamines to both α- and β-adrenergic receptors present on innate immune 
cells such as monocytes and macrophages. Short-term stimulation of  the β receptors 
(in particular β2)  results in attenuation of  the proinflammatory cytokine response 
and augmentation of  anti-inflammatory cytokine levels. This has been extensively 
investigated in vitro; co-incubation with (nor)epinephrine or β-adrenergic agonists 
has been shown to inhibit TNF-α and IL-6, and enhance IL-10 release in LPS-
stimulated human whole blood and isolated monocytes, and this effect was blocked 
by co-incubation with β-adrenergic antagonists36-39. This anti-inflammatory effect 
of  the sympathetic nervous system was shown to be mediated by increased levels 
of  intracellular cAMP36. In contrast, long-term (24 hours) incubation of  monocytes 
with β-adrenergic agonists resulted in decreased cAMP levels below baseline and 
subsequent LPS stimulation showed increased levels of  TNF-α36. In accordance, 
24-hour norepinephrine infusion resulted in increased plasma concentrations 
of  proinflammatory mediators in rats40. In vitro, α2 receptor stimulation has been 
demonstrated to enhance LPS-stimulated TNF-α release in mouse macrophages41. 
Effects of  catecholamines on the innate immune response have also been 
investigated in vivo in humans. In the human endotoxemia model (LPS administration 
in healthy volunteers), antecedent epinephrine infusion starting 3 hours before LPS 
administration resulted in a markedly reduced proinflammatory cytokine response 
and increased levels of  IL-1039,42. Interestingly, epinephrine infusion starting 24 
hours before LPS administration limited the proinflammatory response to a much 
lesser extent39, again emphasizing that there is a strong temporal relation between 
exposure to catecholamines and the inflammatory response. In addition, as part of  
a stress response, an increase in sympathetic activity is often accompanied by HPA 
axis activation and subsequent cortisol release, which is known to inhibit the innate 
immune response. Moreover, catecholamines can also directly activate the HPA axis43. 
These notions strongly support an overall anti-inflammatory effect of  short-term 
activation of  the sympathetic nervous system.
ANS-immune signalling: parasympathetic nervous system; the cholinergic anti-inflammato-
ry pathway
Approximately ten years ago, Kevin Tracey and colleagues discovered that electrical 
stimulation of  the efferent vagus nerve attenuated the LPS-induced inflammatory 
response in rats, while transecting the vagus nerve (vagotomy) enhanced inflammation44. 
Furthermore, it was shown that acetylcholine, the vagal neurotransmitter, inhibited 
LPS-induced release of  proinflammatory cytokines in human macrophages44. 
15
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As acetylcholine can bind both muscarinic and nicotinic acetylcholine receptors, 
macrophages were incubated with acetylcholine in combination with both muscarinic 
and nicotinic acetylcholine receptor antagonists, of  which only the nicotinic antagonist 
α-bungarotoxin was able to block the anti-inflammatory effects of  acetylcholine44. 
Further studies using knockout mice for different nicotinic acetylcholine receptors 
identified the α7 nicotinic acetylcholine receptor (α7nAChR) on macrophages as 
the principal mediator of  the anti-inflammatory effects of  the vagus nerve45. This 
mechanism was termed the cholinergic anti-inflammatory pathway. As the afferent 
arm of  the vagus nerve can sense inflammation in the body and the efferent arm 
limits it, this pathway has been proposed as a reflex-type response to counteract 
excessive inflammation, an anti-inflammatory reflex35 (Figure 1). In this vago-vagal 
reflex, afferent vagus nerve fibres terminating in the nucleus tractus solitarius synapse 
with fibres in the dorsal motor nucleus, where the efferent vagus nerve originates, 
a mechanism well-described in regulation of  digestive functions46. The effects of  
efferent vagus nerve activity on the heart can be measured by heart rate variability 
analysis which will be explained later on in this chapter. 
    Figure 1     The anti-inflammatory reflex 
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With regard to the anatomical basis of  the effects of  the cholinergic anti-inflammatory 
pathway on effector organs, it is thought that in organs that are innervated by the vagus 
nerve, such as the liver47, lungs48, and gut49, acetylcholine released from cholinergic 
nerve terminals activates α7nAChRs on tissue resident macrophages50. A special role 
for the spleen, an important cytokine-producing organ, has been proposed. The spleen 
is not innervated by cholinergic fibres, it solely receives sympathetic input51. However, 
it has been reported to be essential for the anti-inflammatory effects of  the vagus 
nerve52. It was suggested by Tracey’s group that the effects of  vagus nerve stimulation 
on the spleen rely on synaptic activation of  the splenic (sympathetic) nerve by the 
vagus nerve in the celiac-superior mesenteric plexus ganglion53. In turn the splenic 
nerve releases norepinephrine which can directly attenuate cytokine production in 
splenic macrophages via β-receptors54, or enhance splenic acetylcholine levels resulting 
in α7nAChR activation and inhibition of  cytokine production53. Furthermore, it has 
been suggested that via this pathway, circulating leukocytes passing the spleen are 
‘educated’ to release lower levels of  inflammatory cytokines52, 55.
The α7nAChR is widely expressed in the central and peripheral nervous system and has 
been well-characterized therein56. In neurons, the α7nAChR is a pentameric complex 
composed of  five α7 subunits assembled like the staves in a barrel to form an ion channel 
which is gated by the binding of  ligands57, 58, resulting in membrane depolarization 
and Ca2+ influx. Impaired α7nAChR activity has been implicated in pathogenesis of  
Alzheimer’s disease, schizophrenia, and depression59. The presence of  α7nAChR on 
cells of  the innate immune system, such as primary human macrophages and peripheral 
blood mononuclear cells, has more recently been established45, 60, 61. Because these cells 
are non-excitable, the exact structure and intracellular signalling of  the α7nAChR 
have not been completely elucidated62. Nonetheless, the anti-inflammatory effects 
of  α7nAChR agonists, such as nicotine and acetylcholine, in human monocytes and 
macrophages in vitro have been shown by various research groups44, 45, 60, 63. Furthermore, 
the anti-inflammatory effects of  electrical vagus nerve stimulation and nicotine have 
been established in various animal models of  inflammation, including endotoxemia, 
sepsis, postoperative ileus, rheumatoid arthritis, and ischemia/reperfusion injury44, 64-71. 
In addition to the non-specific agonist nicotine, various specific α7nAChR agonists, 
such as AR-R17779, CAP55, PNU-282987, and GTS-21 have been employed in 
animal models of  inflammation and have shown promising results71-78. Alternative 
methods of  activation/stimulation of  the cholinergic anti-inflammatory pathway 
have also been investigated in animal models. Acetylcholinesterase inhibition resulted 
in improved outcome in murine sepsis, supposedly by enhancing acetylcholine 
availability and thereby α7nAChR activation67. Finally, a novel gut-brain-immune axis 
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was identified in which lipid- and protein-enriched nutrition results in the release of  
cholecystokinin (CCK) in the gut, which in turn activates the afferent vagus nerve, 
leading to increased efferent vagus nerve activity (vago-vagal reflex), and ultimately 
attenuation of  the inflammatory response in hemorrhagic shock79 (Figure 2). While the 
aforementioned studies all showed beneficial effects of  stimulation of  the cholinergic 
anti-inflammatory pathway, excessive activation of  the pathway may dampen the 
innate immune response to the point of  immunosupression. This is supported by 
a study showing worsened survival in nicotine-treated mice during bacterial sepsis52. 
Likewise, nicotine pretreatment impaired bacterial clearance and increased mortality 
in murine septic peritonitis80. 
                  Figure 2     The gut-brain-immune axis
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Human data regarding the effects of  the cholinergic anti-inflammatory pathway on 
the innate immune response are very scarce. Several reasons can be put forward: 
First, investigating the effects of  stimulation of  this pathway in humans is 
troublesome. Electrical vagus nerve stimulation has mainly been employed in epilepsy 
and major depression, but requires surgery81. Naturally, this is not feasible in acute 
situations and therefore represents a less relevant treatment option. Pharmacological 
stimulation of  the pathway with acetylcholine is not possible because it is immediately 
degraded by acetylcholinesterases upon parenteral administration. The therapeutic 
potential of  acetylcholine is further hampered by its nonspecificity and unwanted 
side effects such as vasodilatation. Nicotine’s therapeutic potential is limited by its 
lack of  pharmacologic specificity, toxic side effects, and the potential to produce 
physical dependence (addiction). There is one report on the effects of  nicotine on the 
inflammatory response in humans. In this study, transdermal nicotine administration 
during human endotoxemia did not affect proinflammatory cytokine levels, although 
it did potentiate IL-10 levels82. The lack of  an effect on pro inflammation probably 
resulted from the relatively low plasma nicotine levels achieved by transdermal 
administration. The most promising and feasible treatment options are specific 
α7nAChR agonists. As outlined above, many agonists have shown great promise in 
animal models, however, except for GTS-21, these compounds are at this moment 
not suitable for human use. 
Second, measuring vagus nerve activity in humans in vivo is difficult. The only method 
available in humans is heart rate variability (HRV). This method is based on analysis of  
the variation in beat-to-beat intervals. The heart is sped up by sympathetic fibres and 
slowed down by vagus nerve fibres, both synapsing at the sinoatrial node. However, 
the effects of  acetylcholine on the sinoatrial node are much faster than those of  
catecholamines due to shorter latency and faster decay83. Therefore, analysis of  fast 
and slow oscillations in heart rate provides a measure of  cardiac parasympathetic 
(Figure 1) and sympathetic activity. However, ANS outflow might be organ-specific; 
as such, vagal or sympathetic input to the heart may not represent vagal input to the 
spleen, lungs, gut, or liver. Furthermore, animal studies have shown that electrical 
stimulation at levels below the threshold required to change heart rate, and thus alter 
HRV, are sufficient to activate the cholinergic anti-inflammatory pathway84. Another 
confounding factor is represented by breathing patterns; HRV, and especially the 
parasympathetic component of  HRV (respiratory sinus arrhythmia), is thought to 
be predominantly mediated by respiration-induced blood pressure changes which are 
sensed by carotid baroreceptors, leading to (de)activation of  cardiac vagal fibers85, 86. 
Therefore, different breathing patterns might significantly affect HRV, which is very 
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relevant in ICU patients, of  which the majority is ventilated. Finally, medication, and 
especially sedatives, which are used in most ICU patients, are known to affect HRV87. 
HRV analysis as a measure of  ANS activity is therefore highly debated88, however, it is 
the only tool available to measure activity of  both parts of  the ANS in humans in vivo.
Third, the optimal tool to investigate the complex interplay between pro- and anti-
inflammatory mechanisms during a systemic innate immune response in vivo in humans 
is the human endotoxemia model. In this model, a standardized dose of  LPS is 
administered to healthy volunteers under controlled conditions; it therefore represents 
a well-controlled and reproducible model where the timing of  the inflammatory 
stimulus is exactly known. While the human endotoxemia model does not replicate 
the clinical condition of  for instance sepsis, it has been extensively employed to study 
the acute systemic inflammatory response in vivo, and administration of  endotoxin 
affects various systemic physiologic and metabolic processes in a manner similar to 
the early phase of  injury and infection89. This makes it a suitable human model for 
proof-of-principle studies89. However, because of  the logistic complexity, the need for 
intensive monitoring, and safety regulations, this model is only operational in a few 
centres in the world.  
The combination of  these three barriers is likely the reason why the interplay between 
the ANS, and particularly the vagus nerve, and the innate immune system has only 
been sparsely studied in humans in vivo.
20
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Aim and outline of  this thesis
The aim of  this thesis was to perform translational, clinically relevant studies regarding 
the interplay between the autonomic nervous system and the innate immune response 
with a distinct focus on the effects of  stimulation of  the cholinergic anti-inflammatory 
pathway. 
In the first part of  this thesis, the interplay between the autonomic nervous system 
and the innate immune response is assessed, both in patients and healthy volunteers. 
Patients with traumatic brain injury often suffer from a dysregulated autonomic nervous 
system and a severely impaired innate immune response. In chapter 2a, the hypothesis 
is presented that (over)activation of  the cholinergic anti-inflammatory pathway plays 
an important role in the observed immune paralysis in patients with traumatic brain 
injury. In chapter 2b, the possible role of  the cholinergic anti-inflammatory pathway 
in patients with subarachnoid haemorrhage, which are suggested to display increased 
vagus nerve activity, is discussed. In chapter 2c, a possible role for the cholinergic 
anti-inflammatory pathway in the increased mortality observed in critically ill patients 
receiving nicotine replacement therapy is presented. In chapter 3, the relationship 
between autonomic nervous system activity, measured by heart rate variability, and 
the innate immune response in patients with brain injury is investigated. In chapter 4, 
this relationship is examined in healthy volunteers during human endotoxemia.
In the second part of  this thesis, the effects of  stimulation of  the cholinergic 
anti-inflammatory pathway in vitro, in animal models and in humans are described. 
Mechanical ventilation is a lifesaving intervention but can also lead to, or exacerbate 
pre-existing lung injury, a condition called ventilator-induced lung injury. Ventilator-
induced lung injury is a major problem at the ICU, and activation of  the innate 
immune system by mechanical ventilation has been shown to play a pivotal role in this 
condition. In chapter 5, the effects of  vagus nerve stimulation and vagotomy in a two-
hit model of  ventilator-induced lung injury in rats are presented. GTS-21 is the only 
available specific α7nAChR agonist that can be used in humans, as phase I/II trails in 
healthy subjects and schizophrenia patients have been conducted90-92. The intracellular 
mechanisms involved in the anti-inflammatory effects of  pharmacological α7nAChR 
stimulation have been sparsely studied, especially in human cells. In chapter 6, the 
effects and intracellular mechanisms of  action of  GTS-21 and nicotine on the innate 
immune response in primary human leukocytes are investigated. In chapter 7, the 
effects of  GTS-21, acetylcholinesterase inhibition and nAChR blockade are explored 
in a murine ventilator-induced lung injury model. In chapter 8, the potential of  GTS-
21
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21 to attenuate the innate immune response in healthy volunteers during experimental 
endotoxemia is investigated. In chapter 9, a novel gut-brain-immune axis, which 
hitherto has only been described in animal models, is explored in healthy volunteers 
during experimental endotoxemia. In chapter 10, a case study on a Dutch individual 
known as ‘the iceman’ is presented. This individual holds several world records with 
regard to extreme cold tolerance. He claims that he can influence his autonomic 
nervous system and immune response using a concentration/meditation technique. 
The effects of  this concentration/meditation technique on the ANS and the innate 
immune response was investigated, both ex vivo and during human endotoxemia.
In the third part of  this thesis methodological considerations are described. HRV has 
been suggested to be influenced by respiratory patterns. However, this has only been 
investigated under static conditions. In chapter 11, the influence of  different breathing 
patterns on HRV and its reproducibility in healthy subjects is described during 
human endotoxemia in which HRV magnitudes greatly fluctuate. Pharmacological 
intervention trials using the experimental human endotoxemia model are frequently 
designed in a cross-over manner, using an interval of  1-2 weeks93-96. However, repeated 
endotoxin administration may result in endotoxin tolerance97 and it is unknown how 
long this tolerant state persists. Furthermore, ex vivo stimulation of  leukocytes, for 
instance after sepsis or major trauma, is generally accepted to reflect a patient’s in vivo 
immune status. In chapter 12a, the kinetics of  repeated endotoxin administration in 
human volunteers on the innate immune response ex vivo and in vivo are investigated. 
In chapter 12b, an experimental human endotoxemia study employing a cross-over 
design is discussed in light of  the results reported in chapter 12a.    
Finally this thesis is concluded with a summary in chapter 13 and a general discussion 
of  the findings and future perspectives in chapter 14.
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Abstract
Traumatic brain injury (TBI) is a leading cause of  death and disability, especially in 
the younger population. In the acute phase after TBI, patients are more vulnerable 
to infection, associated with a decreased immune response in vitro. The cause of  this 
immune paralysis is poorly understood. Apart from other neurologic dysfunction, 
TBI also results in an increase in vagal activity. Recently, the vagus nerve has been 
demonstrated to exert an anti-inflammatory effect, termed the cholinergic anti-
inflammatory pathway. The anti-inflammatory effects of  the vagus nerve are 
mediated by the α7 nicotinic acetylcholine receptor present on macrophages and 
other cytokine-producing cells. From these observations, we hypothesize that the 
immune paralysis observed in patients with TBI may, at least  in part, result from 
augmented vagal activity and subsequent sustained effects of  the cholinergic anti-
inflammatory pathway. This pathway may counteract systemic proinflammation 
caused by the release of  endogenous compounds termed alarmins as a result of  tissue 
trauma. However, sustained activity of  this pathway may severely impair the body’s 
ability to combat infection. Because the cholinergic anti-inflammatory pathway can 
be pharmacologically modulated in humans, it could represent a novel approach to 
prevent infections in patients with TBI 
35
Increased vagal tone causes immune paralysis in patients with traumatic brain injury
2Introduction
Traumatic brain injury (TBI) is a leading cause of  death and disability in the developed 
world. In the United States, around 1.5 million people sustain a brain injury annually, 
of  whom approximately 50.000 die1, 2. TBI occurs mainly in the younger population, 
resulting predominantly from motor vehicle accidents, sports injuries, falls and acts of  
violence3. Patients with patients are more vulnerable to infection. As a result, infection 
is a common and serious complication following TBI4. A recent study reported that 
especially in the first 20 days after injury, the majority of  patients with TBI die of  
sepsis or pneumonia5. Other workers reported that 77% of  patients developed sepsis 
or systemic inflammatory response syndrome in the first seven days following TBI6. It 
is thought that the phenomenon called post-traumatic immune paralysis is responsible 
for the increased chance of  developing an infection in these patients.   
Immune paralysis in patients with TBI
The innate immune response is the first line of  defense against invading pathogens7. 
This tightly regulated system consists of  a wide variety of  chemokines, cytokines, cell 
associated receptors, and other mediators orchestrating the initial response to infection. 
The adaptive immune response is a more specific and focused system comprised of  
different effector cell types such as B- and T-cells. While these two different systems 
evolved independently, it has become clear that innate immune signaling plays a critical 
role in initiating and instructing the adaptive immune response8. Therefore, effects on 
the innate immune response presumably also alter the adaptive immune response. 
Although limited, there are experimental data concerning the systemic immune paralysis 
observed in patients with brain trauma. After severe head injury, decreased T-helper cell 
activation, attenuated lymphokine-activated killer cell cytotoxicity, and depression of  
proinflammatory cytokine production (IL-2, IFN-g), have been reported9-14. Moreover, 
ex vivo whole blood stimulation with lipopolysaccharide (LPS) shows an attenuated 
production of  pro-inflammatory cytokines TNF-α, IL-1b, IL-6, IL-8, IFN-g, and IL-12 
in polytrauma patients compared with healthy controls15. Another study demonstrated 
decreased TNF-α mRNA levels in human peritoneal macrophages after polytrauma, 
while the anti-inflammatory cytokine IL-10 was upregulated16. Taken together, these 
results suggest that the early innate immune response, as well as the adaptive immune 
response, to pathogens is attenuated in patients with TBI. However, the mechanism 
underlying this immune paralysis following brain injury remains unclear. 
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The central nervous system and TBI
Dysfunction of  the central nerve system (CNS) has been widely reported in patients 
with TBI. Many reports focus on the non-autonomic nervous system, such as motor 
deficits17, 18, while others have evaluated the role of  the autonomic nervous system 
after TBI19-21. The autonomic nervous system comprises a collection of  afferent and 
efferent nerve fibers that regulate important vital functions in the body, including 
blood pressure and heart rate22, 23. The autonomic nervous system is composed of  
two parts, the sympathetic and the parasympathetic (vagal) part. The balance between 
these two subsystems, the sympathovagal balance, generates the net effect of  the 
autonomic nervous system, of  which heart rate is one of  the end products21. Heart 
rate variability reflects the balance between the sympathetic and the parasympathetic 
parts of  the autonomic nervous system, therefore, heart rate variability analysis is 
extensively used to measure autonomic activity (reviewed in24). 
Measurement of  autonomic nervous system activity
Heart variability can be analyzed in the time-domain, yielding normal-to-normal (R-R) 
intervals or by spectral (frequency domain) analysis of  a series of  R-R intervals. In 
the time-domain, heart rate variability is usually expressed as standard deviation of  
R-R intervals (SDNN) or as the SDNN index (SDNNIDX), which is the average of  
SDNN per specified interval25. The spectral analysis of  R-R intervals is especially 
useful because a distinction can be made between low frequency (LF) and high 
frequency (HF) components in heart rate variability, providing information about the 
interplay of  sympathetic and parasympathetic activity. Generally, LF spectral power 
(range 0.04-0.15 Hz) reflects sympathetic input while the HF power (range 0.15-0.4 
Hz) represents parasympathetic influence26, 27. Therefore, the HF/LF ratio represents 
a measure of  sympathovagal balance. A unique in vivo experiment that illustrates this 
balance was conducted in patients with an implanted electrical vagus nerve stimulator 
for the treatment of  epilepsy28. In these subjects, HF power and HF/LF ratio were 
greatly increased when the stimulator was activated, illustrating that these measures 
are reliable indicators of  vagal activity in humans. Nevertheless, caution should be 
taken when evaluating these parameters because other workers have indicated that 
parasympathetic outflow and other factors such as baroreceptor activity also influence 
LF power, thus stating that LF power represents a combination of  sympathetic and 
parasympathetic input29, 30. Moreover, HF power can be influenced by factors like 
respiratory pattern30. 
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2Heart rate variability in patients with acute TBI
Although data are limited, a few human studies have assessed heart rate variability 
after TBI in the acute phase. An increase in HF/LF ratio was reported in the 
acute phase after TBI, indicating dominance of  parasympathetic activity20, 31. In 
these studies, increased intracranial pressure, often present in acute TBI, has been 
linked to the high HF/LF ratios observed20, 32. Along these lines, patients with acute 
subarachnoid hemorrhage, which is associated with a rapid increase in intracranial 
pressure33, displayed significantly increased HF power compared with controls, 
while LF power did not change34. These results suggest that in patients with TBI, 
parasympathetic (vagal) activity is augmented, resulting in an increased HF power and 
increased HF/LF ratio and that elevated intracranial pressure may play an important 
role in this process. In addition to the above described association between TBI/
increased intracranial pressure and heart rate variability as a measure of  vagal tone 
inpatients with TBI, a model of  increased intracranial pressure demonstrated a direct 
link between intracranial pressure and vagal tone. In cats, vagal activity, measured 
by microneurography, was increased relative to the increase in intracranial pressure 
induced by inflating a subdural balloon35. This suggests that high intracranial pressure 
directly influences vagal tone. A potential mechanism behind this phenomenon might 
be compression of  higher vagal nuclei, or the brainstem, leading to vigorous firing of  
the medulla oblongata, the centre where the vagus nerve originates.
Vagal activity and the cholinergic anti-inflammatory pathway
Experimental evidence in the past several years has demonstrated that activation of  
the efferent vagus nerve has an inhibitory effect on the innate immune response (the 
cholinergic anti-inflammatory pathway, reviewed in36-38). Several in vitro studies have 
demonstrated that pretreatment of  cultured human macrophages with the principal 
vagal neurotransmitter acetylcholine, significantly attenuates the LPS-induced release of  
proinflammatory mediators such as TNF-α, IL-6, IL-1b, IL-18, and HMGB1, while 
release of  the anti-inflammatory cytokine IL-10 was unaffected39, 40. Moreover,  vagus 
nerve electrical stimulation attenuates serum TNF-α and IL-6 levels in animals after 
endotoxin administration and prevents the development of  shock39, 41-43. In contrast, 
vagotomized animals exhibited elevated levels of  proinflammatory cytokines with 
aggravation of  shock39, 44, 45. In humans, we know of  only one study that evaluated 
inflammatory mediators in patients with a vagus nerve stimulator46. In this study, 
circulating inflammatory mediators were measured before implantation of  the 
stimulator and after 12 weeks following implantation of  the stimulator in a small 
group of  patients with severe depression. After stimulator implantation, the 
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proinflammatory mediators TNF-α and IL-6 were significantly elevated; however, 
other proinflammatory mediators such as IL-1 and CRP were not. In addition, levels 
of  the anti-inflammatory cytokine TGF-β were also significantly increased, which 
makes it difficult to draw any conclusions regarding the manner in which vagus 
nerve stimulation modulates the immune status in these patients. Moreover, levels of  
circulating inflammatory mediators in these patients do not actually reflect the status 
of  the immune response, because no inflammatory stimulus was present.
The anti-inflammatory effect of  the vagus nerve is mediated by the α7 nicotinic 
acetylcholine receptor (α7nAChR) expressed on macrophages and other cytokine-
producing cells43. The identification of  this receptor stimulated the use of  nicotine 
instead of  acetylcholine in studies exploring the anti-inflammatory effect of  the vagus 
nerve because of  its higher efficiency and selectivity, and has led to the search for 
even more selective α7nAChR agonists40. GTS-21, a specific α7nAChR agonist that 
has already been used in human clinical trials for the treatment of  Alzheimer’s disease, 
has been studied in a murine pancreatitis model. GTS-21 decreased pancreatitis 
severity, associated with reduced IL-6 levels and decreased pancreatic neutrophil 
accumulation45. Furthermore, CNI-1493, a compound exhibiting systemic anti-
inflammatory effects currently used in clinical trials for the treatment of  Crohn 
disease, has recently been shown to activate the vagus nerve via a centrally mediated 
intracerebral effect47, 48. CNI-1493 prevented endotoxin-induced shock and attenuated 
the rise in serum TNF-α levels in rats47, 48. Inhibitors of  α7nAChR have also been 
identified. Mecamylamine, a drug used in humans for the treatment of  hypertension 
and tobacco addiction, has been utilized in experimental settings and exhibited 
effects analogous to vagotomy, such as enhanced serum IL-6 levels and augmented 
severity of  inflammation45. The intracellular cascade after α7nAChR activation has 
been, in part, elucidated by a recent study demonstrating that activation of  α7nAChR 
leads to recruitment and activation of  the anti-inflammatory JAK2-STAT3 (Janus 
kinase-2; signal transducers and activators of  transcription-3) cascade49. While studies 
regarding the cholinergic anti-inflammatory pathway have mainly focused on the 
innate immune system, the adaptive immune response may also be attenuated by 
vagal outflow because of  the vital role the innate immune system plays in initiating 
the subsequent adaptive immune response.
In addition, apart from the anti-inflammatory effects of  the vagus nerve, inflammation 
can also affect vagal tone. Evaluation of  heart rate variability during endotoxic shock 
in humans demonstrated attenuated variability accompanied by a decrease in total 
spectral power50. This may represent a negative feedback mechanism to prevent 
inhibition of  the immune response. In this article we  focus on the anti-inflammatory 
effects of  the vagus nerve. 
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2The cholinergic anti-inflammatory response represents an exciting new pathway that 
modulates the innate, and possibly also the adaptive, immune response and provides 
novel pharmacological treatment opportunities for situations associated with a 
disturbed sympathovagal balance.
Summary and hypothesis
In this report we have discussed three separate observations. 1) The immune response 
is severely impaired in patients after TBI, and is likely to be associated with the high 
prevalence of  infections in these patients. 2) In the acute phase after TBI, vagal 
activity is augmented, resulting in a shift in the sympathovagal balance, possibly as 
a consequence of  increased intracranial pressure 3) Vagal activity has an inhibiting 
effect on the innate immune response. These observations have led us to a new 
hypothesis that could explain the immune paralysis observed in patients with TBI. 
We hypothesize that the impaired immune response in these subjects may, at least in 
part, result from increased vagal activity and subsequent suppression of  the immune 
response (Figure 1).
Figure 1     Traumatic brain injury increases 
vagal tone directly or as a result of  elevated in-
tracranial pressure. Subsequently, vagal activity 
attenuates inflammation via the cholinergic anti-
inflammatory pathway. As a result, susceptibil-
ity toward infections increases, resulting in worse 
outcome.
Discussion
The hypothesis postulated above is 
based on evidence obtained from studies 
with different research objects. To our 
knowledge, no studies are available that 
test this hypothesis directly. Because the 
cholinergic anti-inflammatory pathway 
can be pharmacologically modulated in 
humans, such treatment in patients with 
TBI could represent a novel, promising 
approach to prevent infections in this 
specific group of  patients. 
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Although elevated intracranial pressure appears to be an important link in the 
parasympathetic anti-inflammatory response following TBI, other mechanisms 
have also been suggested. Recently, the role of  endogenous mediators in systemic 
inflammation in the absence of  infection51 was discussed. Toll-like receptors (TLRs) 
are well-known for their role in recognition of  exogenous pathogens and subsequent 
triggering of  immune responses. Excessive or inappropriate activation of  TLRs can 
lead to systemic inflammation and shock, similar to that observed in septic patients. 
In addition to recognizing outside invaders, TLRs, as well as other receptors, also 
recognize endogenous damage signals termed alarmins, such as heat-shock proteins 
and HMGB1. Tissue trauma, for instance resulting from TBI, elicits release of  these 
damage signals52-54. Consequently, trauma can trigger the immune response and this 
could explain the systemic inflammatory reaction in the absence of  infection often 
observed in these patients. An increase in vagal activity may counteract this mechanism 
by attenuating the release of  endogenous inflammatory mediators. In this context, it 
is noteworthy that ex vivo treatment of  human monocytes with nicotine (stimulation 
of  the cholinergic anti-inflammatory pathway) resulted in downregulation of  TLR4 
expression in human monocytes55. This observation may also explain the attenuated 
production of  proinflammatory cytokines in blood of  trauma patients that was 
stimulated ex vivo with LPS, the primary ligand for TLR415. In this prospect, increased 
vagal activity may represent a negative feedback mechanism counteracting the massive 
systemic proinflammatory response. This notion is supported by animal studies in 
which increased vagal activity resulted in attenuation of  inflammation, prevention of  
development of  shock, and decreased mortality after experimental inflammation39, 40, 45. 
In this view, the resultant and sustained immune paralysis is merely a side-effect of  
the negative feedback loop. However, the animal studies mentioned before have all 
been performed using models of  sterile inflammation. In animal experiments using 
live microbial sepsis, activation of  the cholinergic anti-inflammatory pathway resulted 
in worsened survival,  impaired migration of  neutrophils to the inflamed area, and 
increased outgrowth of  bacteria41, 44, 56. Moreover, human data on heart rate variability 
in the acute phase after TBI indicate that increased HF/LF ratios are associated with 
poor outcome and higher mortality57-59. These results suggest that increased vagal 
activity is beneficial in sterile inflammation induced by LPS or chemical compounds 
that evoke inflammation, but may impair the body’s ability to combat an infection 
with live bacteria.
In contrast to aforementioned studies, also a decreased HF power and decreased 
HF/LF ratios have been reported in patients with TBI19, 21, 60 . However, these studies 
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2evaluated patients in the post-acute (chronic) phase of  TBI (>30 days). Along these 
lines, patients in the chronic phase of  subarachnoid hemorrhage demonstrated similar 
HF/LF ratios compared with control subjects, while HF/LF ratios were increased in 
the acute phase, as discussed before34. In the chronic phase of  TBI or subarachnoid 
hemorrhage, patients usually do not have an increased intracranial pressure, possibly 
explaining the absence of  increased vagal activity. Moreover, a potential explanation 
for decreased vagal output in the chronic phase of  TBI may be damage to the 
brainstem and medulla oblongata resulting in impaired activity of  the vagus nerve. 
In the acute phase of  TBI, this effect may be overwhelmed by vigorous firing as 
a consequence of  the compression of  the brainstem. One study in a very acute 
setting (immediately after admission to the intensive care unit one 5-minute ECG was 
recorded) also reported decreased vagal activity and lower HF/LF ratios, indicating 
sympathetic dominance61. However, in this very acute setting, elevated intracranial 
pressure has probably not developed yet. Thus, time after injury appears to be a very 
important factor in autonomic dysfunction. 
Taken together, we believe that our hypothesis may, at least in part, explain the 
immune paralysis observed in the first phase following TBI. Because increased vagal 
tone is associated with increased mortality and poor outcome in patients with TBI, 
intervening in the cholinergic anti-inflammatory pathway could be of  potential 
benefit to these patients. This possibility warrants further research to elucidate the 
mechanism of  immune paralysis in patients with TBI.
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Abstract original article
Sympathetic activation and inflammatory response in patients with subarach-
noid haemorrhage
Naredi S, Lambert G, Friberg P, Zäll S, Edén E, Rydenhag B, Tylman M, Bengtsson A.
Intensive Care Medicine 2006; 32(12):1955-61
Background The aim of  this study was to evaluate the correlation between 
sympathetic nervous activation and the immune response in patients following 
subarachnoid haemorrhage (SAH).
Methods Fourteen patients on a neurosurgical intensive care unit with acute 
non-traumatic SAH were included. Fifteen healthy, age-matched volunteers served as 
controls for measurement of  catecholamine spillover. Blood sampling for C3a, C5b-9, 
IL-6, IL-8 and norepinephrine kinetic determination was made within 48 h, at 72 h 
and on the 7th-10th day after the SAH.
Results  SAH patients exhibited a profound increase in the rate of  
norepinephrine spillover to plasma at 48 h, 72 h and 7-10 days after the insult, 3-4 
times that in healthy individuals. The plasma levels of  C3a, IL-6 and C5b-9 were 
significantly elevated at 48 h, at 72 h and 7-10 days after the SAH, but the plasma level 
of  IL-6 decreased significantly 7-10 days after the SAH. There was no relationship 
between the magnitude of  sympathetic activation and the levels of  inflammatory 
markers.
Conclusions Following SAH a pronounced activation of  the sympathetic nervous 
system and the inflammatory system occurs. The lack of  significant association 
between the rate of  spillover of  norepinephrine to plasma and the plasma levels of  
inflammatory markers indicates that the two processes, sympathetic activation and the 
immune response, following SAH are not quantitatively linked. In spite of  a persistent 
high level of  sympathetic activation the plasma level of  IL-6 decreased significantly 
one week after SAH.
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Does subarachnoid haemorrhage affect the innate immune response?
2To the editor
Immune suppression following injury to the central nerve system is an important 
clinical issue because up to 50% of  brain-injury patients develop infection, especially 
in the first few days following the insult1. Recently, Naredi et al. tried to establish the 
immunomodulating effects of  the sympathetic nervous system following subarachnoid 
haemorrhage2. The authors found increased norepinephrine spillover following 
subarachnoid haemorrhage, indicating sympathetic activation, and elevated levels of  
circulating proinflammatory cytokines and complement such as C3a, IL-6, and C5b-9. 
These parameters were measured to evaluate the relationship between sympathetic 
nervous system activity and the inflammatory response status, but no quantitative 
correlation between these two systems was found. 
Following tissue trauma, as in subarachnoid haemorrhage, circulating levels of  
proinflammatory cytokines may not provide a good measure of  innate immunity 
because these levels are mainly the result of  the trauma itself3 and do not reflect 
the innate immune response to a subsequent trigger. Therefore, the reported rise 
and subsequent normalisation of  the proinflammatory mediators after subarachnoid 
haemorrhage observed in this study is not surprising. To evaluate the status of  the 
immune response after subarachnoid haemorrhage or other tissue trauma, ex vivo 
stimulation of  immune cells obtained from these patients with lipopolysaccharide or 
another inflammation-provoking compound would be more appropriate. Moreover, 
in light of  the recently identified cholinergic anti-inflammatory pathway, future studies 
into this field should probably consider not only the sympathetic activity, but also the 
activity of  the parasympathetic autonomic nervous system (vagal activity) when evaluating 
the modulation of  the immune response4. This relatively newly discovered pathway 
also seems to be relevant in patients with subarachnoid haemorrhage. Apart from 
an increase in plasma catecholamine concentrations, another study in subarachnoid 
haemorrhage patients also found a marked increase in parasympathetic activity in 
the acute phase following subarachnoid haemorrhage5. The rise in parasympathetic 
activity may be the result of  the bleeding and brain injury itself  or mediated by the 
subsequent increase in intracranial pressure. 
In summary, ex vivo cytokine release to an inflammatory stimulus present a better 
measure of  the effect of  subarachnoid haemorrhage on the innate immune response 
than the concentrations of  circulating cytokines. Moreover, not only the sympathetic 
but especially the parasympathetic nerve system may play a pivotal role in the 
modulation of  the innate immune response. Because increased activity of  the vagus 
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nerve has been shown to dampen the immune response in both in vitro and animal 
studies4, this may represent an interesting new avenue for future research and a 
promise for new treatment modalities. 
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Letter to the editor
A possible role for the cholinergic anti-inflammatory
pathway in increased mortality observed in critically ill
patients receiving nicotine replacement therapy
Matthijs Kox, Jan C. Pompe, Cornelia W. Hoedemaekers, Peter Pickkers, 
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Abstract original article 
The association of  nicotine replacement therapy with mortality in a medical 
intensive care unit
Lee AH, Afessa B.
Critical Care Medicine 2007; 35(6):1517-21
Background Smokers admitted to the intensive care unit may receive nicotine 
replacement therapy to prevent withdrawal. However, the safety of  nicotine 
replacement in the critically ill has not been studied. The objective of  this study was to 
determine the impact of  nicotine replacement on the outcome of  critically ill patients.
Methods We performed a retrospective, case-control at the medical intensive 
care unit of  a tertiary academic hospital. Patients who were active smokers at 
admission to the intensive care unit were included in the study. Those who received 
nicotine replacement therapy were considered as cases, and those who did not receive 
nicotine replacement were considered as controls.
Results  For each of  the 90 cases, one control smoker who did not receive 
nicotine replacement therapy was selected based on the severity of  illness and then 
age. Outcome was measured by hospital mortality and 28-day intensive care unit-
free days, defined as the number of  days spent outside of  intensive care or without 
mechanical ventilation by a living patient following admission to intensive care. The 
mean mortality rate predicted by the Acute Physiology and Chronic Health 
Evaluation III was 9.2% for the cases compared with 10.3% for the controls 
(p = .7127). The observed hospital mortality rate was 20% in the cases vs. 7% 
in the control group (p = .0085). When adjusted for the severity of  illness and 
invasive mechanical ventilation, nicotine replacement therapy was independently 
associated with increased mortality (odds ratio, 24.6; 95% confidence interval, 
3.6-167.6; p = .0011). The mean (sd) 28-day intensive care unit-free days were 20.7 
(10.5) in the case group compared with 23.4 (7.1) in the control group (p = .0488).
Conclusions Our study shows that nicotine replacement therapy is associated 
with increased hospital mortality in critically ill patients. However, because of  the 
limitations of  the study, a future study based on a better case-control design is 
warranted.
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Activation of  the cholinergic anti-inflammatory pathway by nicotine replacement therapy
2To the editor
The cholinergic anti-inflammatory pathway is a recently discovered mechanism which 
implies that activation of  the efferent vagus nerve attenuates the innate immune 
response1, 2. The anti-inflammatory effect of  the vagus nerve is mediated by the 
α7 nicotinic acetylcholine receptor (α7nAChR), which is activated by acetylcholine, 
the principal vagal neurotransmitter2. Apart from acetylcholine, nicotinic agonists 
can also activate the α7nAChR and attenuate the innate immune response1, 2. Since 
these discoveries, various research groups have used nicotine, or other more specific 
α7nAChR agonists, to modulate diseases with an overactive immune response, such 
as sepsis or autoimmune disorders. However, sustained activation of  the cholinergic 
anti-inflammatory pathway can also have detrimental effects. As a result of  ‘immune 
paralysis’, it may render the body more susceptible to infection. For instance, in a mouse 
model of  live microbial sepsis nicotine administration resulted in increased mortality1. 
This effect resulted from impaired influx of  immune cells such as neutrophils into the 
inflamed area, leading to inadequate clearance, and therefore outgrowth, of  bacteria.
Recently, Lee et al. investigated the impact of  nicotine replacement therapy (NRT) 
on the outcome of  critically ill patients3. NRT ameliorates withdrawal symptoms in 
smokers and is therefore frequently initiated in hospitalized patients. The authors 
reported increased mortality in patients receiving NRT compared with patients that 
did not. This is quite a remarkable observation, as several clinical trials have proven 
that NRT is not associated with increased mortality in non-critically ill hospitalized 
patients4, 5. Lee et al. speculate that the hemodynamic effects of  nicotine, such as 
increased heart rate, blood pressure, myocardial contractility, and constriction of  
coronary arteries might be responsible for the increased mortality observed. Especially 
intensive care unit patients may be more susceptible to these effects. 
We believe that the cholinergic anti-inflammatory pathway might also play an important 
role in the increased mortality associated with NRT in the critically ill. As highlighted 
previously, nicotine activates the α7nAChR and can therefore attenuate the innate 
immune response, resulting in immune paralysis. As the major causes of  death in the 
NRT group were pneumonia (n=4) and sepsis (n=3), this suggests that these patients 
were more susceptible to infections than were the control group, where 2 patients 
died of  sepsis and none of  other infections. Thus, the absence of  increased mortality 
after NRT in the non-critically ill in earlier trials may be explained by the fact that 
these patients were at a much lower risk of  acquiring a concomitant infection than 
intensive care unit patients. Unfortunately, Lee et al. do not mention the prevalence 
of  infections in the NRT and the control groups, nor do they provide data on the 
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amount or concentration of  nicotine administered to the patients. This information 
would certainly help us evaluate the possible role of  the cholinergic anti-inflammatory 
pathway in the increased mortality found in these patients. 
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The effects of  brain injury on heart rate variability and the 
innate immune response in critically ill patients
Matthijs Kox,  Maarten Q. Vrouwenvelder, Jan C. Pompe, Johannes G. 
van der Hoeven, Peter Pickkers, Cornelia W. Hoedemaekers
Provisionally accepted in Journal of  Neurotrauma
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Abstract 
Background Brain injury and related increased intracranial pressure (ICP) may 
lead to increased vagus nerve activity and subsequent suppression of  innate immunity 
via the cholinergic ant-inflammatory pathway. This may explain the observed increased 
susceptibility to infection in these patients. In the present study, we investigated the 
association between brain injury, vagus nerve activity, and innate immunity.
Methods We determined heart rate variability (HRV) as a measure of  vagus 
nerve activity, plasma cytokines, and cytokine production of ex vivo LPS-stimulated 
whole blood in the first 4 days of  admission to the neurological ICU in 34 patients 
with various forms of  brain damage. HRV, immune parameters, and the correlations 
between these measures were analyzed in the entire group of  patients and in 
subgroups of  patients with conditions associated with high (intracranial hemorrhage 
[ICH]) and normal ICP (subarachnoid hemorrhage [SAH] with an extraventricular 
drain alleviating ICP). Healthy volunteers were used for comparison.
Results  HRV total spectral power and ex vivo stimulated cytokine production 
was severely depressed in patients compared with healthy volunteers (p<0.05). 
Furthermore, HFnu (a HRV parameter corresponding with vagus nerve activity) 
was higher, and the LF/HF ratio (a HRV parameter corresponding with sympathetic 
activity) was lower in patients compared with healthy volunteers (p<0.05). HFnu 
correlated inversely with ex vivo-stimulated TNF-α production (r=-0.22, p=0.025). 
The most pronounced suppression of  ex vivo stimulated cytokine production was 
observed in the ICH group. Furthermore, in ICH patients, HFnu correlated strongly 
with lower plasma TNF-α levels (r=-0.73, p=0.002). 
Conclusions   Our data suggest that brain injury, and especially conditions 
associated with increased ICP, is associated with vagus nerve-mediated immune 
suppression.  
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Introduction
Traumatic brain injury (TBI) is the leading cause of  death and disability in children 
and young adults in the Western World1. The direct effects of  damage to the brain 
account for high mortality, but in patients who survive the initial head injury, infection 
is the most frequently observed complication2-5. The high prevalence of  infectious 
complications indicates that the immune system is compromised after TBI, a condition 
called immune paralysis. Immune paralysis is also present in nontraumatic brain injury 
such as subarachnoid hemorrhage (SAH)2. The mechanism behind immune paralysis 
following (traumatic) brain injury is poorly understood. We recently hypothesized that 
the autonomic nervous system, and in particular increased activity of  the vagus nerve, 
may play a role in the observed immune paralysis6. TBI7-9 and SAH10-12 are associated 
with autonomic dysfunction, and recent evidence indicates that increased vagus nerve 
activity can limit the innate immune response13, 14. In this so-called cholinergic anti-
inflammatory pathway, the vagal neurotransmitter acetylcholine, released in organs 
innervated by the vagus nerve, limits inflammatory cytokine production through 
the α7 nicotinic acetylcholine receptor present on tissue-resident macrophages15. In 
addition, it has been proposed that vagus nerve signaling to the spleen ‘educates’ 
passing circulating leukocytes to release lower levels of  inflammatory cytokines16, 17. 
Excessive or persistent activation of  this anti-inflammatory pathway might lead to an 
immune suppressed state that renders the body vulnerable to infection.
In our hypothesis, we proposed a critical role for increased intracranial pressure (ICP)6. 
Elevated ICP is a common feature of  TBI18 and SAH19. As a result of  high ICP, 
compression of  the brainstem may lead to increased firing of  the medulla oblongata, 
where the efferent vagus nerve originates. Direct evidence for this phenomenon was 
found in cats, where inflation of  a subdural balloon resulted in increased vagus nerve 
discharges relative to ICP levels20. In line, increased parasympathetic predominance 
has been demonstrated in the acute phase of  TBI in patients8, 21. Furthermore, 
significant increases in parasympathetic activity were found in patients in the acute 
phase of  SAH11, and a recent study reported that parasympathetic predominance is a 
predictor of  mortality in SAH10. 
All of  the clinical studies mentioned above have used heart rate variability (HRV) as 
a measure of  autonomic nervous system activity, as this is the only non-invasive tool 
available to monitor both branches of  the autonomic nervous system in humans. 
Power spectral analysis of  short-term (5 minute recordings) HRV provides a measure 
of  autonomic modulation of  the heart rate and is widely used to assess autonomic 
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nervous system activity22, 23.
The aim of  this study was to asses the association between brain injury, vagus nerve 
activity, and innate immunity. To the best of  our knowledge, this has never been 
studied in humans before. We determined HRV and measures of  innate immunity 
in patients admitted to the neurological ICU with various forms of  brain damage. 
Concentrations of  circulating cytokines were analyzed and, in light of  the spleen-
mediated effects of  the vagus nerve on circulating leukocytes, we also assessed the 
inflammatory response of  circulating leukocytes in ex vivo stimulation experiments. 
HRV, immune parameters, and the correlations between these parameters were 
analyzed in the entire group of  patients as well as in subgroups of  patients to compare 
brain injury associated with high and normal ICPs. 
Materials and methods
Study population
We performed an prospective observational study in 34 adult patients admitted to the 
neurological ICU of  a tertiary care university hospital in Nijmegen, the Netherlands 
in 2010 and 2011. Patient inclusion was aided by the help of  nurses of  the research-
ICU department which made rounds along the wards twice daily. The study protocol 
was approved by the Ethics Committee of  the Radboud University Nijmegen Medical 
Centre and complied with the Declaration of  Helsinki including current revisions 
and the Good Clinical Practice guidelines. The Ethics Committee waived the need for 
informed consent, because of  the study’s observational nature. All patients >=18 yrs 
with traumatic and nontraumatic brain injury were eligible for the study. Patients were 
excluded in case of  known arrhythmias or a pre-existent immune compromised status. 
One of  the objectives of  this study was to investigate the relation between conditions 
associated with increased ICP, vagus nerve activity, and the innate immune response. 
Therefore, we aimed to analyze three separate subgroups: subarachnoid hemorrhage 
(SAH), intracranial hemorrhage (ICH) and ICU control patients that suffered from 
trauma without brain damage (TRAUMA). In our institute, most SAHs are treated 
with extraventricular drains, thereby alleviating ICP. Therefore, this group of  patients 
represents isolated brain injury without high ICPs. Baseline HRV data obtained in 
a group of  40 healthy male volunteers that participated in a human endotoxemia 
experiment (previously published in24) were used for comparison. In addition, for 
comparison of  ex vivo stimulation data, we performed whole blood stimulation 
experiments identical to those performed in patients in 4 healthy male volunteers on 
4 different days, where each measurement was separated by 5 days. 
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Data collection
The first measurement was performed within 24 hours of  the initial event. Patients 
were measured every 24 hours for the first 4 days after admission to the ICU (days 0, 
1, 2, and 3),  unless they died or were discharged from the ICU. At these time points, 
blood was drawn for cytokine analysis and ex vivo stimulation, and HRV was mea-
sured. Relevant medications, including antibiotics, sedatives, analgesics, and inotropic 
drugs were recorded on a daily basis. Furthermore, demographic and clinical data as 
well as in-hospital mortality was recorded. 
 
Heart rate variability analysis
A 5 minute 3-lead ECG recording was obtained using a Medilog AR12 recorder 
(Huntleigh Healthcare, Cardiff, UK); patients were not disturbed during the 
measurement. R-peak position was determined at a sample rate of  4096 Hz. HRV 
was analyzed using dedicated software (Medilog Darwin HRV, Huntleigh Healthcare, 
Cardiff, UK). In each 5-min recording, QRS complexes were detected and only 
normal-to-normal beat (NN) intervals were tabulated, yielding an interval tachogram. 
Recordings with artifacts such as premature (supra)ventricular beats or other 
arrhythmias comprising more than 5% of  the total epoch were discarded. After linear 
detrending, power spectral density was determined by fast Fourier transformation 
(FFT) of  interval tachograms using the Welch method and a FFT width of  1024. Very 
low frequency (VLF) power (0.0033-0.04 Hz) can not be reliably obtained from 5-min 
recordings and was therefore not analyzed23. With regard to the expected differences 
in total power and large variations in spectral power between patients, only normalized 
units or ratios are meaningful for comparison. Therefore, high frequency power in 
normalized units (HFnu), a measure of  cardiac vagus nerve activity23, 25, 26, and the 
ratio between low frequency and high frequency power (LF/HF), which is regarded 
to reflect sympathetic activity27, 28, was used to assess autonomic activity. HFnu was 
calculated using the formula: (HF/[total power-VLF])*100.
Ex vivo whole blood stimulation
Ex vivo blood stimulation was performed using an custom in-house developed method 
(ImmuTube). This system consists of  tubes prefilled with 2 mL of  culture medium 
or 2 mL of  culture medium containing lipopolysaccharide (LPS). Prefilled tubes were 
stored at -80 oC and brought to room temperature before use. 0.5 mL of  lithium-
heparin anti-coagulated blood (Vacutainer System, BD, Biosciences, Plymouth, UK) 
was then added to the prefilled tubes and the tubes were gently inverted to ensure 
proper mixing. Subsequently, tubes were incubated for 24 hours at 37 oC, centrifuged 
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(2500g, 4°C, 10 minutes) and the supernatant was stored at -80°C until analysis. In 
non-stimulated samples, no cytokine production was observed in any of  the samples 
from patients or healthy volunteers, ruling out contamination.  
Reagents
Culture medium (RPMI 1640 Dutch modification) was obtained from ICN Biomedicals 
(Costa Mesa, CA, USA). Culture medium was supplemented with gentamicin 10 µg/
mL, L-glutamine 10 mM, and pyruvate 10 mM. Escherichia coli LPS (serotype O55:B5) 
was purchased from Sigma-Aldrich (St. Louis, MO, USA). LPS was further purified as 
described previously29 and used at a final concentration of  10 ng/mL. 
Cytokine measurements 
For plasma cytokine determination, EDTA anticoagulated blood (Vacutainer System, 
BD, Biosciences, Plymouth, UK) was collected from the patient’s arterial catheter and 
immediately centrifuged at 2000g for 10 minutes at 4 oC. Plasma was stored at -80 oC 
until analysis. Plasma concentrations of  TNF-α, IL-6, and IL-10 were measured using 
a simultaneous Luminex Assay according to the manufacturer’s instructions (Milliplex, 
Millipore, Billerica, MA, USA). Cytokine concentrations in ex vivo stimulated whole 
blood supernatants were determined by enzyme-linked immunoassay (ELISA) 
according to the manufacturer’s instructions (IL-6 and IL-10: Human IL-6 Sanquin 
Amsterdam, The Netherlands;  TNF-α: R&D systems, Minneapolis, MN, USA).
Statistical analysis
None of  the measured parameters was normally distributed (calculated using the 
Shapiro Wilk test). Therefore, data are represented as median (range). Statistical 
tests used are indicated in the text and figure legends. Differences between two 
groups were tested with Mann-Whitney U-tests and differences between three or 
more groups/days with Kruskal-Wallis tests with Dunn’s post-hoc test (corrected for 
multiple comparisons). Spearman correlations  Spearman correlation was used unless 
specified otherwise. P values of  correlation analyses in subgroups were corrected 
for multiple testing. P values lower than 0.05 were considered significant. Statistical 
analysis was performed using Graphpad Prism 5 (Graphpad software, San Diego, CA, 
USA) and SPSS 16.0 (SPSS, Chicago, IL, USA).
 
Results
Study population
Demographic characteristics of  the patient population and healthy volunteers 
are shown in Table 1. Physiological parameters and relevant medications are 
listed in Supplementary table 1. The only anti-inflammatory medication used was 
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dexamethasone, by one patient in the ICH group on days 2 and 3. In the group of  
healthy volunteers, median HR was 62 (47-97) beats/min and median MAP 96 (80-
114) mmHg. In all but one of  the SAH patients hydrocephalus was treated upon 
admission by insertion of  an extraventricular drain, thereby alleviating ICP to normal 
values. No patients with isolated TBI were included to enable direct comparison with 
the TRAUMA group.
Table 1     Demographic characteristics
Data are presented as median (range). SAH: subarachnoid hemorrhage, ICH: intracranial hemorrhage. 
The miscellaneous group consisted of  multi-trauma patients with neurological damage (n=3), post-anoxic 
encephalopathy (n=5), transverse myelitis (n=2), cerebellar infarction (n=1), and intoxication (n=1). 
HRV and inflammatory markers in the entire study population
In the entire patient population (n=34), there were no differences in any of  the 
HRV parameters between days. Therefore, data from all 4 days were pooled. HRV 
total spectral power (an overall measure of  variability) was diminished in patients 
compared with healthy volunteers (Figure 1A). As depicted in Figure 1B and 1C, HFnu 
(cardiac vagus activity) was significantly higher, and LF/HF (sympathetic activity) was 
significantly lower in patients compared with healthy volunteers, indicating increased 
cardiac vagus nerve activity. Similar to HRV data, there were no differences over time 
in ex vivo stimulated cytokine production in both healthy volunteers and patients; data 
were therefore pooled. Ex vivo stimulated whole blood of  patients revealed distinct 
hyporesponsiveness to LPS compared with healthy volunteers (TNF-α shown in 
Figure 1D; IL-6: healthy volunteers 9254 [3548-17670] pg/mL vs. patients 1800 [8-
16885] pg/mL, P<0.0001; IL-10: healthy volunteers 293 [120-404] pg/mL vs. patients 
47 [12-366] pg/mL, P<0.0001).
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Figure 1     HRV parameters total spectral power (A), HF normalized units (HFnu, B), and LF/
HF (C) in healthy volunteers and patients. D) TNF-α production in whole blood of  healthy volunteers 
and patients ex vivo stimulated with LPS. Data are represented as box and whiskers (Tukey).  Ex 
vivo stimulation was performed on 4 different days in both healthy volunteers and patients and these data 
were pooled. * indicates p<0.05.
In all healthy volunteers, plasma cytokine levels were below detection limits. In 
patients, plasma IL-6 and IL-10 concentrations were significantly higher on the day 
of  admission and decreased afterwards (Figure 2); this pattern was due to the high 
plasma concentrations in the TRAUMA group on day of  admission as described 
further on in this study. Plasma TNF-α levels were relatively low and did not change 
over time (6 [2-43] pg/mL).   
To investigate the relation between autonomic activity and ex vivo stimulated cytokine 
production or plasma cytokines, we correlated HFnu and LF/HF with these 
inflammatory parameters and found a significant inverse correlation between HFnu 
and ex vivo stimulated TNF-α production (r=-0.22, p=0.025).
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Figure 2     Concentrations of  plasma cytokine IL-6 and IL-10 during the study period in the entire  
patient population. Data are represented as box and whiskers (Tukey). * indicates p<0.05.
Figure 3     TNF-α, IL-6, and IL-10 production in whole blood of  patients and healthy volunteers 
ex vivo stimulated with LPS. Data are represented as box and whiskers (Tukey).  Ex vivo stimulation 
was performed on 4 different days in both patients and healthy volunteers and these data were pooled. * 
indicates p<0.05. Cytokine production in all patient subgroups was significantly lower compared with 
healthy volunteers but, for reasons of  clarity, this is not indicated in the figure.
HRV and inflammatory markers in subgroups of  patients
No differences in HRV parameters between days 0-4 were observed in patients 
in the SAH, ICH, or TRAUMA subgroups. Therefore, HRV data were pooled. 
No significant differences in HRV parameters were found between SAH, ICH, or 
TRAUMA subgroups. Furthermore, no differences in ex vivo stimulated cytokine 
production between days 0-4 were observed within subgroups and data were pooled. 
Ex vivo production of  both pro- (TNF-α and IL-6) and anti-inflammatory (IL-10) 
cytokines in response to LPS stimulation was significantly lower in patients in the 
ICH group compared with the other two groups (Figure 3). Furthermore, stimulated 
IL-10 levels were lower in the TRAUMA group compared with the SAH group. 
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Ex vivo cytokine production in all patient subgroups was significantly lower compared 
with healthy volunteers. The markedly suppressed ex vivo cytokine production in the 
ICH group compared with the other two subgroups could not be explained by large 
differences in immunomodulatory covariates such as anti-inflammatory medication 
or leukocyte counts (Supplementary table 1).
Figure 4     Correlation between HFnu 
and plasma TNF-α in ICH patients. 
For visual purposes, data was log-trans-
formed and Pearson r and p-value is in-
dicated in the graph. Correlation analysis 
on non-log transformed data: Spearman 
r: -0.70, p=0.004.  
Within the TRAUMA group, plasma levels of  IL-6 were significantly higher on day 
0 (146 [83-702] pg/mL) compared with day 2 (48 [13-82] pg/mL, p<0.05). In the 
other two groups, no differences in plasma cytokine levels between days were found. 
Pooling of  the data from the different days revealed significantly higher plasma levels 
of  TNF-α and IL-6 in the TRAUMA group compared with the other two groups 
(TNF-α: TRAUMA 8 [3-15], SAH 4 [2-11], ICH 5 [3-19] pg/mL; IL-6: TRAUMA 83 
[13-702], SAH 26 [2-131], ICH 17 [2-79],  p<0.05). Plasma IL-10 was higher in the 
TRAUMA group compared with the SAH group (TRAUMA: 20 [2-110], SAH: 6 [2-
110] pg/mL, p<0.05). The elevated cytokine levels in the TRAUMA group, especially 
on the day of  admission, were likely due to the trauma insult itself.
We further examined the relation between vagus nerve activity and inflammatory 
parameters in the ICH group, since this group exhibited a greatly suppressed ex 
vivo stimulated cytokine production. Correlation analysis between HFnu and ex vivo 
stimulated cytokine production was not feasible in light of  the very low levels of  
cytokines in the stimulated samples (approximately 50% of  samples were below the 
detection limit). However, we did find a strong inverse correlation between HFnu and 
plasma TNF-α levels, indicating that higher cardiac vagus nerve activity is associated 
with lower plasma TNF-α levels (Figure 4). No such correlations were found in 
the other subgroups, but this could not be explained by large differences between 
subgroups in cardiorespiratory parameters or medications that could influence HRV 
(Supplementary table 1).
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Discussion
In the present study, we report increased HFnu levels, a measure of  cardiac vagus 
nerve activity, in patients with brain damage compared with healthy volunteers. 
Furthermore, these patients exhibited a distinct immune paralysis, reflected by low 
levels of  cytokine production in ex vivo stimulated whole blood. Higher levels of  
HFnu correlated with lower levels of  ex vivo stimulated TNF-α production. The most 
pronounced immune paralysis was found in patients with intracranial hemorrhage, a 
condition associated with high ICP. In these patients, higher levels of  HFnu strongly 
correlated with lower levels of  plasma TNF-α. These observations suggest that brain 
injury, and especially conditions associated with increased ICP, is associated with 
vagus-nerve mediated immune suppression.  
We found markedly lower levels of  overall HRV in our patient population compared 
with healthy volunteers. This is in accordance with previous findings of  various 
investigators showing that brain injury is associated with diminished HRV, and that low 
HRV predicts unfavorable outcome7, 30, 31. The observed decrease in physiological heart 
rate variability indicates the uncoupling of  organ systems generally seen in critically 
ill patients27, 32. Sedatives and analgesics have been shown to contribute to the loss of  
variability33, 34, however, as large decreases in HRV are also found during experimental 
human endotoxemia (LPS administration in healthy volunteers)24, 27, 35, other factors 
must also play a role. Brain injury patients exhibited higher HFnu and lower LF/HF 
ratios compared with healthy volunteers, suggesting a shift in the balance between 
cardiac autonomic activity towards increased vagus nerve signaling. These results are 
in line with previous findings of  parasympathetic predominance in the acute phase 
following SAH11 and severe head injury21. Our findings can not be explained by 
the considerably higher age of  the patient population compared with the healthy 
volunteers, as increased age has been linked to higher LF/HF ratios36.
Ex vivo stimulation of  whole blood with LPS revealed that both pro- and anti-
inflammatory cytokine production was severely impaired in patients compared with 
healthy volunteers. These findings suggest that following brain injury, monocytes (the 
main producers of  the cytokines studied in 24-hour whole blood LPS stimulation 
experiments37) have an reduced capacity to respond to pathogens. Our findings are 
therefore indicative of  a distinct immune paralysis in brain injury patients. To the 
best of  our knowledge, this has never been studied in brain injury patients before. 
A few studies have investigated effects of  severe head injury on T-lymphocytes and 
found decreased T-helper cell activation, attenuated lymphokine-activated killer cell 
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cytotoxicity, and depression of  PHA-induced proinflammatory cytokine production 
(IL-2, IFN-g)38-41. 
In our patient population, we found a significant inverse correlation between cardiac 
vagus nerve activity (reflected by HFnu) and the ex vivo TNF-α production in response 
to LPS. Especially TNF-α production has been shown to be greatly limited by vagus 
nerve stimulation in animal models15, 42. Our findings therefore suggest activation of  
the cholinergic anti-inflammatory pathway, in which increased vagus nerve input to 
the spleen results in ‘education’ of  passing circulating leukocytes to release lower levels 
of  inflammatory cytokines16, 17. Our findings are in line with a recent study in healthy 
volunteers, where significant inverse correlations of  roughly the same magnitude were 
found between HF power and ex vivo LPS-stimulated TNF-α production43. Only one 
study to date has investigated the effects of  electrical vagus nerve stimulation on ex 
vivo cytokine production in humans44. This study in refractory epilepsy patients with 
an implanted vagus nerve stimulator demonstrated a significant reduction in LPS-
stimulated IL-8 production after 6 months of  vagus nerve stimulation. No significant 
effects were observed after 3 weeks of  stimulation, although, interestingly, a trend 
towards lower stimulated TNF-α was present.
Our study was strictly observational, therefore, standard care was not altered for 
study purposes. Unfortunately, ICP was only registered in 2 patients on the day of  
admission. As this was anticipated, we decided prospectively to create subgroups of  
brain injury that are associated with increased and normal ICPs. A significantly more 
pronounced immune suppression was found in the ICH group compared with the 
SAH and TRAUMA groups. This is supportive of  our hypothesis that high ICPs 
result in more pronounced immune suppression. In the ICH group, high ICPs were 
suspected based on the space-occupying lesions that were seen on CT-imaging of  the 
brain, whereas in the TRAUMA group without brain damage, and the SAH group 
in which ICP was alleviated by placement of  extraventricular drains in all but one of  
the patients, intracranial pressure was suspected to be lower. Although HFnu levels 
in the ICH group were not significantly higher compared with the other groups, we 
found a strong inverse correlation between HFnu and plasma TNF-α concentrations, 
indicating anti-inflammatory effects of  increased vagus nerve activity. In accordance, 
correlations between higher vagal HRV parameters and lower plasma levels of  
inflammatory mediators have been found in both healthy volunteers45 and coronary 
heart disease patients46.
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Our study has several limitations. First, HRV only reflects cardiac autonomic activity. 
At present, it is unclear whether cardiac vagus nerve activity reflects vagal input to 
other organs that are important in the immune response, e.g. the spleen. Animal and 
human studies have established that the output of  the sympathetic nervous system 
is highly differentiated47-49. No such investigations on the parasympathetic nervous 
system are known to us, but it appears plausible that differentiated output to organs 
does exist. Unfortunately, besides HRV, no techniques to measure vagus nerve activity 
are currently available in humans. Second, the effects of  ICP on vagus nerve activity 
and the immune response could not be properly assessed in this study, because ICP 
probes were placed in only 2 of  our patients. Third, the question remains whether our 
findings in circulating monocytes can be extrapolated to tissue-resident macrophages, 
which are the predominant cells involved in the initial innate immune response against 
invading pathogens. We have recently shown that after administration of  LPS to healthy 
volunteers, ex vivo hyporesponsiveness to LPS, reflecting the monocyte compartment, 
is present in the acute phase but quickly wanes50. However, in vivo hyporesponsiveness 
to LPS, reflecting the tissue-resident macrophage compartment, persists for several 
weeks50. In this respect, ex vivo hyporesponsiveness might even underestimate the 
capacity of  tissue-resident macrophages to respond to inflammatory stimuli. Finally, 
another contributor to the observed low HRV in our patient population may be 
the considerably higher age of  the patient population compared with the healthy 
volunteers, as increasing age is associated with a decreased HRV36, 51.
In conclusion, in brain injury patients, higher vagus nerve activity is associated with 
attenuated ex vivo LPS-stimulated monocytic TNF-α production. Furthermore, in 
ICH patients, associated with high ICPs, a pronounced ex vivo immune paralysis was 
observed. In addition, in these patients, higher vagus nerve activity was also associated 
with lower levels of  circulating plasma TNF-α. These findings are suggestive of  
effects of  the cholinergic anti-inflammatory pathway and might contribute to the 
immune paralysis in brain injury patients.
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Supplementary material
Supplementary table 1     Physiological parameters and relevant medications 
Data are presented as median (range). SAH: subarachnoid hemorrhage, ICH: intracranial hemorrhage. 
The miscellaneous group consisted of  multi-trauma patients with neurological damage (n=3), Cardio-
pulmonary resuscitation (n=5), transverse myelitis (n=2), cerebellar infarction (n=1,) and intoxication 
(n=1). 
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Abstract
Background The autonomic nervous system (ANS) and the inflammatory 
response are intimately linked. Heart rate variability (HRV) analysis is a widely used 
method to assess cardiac ANS activity, and changes in HRV indices may correlate 
with inflammatory markers. Here, we investigated whether baseline HRV predicts 
the acute inflammatory response to endotoxin. Second, we investigated whether the 
magnitude of  the inflammatory response correlated with HRV alterations.
Methods Forty healthy volunteers received a single intravenous bolus of  2 
ng/kg endotoxin (LPS, derived from E coli O:113). Of  these, 12 healthy volunteers 
were administered LPS again two weeks later. HRV was determined at baseline 
(just prior to LPS administration) and hourly thereafter until 8 hours after LPS 
administration. Plasma cytokine levels were determined at various time points.
Results  Baseline HRV indices did not correlate with the magnitude of  the 
LPS-induced inflammatory response. Despite large alterations in HRV after LPS 
administration, the extent of  the inflammatory response did not correlate with 
the magnitude of  HRV changes. In subjects who were administered LPS twice, 
inflammatory cytokines were markedly attenuated after the second LPS administration, 
whereas LPS-induced HRV alterations were similar.
Conclusions HRV indices do not predict the acute inflammatory response in 
a standardized model of  systemic inflammation. Although the acute inflammatory 
response results in HRV changes, no correlations with inflammatory cytokines were 
observed. Therefore, the magnitude of  endotoxemia-related HRV changes does not 
reflect the extent of  the inflammatory response.
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Introduction
The autonomic nervous system (ANS) and the inflammatory response are intimately 
linked. The sympathetic nervous system can attenuate the systemic inflammatory 
response via activation of  β2-adrenoceptors1-3, but can also enhance the inflammatory 
response locally via stimulation of  α2-adrenoceptors4, 5. The parasympathetic nervous 
system, through the afferent vagus nerve can sense inflammation in the periphery 
and relay this information to the brain, resulting in fever generation and activation 
of  the hypothalamic-pituitary-adrenal axis which in turn leads to cortisol release and 
stimulation of  the sympathetic nervous system6, 7. Furthermore, electrical stimulation 
of   the efferent vagus nerve greatly attenuates the inflammatory response in animal 
models8. These findings indicate that there is considerable crosstalk between the ANS 
and the inflammatory response and that the two branches of  the ANS can modulate 
the inflammatory response.
The ANS innervates virtually every organ in the body. However, outflow of  a 
particular branch of  the ANS might be organ-specific. Heart rate variability (HRV) 
analysis is the only noninvasive tool available in humans to monitor activity of  both 
branches of  the ANS9, but assesses only ANS innervation of  the heart. HRV indices 
(both time and frequency domains) and their physiological correlates10-13 are listed in 
Table 1.  
Decreased HRV is associated with pathological conditions. In systemically inflamed 
critically ill patients, such as in sepsis, HRV is completely diminished14-17 and inversely 
correlated with disease severity15, 16, and reduced HRV is a predictor of  multiorgan 
dysfunction syndrome and death18, 19. These findings suggest that HRV alterations 
may reflect the magnitude of  the inflammatory response. 
In this study, we investigated the interplay between the acute inflammatory response 
to endotoxin and cardiac ANS activity, measured by HRV. We used the experimental 
human endotoxemia model, a well-characterized, standardized model of  systemic 
inflammation widely used to study the acute inflammatory response20. This model 
is not hampered by confounding factors such as sedatives, inotropes, and pressors 
often present in the clinical situation. It therefore provides readily interpretable data 
regarding the interplay between the acute inflammatory response and HRV. Because 
ANS-inflammatory interactions are bidirectional, we determined the relation between 
baseline HRV indices and the inflammatory response as well as the relation between 
the magnitude of  the inflammatory response and HRV alterations.
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Table 1     HRV indices definitions and physiological correlates 
ms: milliseconds. AU: arbitrary units. VLF: very low frequency power.
Materials and methods
Subjects
HRV was measured in a total of  40 healthy young male nonsmoking volunteers 
participating in two human endotoxemia studies. Data of  28 subjects were obtained 
from a study (Clinical Trial Register number NCT00513110) where LPS (endotoxin) 
was administered once; the other 12 subjects participated in a human endotoxemia 
study (Clinical Trial Register number NCT00783068) in which they received LPS 
twice (LPS visits 1 & 2) with a mean interval of  14 days (range, 11-18 days). The 
study protocols were approved by the Ethics Committee of  the Radboud University 
Nijmegen Medical Centre and comply with the Declaration of  Helsinki including 
current revisions and the Good Clinical Practice guidelines. Written informed consent 
was obtained from all study participants. The findings of  the physical examinations, 
electrocardiography, and routine laboratory studies on all the volunteers before 
the start of  the experiment showed normal results. Volunteers were not taking any 
prescription medications, and they were negative for hepatitis B surface antigen and 
HIV infection. 
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Human endotoxemia model
Subjects refrained from food 12 hours before the start of  the experiment, and caffeine- 
or alcohol-containing substances 24 hours before the start of  the experiment. The 
experiments were performed at the research unit of  the intensive care department, 
with subjects in supine position. After administration of  local anesthesia (lidocaine 
HCl 20 mg/mL) the radial artery was cannulated using a 20 Gauge arterial catheter 
(Angiocath, Becton Dickinson, Sandy, Utah) and connected to an arterial pressure 
monitoring set (Edwards Lifesciences LLC, Irvine, CA, USA), connected to a Phillips 
IntelliVue MP70 monitor (Philips Medical Systems, Eindhoven, The Netherlands). 
A cannula was placed in the antecubital vein to permit infusion of  2.5% glucose/ 
0.45% saline solution; subjects received a bolus of  1.5 L during one hour before LPS 
infusion (prehydration), followed by 150 ml/h until 6 hours after LPS infusion and 75 
ml/h until the end of  the experiment. U.S. Reference Escherichia coli endotoxin (LPS 
derived from E. coli O:113; Clinical Center Reference Endotoxin, National Institute 
of  Health, Bethesda, MD, USA) was used. Ec-5 endotoxin, supplied as a lyophilized 
powder, was reconstituted in 5 ml saline 0.9% for injection and vortex-mixed for at 
least 10 minutes after reconstitution. The endotoxin solution was administered as an 
intravenous bolus injection at a dose of  2 ng/kg of  body weight. Vital signs, including 
heart rate (HR) and mean arterial pressure (MAP) were monitored continuously 
throughout the study protocol. 
HRV measurements
HRV was measured hourly by 5-min recordings starting just before LPS administration 
(T=0 or baseline) up to 8 hours after LPS administration. HRV was measured in 
supine position and during quiet circumstances. A 3-lead electrocardiogram signal 
was obtained using a Medilog AR12 recorder (Huntleigh Healthcare, Cardiff, UK). 
R-peak position was determined at a sample rate of  4096 Hz. HRV was analyzed 
using dedicated software (Medilog Darwin HRV, Huntleigh Healthcare, Cardiff, UK). 
In each 5-min recording, QRS complexes were detected, and only normal-to-normal 
beat (NN) intervals were tabulated, yielding an interval tachogram. Recordings with 
artifacts such as premature (supra)ventricular beats or other arrhythmias comprising 
more than 5% of  the total epoch were discarded. After linear detrending, power 
spectral density was determined by fast Fourier transformation of  interval tachograms 
using the Welch method and a fast Fourier transformation width of  1024. Very-low-
frequency (VLF) power (0.0033-0.04 Hz) can not be reliably obtained from 5-min 
recordings and was therefore not analyzed11.  
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Cytokine measurements 
EDTA anticoagulated blood was collected from the arterial line and immediately 
centrifuged at 2000g for 10 minutes at 4 oC. Concentrations of  TNF-α, IL-6, IL-10, 
and IL-1RA in plasma were measured using a simultaneous Luminex Assay according 
to the manufacturer’s instructions (Bio-plex cytokine assay, Bio-Rad, Hercules, CA, 
USA). Samples from both LPS visits of  the 12 subjects who received LPS twice were 
analyzed on the same day.
Calculations and statistical analysis
Based on distribution (calculated by the Shapiro-Wilk test), data are represented as 
medians or means as indicated. Non-normally distributed HRV indices and cytokine 
values were successfully log transformed. Statistical tests used are indicated in the 
figure legends. A p-value <0.05 was considered significant. Statistical analysis was 
performed using SPSS 16.0 (SPSS, Chicago, IL, USA) and Graphpad Prism 5 
(Graphpad software, San Diego, CA, USA).
Results
Correlation between baseline HRV and the LPS-induced cytokine response
LPS administration resulted in a typical transient inflammatory cytokine response, 
decreased MAP and increased HR (Figure 1). We did not find any significant 
correlations between basal HRV indices and the Area Under Curve (AUC; all 
correlations listed in Table 2; most relevant indices shown in Figure 2) or peak levels 
(Supplementary Table 1) of  any of  the cytokines measured.
Correlation between the LPS-induced cytokine response and HRV alterations
LPS administration resulted in characteristic HRV alterations (SDNN, LF/HF, 
LFnu, and HFnu depicted in Figure 3; other indices are shown in Supplementary 
Figure 1),  similar to earlier reports2, 10, 21, 22. To determine whether the magnitude 
of  the inflammatory response was correlated with the magnitude of  changes in 
HRV indices, we correlated peak and AUC cytokine levels with maximum/minimum 
levels of  HRV after LPS administration. No significant correlations were found 
(Supplementary Table 2&3). Furthermore, we correlated the peak and AUC cytokines 
to the increase or decrease in HRV indices (represented as slope of  increase/decrease 
calculated between baseline and time of  maximum/minimum value). Apart from one 
weak correlation between IL-1RA and the decrease in LF power, the magnitude of  
the cytokine response (AUC) did not correlate to changes in HRV indices as well 
(Table 3); this was also true when peak cytokine levels were used for the calculations 
(Supplementary Table 4). 
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Figure 1
Plasma concentrations of  cyto-
kines (TNF-α, IL-6, IL-10 
and IL-RA), mean arterial 
pressure (MAP) and heart rate 
(HR) during human endotox-
emia. Data are expressed as me-
dian ± interquartile range (cyto-
kines) or mean ± SEM (MAP 
& HR) of  40 subjects. p-value 
was calculated by Friedman test 
(cytokines) or one-way ANOVA 
(MAP & HR). 
Table 2     Correlations between baseline HRV indices and the LPS-induced cytokine response 
Baseline HRV indices were calculated at t=0, just prior to LPS administration. Cytokine response is 
defined as the Area Under Curve (expressed in pg/mL.hr) of  plasma cytokine concentrations over time. 
ms indicates milliseconds. AU indicates arbitrary units. n=40 subjects. p-values are not reported because 
none of  the listed correlations were statistically significant. 
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Figure 2     Scatterplots of  the association between basal HRV indices (calculated at t=0, just prior 
to LPS administration) and the Area Under Curve of  the LPS-induced proinflammatory cytokine 
response (TNF-α and IL-6, expressed in pg/mL.hr) of  40 subjects. ms indicates milliseconds; AU 
indicates arbitrary units. Solid and dashed lines represent TNF-α and IL-6 regression lines, respectively. 
Pearson correlation coefficients (none statistically significant) are indicated in the plots.
Figure 3
HRV indices during human endo-
toxemia. Data are expressed as mean 
± SEM of  40 subjects. ms indicates
 milliseconds; AU indicates arbitrary 
units. p-values were calculated by one-
way ANOVA. 
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Table 3     Correlations between LPS-induced cytokine response and alterations in HRV indices.
Cytokine response is defined as the Area Under Curve (expressed in pg/mL.hr) of  plasma cytokine 
concentrations over time. LPS-induced HRV alterations were defined as the slope of  increase/decrease of  
the interval between baseline (t=0, just prior to LPS administration) and the LPS-induced maximum/
minimum value. LPS administration resulted in a decrease in SDNN, r-MSSD, pNN50%, LF, HF, 
total (minimum values at t=4) and HFnu (minimum value at t=3). LPS administration resulted in 
an increase in LF/HF and LFnu (maximum values at t=3). ms indicates milliseconds. AU indicates 
arbitrary units. n=40 subjects. * indicates p=0.045.
LPS-induced HRV alterations in subjects who received LPS twice
The lack of  correlation between the magnitude of  the inflammatory response and 
HRV alterations was strengthened by HRV data obtained from subjects who received 
LPS twice with an interval of  approximately two weeks. During the second visit, 
median peak levels of  TNF-α, IL-6, IL-10 and IL-1RA were 43% (p=0.0024), 41% 
(p=0.0024), 54% (p=0.0038) and 8% (p=0.11) lower compared with the first visit 
3(Figure 4, upper left panel) due to the development of  endotoxin tolerance23. This 
phenomenon allowed us to investigate the relation between the inflammatory response 
and HRV within the same subjects. Despite the remarkably attenuated inflammatory 
response, LPS-induced HRV alterations were not different between both visits. The 
time-courses of  SDNN, LFnu, and HFnu during both endotoxemia visits are shown 
in Figure 4. Other changes in HRV indices were equally similar between both visits 
(Supplementary Figure 2).
82
Chapter 4
Figure 4     Peak cytokine levels (upper left panel) and HRV indices (other panels) during human en-
dotoxemia of  subjects who received LPS on two separate occasions (visit 1 and visit 2) with an interval of  
approximately two weeks. Cytokine data are expressed as box and whiskers (whiskers indicating range), 
HRV indices are expressed as mean ± SEM. n= 12 subjects. ms indicates milliseconds; AU indicates 
arbitrary units. p-values of  peak cytokine levels were calculated by Mann Whitney U test. p-values of  
HRV indices were calculated by two-way ANOVA (interaction term). * indicates p<0.05.
Discussion
In the present study, we investigated the interplay between the LPS-induced acute 
inflammatory response and ANS outflow to the heart, determined by HRV in a large 
group of  healthy male subjects who participated in human endotoxemia experiments. 
We did not find any correlations between basal HRV indices and the inflammatory 
response or between the magnitude of  the inflammatory response and HRV 
alterations. 
We first set out to investigate the relation between baseline HRV and the inflammatory 
response. None of  the baseline HRV indices, determined before LPS administration, 
correlated with the magnitude of  the LPS-induced inflammatory response in our 
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study. In contrast, weak (r-values of  0.4 to 0.43) but significant correlations between 
baseline HRV indices and the LPS-induced inflammatory response were recently 
reported using a similar experimental protocol, resulting in HRV changes identical 
to our study22. In our study, all indices of  HRV except LFnu, HFnu, and pNN50 
displayed a markedly skewed distribution, as did the peak and AUC cytokine levels. 
This is consistent with other HRV studies24-27. Therefore, we log transformed the 
skewed variables, which probably explains the contrasting conclusions between the 
two studies. In addition, considering the well-established anti-inflammatory effects 
of  vagus nerve stimulation8, 28, 29, there is no plausible mechanism to explain why 
the reported higher levels of  vagal HRV indices are correlated with elevated TNF-α 
levels22. Especially TNF-α has been extensively studied in the context of  the cholinergic 
anti-inflammatory pathway and is greatly reduced by vagus nerve stimulation or 
cholinergic agonists in animals and in vitro8, 29-33. The results from our prospective 
study in a relatively large group using a standardized model of  inflammation suggest 
that there is no relation between basal cardiac ANS activity and the inflammatory 
response. A possible explanation is that vagus nerve innervation of  the heart does 
not reflect outflow to other organs that play an important role in the inflammatory 
response. For example, a key effector organ of  the cholinergic anti-inflammatory 
pathway is the spleen, one of  the major cytokine-producing organs34, 35. As basal vagal 
input to the spleen may be different from vagal input to the heart, HRV might not 
be an appropriate method to assess activation of  the cholinergic anti-inflammatory 
pathway. However, because no other measures of  ANS activity were determined in 
this study, we can not provide a definitive answer to this question. Moreover, although 
we did not find correlations between HRV and plasma cytokines, it is conceivable that 
cardiac ANS activity is related to other measures of  inflammation, such as immune 
cell subsets.
To further characterize the interplay between the inflammatory response and HRV, 
we examined the effects of  inflammation on cardiac ANS outflow by correlating the 
magnitude of  the LPS-induced inflammatory response to the magnitude of  HRV 
alterations. Again, we could not demonstrate a relation between these parameters. The 
most compelling evidence for a lack of  this relation was observed in subjects who 
received LPS on two occasions with an interval of  two weeks. Whereas inflammatory 
cytokine levels were roughly halved during the second LPS administration due to the 
development of  LPS tolerance, changes in HRV were identical to the first endotoxemia 
experiment, indicating that although the HRV alterations are associated with systemic 
inflammation, the magnitude of  their change is not a measure of  the extent of  the 
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inflammatory response. Our findings are corroborated by a recent human endotoxemia 
study investigating the effects of  hydrocortisone on the inflammatory response21. 
Hydrocortisone treatment greatly reduced LPS-induced inflammatory cytokine levels, 
but did not influence the LPS-induced decrease in HRV. To our knowledge there 
is only one human study demonstrating effects of  immunomodulation on HRV. In 
this study, epinephrine attenuated the inflammatory response associated with further 
reduced vagal HRV indices after LPS administration2. This is likely due to epinephrine’s 
sympathomimetic properties rather than through an immunomodulatory effect, 
especially because attenuation of  the inflammatory response is anticipated to result in 
less reduction of  HRV indices. Taken together, these findings indicate that changes 
in cardiac ANS outflow determined by HRV alterations do not reflect the magnitude 
of  the inflammatory response in a controlled model of  systemic inflammation, 
which is not confounded by factors such as sedatives, inotropes, and pressors often 
present in the clinical situation. In contrast, in septic patients, rather strong inverse 
correlations between log IL-6 levels and log LF (r=-0.76) and log HF  (r=-0.53) power 
were found, suggesting that HRV does reflect the extent of  inflammation in these 
patients36. Possibly other inflammation-associated factors that are not induced during 
the milder human endotoxemia model account for the observed changes in HRV in 
septic patients, but at present, this discrepancy cannot be explained. 
With regard to the validity of  our data, the LPS-induced changes in HRV observed 
in our study are analogous to those observed in similar human endotoxemia 
experiments2, 10, 21, 22. All ‘raw’ time-domain and frequency-domain indices were 
severely depressed after LPS administration, with minimum values observed at 4 hours 
post-LPS. In this dynamic setting (where total power gradually decreases in time), 
normalized HRV indices and the LF/HF ratio probably provide more meaningful 
information about the relative contributions of  the two branches of  the ANS11. 
Both LFnu and LF/HF are regarded to reflect sympathetic activity while HFnu 
corresponds to parasympathetic activity10, 11. After LPS administration, both LFnu 
and LF/HF increased; by analogy, HFnu decreased. These findings indicate that LPS 
administration results in cardiac sympathetic predominance, probably as a result of  
the stress-response induced by LPS administration. In accordance, increased levels of  
the stress-hormone cortisol and catecholamines have been reported during human 
endotoxemia21, 37, 38 and interestingly, peak levels of  cortisol and epinephrine were 
observed at 3-4 hours after LPS administration, coinciding with maximum/minimum 
levels of  HRV indices21, 37, 38. Future studies are warranted to evaluate the relationship 
between cortisol/catecholamines and HRV after LPS administration. As opposed to 
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the cardiac sympathetic predominance, muscle sympathetic nerve activity (measured 
in the peroneal nerve) was found to be suppressed after LPS administration37. These 
findings strengthen the notion that autonomic outflow can not be regarded as a 
general response, but appears to be organ-specific.
In conclusion, we demonstrate that there is no relation between HRV and the 
inflammatory response and vice versa in a standardized model of  systemic 
inflammation. This suggests that cardiac ANS activity may not be representative for 
ANS outflow to other organs involved in the inflammatory response and indicates 
that changes in HRV are not a reliable surrogate measure for the extent of  the 
inflammatory response. 
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Supplementary material
Supplementary table 1      Correlations between baseline HRV indices and the LPS-induced peak 
cytokine levels.
Baseline HRV indices were calculated at t=0, just prior to LPS administration. ms indicates millisec-
onds. AU indicates arbitrary units. n=40 subjects. p-values are not reported because none of  the listed 
correlations were statistically significant. 
Supplementary figure 1      HRV indices during human endotoxemia. Data are expressed as 
mean ± SEM of  40 subjects. ms indicates milliseconds. p-values were calculated by one-way ANOVA.
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Supplementary table 2     Correlations between LPS-induced peak cytokine levels and LPS-
induced maximum/minimum levels of  HRV indices.
LPS administration resulted in a decrease in SDNN, r-MSSD, pNN50%, LF, HF, total (mini-
mum values at t=4) and HFnu (minimum value at t=3). LPS administration resulted in an increase 
in LF/HF and LFnu (maximum values at t=3). ms indicates milliseconds. AU indicates arbitrary 
units. n=40 subjects. p-values are not reported because none of  the listed correlations were statistically 
significant.
Supplementary table 3     Correlations between LPS-induced cytokine response and LPS-induced 
maximum/minimum levels of  HRV indices.
Cytokine response is defined as the Area Under Curve (expressed in pg/mL.hr) of  plasma cytokine 
concentrations over time. LPS administration resulted in a decrease in SDNN, r-MSSD, pNN50%, 
LF, HF, total (minimum values at t=4) and HFnu (minimum value at t=3). LPS administration 
resulted in an increase in LF/HF and LFnu (maximum values at t=3). ms indicates milliseconds. AU 
indicates arbitrary units. n=40 subjects. p-values are not reported because none of  the listed correlations 
were statistically significant.
91
Interplay between the acute inflammatory response and HRV in healthy human volunteers
4
Supplementary table 4       Correlations between LPS-induced peak cytokine levels and alterations 
in HRV indices.
LPS-induced HRV alterations were defined as the slope of  increase/decrease of  the interval between 
baseline (t=0, just prior to LPS administration) and the LPS-induced maximum/minimum value. LPS 
administration resulted in a decrease in SDNN, r-MSSD, pNN50%, LF, HF, total (minimum values 
at t=4) and HFnu (minimum value at t=3). LPS administration resulted in an increase in LF/HF 
and LFnu (maximum values at t=3). ms indicates milliseconds. AU indicates arbitrary units. n=40 
subjects. * indicates p=0.036.
Supplementary figure 2     HRV indices during human endotoxemia of  subjects who received LPS 
on two separate occasions (visit 1 and visit 2) with an interval of  approximately two weeks. Data are 
expressed as mean ± SEM. n= 12 subjects. ms indicates milliseconds; AU indicates arbitrary units. 
p-values were calculated by two-way ANOVA (interaction term).
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Part two
Limiting the innate immune response through the 
cholinergic anti-inflammatory pathway; in vitro, animal, and 
human studies
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Abstract
Background Pulmonary inflammation contributes to ventilator-induced lung 
injury (VILI). Sepsis-induced pulmonary inflammation (first hit) may be potentiated 
by mechanical ventilation (MV, second hit). Electrical stimulation of  the vagus nerve 
has been shown to attenuate inflammation in various animal models through the 
cholinergic anti-inflammatory pathway. We determined the effects of  vagotomy 
(VGX) and vagus nerve stimulation (VNS) in a two-hit VILI model.    
Methods Male Sprague-Dawley rats were i.v. administered lipopolysaccharide 
(LPS) and subsequently underwent VGX, VNS, or a sham operation. 1 hour following 
LPS, MV with low (8 mL/kg) or moderate (15 mL/kg) tidal volumes was initiated, or 
animals were left breathing spontaneously (SP). After 4 hours of  MV or SP, rats were 
sacrificed. Cytokine and blood gas analysis was performed. 
Results  MV with 15, but not 8 mL/kg, potentiated the LPS-induced 
pulmonary proinflammatory cytokine response (TNF-α, IL-6, KC: p<0.05 compared 
with LPS-SP), but did not impair oxygenation. VGX enhanced the LPS-induced 
pulmonary proinflammatory cytokine response in spontaneously breathing, but not 
in MV animals (TNF-α, IL-6, KC: p<0.05 compared with sham-operated animals) 
and resulted in decreased pO2 (p<0.05 compared with sham-operated animals). VNS 
did not affect any of  the studied parameters in both SP and MV animals.  
Conclusions MV with moderate tidal volumes potentiates the pulmonary 
inflammatory response elicited by systemic LPS administration. No beneficial effects 
of  vagus nerve stimulation performed following LPS administration were found. 
These results questions the clinical applicability of  stimulation of  the cholinergic anti-
inflammatory pathway in systemically inflamed patients admitted to the ICU where 
MV is initiated. 
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Introduction
Patients with severe sepsis and septic shock often suffer from respiratory failure, 
placing them in need of  mechanical ventilation (MV). While this intervention is 
lifesaving, MV can lead to, or worsen lung injury; a condition called ventilator-induced 
lung injury (VILI)1. MV-induced cyclic stretch and/or overinflation elicits a pulmonary 
inflammatory response (biotrauma) characterized by cytokine production, neutrophil 
recruitment, and lung edema, resulting in impaired lung function2, 3. Patients with 
systemic inflammation, such as in sepsis, are at increased risk for developing VILI4. 
It is thought that the additional inflammatory insult, or second ‘hit’ induced by MV, 
synergizes with the underlying systemic inflammatory process, resulting in detrimental 
effects on the lungs and other organs (multiple-hit theory)5, 6. This cascade of  events 
can ultimately lead to multiple organ dysfunction syndrome (MODS), associated with 
high mortality7. In clinical practice, treatment aimed to limit the initial overwhelming 
systemic proinflammatory state in sepsis has not proved very successful8. However, 
limiting the second inflammatory hit caused by MV may represent a viable therapy 
to reduce lung injury and subsequent multi-organ failure in systemically inflamed 
patients.
Recently, it was demonstrated that the vagus nerve can reflexively limit the innate 
immune response via binding of  its neurotransmitter acetylcholine to the α7 nicotinic 
acetylcholine receptor (α7nAChR) present on macrophages9, 10. This mechanism was 
named the cholinergic anti-inflammatory pathway. Electrical stimulation of  the vagus 
nerve has shown to attenuate inflammation and improve outcome in several animals 
models11-13. However, this pathway has been relatively sparsely studied in VILI. We 
have recently shown that pre-treatment with the selective α7nAChR agonist GTS-21 
ameliorates VILI in mice14. In addition, a very recent investigation demonstrated that 
electrical vagus nerve stimulation attenuates VILI in a two-hit model (haemorrhagic 
shock followed by MV), whereas transection of  the vagus nerve (vagotomy) resulted in 
worse outcome15. However, in these studies, stimulation or ablation of  the cholinergic 
anti-inflammatory pathway was performed before the initial insult14, or twice, before 
the first and second insult15, thereby limiting its clinical applicability.  
In the present study we investigated the effects of  vagus nerve stimulation and 
vagotomy on inflammation and lung injury using a two-hit model of  VILI in rats. 
We used lipopolysaccharide (LPS) administration as the first hit, and MV using 
low and moderate tidal volumes to model the sepsis patient that is admitted to the 
ICU, in a hyperinflammatory state, where MV is initiated. As mitigating the initial 
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proinflammatory hit is often not possible in daily practice, we applied vagus nerve 
stimulation or vagotomy after LPS administration and before the start of  mechanical 
ventilation. 
Materials and methods
Reagents
Lipopolysaccharide (LPS, derived from E. coli, serotype 0111:B4) was obtained from 
Sigma-Aldrich (St Louis, MO, USA) and was dissolved in 0.9% NaCl. The LPS 
solution was sonicated for a minimum of  30 minutes prior to use. Alfaxalone was 
purchased from Vétoquinol (Buckingham, UK).
Animals 
All procedures described were in accordance with the requirements of  the Dutch 
Experiments on Animals Act, the EC Directive 86/609 and approved by the Animal 
Ethics Committee of  the Radboud University Nijmegen Medical Center. Male 
Sprague-Dawley rats (Charles River, Sutzfield, Germany) weighing 300-450 gram 
were used in all experiments.  
Experimental protocol
The tail vein was cannulated for anaesthesia induction and maintenance. Anaesthesia 
was induced by infusion of  alfaxalone (15 mg/kg) and maintained by continuous 
infusion of  33 mg/kg/hour alfaxalone throughout the experiment. The right femoral 
artery was cannulated to allow continuous blood pressure monitoring, Ringer’s lactate 
administration (5 mL/kg/hour, containing 4 IE/mL heparin) and blood sampling. 
LPS (10 mg/kg) or placebo (0.9% NaCl) was administered via the tail vein (time 
point T=-1). Next, a cervical midline incision was made and the left vagus nerve was 
exposed. In sham-animals (SHAM), the wound was covered with moist gauze for 10 
minutes. In vagus nerve stimulation animals (VNS), the vagus nerve was prepared 
free from the carotid artery and, without transecting the nerve, placed on a bipolar 
platinum electrode (Plastics One, Roanoke, VA, USA) connected to a Grass S88 
stimulator with a SIU5 stimulus isolation unit. The nerve was stimulated for 3 minutes 
at 5 V, 5 Hz, 2 ms16, 17. In vagotomy animals (VGX), both the left and right vagus 
nerves were transected (bilateral vagotomy). Subsequently, rats were tracheotomized 
and a tracheal cannula was inserted and fixed with ligatures. Animals were left 
spontaneously breathing using a nose cone supplying air with an FiO2 of  40% until 
1 hour after LPS/placebo administration, when mechanical ventilation (MV) was 
started (T=0). Animals were ventilated using a Ugo Basile UB7025 ventilator (Hugo 
Sachs Elektronik-Harvard Apparatus, March-Hugstetten, Germany). Ventilation 
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parameters: tidal volume 8 or 15 mL/kg, frequency 75 (8 mL/kg) or 40 (15 mL/kg) 
breaths/min, PEEP 1 cmH2O, FiO2 40%. Spontaneously breathing (SP) animals were 
not connected to the ventilator, but continued breathing air with an FiO2 of  40% 
using the nose cone. Rectal temperature was monitored throughout the experiment 
and was kept between 36.5° C and 37.5° C using a heating pad and blankets. All 
animals were sacrificed by exsanguination after 4 hours of  mechanical ventilation/
spontaneous breathing (T=4). The experimental protocol is illustrated in Figure 1.
Figure 1     Experimental procedures
Blood gas and cytokine measurements
Blood gas parameters pH, pO2, pCO2, BE, HCO3, and lactate were determined with 
an i-STAT Blood Gas Analyzer (Abbot, Hoofddorp, The Netherlands). EDTA 
anticoagulated blood was centrifuged for 5 minutes at 14000 rpm and plasma was 
stored at -80° C until analysis by simultaneous Luminex assay (Milliplex, Billerica, MA, 
USA), according to the manufacturer’s instructions. Immediately after exsanguination, 
the lungs were carefully removed. The upper part of  the left lung was snap-frozen in 
liquid nitrogen and stored at -80° C until analysis. Lungs were homogenized in T-PER 
(Thermo Fisher scientific, Rockford, IL, USA) supplemented with  protease inhibitor 
(complete EDTA-free tablets, Roche, Woerden, The Netherlands) in M-Tubes using 
a GentleMACS dissociater (protein_01 program, Miltenyi Biotec, Utrecht, The 
Netherlands). M-tubes with homogenates were centrifuged (4000g, 5 min, 4 oC), after 
which the supernatant was transferred to an eppendorf  tube and centrifuged again 
(14000g, 10 min, 4 oC). Cytokines in supernatants were measured by ELISA (Duoset, 
R&D systems, Minneapolis, MN, USA) according to the manufacturer’s instructions.
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Calculations and statistical analysis
Data are expressed as mean±SEM. The Grubbs test (extreme studentized deviate 
method) was performed and significant outliers were excluded from analysis 
(maximum of  one exclusion per dataset). Statistical differences between groups were 
detected by one-way ANOVA with Bonferroni post-hoc test. A p-value less than 0.05 
was considered statistically significant. All tests were performed with Graphpad Prism 
5 (Graphpad Software, La Jolla, USA). 
Results
MV with 8 mL/kg does not elicit a pulmonary inflammatory response or amplify the LPS-induced 
inflammatory response
Compared with spontaneously breathing animals, MV with a tidal volume of  8 mL/
kg did not result in an increase in pulmonary levels of  the proinflammatory cytokine 
TNF-α or the anti-inflammatory cytokine IL-10 (Figure 2). LPS administration in 
spontaneously breathing animals significantly increased pulmonary cytokine levels. 
However, MV did not enhance the LPS–induced cytokine response (Figure 2). A 
similar pattern was observed for other proinflammatory cytokines (IL-6 and KC, data 
not shown). 
Figure 2     Pulmonary concentrations of  pro-(A: TNF-α) and anti-inflammatory (B: IL-10) cy-
tokines in placebo- and LPS-treated spontaneously breathing and mechanically ventilated (MV) rats. 
Pulmonary cytokine levels are normalized to the total amount of  protein in each lung homogenate. Data 
are represented as mean ± SEM of  8-9 animals per group. * indicates p<0.05, one-way ANOVA 
with Bonferroni post-hoc test.
MV did not result in increased levels of  plasma cytokines (Figure 3). As expected, 
LPS administration resulted in high plasma cytokine levels, however, similar to the 
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lung data, MV did not further increase or sustain cytokine levels. Again, this pattern 
was similar for IL-6 and KC (data not shown). 
Figure 3      Plasma concentrations of  pro-(A: TNF-α) and anti-inflammatory (B: IL-10) cytokines 
in placebo- and LPS-treated spontaneously breathing (SP) and mechanically ventilated (MV) rats. Data 
are represented as mean ± SEM of  8-9 animals per group. * indicates p<0.05 between placebo- and 
LPS-treated groups (one-way ANOVA with Bonferroni post-hoc test). There were no differences between 
the placebo-SP and placebo-MV or the LPS-SP and LPS-MV groups.
In placebo-treated animals, MV resulted in increased pH and decreased pCO2 
compared with spontaneously breathing animals (Table 1). LPS administration 
resulted in significantly lower arterial blood pressure compared with placebo in both 
spontaneously breathing and MV animals. Furthermore, the increase in pH observed 
upon ventilation in placebo-treated animals was not present in LPS-treated animals. 
In spontaneously breathing rats, LPS administration resulted in lower pCO2 levels 
compared with placebo, probably as a result of  inflammation-induced hyperventilation. 
No differences in oxygenation were observed between any of  the groups.
MV with 15 mL/kg does not elicit an inflammatory response, but amplifies the LPS-induced 
pulmonary inflammatory response
Similar to MV with 8 mL/kg, MV with a tidal volume of  15 mL/kg did not result in 
pulmonary cytokine production (TNF-α shown in Figure 4A). LPS administration in 
spontaneously breathing animals significantly increased pulmonary cytokine levels, 
and MV significantly enhanced LPS–induced proinflammatory (TNF-α, IL-6, and KC; 
TNF-α shown in Figure 4A), but not anti-inflammatory (IL-10) pulmonary cytokine 
levels. MV with 15 mL/kg did not result in increased plasma cytokine levels (data not 
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shown). Similar to the data presented in Figure 3, LPS administration resulted in high 
plasma cytokine levels, however, MV did not affect plasma cytokine levels (data not 
shown).
Table 1     Cardiorespiratory parameters in placebo and LPS-treated (10 mg/kg) rats ventilated with 
8 ml/kg or left breathing spontaneously. 
LPS/placebo administered at T=-1, MV started at T=0. Data are represented as mean ± SEM of  
8-9 animals per group. * indicates p<0.05, one-way ANOVA with Bonferroni post-hoc test.
At T=0 and T=2 (1 and 3 hours post-administration), both spontaneously breathing 
and ventilated rats treated with LPS displayed a significantly lower blood pressure 
compared with placebo-treated ventilated animals (Table 2). At T=4, blood pressure 
was restored in LPS-treated spontaneously breathing rats, but still significantly 
decreased in LPS-MV rats. pH was significantly lower and pCO2 significantly higher in 
spontaneously breathing LPS-treated rats compared with the other groups. Compared 
with placebo-treated ventilated animals, oxygenation was significantly lower in LPS-
treated spontaneously breathing animals. However, no difference in oxygenation 
between LPS-treated ventilated animals and placebo-treated ventilated animals was 
found.
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Figure 4     A: Pulmonary concentrations of  TNF-α in placebo- and LPS-treated spontaneously 
breathing and mechanically ventilated (MV, 8 or 15 mL/kg) rats. B: Pulmonary concentrations of  
TNF-α in LPS-treated spontaneously breathing and mechanically ventilated (MV, 15 mL/kg) rats 
that underwent a sham operation, bilateral vagotomy (VGX) or vagus nerve stimulation (STM).  Pul-
monary cytokine levels are normalized to the total amount of  protein in each lung homogenate. Data are 
represented as mean ± SEM of  6-8 animals per group. * indicates p<0.05, one-way ANOVA with 
Bonferroni post-hoc test.
Table 2     Cardiorespiratory parameters in placebo and LPS-treated (10 mg/kg) sham-operated rats 
ventilated with 15 mL/kg or left breathing spontaneously. 
LPS/placebo administered at T=-1, MV started at T=0. Data are represented as mean ± SEM of  6 
animals per group. * indicates p<0.05, one-way ANOVA with Bonferroni post-hoc test.
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Vagotomy enhances pulmonary inflammation and impairs oxygenation in spontaneously breathing, 
but not in ventilated rats 
Vagotomy resulted in significantly increased pulmonary levels of  all proinflammatory 
cytokines in LPS-treated spontaneously breathing animals compared with sham 
operated or vagus nerve stimulated rats (TNF-α depicted in Figure 4B). IL-10 was not 
affected by vagotomy (data not shown). Furthermore, vagotomy exerted no effects 
in ventilated rats (Figure 4B). Plasma cytokine levels were not affected by vagotomy 
in spontaneously breathing or ventilated LPS-treated animals. In ventilated animals, 
no effects of  either vagotomy or vagus nerve stimulation on blood pressure or blood 
gas parameters were found (data not shown). However, in spontaneously breathing 
rats, vagotomy resulted in significantly lower blood pressure at T=0, and lower pO2 
levels at T=0 and T=2 compared with sham-operated animals (Table 3). Vagus nerve 
stimulation affected neither pulmonary or plasma cytokine levels, nor blood gas 
parameters in both spontaneously breathing and ventilated (15 mL/kg) LPS-treated 
animals.
Table 3     Cardiorespiratory parameters in placebo and LPS-treated (10 mg/kg) spontaneously 
breathing rats.
LPS/placebo administered at T=-1. VGX: vagotomy, STM: vagus nerve stimulation. Data are repre-
sented as mean ± SEM of  6 animals per group. * indicates p<0.05, one-way ANOVA with Bonfer-
roni post-hoc test.
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Discussion
In this study we show that mechanical ventilation with moderate, but not with low tidal 
volumes potentiates the pulmonary inflammatory response elicited by systemic LPS 
administration. Vagotomy applied after LPS administration resulted in amplification 
of  the LPS-induced pulmonary inflammatory response and reduced oxygenation 
in spontaneously breathing animals. However it did not affect inflammatory or 
respiratory parameters in ventilated rats. Vagus nerve stimulation performed after 
LPS administration had no effects in either ventilated or spontaneously breathing rats.
In the absence of  LPS, MV with low (8 mL/kg) or moderate (15 mL/kg) tidal volumes 
did not result in a pulmonary or systemic inflammatory response. In contrast, we14, 18 
and others19 have recently shown that 4-5 hours of  MV with 8 mL/kg in mice results 
in increased levels of  inflammatory cytokines in both lungs and plasma. It appears that 
rats are less susceptible to MV-induced pulmonary inflammation. For instance, 4-hour 
ventilation with 8 mL/kg did not result in increased levels of  pulmonary cytokines 
or neutrophils6. Even MV with 24 mL/kg did not lead to increased wet/dry ratios 
or impaired oxygenation, while only moderate  increases in pulmonary inflammation 
were found6. This probably accounts for the common use of  very high tidal volumes 
(>30 mL/kg) in rat VILI models, which hinders interpretation with regard to the 
human situation20-22. These findings signify that there are large interspecies differences 
with regard to the inflammatory response to MV. With respect to humans, a recent 
study demonstrated that, in ARDS patients, lowering of  tidal volumes from 6.3 to 4.2 
mL/kg accompanied by extracorporeal carbon dioxide removal was associated with 
a significant decrease in inflammatory mediators in bronchoalveolar lavage fluid23, 
suggesting that there is no clear cutoff  value for safe tidal volumes in humans.
The second hit MV potentiated the first hit induced by systemic LPS administration 
with regard to pulmonary inflammation, but only when a moderately high tidal 
volume of  15 mL/kg was used. This tidal volume might still be clinically relevant in 
light of  the partially collapsed or fluid-filled ‘baby lungs’24 observed in septic patients 
with lung injury, of  which only a portion is ventilated15. We chose to start MV one 
hour after LPS administration. At this time point, high plasma concentrations of  
TNF-α, an important cytokine in the pathophysiology of  VILI25, are found. Using 
this approach, we attempted to simulate  a patient with systemic hyperinflammation 
admitted to the ICU for initiation of  mechanical ventilation. While we did find 
increased levels of  all proinflammatory cytokines in lungs of  LPS-treated ventilated 
animals compared with LPS-treated spontaneously breathing rats, we could not 
106
Chapter 5
demonstrate a statistically significant impaired gas exchange. In this respect, our two-
hit model does not represent a true lung injury model. The direct interaction of  
systemic LPS administration and MV has been sparsely studied. The most commonly 
used two-hit models employ intratracheal LPS administration or haemorrhagic shock 
followed by MV15, 26-28. Both of  these treatments are expected to have a more severe 
effect on lung function compared with systemic LPS administration, which might 
explain the lack of  an effect on gas exchange in our study. In a rat study where 
LPS was also i.v. administered one hour before the start of  4-hour MV, increased 
lung inflammation and injury was found in LPS-treated ventilated rats compared with 
non-ventilated non-LPS-treated rats29. Unfortunately, no spontaneously breathing 
LPS-treated group or placebo-treated MV group was studied for comparison29. Two 
similar studies in rabbits have investigated direct interactions between systemic LPS 
and MV using moderate tidal volumes (10-15 mL/kg)30, 31. However, in these studies, 
LPS was administered 2 hours after the start of  a 6-8 hour MV period. Nevertheless, 
the authors did find impaired oxygenation, altered histopathological lung alterations, 
and reduced compliance in LPS-treated MV animals compared with a spontaneously 
breathing LPS-treated group or placebo-treated MV group. In line with our results, 
these studies also demonstrated that MV potentiates the pulmonary, but not systemic, 
inflammatory response to i.v. LPS administration30, 31. 
Our result partly corroborate previously described findings of  increased pulmonary 
inflammation after vagotomy15. In spontaneously breathing rats, vagotomy enhanced 
LPS-induced pulmonary inflammatory cytokine levels and was associated with 
impaired oxygenation. However, no effects were observed in LPS-treated MV rats. 
We do not have a clear explanation for this discrepancy but it could be speculated that 
the MV-induced potentiation of  the pulmonary inflammatory response elicited by 
LPS somehow overrides the vagotomy-associated amplification of  the inflammatory 
response. Furthermore, plasma cytokine levels were not affected by vagotomy in any 
of  the groups. Several other groups have reported elevated plasma cytokine levels 
in vagotomized rats11, 16, 32, 33. This disparity could be due to timing, because in the 
other studies, vagotomy was performed prior to the inflammatory insult while we 
transected the vagus nerve in between two inflammatory ‘hits’, representing a more 
clinically relevant time point.
It was recently demonstrated that vagus nerve stimulation attenuates the pulmonary 
inflammatory response and improves oxygenation in mice ventilated for 3 hours with 
injurious tidal volumes (20 mL/kg)15. Similar effects were found in rats that were 
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subjected to haemorrhagic shock and subsequent MV with 12 mL/kg for 4 hours15. 
In contrast, we found no effects of  vagus nerve stimulation on any of  the studied 
parameters. This could be due to a number of  factors. First, we used a different 
first hit, namely LPS administration compared with haemorrhagic shock. Second, one 
might argue that we have stimulated the nerve for a too short period (3 minutes). This 
appears not to be a plausible explanation however, as in mice, the anti-inflammatory 
effects of  vagus nerve stimulation were equal whether it was performed for 0.5, 2 
or 20 minutes17. Finally and most likely, the lack of  an effect could be due to the 
timing of  the intervention. In the aforementioned study, vagus nerve stimulation was 
performed prior to the induction of  haemorrhagic shock, hence before the ‘first hit’15. 
We stimulated the vagus nerve following the first hit but before initiation of  MV; in 
our view a more clinically relevant time point. The inflammatory cascade induced by 
LPS administration might have been too far advanced for vagus nerve stimulation to 
limit it. However, this does not explain why stimulation did not attenuate the MV-
induced increase in pulmonary inflammation elicited by LPS. Nevertheless, almost all 
studies that reported beneficial results of  vagus nerve stimulation on inflammation 
have performed stimulation before or simultaneous to the inflammatory stimulus/
insult10-13, 15-17, 34-36. Only two investigations assessed delayed stimulation of  the 
cholinergic anti-inflammatory pathway, and they have yielded conflicting results37, 38. 
Both studies used a murine cecal ligation and puncture (CLP) model, which is widely 
used to study polymicrobial sepsis. The acetylcholinesterase inhibitor physostigmine, 
which reinforces the cholinergic anti-inflammatory pathway by increasing ACh 
availability, attenuated inflammation and septic shock when administered before CLP 
induction, but not when administered 6 hours afterwards37. In contrast, another study 
reported beneficial effects of  administration of  the α7nAChR agonist nicotine 24 
hours after induction of  CLP38. 
In conclusion, this study demonstrates no beneficial effects of  vagus nerve stimulation 
in a two-hit model in rats, where stimulation was performed at a clinically relevant 
time point: following the initial hit but before initiation of  MV. This questions the 
clinical applicability of  stimulation of  the cholinergic anti-inflammatory pathway in 
systemically inflamed patients admitted to the ICU where MV is initiated. 
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GTS-21 inhibits proinflammatory cytokine release 
independent of  the Toll-like receptor stimulated via 
a transcriptional mechanism involving JAK2 activation
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Abstract
Background The vagus nerve can limit inflammation via the α7 nicotinic 
acetylcholine receptor (α7nAChR). Selective pharmacological stimulation of  the 
α7nAChR may have therapeutic potential for the treatment of  inflammatory 
conditions. 
Methods We determined the anti-inflammatory potential of  GTS-21, an 
α7nAChR-selective partial agonist, on primary human leukocytes and compared it 
with nicotine, the nAChR agonist widely used for research into the anti-inflammatory 
effects of  α7nAChR stimulation. Furthermore, we investigated whether the effects of  
both nicotinic agonists were restricted to specific Toll-like receptors (TLRs) stimulated 
and explored the mechanism behind the anti-inflammatory effect of  GTS-21.
Results  GTS-21 and nicotine inhibited the release of  proinflammatory 
cytokines in peripheral blood mononuclear cells (PBMCs), monocytes, and whole 
blood independent of  the TLR stimulated, with higher potency/efficacy for GTS-
21 compared with nicotine. The anti-inflammatory cytokine IL-10 was relatively 
unaffected by both nicotinic agonists. The effects of  GTS-21 and nicotine could not 
be reversed by nAChR antagonists, while the JAK2 inhibitor AG490 abolished the 
anti-inflammatory effects. GTS-21 downregulated monocyte cell-surface expression 
of  TLR2, TLR4, and CD14. qPCR analysis demonstrated that the anti-inflammatory 
effect of  GTS-21 is mediated at the transcriptional level and involves JAK2-STAT3 
activation.
Conclusions GTS-21 has a profound anti-inflammatory effect in human 
leukocytes and GTS-21 is more potent/efficacious than nicotine. The absence of  a 
blocking effect of  nAChR antagonists in human leukocytes might indicate different 
pharmacological properties of  the α7nAChR in human leukocytes compared with 
other cell types. GTS-21 may be promising from a therapeutic perspective because of  
its suitability for human use.
115
Anti-inflammatory effects of  GTS-21 on human leukocytes
6
Introduction
In the past few years, a novel link between the vagus nerve and the inflammatory 
response has been established. In addition to ‘sensing’ focal inflammation in 
the periphery and relaying it to the brain via afferent fibers1-3, recent work has 
demonstrated that the efferent vagus nerve can modulate the inflammatory response 
in a reflex-like fashion, termed ‘the cholinergic anti-inflammatory pathway’4. It has 
become clear that the α7 nicotinic acetylcholine receptor (α7nAChR), expressed in 
various cell types including human leukocytes5, is an essential regulator of  this anti-
inflammatory effect of  the vagus nerve6. Consequently, more specific agonists of  
this receptor were identified or developed and used in various studies7-9. To date, 
one of  the most effective α7-selective partial agonists for modulating inflammatory 
responses is 3-(2,4-dimethoxybenzylidene)-anabaseine (GTS-21) which has proven to 
be effective in attenuating the immune response and improving outcome in animal 
models of  pancreatitis9, endotoxemia7, 8, sepsis7, acute lung injury10, 11, and ischemia-
reperfusion injury12. However, its anti-inflammatory potential in human inflammatory 
cells has never been evaluated. This is of  particular interest because GTS-21, which 
has been primarily developed for the treatment of  Alzheimer’s disease, has been 
administered to human volunteers and patients, and is well tolerated without clinically 
significant safety findings13. Therefore, GTS-21 may have therapeutic potential for 
the treatment of  inflammatory conditions and is preferred above nicotine which 
lacks pharmacologic specificity and has toxic side effects and the potential to produce 
physical dependence (addiction). 
Although comparisons between GTS-21 and non-selective nAChR agonists have been 
reported at α7nAChR receptor activation level in electrophysiological studies using 
heterologous expression in Xenopus laevis oocytes14, 15, the immunomodulating effects 
of  selective and non-selective agonists of  the α7nAChR have not been compared. 
Furthermore, in vitro studies investigating the cholinergic anti-inflammatory pathway 
almost exclusively used the principal Toll-like receptor 4 (TLR4) agonist LPS as a trigger 
for inflammation. It is unknown whether the cholinergic anti-inflammatory pathway 
is restricted to certain TLRs stimulated or is a general mechanism not constrained 
to a specific stimulus. Finally, the mechanism by which α7nAChR stimulation 
attenuates proinflammatory cytokine production has not been fully elucidated and 
sparsely studied in human cells. A role for the JAK2-STAT3 pathway16-19 as well as 
suppression of  NFκB transcriptional activity 20, 21 is implied. However, the cholinergic 
anti-inflammatory pathway is believed to be regulated at a posttranscriptional level4, 16. 
Mechanistic studies regarding the anti-inflammatory effect of  GTS-21 are limited to 
one study reporting decreased NFκB activity in a murine cell line7.
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In this study, we investigated for the first time the anti-inflammatory potential of  
GTS-21 on primary human leukocytes and compared it with nicotine. Furthermore, 
we investigated whether the effects of  both nicotinic agonists were restricted to 
specific TLRs stimulated and whether they affected cell-surface expression of  
receptors involved in the innate immune response. Finally, we studied whether the 
anti-inflammatory effects of  GTS-21 and nicotine are regulated at the transcriptional 
level, and determined the involvement of  the JAK-STAT signal transduction pathway.
Materials and methods
General reagents
RPMI culture medium (RPMI 1640 Dutch modification, ICN Biomedicals; Costa 
Mesa, CA, USA) was supplemented with gentamicin 10 µg/mL, L-glutamine 10 mM, 
and pyruvate 10 mM. GTS-21 was obtained from the University of  Florida (a kind 
gift of  Prof. Dr. Roger L. Papke) and from Comentis inc. (South San Francisco, CA, 
USA). No differences in potency/efficacy between GTS-21 from the  University of  
Florida and from Comentis inc. were observed (data not shown). Nicotine (liquid, 
naturally occurring isomer), mecamylamine, α-bungarotoxin, methyllycaconitine 
(MLA), tyrphostin AG490, d-tubocurarine, and Escherichia coli lipopolysaccharide 
(LPS, serotype O55:B5) were obtained from Sigma-Aldrich (St Louis, MO, USA). 
LPS was further purified as described previously22. LPS concentration was 1 ng/mL 
in all experiments. Pam3Cys was purchased from EMC Micro-collections (Tübingen, 
Germany). Flagellin and polyI:C were obtained from InvivoGen (San Diego, CA, 
USA). All stimuli except AG490, which was dissolved in ethanol, were dissolved in 
RPMI. 
Peripheral blood mononuclear cells, monocyte and whole blood stimulation
After obtaining informed consent, venous blood was drawn from the cubital vein of  
healthy non-smoking male volunteers into EDTA or lithium heparin tubes (Vacutainer 
System, BD Biosciences, Plymouth, UK). All volunteers refrained from caffeine-
containing beverages/food for at least 12 hours before blood collection. Peripheral 
blood mononuclear cells (PBMCs) were isolated from EDTA anticoagulated blood 
by density gradient centrifugation over Ficoll-Hypaque (Amersham Biosciences, 
Uppsala, Sweden), washed three times in ice-cold sterile phosphate-buffered saline 
(B Braun Melsungen AG, Melsungen, Germany), and resuspended in RPMI 1640 
culture medium supplemented with 10% autologous serum obtained by centrifugation 
(6000 rpm, 10 min) of  lithium-heparin anticoagulated blood. Cells were counted 
in a Bürker hemocytometer and viability was assessed using trypan blue (viability 
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was >95%). The number of  cells was adjusted to 2.5 x 106/mL and 5 x 105 cells 
per well (200 µL) were seeded in duplicate in 96-well flat bottom plates (Greiner, 
Alphen a/d Rijn, The Netherlands) and stimulated for 22 hours (37 oC, 95% O2, 5% 
CO2) with various compounds. Incubation with RPMI alone served as a negative 
control. Nicotine or GTS-21 were added 30 minutes before TLR agonists. Nicotinic 
antagonists or the JAK2 inhibitor AG-490 were added 30 minutes before nicotine or 
GTS-21.
Primary monocytes were obtained from PBMCs using magnetic bead negative 
depletion (Monocyte Isolation kit II and LS columns, Miltenyi Biotec, Utrecht, The 
Netherlands). This procedure yields untouched monocytes suitable for short-term 
stimulation experiments where magnetic beads attached to cell surface epitopes are 
unwanted. Monocyte purity was evaluated using flow cytometry and was 85-90%. 
1 x 105 cells per well (200 µL) in duplicate were stimulated in the presence of  10% 
autologous serum for 22 hours as described above.
After stimulation, PBMC/monocyte well plates were centrifuged (1700 rpm, 8 min) 
and supernatants were stored at -80 oC until assayed.
For whole blood stimulation experiments, venous blood was drawn into 2 mL 
lithium-heparin containing vacutainers (Vacutainer System, BD Biosciences). Whole 
blood was diluted 1:5 in RPMI and stimulated for 24 hours as described above. After 
stimulation, whole blood cultures were centrifuged (14000 rpm, 5 min) after which 
supernatants were stored at -80 oC until assayed.
Cytokine measurements
Cytokines in supernatants of  whole blood cultures were determined using a 
simultaneous Luminex Assay according to the manufacturer’s instructions (Bio-plex 
cytokine assay, BioRad, Hercules, CA, USA). Cytokines in supernatants of  PBMC 
and monocytes cultures were determined using enzyme-linked immunosorbent 
assays. TNF-α was determined by a specific ELISA using four antibodies as described 
previously23. IL-1β, IL-6, and IL-10 were measured by commercial ELISA kits (IL-1β: 
R&D systems, Minneapolis, MN, USA; IL-6 and IL-10: Pelikine Compact, Sanquin, 
Amsterdam, The Netherlands, according to the manufacturer’s instructions).
Viability assays
Monocyte viability was assessed using the in vitro toxicology assay kit, 
[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) based (Sigma-
Aldrich). Monocytes were stimulated as described above (22 hours). After stimulation, 
plates were centrifuged (1700 rpm, 8 min), 100 µL of  supernatant was stored at 
118
Chapter 6
-80 oC for cytokine analysis, and 10 µL of  MTT stock solution (5 mg/mL) was added 
to the wells. Monocytes were incubated at 37 oC for an additional 4 hours after which 
formazan crystals were solubilized and absorbance at 570 nm was measured in a plate 
reader. Additionally, lactate dehydrogenase (LDH) was determined in supernatants of  
PBMCs stimulated for 22 hours as described above.
Flow cytometry
Flow cytometry was performed on PBMCs stimulated as described in section 2.2 (22 
hours), After stimulation, plates were centrifuged (1700 rpm, 8 min), supernatants 
were stored at -80 oC for cytokine analysis and adherent cells were detached by adding 
200 µL of  ice-cold FACS buffer (PBS with 0.5 % BSA) and incubating the plate 
for 15 min on ice. Subsequently, cells were collected by vigorous resuspending and 
scraping of  the bottom of  the wells and washed twice in ice-cold FACS buffer. TLR2, 
TLR4, and CD14 expression was determined with the following directly conjugated 
antibodies: CD282 PE (mouse IgG2a, TLR 2.1 clone, eBioscience, San Diego, CA, 
USA), CD284 PE-Cy7 (TLR4, mouse IgG2a, HTA125 clone eBioscience), CD14 
ECD (mouse IgG2a, RMO52 clone Immunotech, Beckman Coulter, Mijdrecht, The 
Netherlands). Expression of  α7nAChR on monocytes was determined with a primary 
antibody against α7nAChR (rat IgG1 monoclonal, 319 clone, Abcam, Cambridge, 
UK) and CD14 ECD followed by a FITC labeled secondary antibody (donkey anti-
rat FITC, Beckman Coulter). After antibody incubation, cells were washed with FACS 
buffer, resuspended, and analyzed on a Beckman Coulter FC500 flow cytometer. 
TLR2, TLR4, CD14, and α7nAChR expression were analyzed within CD14 positive 
monocytes.
Quantitative PCR and JAK-STAT signaling arrays
Untouched primary monocytes were isolated as described in section 2.2 and seeded in 
duplicate at a density of  1 x 106/well in 24-well plates in the presence and absence of  
LPS and nicotinic agonists. After 4 hours, plates were centrifuged (1700 rpm, 8 min) and 
supernatants were aspirated. Subsequently, RNA was isolated using RNeasy plus mini 
kits (Qiagen, Venlo, The Netherlands) according to the manufacturer’s instructions. 
RNA concentration was determined using a Nanodrop ND-1000 spectrophotometer 
(Thermo Scientific). Per experiment, equal amounts of  RNA (150-400 ng) were used 
for cDNA synthesis using iScript cDNA synthesis kits (Bio-Rad). Negative control 
reactions were performed in the absence of  reverse transcriptase.
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The sequences of  the primer pairs used were:
TLR2   forward:  5‘-GAATCCTCCAATCAGGCTTCTCT-3’
reverse:   5’-GCCCTGAGGGAATGGAGTTTA-3
TLR4  forward:  5’-GGCATGCCTGTGCTGAGTT-3’
reverse:  5’-CTGCTACAACAGATACTACAAGCACACT-3’
TNF-α   forward:  5’-TGGCCCAGGCAGTCAGA-3’
reverse:  5’-GGTTTGCTACAACATGGGCTACA-3’
IL-1β   forward:  5’-CAGCTACGAATCTCCGACCAC-3’
reverse:   5’-GGCAGGGAACCAGCATCTTC-3’
IL-6   forward:  5’-AATTCGGTACATCCTCGACGG-3’
reverse:   5’-GGTTGTTTTCTGCCAGTGCCT-3’
IL-10   forward:  5’-CAACCTGCCTAACATGCTTCG-3’
reverse:   5’-TCATCTCAGACAAGGCTTGGC-3’
CD14   forward:  5’-ACGCCAGAACCTTGTGAGC-3’
reverse:   5’-GCATGGATCTCCACCTCTACTG-3’
α7nAChR  forward:  5’-AAACTCACAGATGGGCAAGG-3’
reverse:  5’- AGGGAACACTGGAGTTGTGG-3’
B2M  forward:  5’-ATGAGTATGCCTGCCGTGTG-3’
reverse:  5’-CCAAATGCGGCATCTTCAAAC-3’
Primers were obtained from Biolegio (Nijmegen, The Netherlands). The quantita-
tive PCR (qPCR) reaction was performed using Power SybrGreen master mix (Ap-
plied Biosystems, Nieuwekerk a/d Ijssel, The Netherlands) on an ABI Prism 7300 
Real Time PCR system (Applied Biosystems). Negative control reactions were cycled 
alongside test samples to ensure the absence of  contaminating genomic DNA. The 
amplification of  a single product was ensured by melt-curve analysis for each primer 
pair. A standard curve constructed from 1:5 serial dilutions of  a mixture of  cDNA 
of  the samples in the same run was included for each primer pair in every run to 
perform relative quantification of  mRNA expression. To investigate the involvement 
of  the JAK-STAT signaling pathway we used RT2 Profiler JAK-STAT qPCR arrays 
(PAHS-039, SABiosciences, Frederick, MD, USA) according to the manufacturer’s in-
structions. For these experiments, isolated monocytes of  three different donors were 
stimulated and mRNA was isolated as described above. Four housekeeping genes, 
hypoxanthine phosphoribosyltransferase (HPRT1), glyceraldehyde-3-phosphate de-
hydrogenase  (GAPDH), β-actin (ACTB) and β2 microglobulin (B2M) present on the 
PCR array were used for normalization.
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Calculations
Data are expressed as mean±SEM except for whole blood stimulation data which 
are expressed as median±interquartile range as they were not normally distributed. 
Statistical significance in the dose-response curves of  nicotine and GTS-21 was 
evaluated using repeated measures one-way analysis of  variance with Bonferroni 
post-hoc test. Elsewhere, the paired student’s t-test was used to test for statistical 
significance except for the whole blood data which was analyzed using the Wilcoxon 
matched pairs test and the qPCR JAK-STAT array data for which the analysis 
procedure is described below. A p-value below 0.05 (except for qPCR JAK-STAT 
array data, p<0.01) was considered statistically significant.
For whole blood experiments, % inhibition/stimulation was calculated as follows: 
100x (TLR-agonist-induced cytokine release in the presence of  GTS-21 or nicotine / 
TLR-agonist-induced cytokine release in the absence of  GTS-21 or nicotine) – 100. If  
more than 50% of  the subjects had a cytokine response in response to a TLR-agonist 
in the absence of  a nicotinic agonist that was lower than 4 times the detection limit, 
no inhibition/stimulation calculations for this TLR-agonist-cytokine combination 
were performed.
In the experiments where nAChR antagonists were used, the % blocking effect of  
the nAChR antagonists was calculated by subtracting the % inhibition of  the LPS-
response by GTS-21 or nicotine in presence of  the nAChR antagonist from the % 
inhibition of  the LPS-response by GTS-21 or nicotine in the absence of  the nAChR 
antagonist.
qPCR data was analyzed using ABI Prism software and calculations were performed 
as follows: per sample, the relative quantity of  mRNA of  the gene of  interest (e.g. 
TNF-α) was divided by the relative quantity of  the housekeeping gene B2M. To 
calculate fold induction compared with the control sample, we divided the TNF-α/
B2M ratio by the TNF-α/B2M ratio of  the unstimulated control (RPMI) sample. If  
fold induction was <1, it was represented as -(1/fold induction).
For the JAK-STAT qPCR array experiments each replicate cycle threshold (CT) was 
normalized to the average CT of  four housekeeping genes on a per plate basis. The 
2−ΔΔCT method was used to calculate the relative quantification of  gene expression 
in stimulated samples compared with RPMI samples. A gene was considered not 
detectable when CT >35. CT was defined as 35 for the 2−ΔΔCT calculation when the 
signal was below detectable limits. If  for a specific gene both the stimulated and control 
sample expression was below detectable limits the sample was excluded from analysis. 
Genes were considered differentially expressed if  mean up- or downregulation was 
equal or greater than 2-fold and p<0.01 (permutation test, 100 permutations).
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Statistical calculations were performed using Graphpad Prism V4.03 (Graphpad 
software) except for the permutation tests in the JAK-STAT qPCR array experiments 
which were analyzed with Multi-experiment Viewer V4.3 (TM4 software suite).
Results
Nicotine and GTS-21 dose-dependently inhibit LPS-induced cytokine production in PBMCs
To determine the effect of  nAChR agonists on LPS-induced cytokine release we 
incubated human PBMCs with 1 ng/mL LPS in combination with nicotine or GTS-
21 for 22 hours. The classic nAChR agonist nicotine dose-dependently inhibited 
production of  the proinflammatory cytokines TNF- α, IL-1β, and IL-6 (Figure 1) 
with a maximum inhibition of  30±4%, 65±2%, and 36±5% respectively at the highest 
dose of  nicotine used (1 mM). The anti-inflammatory cytokine IL-10 was relatively 
unaffected, with a small but significant inhibition at a submaximal concentration of  
nicotine (21±3% at 100 µM).  
Figure 1
Dose-response curves of  the effect 
of  nicotine on cytokine produc-
tion in human PBMC stimulated 
with 1 ng/mL LPS for 22 hours. 
Data are represented as mean ± 
SEM (8 different donors, two 
independent experiments). * in-
dicates p<0.05 compared with 
the LPS response in the absence 
of  nicotine (repeated measures 
ANOVA with Bonferroni post-
hoc test).
The selective α7nAChR agonist GTS-21 also dose-dependently inhibited TNF-α and 
IL-1β  (Figure 2), but was more potent and efficacious than nicotine with a maximum 
inhibition of  87±2% (IC
50
: 8.9 μM) and 89±3% (IC
50
:17.9 μM) respectively at the 
highest dose of  GTS-21 used (100 µM). Production of  IL-6 was not affected by 
GTS-21. IL-10 was only inhibited by the highest dose of  GTS-21 used (42±20% at 
100 µM) but not at 10 µM GTS-21, a dose which strongly inhibited release of  TNF-α 
and IL-1β.
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Figure 2 
Dose-response curves of  the effect of  
GTS-21 on cytokine production in 
human PBMC stimulated with 1 ng/
mL LPS for 22 hours. Data are rep-
resented as mean ± SEM (8 different 
donors, two independent experiments). 
* indicates p<0.05 compared with the 
LPS response in the absence of  GTS-
21  (repeated measures ANOVA with 
Bonferroni post-hoc test).
Inhibition of  proinflammatory cytokine production by nicotine and GTS-21 is mediated by monocytes 
and does not involve cell death
To investigate which cell type is involved in the inhibition of  proinflammatory cytokine 
production by nAChR agonists we performed stimulation experiments on isolated 
primary human monocytes using the same experimental conditions as in PBMCs. 
GTS-21 and nicotine both significantly inhibited TNF-α production to a similar 
extent as in PBMCs with GTS-21 showing a distinctively more pronounced effect 
than nicotine (84±3% and 39±8% respectively, Figure 3A). To exclude the possibility 
that loss of  viability or cell death was responsible for the observed inhibition of  
cytokine production we performed MTT viability assays on the stimulated monocytes 
which revealed no loss of  cell viability with any of  the stimuli used (Figure 3B). 
Moreover, lactate dehydogenase levels in supernatants of  stimulated PBMCs were not 
elevated compared with control (RPMI) in any of  the samples (n=4; RPMI 75.3±6.2 
U/L, LPS 72.0±5.8 U/L, GTS-21 100 μM 57.5±4.1 U/L, nicotine 1 mM 53.5±4.9 
U/L, LPS+GTS-21 100 μM 76.5±6.1 U/L, LPS+nicotine 1 mM 66.0±3.4 U/L).
Inhibition of  proinflammatory cytokine production by nicotine and GTS-21 is not restricted to a 
specific TLR stimulated
Pattern recognition of  the diverse classes of  microbial products causing infection 
involves various TLRs that modulate the subsequent immune response and cytokine 
profiles24. To explore whether the anti-inflammatory effects of  nicotine and GTS-
21 are dependent on a specific TLR stimulated we incubated human whole blood 
cultures with TLR2 (Pam3Cys, 1 µg/mL), TLR3 (PolyI:C, 50 µg/mL), TLR4 (LPS, 
1 ng/mL), and TLR5 (flagellin, 1 µg/mL) agonists in combination with nicotine and 
GTS-21. Incubation with TLR2, TLR4, and TLR5 agonists resulted in production of  
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pro- (TNF-α, IL-1β, IL-6, and IFN-γ) as well as anti-inflammatory (IL-10) cytokines 
(data not shown). The TLR3 agonist PolyI:C only evoked a robust IL-6 release while 
TNF-α and IFN-γ were secreted in very small quantities in whole blood cultures 
of  some but not all of  the subjects (and therefore were excluded from inhibition/
stimulation calculations). PolyI:C did not result in release of  IL-1β and IL-10 in whole 
blood of  any of  the subjects.
Figure 3     A) Effects of  nicotine and GTS-21 on TNF-α production in isolated primary human 
monocytes stimulated with LPS (1 ng/mL) for 22 hours. Both GTS-21(100 μM) and nicotine (1 
mM) attenuate TNF-α production in isolated monocytes stimulated with LPS. Data are represented 
as mean ± SEM (6 different donors, two independent experiments). * indicates p<0.05 compared with 
the LPS alone (paired Student’s t-test). B) MTT viability assay on isolated primary human monocytes 
stimulated with LPS, nicotine and GTS-21. Percentage viability was calculated relative to viability in the 
control (RPMI) samples. Data are represented as mean ± SEM (6 different donors, two independent 
experiments).
Coincubation with 100 µM of  nicotine inhibited TLR-agonist induced proinflammatory 
cytokine release in a mild fashion (data not shown) but 1 mM of  nicotine inhibited 
cytokine release up to 100%, independent on the TLR stimulated (Figure 4, upper 
panel). The anti-inflammatory cytokine IL-10 was not significantly inhibited by either 
100 µM or 1 mM of  nicotine.
The selective α7nAChR agonist GTS-21 (100 µM) also significantly inhibited nearly 
all TLR-agonist induced proinflammatory cytokines (up to 95% inhibition, Figure 
4, lower panel). As with nicotine, GTS-21 did not attenuate the anti-inflammatory 
cytokine IL-10 release to a great extent, only TLR5-induced IL-10 production was 
significantly inhibited.
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Figure 4     Percentage inhibition/stimulation of  TLR-agonist induced cytokine production in human 
1:5 diluted whole blood by 1 mM nicotine and 100 μM GTS-21(24-hour stimulation). TLR agonists 
used were TLR1+2: Pam3Cys (1 μg/mL); TLR3: PolyI:C (50 μg/ml); TLR4: LPS (1 ng/mL); 
TLR5: flagellin (1 μg/mL). Data are represented as median and interquartile range (6 different donors). 
* indicates p<0.05, Wilcoxon Matched Pairs test. Concentrations of  cytokines in absence of  nicotine or 
GTS-21 after stimulation with TLR2, TLR3, TLR4  and TLR5 agonists in pg/mL (interquartile 
range) were; TNF-α: 154 (41-592), 6 (2-15), 3150 (2020-3927), 2054 (692-4309). IL-6: 1374 
(482-4406),  89 (61-134), 6979 (4678-9309), 8341 (4864-11842). IL-1β: 19 (3-80), 0 (0-2), 
1637 (922-1963), 1502 (740-2126). IFN-γ 106 (33- 349), 9 (0-27), 734 (521- 954), 802 (593-
1072). IL-10: 43 (6-120), 0 (0-0), 76 (56-116), 221 (99-447).
Nicotinic antagonists do not restore cytokine production
As the α7nAChR has been proposed as the receptor responsible for the anti-
inflammatory effect of  nicotinic agonists6, we attempted to reverse the effects of  
nicotine and GTS-21 with nAChR antagonists. However, coincubation with both 
α7nAChR-specific antagonists α-bungarotoxin (10 nM – 1 µM) and methyllycaconitine 
(10 µM) as well as non-specific nAChR antagonists mecamylamine (10 nM-100 µM) 
and d-tubocurarine (10-100 µM) could not reverse the anti-inflammatory effects of  
any of  the concentrations of  nicotine and GTS-21. Inhibition of  the GTS-21 (100 
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µM) induced attenuation of  the cytokine response by the highest concentration of  
the nAChR blockers was: α-bungarotoxin 1.9 ± 1.3% (n=6),  methyllycaconitine 
-2.9 ± 1.0% (n=4), mecamylamine -1.8 ± 3.2% (n=6), d-tubocurarine 2.8 ± 2.8% 
(n=4). % inhibition of  the nicotine (1 mM) induced cytokine attenuation by the 
highest concentration of  the various nAChR blockers was: α-bungarotoxin 5.7 ± 
3.4% (n=6),  methyllycaconitine 0.6 ± 6.9% (n=4), mecamylamine 2.3 ± 4.1% (n=6), 
d-tubocurarine -10.3 ± 8.1% (n=4). Coincubation of  other concentrations of  GTS-
21/nicotine with the various concentrations of  the nAChR blockers mentioned above 
was also ineffective in blocking anti-inflammatory effects (data not shown).
GTS-21 downregulates cell surface receptors on monocytes
To obtain more insight into the mechanisms by which nicotine and GTS-21 exhibit 
their anti-inflammatory effects, we stimulated human PBMCs with LPS in combination 
with nicotine and GTS-21 and determined cell surface expression of  TLR2, TLR4, 
α7nAChR, and CD14 on the monocyte fraction by flow cytometry.  We chose the 
22-hour incubation based on similar experiments where LPS induced significant 
upregulation of  TLR2 and TLR4 after 24 hours of  incubation25. As depicted in 
Figure 5, LPS incubation upregulated monocyte cell-surface expression of  TLR2 and 
TLR4 compared with control (RPMI). CD14 expression was also upregulated by LPS 
(2990±237.8 vs. 2173±227.3,  p<0.05). GTS-21 inhibited LPS-induced upregulation 
of  TLR2 and CD14 (2467±218.9, p<0.05 compared with LPS) and abolished LPS-
induced TLR4 upregulation. Moreover, in the absence of  LPS, GTS-21 lowered 
TLR4 expression below control levels. LPS had no effect on α7nAChR expression, 
while GTS-21 in the absence of  LPS inhibited α7nAChR expression below control 
level (387±50.6 vs. 713.3±116.3,  p<0.05). Nicotine had no effects on expression of  
any of  the measured receptors (data not shown).
GTS-21, but not nicotine, regulates cytokine production at the transcriptional level
To investigate whether the anti-inflammatory effects of  GTS-21 and nicotine 
are transcriptionally regulated we assessed mRNA levels of  pro- and anti-
inflammatory cytokines and receptors using quantitative PCR on isolated 
monocytes stimulated for 4 hours. As expected, incubation with LPS 
significantly upregulated TNF-α, IL-1β, IL-6, and IL-10 mRNA expression 
(respectively 5.4, 14.7, 1715, and 9.7-fold compared with RPMI, Figure 6). GTS-
21 significantly attenuated LPS-induced upregulation of  TNF-α and IL-1β 
(-2.1 and 4.1-fold compared with RPMI respectively). Moreover, GTS-21 in the 
absence of  LPS significantly decreased TNF-α mRNA levels (-9.6-fold compared 
with RPMI) while there was a trend towards IL-1β downregulation (-11.9-fold 
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compared with RPMI). There was also a trend towards inhibition of  LPS-induced 
upregulation of  IL-6 and IL-10 expression (637.8 and 5-fold compared with 
RPMI respectively) by GTS-21 as well as downregulation of  IL-10 in the absence 
of  LPS (-4.5 compared with RPMI). TLR2 and TLR4 mRNA expression was not 
altered by LPS. GTS-21 significantly downregulated TLR2 in the absence of  LPS 
(-3.2-fold compared with RPMI) but had no effect on TLR4 mRNA levels. LPS 
significantly downregulated CD14 (data not shown, -5.6 fold compared with RPMI), 
this was inhibited by GTS-21 (-3.5 fold compared with RPMI). Nicotine did not alter 
expression of  any of  the cytokine genes assessed (data not shown). α7nAChR gene 
expression was not altered by any stimulus (data not shown).
Figure 5     Flow cytometric analysis of  the effects of  LPS (1 ng/mL) and GTS-21 (100 μM)  on 
cell-surface expression of  TLR2 and TLR4 on primary human monocytes incubated for 22 hours. In 
the lower panels overlays of  histograms depicting TLR2 and TLR4 expression on incubated monocytes 
of  a typical subject are displayed. The dashed line represent isotype control, dark grey represents RPMI, 
light grey represents LPS and white represents LPS+GTS-21. Data are represented as mean ± SEM 
(8 different donors, two independent experiments). # indicates p<0.05 compared with RPMI, * indicates 
p<0.05 compared with LPS (paired Student’s t-test).
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primary human monocytes stimulated with LPS (1 ng/mL) and GTS-21 (100 μM) for 4 hours. Data 
are represented as mean ± SEM fold expression of  the gene of  interest relative to control (expression in 
monocytes incubated with medium alone). Data from 5 different donors, three independent experiments 
are shown. # indicates p<0.05 compared with medium, * indicates p<0.05 compared with LPS (paired 
Student’s t-test).
The anti-inflammatory effect of   GTS-21 and nicotine are dependent on JAK2 phosphorylation
To evaluate the involvement of  the JAK-STAT pathway in the anti-inflammatory effects 
of  nicotine and GTS-21 we incubated PBMCs with LPS, nicotine, and GTS-21 in 
combination with AG490, a selective inhibitor of  JAK2 phosphorylation16, 17, 26. 100 μM 
AG490 inhibited the anti-inflammatory effect of  100 µM GTS-21 while completely 
restoring the attenuated TNF-α production by 10 µM GTS-21 and 1 mM nicotine 
(Figure 7). AG490 alone or vehicle (1% etOH) had no significant effects on LPS-
induced TNF-α release (LPS+AG490 2719± 379 pg/mL; LPS+1% etOH 1666±333 
pg/mL).
GTS-21 effects are likely mediated by JAK2/STAT3 signaling
To further explore the role of  the JAK-STAT signaling pathway in the anti-
inflammatory effects of  GTS-21 we used RT2 profiler qPCR arrays which contain a 
panel of  84 genes related to JAK-STAT-mediated signaling on isolated monocytes. 
Genes that were significantly and more than twofold up- or downregulated by 4-hour 
incubations with GTS-21, LPS and LPS+GTS-21 are shown in Table 1. GTS-21 
clearly inhibited LPS-induced expression of  IFN-γ and IFN-γ-inducible genes such 
as CXCL9, GBP1, and OAS127-29. In concordance with the implicated pivotal role 
for the JAK2-STAT3 pathway in α7nAChR signaling, GTS-21 upregulated STAT3 
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expression in the presence of  LPS. Furthermore, LPS-induced downregulation of  
F2 (thrombin), an activator of  JAK2/STAT3 pathway and SH2B1, a JAK2 activator, 
were abolished by GTS-21 whereas GTS-21 upregulated OSM which is involved in 
STAT3 phosphorylation and PRLR, a receptor which upon ligand binding activates 
JAK230-33. In the presence of  LPS, GTS-21 induced upregulation of  PTPN1, a 
protein tyrosine phosphatase which dephosphorylates JAK2, which may represent a 
negative feedback mechanism preventing excessive JAK2 activation34. STAT5A was 
upregulated by GTS-21 in the presence of  LPS while LPS-induced downregulation of  
STAT5B was blocked by GTS-21 indicating activation of  the JAK2-STAT5 pathway. 
The transcription of  NFκB and SOCS3 was upregulated by LPS but not affected by 
co-incubation with GTS-21.
Figure 7     Effects of  the JAK2 inhibitor AG490 (100 μM) on TNF-α production in human 
PBMCs stimulated with LPS (1 ng/mL), GTS-21 (10 and 100 μM) and nicotine (1 mM) for 22 
hours. Data are represented as mean ± SEM (5-7 different donors, two independent experiments). * 
indicates p<0.05 compared with LPS, # indicates p<0.05 compared with TNF-α response with the 
same (concentration of) nicotinic agonist in the absence of  AG490 (paired Student’s t-test).
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Table 1     up/down regulation of  JAK-STAT related genes compared with RPMI. Only genes 
which are significantly and more than twofold up/downregulated are shown
130
Chapter 6
Discussion
The cholinergic anti-inflammatory pathway may represent new treatment options for 
inflammatory conditions such as sepsis, acute lung injury and autoimmune diseases. 
Vagus nerve stimulation in humans is a very invasive procedure and is not feasible 
in acute situations. Therefore, pharmacological stimulation of  the cholinergic anti-
inflammatory pathway via the α7nAChR is a more practical approach. The nonspecific 
nAChR agonist nicotine has little therapeutic potential because of  its toxicity and 
other unwanted side effects. We are the first to show that GTS-21, a compound acting 
specifically at the α7nAChR, is a strong inhibitor of  proinflammatory cytokine release 
in primary human leukocytes while leaving anti-inflammatory cytokine production 
relatively unaffected. Nicotine has similar effects, but much less pronounced. 
Therefore, GTS-21 causes a profound shift in the pro-/anti-inflammatory balance 
towards an anti-inflammatory phenotype. While earlier reports state that the anti-
inflammatory effect of  α7nAChR stimulation relies on a post-transcriptional 
mechanism4, 16, we present evidence that GTS-21 attenuates the inflammatory 
response at the transcriptional level.
In our study, GTS-21 and nicotine exerted their anti-inflammatory effects equally on 
PBMCs and isolated monocytes suggesting that these effects are mainly monocyte-
mediated.  However, because the monocyte isolation method we employed does not 
yield completely pure monocytes, effects of  the nicotinic agonists on lymphocytes or 
other cell types present in PBMCs cannot be ruled out. In this respect, it is of  note 
that in whole blood experiments the T-cell/NK-cell cytokine IFN-γ was significantly 
inhibited by both nicotinic agonists. Non-activated lymphocytes are generally not 
noted for TLR-responses but NK cells have been reported to produce IFN-γ after 
TLR-stimulation35.  Whether the observed inhibition of  IFN-γ production represents 
a direct inhibitory effect on NK-cells or an indirect effect via attenuation of  cytokines 
that stimulate TLR-induced IFN-γ production by these cells, such as IL-12 and 
TNF-α, has to be determined. Nonetheless, while we have focused on the effects of  
GTS-21 and nicotine on innate immune responses, an effect on the adaptive immune 
system by these compounds is anticipated because of  alterations in costimulatory 
factors, cell interactions, and interplay between cytokines. Moreover, because primary 
human lymphocytes express the α7nAChR, a direct effect of  α7nAChR agonists on 
these cells and the adaptive immune response should not be neglected36, 37 The lack of  
an inhibitory effect on IL-6 release by GTS-21 is in line with a study in mice which 
demonstrates a rather selective effect of  GTS-21 on TNF-α release8, 37.  There was a 
trend towards lower IL-6 mRNA levels in GTS-21-treated monocytes, but it did not 
reach statistical significance.
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We further demonstrate, using a whole blood stimulation assay, that the anti-
inflammatory effects of  both nicotine and GTS-21 are not specific for the TLR 
stimulated. This is important because pattern recognition of  the diverse classes of  
microbial products involves various TLRs that modulate the subsequent immune 
response24, 38. As a consequence, cytokine release profiles evoked by Gram-positive 
bacteria, Gram-negative bacteria, viruses, and various endogenous agonists differ. 
Previous work of  our group has shown that the effect of  immunomodulating 
compounds can differ depending on the TLR stimulated39.  The data in this paper 
illustrate that both nicotinic compounds exhibit a generalized anti-inflammatory 
effect not dependent on the inflammatory stimulus and therefore not confined to a 
specific sort of  infection or endogenous stimulus. Additionally, we affirm the anti-
inflammatory potential of  GTS-21 and nicotine in whole blood containing all cell 
types and humoral factors present, which is more reflective of  in vivo conditions than 
an isolated cell model.
While the α7nAChR has been identified as the pivotal receptor in the cholinergic 
anti-inflammatory pathway6, we could not reverse the actions of  nicotine or GTS-21 
with antagonists of  this receptor (α-bungarotoxin and MLA), or with non-specific 
nAChR antagonists (mecamylamine and d-tubocurarine) in human immune cells. In 
accordance, for nicotine, blockade of  the anti-inflammatory effect by α-bungarotoxin 
has been described by some16, 40 but not all41. To date, no attempts have been made 
to reverse the anti-inflammatory effect of  GTS-21 by nAChR antagonists. There are 
a number of  possible reasons to explain the failure to block GTS-21 and nicotine 
effects by α7 antagonists. First of  all, the possibility remains that some of  the nicotine 
or GTS-21 effects in human leukocytes are mediated by a non-α7nAChR-related 
mechanism which remains to be elucidated. Another explanation might rely on 
differences in the α7nAChR between cell types. In excitable neuronal cells, α7nAChRs 
are ligand-gated ion channels composed of  5 α7 subunits which upon activation 
cause depolarization of  the cell membrane and influx of  Ca2+ via voltage-operated 
Ca2+ channels. However, leukocytes do not possess these Ca2+ channels and it was 
demonstrated that in PBMCs, α7nAChRs stimulation by nicotine or acetylcholine 
does not result in detectable membrane currents, while it does in neuronal cells42. 
Others have demonstrated that, despite the fact that T-cells express an essentially 
identical transcript for the α7nAChR subunit as neuronal cells, they do not form 
functional ligand-gated ion channels37. Furthermore, it was shown that leukocytes 
do not express the normal α7 subunit, but an α7 duplicate nicotinic acetylcholine 
receptor-related protein (dupα7) which lacks the α-bungarotoxin binding site and 
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has most likely different pharmacological properties42. This is supported by the 
aforementioned study in T-cells, where the α7nAChR specific antagonist MLA and 
α-bungarotoxin did not inhibit nicotine-induced effects37. Different pharmacological 
properties may also explain why the partial α7nAChR agonist GTS-21 has a much 
more potent effect on cytokine release in primary human leukocytes than the full 
agonist nicotine, while in classic α7nAChRs, the opposite is true43. Interestingly, bone 
marrow and brain cells were positive for both the normal α7 and the dupα7 subunit42. 
This indicates that the presence of  the normal α7nAChR or the dupα7 might vary 
between different cell types, which could explicate why nicotinic blockers antagonize 
α7nAChR in some cell types but not in others.
LPS-induced increases in monocyte cell-surface expression of  TLR2 and TLR4 have 
been described previously25. We confirm these findings and demonstrate that LPS also 
increases cell surface expression of  CD14 which is essential in LPS-induced cytokine 
production44. GTS-21, but not nicotine, inhibits TLR and CD14 upregulation and this 
could play a role in the diminished proinflammatory cytokine production in GTS-21 
treated leukocytes, because modulation of  cell-surface expression of  TLR4 has been 
linked to the degree of  cytokine production45. The observed LPS-induced upregulation 
of  TLRs could also be mediated by cytokine production, so-called ‘priming’, which 
would explain why the non-TLR2 agonist LPS increases TLR2 expression46. In this 
respect inhibition of  cell-surface expression of  the TLRs by GTS-21 might be a result 
of  inhibition of  cytokines rather than a cause. mRNA levels of  TLR4 and TLR2 were 
not affected by LPS and only TLR2 mRNA expression was modestly inhibited by 
GTS-21. The discrepancies between TLR protein and mRNA expression might result 
from the different incubation period used in the protein expression experiments 
compared with the mRNA experiments (22 hours vs. 4 hours) but can also indicate that 
the modulation of  TLR cell-surface expression relies mainly on post-transcriptional 
mechanisms. An earlier report demonstrates that nicotine downregulates cell-surface 
expression of  TLR4 and CD14 on human monocytes47. This discrepancy with our 
study might be explained by the modest anti-inflammatory effect of  nicotine in our 
experiments.
De Jonge et al. have demonstrated that the anti-inflammatory effect of  nicotine in 
murine macrophages acts through the recruitment of  JAK2 to the α7nAChR and 
subsequent phosphorylation of  JAK2, thereby initiating the anti-inflammatory STAT3 
cascade16. We show that in primary human leukocytes, both GTS-21 and nicotine 
effects could be inhibited by AG490, a JAK2 phosphorylation inhibitor, confirming 
a pivotal role for JAK2 activation. We further explored activation of  the JAK-STAT 
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pathway using quantitative PCR arrays. Although these arrays do not provide data on 
phosphorylation of  JAK-STAT family members, it evaluates expression of  known 
activators/inhibitors of  this signaling cascade at the transcriptional level. Our results 
indicate that GTS-21 strongly downregulates IFN-γ-inducible genes related to STAT1 
activation in monocytes48. Therefore, as stated before, GTS-21 may have a pronounced 
inhibitory effect on the adaptive immune response which warrants future research. 
JAK2/STAT3 signaling appeared to be activated by GTS-21 reflected by increased 
expression of  STAT3, receptors activating JAK2 (PRLR) and activators of  STAT3 
(OSM). Furthermore, GTS-21 blocked LPS-induced downregulation of  JAK2/
STAT3 activators (F2, SH2B1). The upregulation of  STAT5A and the blockade of  
LPS-induced downregulation of  STAT5B by GTS-21 further indicate JAK2 activity 
as STAT5 is also activated by JAK2 in monocytes49. There is much debate regarding 
the pro- and anti-inflammatory roles of  STAT3 which appear to be highly cell- and 
stimulation-specific. A number of  studies implicate proinflammatory actions of  
STAT3, such as a recent paper describing the critical role of  STAT3 activation in 
IL-1β and IL-6 production in a RAW 264.7 macrophage cell line50. However, there 
is also a large body of  evidence associating STAT3 activity with anti-inflammatory 
effects. For instance, STAT3 is essential for responsiveness to IL-10 which is known 
to deactivate macrophages51, 52 and STAT3 deficient macrophages are constitutively 
activated and secrete large amounts of  proinflammatory mediators52. Blocking STAT3 
in tumor cells increases expression of  proinflammatory cytokines and mice lacking 
STAT3 in macrophages and neutrophils are highly susceptible to endotoxic shock52, 53. 
Moreover, mice bearing a STAT3 deletion in bone marrow cells display higher levels 
of  circulating TNF-α and IFN-γ compared with control mice in the absence of  an 
inflammatory process54. The mechanism by which GTS-21 (and probably nicotine) 
inhibits cytokine release may rely on enhanced IL-10 signaling or actions mimicking 
IL-10 signaling, resulting in STAT3 activation. Because IL-10 downregulates its own 
production, excessive IL-10 signaling could account for the inhibited production 
of  IL-10 observed with the highest dose of  GTS-21 used (100 µM)51. Similar to 
what has been reported for nicotine16, SOCS3 appears not to play a role in the 
anti-inflammatory effects of  GTS-21, as the LPS-induced upregulation of  SOCS3 
was not further enhanced by GTS-21. Our quantitative PCR experiments illustrate 
that GTS-21 inhibits LPS-induced upregulation of  proinflammatory cytokines at 
the transcriptional level. While others argue that the anti-inflammatory effects of  
α7nAChR stimulation predominantly rely on post-transcriptional modulation4, 16, our 
data are in accordance with IL-10 (-like) signaling which inhibits TNF-α production at 
both the transcriptional and the translational level55. Moreover, GTS-21 and nicotine 
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both have been reported to inhibit LPS-induced NFκB activation which implies 
transcriptional modulation7, 20, 21. While our JAK-STAT array results demonstrate that 
the transcription of  NFκB is not downregulated by GTS-21 compared with LPS, 
this does not exclude the possibility that GTS-21 modulates NFκB activity/nuclear 
translocation, as this is not dependent on transcription or translation56. Nicotine did 
not affect mRNA levels of  any of  the genes assessed. Whether this is due to the 
relatively low anti-inflammatory potential that nicotine displayed in our experiments 
or to other factors remains to be elucidated.
The proposed mechanisms of  GTS-21 signaling in primary human monocytes is pre-
sented in Figure 8.
Figure 8     Mechanisms of  GTS-21 signaling in primary human monocytes
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In conclusion, GTS-21 represents novel opportunities for human research into 
the cholinergic anti-inflammatory pathway and possibly for future therapeutic 
applications. It is more effective than nicotine in modulating the immune response in 
human leukocytes and its suitability for human use makes it a candidate for human in 
vivo trials to further explore the cholinergic anti-inflammatory pathway.
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Abstract
Background Mechanical ventilation (MV) induces an inflammatory response that 
can lead to lung injury. The vagus nerve can limit the inflammatory response through 
the cholinergic anti-inflammatory pathway. We evaluated the effects of  stimulation of  
the cholinergic anti-inflammatory pathway with the selective partial α7nAChR agonist 
GTS-21 on inflammation and lung injury induced by MV using clinically relevant 
ventilator settings. Furthermore, we investigated whether altering endogenous 
cholinergic signalling, by administration of  the nonspecific nicotinic acetylcholine 
receptor antagonist mecamylamine and the peripherally acting acetylcholinesterase 
inhibitor neostigmine, modulates the MV-induced inflammatory response.
Methods C57BL6 mice were injected i.p. with either the selective α7nAChR 
agonist GTS-21 (8 mg/kg), acetylcholinesterase inhibitor neostigmine (80 μg/kg), 
nAChR antagonist mecamylamine (1 mg/kg), or placebo; followed by 4 hours of  MV 
(8 mL/kg, 1.5 cmH2O PEEP).
Results  MV resulted in release of  cytokines in plasma and lungs compared 
with unventilated mice. Lung  and plasma levels of  TNF-α, but not of  IL-10, were 
lower in GTS-21-treated animals compared with placebo (p<0.05). In addition, GTS-
21 lowered the alveolar-arterial gradient indicating improved lung function (p=0.04). 
Neither neostigmine nor mecamylamine had an effect on MV-induced inflammation 
or lung function.
Conclusions MV with clinically relevant ventilator settings results in pulmonary 
and systemic inflammation. Stimulation of  the cholinergic anti-inflammatory pathway 
with GTS-21 attenuates MV-induced release of  TNF-α, which was associated with 
reduced lung injury. Modulation of  endogenous cholinergic signalling did not affect 
the MV-induced inflammatory response. Selective stimulation of  the cholinergic anti-
inflammatory pathway may represent new treatment options for MV-induced lung 
injury.
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Introduction
Mechanical ventilation (MV) is a lifesaving intervention but can also lead to, or 
exacerbate pre-existing lung injury, a condition called ventilator-induced lung injury 
(VILI)1. This inflammatory response, reflected by release of  inflammatory cytokines, 
recruitment of  neutrophils and lung oedema, impairs lung function2-4 and is proposed 
to play a pivotal role in the pathogenesis of  VILI1, 5. In addition, inflammation of  
the lungs can spread systemically and cause multiple organ dysfunction syndrome 
(MODS)6. Patients with an underlying inflammatory process are particularly susceptible 
to MODS7, 8. We and others have shown that not only ventilation with high tidal 
volumes but so-called ‘protective ventilation’ leads to the release of  proinflammatory 
mediators and lung oedema9, 10. These data suggest that limiting the inflammatory 
response during MV may provide new therapeutic options to reduce lung injury and 
subsequent multi-organ failure.
Recently, it was discovered that stimulation of  the efferent vagus nerve attenuates 
the innate immune response11. This so-called ‘cholinergic anti-inflammatory pathway’ 
is based on binding of  the vagal neurotransmitter acetylcholine (ACh) to the α7 
nicotinic acetylcholine receptor (α7nAChR) present on resident macrophages and 
other immune cells resulting in inhibition of  proinflammatory cytokine release12. In 
several animal studies, 3-(2,4-dimethoxybenzylidene)-anabaseine (GTS-21), a selective 
partial α7nAChR agonist, has proven to be effective in attenuating the immune 
response and improving outcome13-15. GTS-21, which has been primarily developed 
for the treatment of  Alzheimer’s disease and schizophrenia, has been administered to 
human volunteers and patients and is well tolerated with no clinically significant safety 
findings16, 17. Therefore, GTS-21 might represent a new clinically relevant treatment 
option for inflammatory conditions. 
The cholinergic anti-inflammatory pathway is regarded as a regulatory system, a 
reflex-type response to limit excessive inflammation18. Endogenous activation of  the 
cholinergic anti-inflammatory pathway results in increased ACh release by the vagus 
nerve. Recently, it was shown that cholinesterase inhibition attenuates the cytokine 
response and lowers mortality in experimental sepsis, suggesting that cholinesterase 
inhibition reinforces the cholinergic anti-inflammatory response by increasing ACh 
availability19. Therefore, cholinesterase inhibition might represent another clinically 
relevant means of  limiting excessive inflammation.
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In the present study, we investigated the effects of  direct stimulation of  the 
cholinergic anti-inflammatory pathway by GTS-21 on inflammation and lung injury 
induced by MV using clinically relevant ventilator settings in mice. To determine 
whether alterations of  endogenous cholinergic signalling modulate the MV-induced 
inflammatory response, we studied the effects of  the acetylcholinesterase inhibitor 
neostigmine and the non-specific nAChR antagonist mecamylamine.
Materials and methods
Reagents
3-(2,4-dimethoxybenzylidene)-anabaseine (GTS-21) was a kind gift from Comentis 
Inc (San Francisco, CA, USA). Neostigmine methylsulphate was purchased from 
Centrafarm (Etten-Leur, The Netherlands), lipopolysaccharide (LPS, derived from E. 
coli serotype O55:B5) and mecamylamine hydrochloride from Sigma-Aldrich (St Louis, 
MO, USA), ketamine from Eurovet (Bladel, The Netherlands), dexmedetomidine 
from Pfizer (Berlin, Germany) and atropine from Pharmachemie (Haarlem, The 
Netherlands). LPS was further purified as described previously20. RPMI culture 
medium (RPMI 1640 Dutch modification, ICN Biomedicals; Costa Mesa, CA, 
USA) was supplemented with 10% fetal calf  serum, 10 µg/mL gentamicin, 10 mM 
L-glutamine, and 10 mM pyruvate.
Animals
All procedures described were in accordance with the requirements of  the Dutch 
Experiments on Animals Act, the EC Directive 86/609 and approved by the Animal 
Ethics Committee of  the Radboud University Nijmegen Medical Centre. Male 
C57BL6 mice (Charles River, Sutzfield, Germany) aged 10 to 12 weeks and weighing 
23-29 g were used in all experiments.
Experimental protocols
Non-ventilated control group:
A group of  8 mice that were immediately killed after anaesthesia induction were used 
as non-ventilated controls in all following protocols (NV group).
GTS-21 protocol:
Mice received either an i.p. injection of  phosphate buffered saline (PBS, 200 μL) 
30 minutes before the start of  ventilation (placebo-MV group, n=18) or an i.p. 
injection of  GTS-21 (8 mg/kg in 200 μL PBS) 30 minutes before the start of  
ventilation (GTS21-MV group, n=16). Earlier reports have demonstrated that the 
anti-inflammatory effects of  GTS-21 in mice are dose-dependent and that 4 mg/kg 
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significantly attenuates cytokine production14, 21. To maximize its effects, we used 8 
mg/kg, which is still a non-toxic dose according to the manufacturer. One mouse in 
the GTS21-MV group died shortly after the start of  MV.
neostigmine/mecamylamine protocol:
Mice received either an i.p. injection with 200 μL PBS 30 minutes prior to the start 
of  ventilation (placebo-MV group, n=15) or of  neostigmine (80 μg/kg i.p. in 200 
μL PBS) 30 minutes before the start of  ventilation (neostigmine-MV group, n=14), 
or of  mecamylamine (Sigma-Aldrich, 1 mg/kg dissolved in 200 μL PBS) 30 minutes 
before the start of  ventilation (mecamylamine-MV group, n=15). Neostigmine and 
mecamylamine doses were based on previous studies15, 22. Three mice died before the 
start of  MV (two in the neostigmine-MV group and one the placebo-MV group).
Instrumentation and MV
With the exception of  the NV group, all mice were mechanically ventilated for 4 
hours in an identical fashion. Before intubation, mice were anaesthetized with an 
i.p. injection of  126 mg/kg ketamine, 0.4 mg/kg dexmedetomidine, and 0.5 mg/kg 
atropine. Atropine is a vagolytic drug, but it predominantly antagonizes muscarinergic 
ACh receptors (mAChRs); it is therefore not expected to interfere with the anti-
inflammatory effects of  the vagus nerve to a great extent11. Mice were intubated 
with an tracheal tube and the carotid artery was cannulated to administer Ringer’s 
lactate with heparin (4 IU/mL) and to monitor arterial pressure. Mice were ventilated 
(MiniVent® type 845; Hugo Sachs Elektronik-Harvard Apparatus, March-Hugstetten, 
Germany) with clinically relevant settings: a tidal volume (Vt) of  8 mL/kg, a breathing 
frequency of  160-170 per minute, a PEEP of  1.5 cm H2O and a fraction of  inspired 
oxygen (FiO2) of  45%. Anaesthesia was maintained by administration of  18 mg/kg
 
ketamine, 20 μg/kg dexmedetomidine, and 37.5 μg/kg atropine as a bolus every 30 
minutes via an intraperitoneally placed catheter. Furthermore, depth of  anaesthesia 
was checked regularly by elicitation of  the pedal withdrawal reflex. When mice reacted 
to the stimulus by pedal withdrawal, an increase in heart rate or blood pressure (a 
sign of  discomfort), or both, an additional dose of  maintenance anaesthesia was 
administered. Rectal temperature was monitored throughout the experiment and was 
kept between 36.5° C and 37.5° C using a heating pad and blankets. 
Material harvesting 
After four hours of  ventilation, mice were killed by exsanguination. We chose this 
specific time-point based on previous work of  our group9, where a transient increase 
in inflammatory mediators was demonstrated with nearly all mediators peaking after 
four hours of  MV. Blood gas analysis was performed using an i-STAT Blood Gas 
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Analyzer (Abbot, Hoofddorp, The Netherlands) and plasma was stored at -80° C until 
analysis. Immediately after exsanguination, the lungs were carefully removed. The 
middle lobe of  the right lung was fixed for light microscopic histological examination. 
The left lung (cytokine & myeloperoxidase [MPO] determination] and one lobe of  
the right lung (mRNA analysis) were snap-frozen in nitrogen and stored at -80° C 
until analysis. 
Isolation and stimulation of  alveolar macrophages
Alveolar macrophages from 3 healthy, non-ventilated mice were isolated by 
bronchoalveolar lavage. Under anaesthesia, the trachea was isolated, incised, and a 
20g endotracheal catheter (Angiocath, BD medical, Sandy, UT, USA) was inserted. 
Lungs were lavaged 10 times with 1 mL of  sterile PBS. Lavage fluid was centrifuged 
at 300g to pellet alveolar macrophages and cells were resuspended and cultured in 
12-well plates at a concentration of  3 X 105 cells per well in 1 mL RPMI at 37 oC, 
95% O2, 5% CO2. After 2 hours of  incubation, nonadherent cells were discarded 
and the culture medium refreshed. Cells were then incubated with medium, LPS 
(100 ng/mL) or LPS + GTS-21 (10 μM) for 4 hours. GTS-21 was added 30 minutes 
prior to LPS. The supernatants were stored at -20° C until analysis by ELISA. cells 
were lysed by addition of  350 μL RLT buffer to each well and RNA was purified 
according to the RNeasy plus mini kit protocol (RNeasy plus mini kit, Qiagen, Venlo, 
The Netherlands). 
Histological examination
Lung tissue was fixed for 24 hours in Unifix (Klinipath, Duiven, The Netherlands), 
dehydrated and embedded in paraffin wax. Sections of  4-µm thickness were used. 
Pulmonary neutrophil influx was visualized using chloracetatesterase (Leder) staining. 
Neutrophils were counted manually in a blinded fashion (20 fields per mouse, 8-14 
mice per group), and after automated correction for air/tissue ratio, the number of  
neutrophils/µm2 was calculated. 
 
Cytokine and MPO assays 
A simultaneous Luminex assay was used to determine plasma cytokine levels (IL-6, 
IL-10, and keratinocyte-derived chemokine [KC]: Bio-Plex cytokine assay, BioRad, 
Hercules, CA, USA; TNF-α: Fluorokine MAP, R&D systems, Minneapolis, USA). 
For lung cytokine determination, snap-frozen tissue was placed in 500 μL 
lysisbuffer containing PBS, 0.5% triton X-100 and protease inhibitor (complete 
EDTA-free tablets, Roche, Woerden, The Netherlands), homogenized using a 
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polytron and subjected to two rapid freeze-thaw cycles using liquid nitrogen. Finally, 
homogenates were centrifuged (10 minutes, 14000 rpm, 4 °C) and the supernatant 
was stored at -80° C until analysis. In lung homogenates and alveolar macrophage 
culture supernatants, cytokines were determined by enzyme-linked immunosorbent 
assays (ELISA; IL-6 and IL-10: CytoSet, Invitrogen, Breda, The Netherlands; 
KC and TNF-α: ELISA DuoSet, R&D Systems). Total protein concentration was 
determined using the BCA protein assay (Thermo Fisher Scientific, Etten-Leur, The 
Netherlands). MPO was quantitated using ELISA (HK210, Hycult biotechnology, 
Uden, The Netherlands).
Quantitative PCR analysis
Snap frozen lung tissue was placed in ceramic bead tubes (MagNAlyser Green 
Beads, Roche) containing RLT Buffer (RNeasy plus mini kit, Qiagen, Venlo, The 
Netherlands) and was lysed in a MagNAlyser instrument (3X20 sec, 6500 rpm). RNA 
was purified according to the RNeasy plus mini kit protocol and RNA concentration 
was determined using a Nanodrop ND-1000 spectrophotometer (Thermo Fisher 
Scientific). 1 µg of  RNA (lung) or 30 ng of  RNA (alveolar macrophage cultures) 
was used for cDNA synthesis using the iScript cDNA synthesis kit (Bio-Rad). The 
quantitative PCR (qPCR) reaction was performed using Power SybrGreen master 
mix (Applied Biosystems, Nieuwekerk a/d Ijssel, The Netherlands) on an ABI Prism 
7300 Real Time PCR system (Applied Biosystems). Negative control reactions were 
performed in the absence of  reverse transcriptase alongside test samples to ensure the 
absence of  contaminating genomic DNA. The amplification of  a single product was 
ensured by melt-curve analysis for each primer pair. A standard curve constructed 
from 1:5 serial dilutions of  a mixture of  cDNA of  the samples in the same run 
was included for each primer pair in every run to perform relative quantification of  
expression. The housekeeping gene β-actin was used for normalization: the relative 
quantity of  gene of  interest was divided by the relative quantity of  beta-actin.
The sequences of  the primer pairs used were:
TNF-α   forward:  5’-CAGACCCTCACACTCAGATCATCT-3’
reverse:  5’-CCTCCACTTGGTGGTTTGCTA-3’
IL-6   forward: 5’-CAAGTCGGAGGCTTAATTACACATG-3’
reverse:  5’-ATTGCCATTGCACAACTCTTTTCT-3’
IL-10   forward: 5’-CCAGGGAGATCCTTTGATGA-3’
reverse:   5’-AACTGGCCACAGTTTTCAGG-3’
β-actin   forward: 5’-GGCTGTATTCCCCTCCATCG-3’
reverse:  5’-CCAGTTCGTAACAATGCCATGT-3’
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Statistical Analysis
Data were normally distributed (calculated by the Kolmogorov-Smirnov test). 
Because there was a considerable variation in the LPS response between alveolar 
macrophage cultures obtained from 3 different mice, the effect of  GTS-21 was 
expressed as % of  the LPS-induced TNF-α production in the absence of  GTS-
21. Alveolar-arterial gradient was calculated using the formula: FiO2*(Atmospheric 
pressure-H2O pressure) - (PaCO2/0.8) - PaO2. The Grubbs test (extreme studentized 
deviate method) was performed and significant outliers were excluded from analysis 
(maximum of  one exclusion per dataset). Statistical differences between the groups 
were detected by one-way analysis of  variance (ANOVA, with a Bonferroni post-
hoc test to check for significant differences between ventilated groups) or unpaired 
two-sided Student’s t-tests as appropriate. Pearson correlation analysis was used to 
investigate the relation between TNF-α, IL-6, and KC concentrations. A p-value 
less than 0.05 was considered statistically significant. All tests were performed with 
Graphpad Prism 5 (Graphpad Software, La Jolla, USA). 
Results
Treatment with the selective partial α7nAChR agonist GTS-21 attenuates MV-induced TNF-α 
production at the transcriptional level
In ventilated placebo-treated mice both proinflammatory (TNF-α, IL-6, and KC) and 
anti-inflammatory (IL-10) mediators were increased in plasma compared with non-
ventilated controls (Figure 1A). Similarly, in lung homogenates, TNF-α, IL-6, and 
KC levels were elevated in ventilated animals compared with the NV group (Figure 
1B). Pretreatment with GTS-21 significantly attenuated MV-induced TNF-α levels in 
plasma and lung homogenates. Although plasma and lung concentrations of  TNF-α 
correlated with levels of  the other proinflammatory cytokines IL-6 and IL-10 in our 
model (supplementary Figure 1), GTS-21 pretreatment did not affect these cytokines 
or the anti-inflammatory mediator IL-10. 
Four hours of  MV upregulated TNF-α and IL-10, but not IL-6 mRNA expression in 
lung tissue, measured by quantitative PCR analysis (Figure 2). GTS-21 pretreatment 
abrogated the MV-induced TNF-α upregulation while not significantly affecting IL-10 
expression, indicating that GTS-21 inhibits TNF-α production at the transcriptional 
level. 
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Figure 1     Inflammatory cytokine levels in plasma (A) and lung homogenate (B) of  non-ventilated 
(NV, n=8), placebo-treated & ventilated (placebo-MV, n=18) and GTS-21 treated & ventilated 
(GTS21-MV, n=16) mice. Lung homogenate cytokine levels are normalized to the total amount of  
protein in each homogenate. ANOVA p-values: plasma: TNF-α p=0.0002, IL-6 p=0.0008, KC 
p=0.0035, IL-10 p<0.0001. Lung: TNF-α p=0.034, IL-6 p<0.0001, KC p=0.0007, IL-10 
p=0.0048. Data are represented as mean+SD. * indicates p<0.05 compared with placebo-MV (Bonfer-
roni post-hoc test of  placebo-MV vs. GTS21-MV).
Figure 2     mRNA expression (relative to the housekeeping gene beta-actin) of  inflammatory cytokines 
in lung tissue of  non-ventilated (NV, n=7), placebo-treated & ventilated (placebo-MV, n=7), and 
GTS-21 treated & ventilated (GTS21-MV, n=7). ANOVA p-values: TNF-α p=0.0017, IL-6 
p=0.45, IL-10 p=0.0013. Horizontal line indicates mean. * indicates p<0.05 compared with placebo-
MV (Bonferroni post-hoc test of  placebo-MV vs. GTS21-MV).
150
Chapter 7
Because alveolar macrophages are important cytokine-producing cells in the lung, we 
wanted to confirm whether GTS-21 inhibited TNF-α transcription and production in 
these cells. Therefore, we isolated murine alveolar macrophages and stimulated them 
with LPS in the presence and absence of  GTS-21 and found that GTS-21 inhibited 
LPS-induced TNF-α production (Figure 3A) and TNF-α gene expression (Figure 3B). 
Figure 3     TNF-α production (A, represented as % of  LPS-induced production) and mRNA 
expression (B, relative to the housekeeping gene beta-actin) in isolated alveolar macrophages stimulated 
with LPS (100 ng mL-1) for four hours in the presence and absence of  GTS-21 (100 μM). TNF-α 
production in the absence of  LPS is below the detection limit (32 pg mL-1); mean LPS-induced TNF-α 
production is 2503 ± 1462 pg mL-1. Data are represented as individual data points of  3 macrophage 
cultures obtained from 3 different mice. Horizontal lines indicate mean.
GTS-21 does not influence MV-induced increases in pulmonary neutrophil influx or lung MPO 
levels 
As depicted in supplementary Figure 2, four hours of  MV resulted in a increase 
in pulmonary neutrophils compared with non-ventilated animals but GTS-21 
pretreatment did not have an effect on neutrophil influx (NV: 4.3 ± 1.5 X 10-4, 
placebo-MV:  8.6 ± 3.0 X 10-4, GTS21-MV: 9.6 ± 3.1 X 10-4 neutrophils/μm2; ANOVA 
p-value: p=0.0012; post-hoc test placebo-MV vs. GTS21-MV: p=NS). Similarly, lung 
homogenate MPO levels were not affected by pretreatment with GTS-21 (placebo-
MV: 45.6 ± 7.0 ng/mg protein, GTS21-MV: 44.9 ± 9.2 ng/mg protein; p=0.86).
GTS-21 lowers the arterial-alveolar gradient
Both placebo- and GTS-21-treated animals exhibited stable haemodynamic parameters 
throughout the experiment (Table 1). Mean arterial pressure (MAP) decreased from 
approximately 100 mmHg at the beginning of  the ventilation period to 80 mmHg 
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after 4 hours in both groups. Lung function after 4 hours of  MV was better in GTS-
21 pretreated mice compared with placebo, reflected by a trend towards a higher 
PaO2, and a significant reduction in the Alveolar-arterial (A-a) gradient. 
Table 1     Cardiorespiratory parameters after four hours of  MV in placebo- and GTS-21-treated 
ventilated animals. 
Data are represented as mean ± SD. p-values are t-test. Values in bold indicate significant p-value.
Table 2     Cardiorespiratory parameters after four hours of  MV in placebo-, neostigmine, and meca-
mylamine-treated animals. 
Data are represented as mean ± SD. p-values are one-way ANOVA.
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Neither the acetylcholinesterase inhibitor neostigmine nor the nAChR antagonist mecamylamine 
affects the MV-induced inflammatory response or change in lung function
To investigate whether alterations of  endogenous cholinergic signalling modulate the 
MV-induced inflammatory response, we determined the effects of  acetylcholinesterase 
inhibition by neostigmine and nAChR blockade by mecamylamine. As shown in 
Table 2 and Figure 4, pretreatment with neostigmine or mecamylamine had no effect 
on MV-induced changes in inflammatory mediators, haemodynamic parameters, or 
blood gas measures.
Figure 4     Inflammatory cytokine levels in plasma (A) and lung homogenate (B) of  non-ventilated 
(NV, n=8), placebo-treated & ventilated (placebo-MV, n=15), neostigmine treated & ventilated 
(neostigmine-MV, n=14), and mecamylamine-treated & ventilated (mecamylamine-MV, n=15) mice. 
Lung homogenate cytokine levels are normalized to the total amount of  protein in each homogenate. 
ANOVA p-values: plasma: TNF-α p=0.0046, IL-6 p<0.0001, KC p=0.0051, IL-10 p=0.0060. 
Lung: TNF-α p=0.0462, IL-6 p=0.0250, KC p=0.0003, IL-10 p=0.5006. Data are represented 
as mean+SD.
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Discussion
In the present study, we demonstrate that MV with clinically relevant settings 
elicits a local and systemic inflammatory response. Pretreatment with the selective 
partial α7nAChR agonist GTS-21 attenuates MV-induced TNF-α production at the 
transcriptional level and improves lung function.
Recently, it was demonstrated that administration of  a centrally acting vagus-mimetic 
drug attenuates VILI induced by high tidal volumes (20 mL/kg)24. In the present 
study, we demonstrate that selective pharmacological stimulation of  the peripheral 
branch of  the cholinergic anti-inflammatory pathway attenuates VILI elicited by MV 
with clinically relevant settings as well. This study confirms earlier findings from our 
group and others that MV using clinically relevant settings results in local and systemic 
cytokine release9, 10. In addition to these studies, we show upregulation of  cytokine 
mRNA (TNF-α and IL-10) in lung tissue, suggesting that the MV-induced elevation 
of  pulmonary cytokine levels is the result of  local production and not merely of  
systemic spillover. As we have shown earlier, using electron microscopy, alveolar 
integrity is preserved with a tidal volume of  8 mL/kg in this model9, indicating that 
the observed inflammatory response is a result of  biotrauma1, 3, 25. We used the same 
protocol in the present study and demonstrate that GTS-21 attenuates the MV-
induced proinflammatory response (TNF-α) at the transcriptional level, but does not 
dampen anti-inflammation (IL-10). These effects are associated with an improved 
lung function. How TNF-α affects lung function is largely unknown, but a critical 
role for this cytokine in the pathophysiology of  VILI has been underlined by others, 
as in a rabbit VILI model, intratracheal administration of  TNF-α antibody improved 
oxygenation and respiratory compliance26. In the absence of  a reduction in alveolar 
inflammatory cell infiltration, the beneficial effects of  GTS-21 on oxygenation in 
our model might be mediated by effects on alveolar capillary membrane integrity, 
which was  previously shown to be compromised in our model9. However, because 
we did not measure wet/dry weight ratios in this study, this remains speculative. 
Another possible explanation for the improvement in lung function by GTS-21 
might rely on regulation of  p38 mitogen-activated protein kinase (MAPK) and c-Jun 
N-terminal kinase (JNK) phosphorylation. These signalling molecules have been 
implicated in the proinflammatory response related to oxygenation in VILI27-31, and 
cholinergic stimulation has been shown to mitigate hypoxia-induced MAPK and JNK 
phosphorylation32.
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Our data are in accordance with recent in vitro studies of  our group and others 
demonstrating that GTS-21 limits TNF-α mRNA expression and production 
in response to various Toll-like receptor agonists in isolated primary human 
monocytes33, 34. Similar to these in vitro studies, GTS-21 did not attenuate MV-induced 
IL-6 release in our model. i.p. GTS-21 also limits plasma TNF-α, but not IL-6, in a 
murine peritonitis model13 and GTS-21 administered locally in the airways inhibits 
TNF-α, but not IL-6 release, in the mouse lung after intratracheal LPS delivery21. The 
anti-inflammatory effects of  GTS-21 in our VILI model are probably attributable 
to its effect on alveolar macrophages, because these are the most likely target for 
GTS-2135, 36, given that it inhibits LPS-induced TNF-α transcription and production 
in these cells.
Despite limiting pulmonary TNF-α production, lung neutrophil influx was not 
inhibited by GTS-21 in our study. This may be explained by the fact that although lower 
TNF-α levels correlated with lower KC concentrations, GTS-21 did not significantly 
reduce KC in our model. KC (the murine homolog of  human IL-8) is an important 
chemokine that plays a major role in attracting neutrophils36, 37. These findings are in 
accordance with those of  the intratracheal LPS instillation model, where GTS-21 did 
not influence pulmonary neutrophil influx21. In contrast, in the peritonitis study13, 
GTS-21 did attenuate neutrophil influx into the pancreas, indicating that the effect 
of  GTS-21 on neutrophil tissue infiltration may be dependent on other factors such 
as tissue type, dose, and timing of  drug delivery21. The lack of  effects of  TNF-α 
reduction on neutrophil influx is of  interest in view of  the failure of  anti-TNF-α 
therapy in changing outcomes in clinical trials.
In our model, the peripheral acetylcholinesterase inhibitor neostigmine had no anti-
inflammatory effects. We chose to administer the same dose (80 µg/kg) which was 
shown by Hofer and colleagues to have remarkable anti-inflammatory effects in a 
murine caecal ligation and puncture (CLP) sepsis model19. In contrast, neostigmine 
in a comparable dose was not protective against endotoxin-induced histopathological 
organ injury in mice38. There are several possible explanations for the lack of  an effect 
in our study. First, the cholinergic anti-inflammatory pathway is regarded as a reflex-
type response to control excessive inflammation18, and peripheral acetylcholinesterase 
inhibition can merely reinforce this endogenous pathway trough increasing ACh 
availability at the α7nAChR. The relatively mild MV-induced inflammatory response 
in our model (especially compared with the fulminant sepsis caused by CLP) may not 
be severe enough to activate this pathway. Along these lines, there would be no vagus-
155
GTS-21 attenuates ventilator-induced TNF-α production and lung injury
7
borne ACh release into the tissues, hence no pronounced anti-inflammatory effect of  
inhibition of  ACh breakdown. The lack of  endogenous activation of  the cholinergic 
anti-inflammatory pathway might also explain why, in our study, nAChR blockade 
with mecamylamine did not worsen the MV-induced inflammatory response, while 
in murine pancreatitis15, mecamylamine treatment led to an amplified inflammatory 
response and enhanced severity. However, mecamylamine is not selective for the 
α7nAChR and might therefore exert various other, yet unknown, effects. Future 
experiments with α7nAChR deficient mice in our model could give a definitive answer 
whether the cholinergic anti-inflammatory pathway is activated in VILI. Another 
explanation for the ineffectiveness of  neostigmine in our study might depend on the 
brain’s impermeability to neostigmine. Although Hofer and colleagues demonstrated 
that neostigmine was equally effective as physostigmine (an acetylcholinesterase 
inhibitor that crosses the blood-brain barrier) in attenuating the inflammatory response 
in murine sepsis, other studies suggest otherwise. For instance, it was demonstrated 
that anti-inflammatory effects of  other acetylcholinesterase inhibitors that cross the 
blood brain barrier are blocked by atropine and vagotomy, but not by atropine methyl 
nitrate, which does not enter the brain39. These data suggest that acetylcholinesterase 
inhibitors dampen inflammation through increasing brain acetylcholine levels leading 
to enhanced activation of  mAChRs and subsequent increased vagus nerve activity. In 
accordance, direct central mAChR stimulation results in activation of  the cholinergic 
anti-inflammatory pathway40. 
A potential limitation of  this study is the use of  atropine as part of  the anaesthetic 
regime. While atropine is a classic mAChR agonist, several studies have demonstrated 
that atropine can also (partially) block nicotinic acetylcholine receptor responses 
in Xenopus laevis oocytes and bovine adrenal chromaffin cells41, 42. Very recently, 
atropine was shown to reduce the mitigating effects of  acetylcholine on hypoxia–
induced TNF-α expression in a cardiomyocyte cell line32, and interestingly, it also 
blocked vasodilatory effects of  acetylcholinesterase inhibitors, including neostigmine, 
in porcine arterial rings43. This could represent another explanation for the lack 
of  an effect of  neostigmine in our model. However, atropine did not block anti-
inflammatory effects of  acetylcholine in human macrophages11, and the fact that 
GTS-21 limits inflammation in our model suggests that α7nAChR signalling is still 
functional in the presence of  atropine. 
In conclusion, our data show that stimulation of  the cholinergic anti-inflammatory 
pathway by the selective partial α7nAChR agonist GTS-21 attenuates the inflammatory 
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response induced by four hours of  MV using clinically relevant ventilator settings and 
improves lung function. Modulation of  endogenous cholinergic signalling by either 
peripheral cholinesterase inhibition or nAChR blockade did not affect MV-induced 
inflammation or lung function. GTS-21 might be a promising compound because of  
its suitability for human use, and therefore, further research regarding its effects on 
VILI is warranted. 
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Supplementary material
Supplementary figure 1      Scatterplots of  the association between plasma/lung levels of  TNF-α 
and KC (upper panels) and IL-6 (lower panels). Data depicted were obtained from the neostigmine/
mecamylamine protocol (all three ventilated groups, n=44). Pearson correlation coefficients and p-values 
are indicated in the plots.
Supplementary figure 2     Histochemical analysis of  lung tissue in non-ventilated (A), placebo-
treated & ventilated (B) and GTS-21-treated & ventilated mice (C). Neutrophils are stained black 
(chloracetatesterase staining).
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Abstract 
Background The vagus nerve can reflexively attenuate the innate immune 
response via binding of  the vagal neurotransmitter acetylcholine to the α7 nicotinic 
acetylcholine receptor (α7nAChR). We recently reported potent anti-inflammatory 
effects of  the a7nAChR agonist GTS-21 in human leukocytes. In the present work, 
we investigated the anti-inflammatory effects of  GTS-21 on the innate immune 
response during experimental human endotoxemia. 
Methods We performed a double-blind placebo-controlled pilot study in 14 
healthy nonsmoking male volunteers. Subjects received 150 mg GTS-21 (n=7) or 
placebo (n=7) orally three times per day during 3 days before endotoxin administration 
and on the day of  the human endotoxemia experiment. This GTS-21 dosage 
scheme is the highest reported to be safe in humans. Subsequently, subjects were 
intravenously administered 2 ng/kg endotoxin (LPS derived from E coli O:113). Serial 
blood withdrawals were performed to determine GTS-21 plasma concentrations and 
inflammatory mediators.
Results  Plasma concentrations of  GTS-21 and its active metabolite 4-OH-
GTS-21 were highly variable between subjects. LPS administration resulted in a 
transient inflammatory response. There were no differences in the LPS-induced 
cytokine response between the GTS-21- and placebo-treated groups. However, 
within the GTS-21-treated group, higher GTS-21 plasma concentrations correlated 
with lower levels of  TNF-α (r=-0.78, p=0.03), IL-6 (r=-0.76, p=0.04) and IL-1RA 
(r=-0.86, p=0.01), but not IL-10 (r=-0.35, p=0.25).
Conclusions  Although higher GTS-21 plasma concentrations significantly 
correlated with lower cytokine levels, the highest dose tested to be safe in humans did 
not result in significant differences in inflammatory mediators between the GTS-21- 
and placebo-treated groups. 
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Introduction 
The innate immune system is crucial to host defense because it embodies the initial 
inflammatory response to invading pathogens1. However, an excessive inflammatory 
response, reflected by high levels of  inflammatory mediators such as TNF-α, can lead 
to tissue damage and organ injury2. These detrimental effects are often observed in 
critically ill patients, for instance in the syndrome of  sepsis or after major trauma, 
but also in autoimmune disorders such as rheumatoid arthritis and inflammatory 
bowel disease3.  As such, modulation of  the innate immune system could prove to be 
beneficial.  
In the past two decades, the interplay between the vagus nerve and the immune system 
has been firmly established. Inflammatory mediators in the periphery are sensed by 
the afferent vagus nerve, and this information is relayed to the brain, resulting in fever 
generation and activation of  the hypothalamic-pituitary-adrenal axis4, 5. More recently, 
it was demonstrated  in animal models that the vagus-immune link is bidirectional; 
efferent vagus nerve activity can dampen inflammation in a reflex-like fashion via the 
so-called cholinergic anti-inflammatory pathway6. The anti-inflammatory effect of  
the vagus nerve is mediated via binding of  the vagal neurotransmitter acetylcholine to 
the α7 nicotinic achetylcholine receptor (α7nAChR) expressed on macrophages and 
other cytokine-producing cells7.
 
Human data regarding the cholinergic anti-inflammatory pathway is scarce. To date, only 
one study has reported the effects of  stimulation of  the cholinergic anti-inflammatory 
pathway on the inflammatory response in man. Transdermal administration of   the 
nonselective nAChR agonist nicotine during human endotoxemia did not affect 
proinflammatory cytokine levels, however, it did increase plasma concentrations of  
the anti-inflammatory cytokine IL-108.  
GTS-21 (3-(2,4-dimethoxybenzylidene) anabaseine, also known as DMXBA, is an 
α7nAChR agonist that enhances cholinergic transmission in the brain. Studies using 
human α7nAChR expressed in Xenopus oocytes have demonstrated that specific 
α7nAChR antagonists block GTS-21 receptor activation, and that GTS-21 has only 
very weak agonist activity at other nAChRs9. Therefore, GTS-21 is widely regarded 
as a selective α7nAChR agonist10-17. GTS-21 is suitable for human use and underwent 
phase I/II trials in healthy subjects and for the treatment of  schizophrenia18-20. Apart 
from neuronal effects, in vitro experiments in cell lines and in vivo animal studies have 
investigated the effects of  GTS-21 on inflammation. These studies demonstrated that 
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GTS-21 inhibits TNF-α and high-mobility group box protein 1 (HMGB1) release and 
improves survival during endotoxemia and severe sepsis in mice12, 15. Recently, we and 
others demonstrated that stimulation of  the α7nAChR by GTS-21 in primary human 
monocytes, peripheral blood mononuclear cells, and whole blood leads to a dose-
dependent inhibition of  proinflammatory, but not anti-inflammatory cytokine release 
induced by stimulation of  various Toll-like receptors16, 21. These results suggest that 
GTS-21 might be effective in limiting the inflammatory response in humans. So far, 
no data are available on the immunomodulatory effects of  GTS-21 in humans in vivo.
In this proof-of-principle pilot study, our primary aim was to investigate the effects of  
oral administration of  GTS-21 (in the maximum dose reported to be safe in humans) 
on the innate immune response using the human endotoxemia model. Second, we 
wanted to study whether higher GTS-21 plasma concentrations were associated with 
lower LPS-induced cytokine levels, both in vivo and ex vivo.
 
Materials and methods
Subjects & medication
We performed a prospective double-blind, placebo-controlled, randomized pilot 
human endotoxemia study (Clinical Trial Register number NCT00783068) in 14 
healthy young male subjects (range 18-28 years). Furthermore, we assessed the effects 
of  oral treatment with GTS-21 on the cytokine response ex vivo in 6 healthy male 
volunteers (range 19-25 years). 
After approval by the local ethics committee of  the Radboud University Nijmegen 
Medical Centre, all healthy volunteers signed written informed consent. Screening 
of  the subjects within 14 days before the test revealed no abnormalities in medical 
history or physical examination. Exclusion criteria were use of  any medication, 
smoking, history of  cardiovascular disease, (family) history of  cerebrovascular 
disease, previous vagal collapse, hypertension (RR systolic > 160 or RR diastolic 
> 90 mmHg), hypotension (RR systolic < 100 or RR diastolic < 50 mmHg), renal 
impairment (plasma creatinine > 120 µmol/l), liver enzyme abnormalities, and 
positive hepatitis or HIV serology. Subjects refrained from food 12 hours before 
the start of  the experiment, and caffeine or alcohol containing substances 24 hours 
before the start of  the experiment. GTS-21 and placebo capsules were a kind gift 
from CoMentis Inc (South San Francisco, CA, USA). 
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Study protocols
Endotoxemia protocol
Subjects ingested capsules of  150 mg GTS-21 (n=7) or placebo (n=7) three times 
per day starting 3 days before the endotoxemia experiment (day -3; 10 am, 6 pm, and 
11 pm), and a single oral dose of  150 mg of  GTS-21 or placebo on the endotoxin 
infusion (experimental) day before 7 am. Subjects then received an oral dose of  150 
mg GTS-21 or placebo at 8 am and another oral dose of  150 mg GTS-21 or placebo 
at 1 hour before endotoxin infusion. The last dose of  GTS-21 was administered 
1 hour before endotoxin administration. All experiments were performed at the 
research unit of  the intensive care department, with subjects in supine position. After 
local anesthesia (lidocaine HCl 20 mg/ml) the radial artery was cannulated using 
a 20-Gauge arterial catheter (Angiocath; Becton Dickinson, Sandy UT, USA) and 
connected to an arterial pressure monitoring set (Edwards Lifesciences LLC, Irvine 
CA, USA), connected to a Phillips IntelliVue MP70 monitor (Philips Medical Systems, 
Eindhoven, The Netherlands). The arterial line was used for continuous monitoring 
of  blood pressure and blood sampling. A cannula was placed in the antecubital vein 
to permit infusion of  2,5% glucose/0,45% saline solution; subjects received 1,5 L 
during one hour starting one hour before endotoxin infusion (prehydration), followed 
by 150 ml/h until 6 hours after endotoxin infusion and 75 ml/h until the end of  
the experiment. Body temperature was measured every 30 minutes using an infrared 
tympanic thermometer (FirstTemp Genius, Sherwood Medical, Crawley/Sussex, 
UK). Heart rate was continuously monitored using a 3-lead ECG. Subjects received 
U.S. Reference Escherichia coli endotoxin (LPS derived from Escherichia coli O:113, 
Clinical Center Reference Endotoxin; National Institute of  Health, Bethesda, MD). 
Endotoxin, supplied as a lyophilized powder, was reconstituted in 5 ml saline 0.9% for 
injection and vortex-mixed for at least 10 minutes after reconstitution. The endotoxin 
solution was administered as an intravenous bolus injection at a dose of  2 ng/kg 
of  body weight. Blood withdrawal time points for GTS-21/4-OH-GTS-21 plasma 
concentration and cytokine measurements are indicated in the corresponding graphs. 
Ex vivo protocol
Subjects ingested capsules of  150 mg GTS-21 three times per day starting 1 day 
before the experimental day (day -1; 10 am, 6 pm, and 11 pm), and two 150 mg doses 
on the experimental day (the first before 7 am, the second at 10 am, which was set at 
T=0). The rest of  the protocol was identical to the endotoxemia protocol, with the 
exception of  LPS administration. Blood was drawn from the arterial line for GTS-21 
plasma concentration measurement and ex vivo whole-blood stimulation at day -1, 
T=0, T=1, T=1.5, T=2, T=4, and T=6.
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GTS-21 and 4-OH-GTS-21 plasma concentration
Blood samples to determine GTS-21 and its active metabolite 4-OH-GTS-21 
concentrations were collected in lithium-heparin-containing tubes (Vacutainer System, 
Becton Dickinson; Rutherford, NJ, USA), centrifuged for 10 minutes at 2450 g at 4°C 
after which plasma was collected and stored at -80 oC until analysis. Pharmacokinetic 
(PK) analysis was performed by Absorption Systems (Exton, PA, USA) using a high-
performance liquid chromatography assay. Blood tests on day -1 & -3 were performed 
on venous blood samples; on the experimental days, tests were performed on blood 
samples drawn from the arterial cannula.
Ex vivo whole-blood stimulation
Blood was drawn into 4 mL lithium-heparin-containing vacutainers (Vacutainer 
System, BD Biosciences). Whole blood was diluted 1:5 in culture medium (RPMI 
1640 Dutch modification; ICN Biomedicals, Costa Mesa, CA, USA; supplemented 
with gentamicin 10 µg/mL, L-glutamine 10 mM and pyruvate 10 mM) and placed in 
24-well plates (1 mL/well) for 24 hours in the presence and absence of  100 pg/mL 
E. coli LPS (serotype O55:B5, Sigma-Aldrich, St Louis, MO, USA; further purified as 
described previously22). After incubation for 24 hours at 37 oC, 95% O2 and 5% CO2, 
whole-blood cultures were centrifuged (14000 rpm, 5 min) after which supernatants 
were stored at -80 oC until assayed. 
Cytokine measurements
Plasma concentrations of  TNF-α, IL-6, IL-10 and IL-1RA were measured using a 
simultaneous Luminex Assay according to the manufacturer’s instructions (Bio-plex 
cytokine assay, BioRad, Hercules, CA, USA). Plasma concentrations of  HMGB1 were 
measured using the HMGB1 ELISA kit II according to the manufacturer’s instructions 
(Shino-Test corporation, Kanagawa, Japan). Apart from the acute endotoxemic 
phase, HMGB1 levels were also assessed 24 hours after LPS administration, because 
HMGB1 levels peak 16 to 32 hrs after endotoxin exposure in mice23. IL-6 in ex 
vivo stimulated whole-blood supernatants was determined by a commercial ELISA 
according to the manufacturer’s instructions (Pelikine Compact, Sanquin, Amsterdam, 
The Netherlands). TNF-α in supernatants was determined by a specific ELISA using 
four antibodies as previously described24.
Data analysis, calculations, and statistics
Because the in vivo immunomodulatory potency of  GTS-21 was unknown, a formal 
power calculation was not possible. Therefore we decided to perform a pilot study of  
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7 subjects per group and based on the data of  these 14 subjects, a power calculation 
using the Areas Under Curve (AUCs) of  the LPS-induced cytokine response was 
performed to decide whether a larger study was necessary or feasible. In view of  
the relatively small group size (n=7), the normality of  distribution was not assumed. 
Data are expressed as median (interquartile range) unless specified otherwise. Mann-
Whitney U tests and Friedman tests were used as indicated (two-sided p-values). To 
increase the sensitivity of  this pilot study, the AUCs of  GTS-21 and 4-OH-GTS-21 
plasma concentrations obtained in GTS-21-treated subjects were correlated with their 
AUC cytokine responses. Because GTS-21 plasma concentrations were frequently 
measured during endotoxemia, an accurate PK profile for AUC calculation was 
obtained. Pearson correlation was used for regression analysis of  log-transformed 
variables. Because we investigated whether increasing plasma concentrations of  GTS-
21 were associated with a lower cytokine response, both in vivo and ex vivo, one-sided 
p-values were calculated in the correlation analysis. A p-value <0.05 was considered 
significant. Statistical analyses were performed using Graphpad Prism 5.0 (Graphpad 
Software, San Diego, CA, USA).
Results
Baseline characteristics and safety
Demographic data are shown in Table 1. No relevant differences in baseline 
characteristics between both endotoxemia groups were present. No serious adverse 
events occurred and no abnormal laboratory findings were found during the trial. 
Two subjects had minor abdominal discomfort after ingestion of  GTS-21, without 
vomiting or pain. 
Table 1     Demographic characteristics
BMI, body mass index; HR, heart rate; MAP, mean arterial blood pressure. Data are presented 
as mean ± SEM of  7 (endotoxemia protocol) and 6 (ex vivo protocol) subjects per group.
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GTS-21 and 4-OH-GTS-21 PK during endotoxemia
GTS-21 plasma concentrations were not detectable in any of  the subjects of  the 
placebo group at any time point or in the GTS-21 group before the start of  treatment 
(data not shown). Median plasma concentrations of  GTS-21 and its metabolite 4-OH-
GTS-21 on the endotoxin infusion day are shown in Figure 1. GTS-21 and 4-OH-
GTS-21 levels were highly variable between subjects. 4-OH-GTS-21 levels were 
consistently higher than GTS-21 levels, but displayed a virtually identical PK profile, 
as depicted in Figure 1 and also per subject (data not shown). Peak concentrations 
of  both GTS-21 and its metabolite were observed on  T=-1 hrs (approximately one 
hour after the penultimate GTS-21 dose) and decreased at T=0 hrs (one hour after 
the last GTS-21 dose), probably as a result of  prehydration of  the subjects before the 
LPS administration. At T=0 hrs (time of  LPS administration) plasma concentration 
of  GTS-21 ranged from 3 to 89 ng/mL (median 13 ng/mL, equivalent to 34 nM). 
The highest concentration of  GTS-21 measured in a subject was 199 ng/mL (524 
nM at T=1 hr). 
Figure 1     Box-and-whisker plots of  plasma concentration of  GTS-21 and its metabolite 4-OH 
GTS-21 in GTS-21-treated subjects. Whiskers indicate maximum/minimum. n=7 subjects.
Hemodynamic, hematological, and clinical parameters during endotoxemia
As summarized in Table 2, LPS administration resulted in typical changes in 
hemodynamic, hematological and, clinical parameters in both groups. All LPS-induced 
changes were statistically significant in both groups, but there were no differences 
between the placebo- and the GTS-21-treated groups.
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Table 2     LPS-induced changes in hematological and clinical parameters
MAP, mean arterial pressure (minimum value at T=7); HR, heart rate (maximum value at T=4); 
TEMP, temperature (minimum value at T=3.5); WBC, white blood cell count (minimum value at T=1, 
maximum value at T=8). Data are presented as median (interquartile range) of  7 subjects per group. 
p-values within groups were calculated by Friedman’s test (entire curve, all time points); p-values between 
groups were calculated by Mann-Whitney U-test of  AUCs of  the entire curve.
Plasma cytokines during endotoxemia
LPS administration resulted in a significant transient increase of  inflammatory 
cytokines (TNF-α, IL-6, IL-10 and IL-1RA) in both groups (Figure 2). There were no 
significant differences in cytokine response between the GTS-21- and placebo-treated 
group. Plasma HMGB1 levels were not increased during endotoxemia, neither in the 
acute (4 and 8 hours post-LPS), nor the late phase (24 hours post-LPS). Moreover, 
there were no differences between placebo- and GTS-21-treated subjects. Data of  the 
whole group (n=14) are reported: baseline (T=0): 0.85 (0.93) ng/mL vs. T=24: 1.02 
(0.94) ng/mL; p=0.19.
Correlation between GTS-21 plasma concentrations and cytokine response during endotoxemia
One GTS-21-treated subject had barely detectable plasma concentrations of  GTS-21; 
this subject was excluded from the correlation analysis. As depicted in Figure 3, higher 
GTS-21 plasma concentrations were strongly associated with lower levels of  TNF-α, 
IL-6, and IL-1RA, but not IL-10. Correlation coefficients between 4-OH-GTS-21 
and cytokines were TNF-α: r=-0.58 (p=0.11); IL-6: r=-0.73 (p=0.05); IL-10: r=0.01 
(p=0.49) and IL-1RA: r=-0.89 (p=0.01).  
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Figure 2     Box-and-whisker plots of  plasma concentrations of   inflammatory cytokines after 
LPS administration. Whiskers indicate maximum/minimum. n=7 subjects per group. Time p-value 
indicates the cytokine response in time within both groups (Friedman test); Plac vs. GTS-21 p-value 
represents comparison of  Area Under Curves (AUC) between both groups (Mann-Whitney U test).
Figure 3     Correlation between log Area Under Curve (AUC) of  the plasma concentrations of  GTS-
21 and the log AUC of  the TNF-α, IL-6, IL-10 and IL-1RA plasma concentrations per subject. 
Pearson correlation coefficient (r) and significance (p) are indicated in the plots. n=7 subjects. Arrows 
indicate excluded subject.
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Power calculation using the obtained results from the endotoxemia protocol
To determine how many subjects would be needed to detect a statistically significant 
difference, we performed a power calculation on the obtained TNF-α AUC data. 
With a mean±SD AUC TNF-α of  2518±2166 in the placebo group and 1703±1295 
in the GTS-21 group, we determined that in order to achieve a power of  80%, 61 
subjects per group would be needed. 
Cytokine production in ex vivo LPS-stimulated whole blood obtained from GTS-21-treated subjects
In a separate set of  healthy male volunteers (n=6), we studied the cytokine production 
in ex vivo LPS-stimulated whole blood obtained before and at various time points after 
GTS-21 administration. GTS-21 plasma concentrations were again highly variable 
between subjects and somewhat higher compared with those enrolled in the endotoxin 
protocol (22.0 (103.5) vs. 12.7 (47.0) ng/mL 1 hour after the last GTS-21 dose and 
43.8 (105.8) vs. 12.6 (130.6) ng/mL 1.5 hours after the last GTS-21 dose, data of  6 
and 7 subjects, respectively). Ex vivo stimulation with LPS led to robust release of  
TNF-α and IL-6 compared with incubation with medium alone (TNF-α: 413 (254) vs. 
48 (79) pg/mL; IL-6: 2062 (2490) vs. 237 (441) pg/mL, data of  6 subjects measured 
at 7 time points). However, neither TNF-α nor IL-6 production was influenced by 
GTS-21 treatment; production was similar in whole blood obtained before GTS-21 
treatment compared with blood obtained at any of  the time-points following GTS-
21 administration (data not shown). We also correlated plasma concentrations of  
GTS-21 to cytokine production of  blood obtained at the same time point, but no 
significant correlations were found (log GTS-21 – log TNF-α: r=0.11, p=0.27; log 
GTS-21 – log IL-6: r=0.18, p=0.15).  
Discussion 
We and others have demonstrated that GTS-21 potently attenuates the LPS-induced 
inflammatory response in human leukocytes16, 21. Furthermore, GTS-21 has been 
shown to limit the LPS-induced inflammatory response in animals in vivo12, 13, 15. 
Because GTS-21 is suitable for human use, herein we investigated whether GTS-21 
modulates the LPS-induced innate immune response in humans in vivo. We used the 
human endotoxemia model, a standardized model to study the systemic inflammatory 
response in vivo in man25.  Subjects were administered GTS-21 at the maximum dose 
that has been tested safe in humans19. We found large interindividual variations of  
obtained GTS-21 plasma concentrations and cytokine responses and did not find 
differences in LPS-induced plasma cytokine levels between the GTS-21- and placebo-
treated groups. However, within the group of  GTS-21-treated subjects, higher plasma 
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concentrations of  GTS-21 correlated with lower cytokine levels. GTS-21 treatment 
did not exert anti-inflammatory effects in ex vivo LPS-stimulated whole blood.
An explanation for the lack of  differences in cytokine response between the GTS-
21- and placebo-treated group could be the highly variable (between subjects) and 
relatively low median plasma GTS-21 concentrations observed in our study. We have 
shown earlier that GTS-21 is effective in attenuating LPS-induced cytokine release 
from primary human leukocytes in a dose-dependent manner with concentrations 
ranging from 1 μM to 100 μM21. In accordance, animal in vivo studies have shown 
that the effects of  GTS-21 are highly dose dependent13, 15. The highest concentration 
of  GTS-21 found in a subject in our study (approximately 0.5 μM)  was still below 
the concentration found to be effective in vitro. To our knowledge, Kitagawa et al. 
performed the only PK study on GTS-2119. To maximize GTS-21 effects, we dosed 
the subjects with the highest dose per day that has been reported in man (150 mg three 
timers per day. in the aforementioned pharmacokinetics study19); this dose was found 
to be well-tolerated without significant side effects in healthy volunteers. In addition, 
to limit intersubject variability in plasma concentrations, which has been shown to 
decrease with continued dosing19, and to maximize tissue penetration and receptor 
activation we started treatment 3 days before LPS administration. We administered the 
last dose of  GTS-21 one hour before LPS administration because the Tmax of  GTS-
21 is approximately 1 hour19. The distinct dip in the plasma concentration of  GTS-21 
one hour after ingestion of  the last dose was probably a result of  prehydration of  the 
subjects with  1.5 L of  fluid administered before LPS administration, which might 
have reduced the effectiveness of  GTS-21 in our study. The prehydration is part 
of  our standard human endotoxemia protocol to attenuate the chances of  a vagal 
collapse26. In accordance with our study, Kitagawa et al. also found a large between-
subject variability with maximum plasma concentrations ranging from 9 to 147 ng/
mL using a similar dosing scheme (5 days, 150 mg three times per day)19. Plasma 
levels of  the GTS-21 metabolite 4-OH-GTS-21 were also determined because this 
metabolite displays higher efficacy than GTS-21 for stimulating human α7nAChR27. 
Concentrations of  4-OH-GTS-21 were higher than those of  GTS-21, probably as 
a result of  accumulation of  the metabolite during the previous 3 days of  GTS-21 
dosing, but displayed a virtually identical pharmacokinetic profile. 
Because of  the relatively low median plasma concentrations and high interindividual 
variation in GTS-21/4-OH-GTS-21 plasma concentrations, we aimed to improve 
the sensitivity of  our study by examination of  a correlation of  plasma drug 
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concentrations and cytokine concentrations per subject. Significantly lower levels 
of  TNF-α, IL-1RA and IL-6 were observed with increasing GTS-21 concentrations. 
Plasma IL-10 did not correlate with drug levels. In concordance, GTS-21 strongly 
attenuates endotoxin-induced TNF-α production in vitro while IL-10 production is 
not affected at doses of  1-10 µM21. While IL-1RA is generally regarded as an anti-
inflammatory mediator, its production is induced by TNF-α and IL-628, 29. In addition, 
established anti-inflammatory compounds such as epinephrine or glucocorticoids also 
downregulate IL-1RA (and TNF-α and IL-6) plasma levels, whereas IL-10 production 
is enhanced30-33. As such, our findings suggests an anti-inflammatory effect of  GTS-
21 at higher plasma concentrations. After our pilot study, we performed a power 
calculation with the obtained results and found that to achieve a power of  80%, 
61 subjects per group would be needed.  It was not feasible to conduct a study of  
this size. Moreover, in light of  the highly variable and relatively low GTS-21 plasma 
concentrations, higher dosage schemes or another route of  administration for GTS-
21 should first be tested for suitability/safety. Therefore, we decided not to extend 
this pilot-study.
Our previous data show that GTS-21 potently inhibits LPS-induced cytokines in 
whole blood, peripheral blood mononuclear cells, and isolated monocytes in vitro21. 
Anti-inflammatory effects between the three cell systems were very similar, indicating 
that, in short-term stimulation experiments (up to 24 hours), GTS-21 effects 
are mainly mediated by monocytes in these cell systems. However, during human 
endotoxemia, most of  the cytokines are produced by tissue-resident macrophages, 
not circulating monocytes. We wanted to exclude the possibility that the absence 
of  an anti-inflammatory effect of  GTS-21 at the group level was caused by the 
difference in cell populations responsible for cytokine production between the in 
vivo and in vitro situation. Apart from the lower plasma concentrations of  GTS-21 
obtained in vivo compared with the in vitro experiments, this could represent another 
explanation of  the observed results. To this end, we studied the cytokine production 
in ex vivo LPS-stimulated whole blood obtained before and at various time-points 
after GTS-21 administration (in subjects in vivo) in a separate set of  healthy volunteers 
and observed no anti-inflammatory effects of  GTS-21. These findings indicate that 
not the difference in cell populations, but the relatively low plasma concentrations 
account for the difference between the in vivo and in vitro experiments. The fact that 
significant correlations between higher plasma levels of  GTS-21 and lower cytokine 
levels were observed during human endotoxemia but not in the ex vivo protocol might 
rely on tissue accumulation of  GTS-21 and hence more pronounced effects on tissue-
resident macrophages.
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Human data regarding the cholinergic anti-inflammatory pathway are very limited. 
A number of  association studies investigated the relationship between heart rate 
variability (HRV), as a measure of  cardiac vagal function, and inflammatory mediators 
such as C-reactive protein and IL-6 in healthy adults. It was found that higher cardiac 
vagal tone correlates with lower levels of  inflammatory markers34, 35. Recently, the 
correlation between HRV measures and the inflammatory response was investigated 
in the human endotoxemia model. Surprisingly, this study did not reveal a correlation 
between baseline vagal HRV measures and cytokine release36.  
Our study is the first to investigate selective stimulation of  the cholinergic anti-
inflammatory pathway in humans. In the only other study that investigated stimulation 
of  the cholinergic anti-inflammatory pathway in humans, Wittebole et al. evaluated 
the effectiveness of  the nonselective nAChR agonist nicotine using a similar human 
endotoxemia study design8. Healthy volunteers received a cutaneously applied 
nicotine or placebo patch after which they were injected with 2 ng/kg LPS. This study 
failed to show an effect of  nicotine on proinflammatory cytokine release. There was 
a slight, but statistically significant, increase in the anti-inflammatory cytokine IL-10 
in the nicotine-treated group. However, because nicotine is nonselective, its effects 
might be mediated via other pathways than α7nAChR stimulation. In accordance, 
the authors speculate that the increase in IL-10 might result from increased cortisol 
levels found in the nicotine-treated group rather than a direct effect of  α7nAChR 
stimulation, because glucocorticosteroids have been shown to enhance IL-10 
production during human endotoxemia31, 32. Possibly, the lack of  an effect of  nicotine 
on proinflammatory cytokine production in this study was also caused by low plasma 
concentrations of  nicotine. In vivo, nicotine is rapidly metabolized into cotinine; 
as such nicotine concentrations were not determined in this study8. Mean plasma 
cotinine concentration was 52 ng/mL8. Because plasma levels of  cotinine are higher 
than those of  nicotine37, it is highly unlikely that plasma nicotine concentrations were 
achieved that have been shown to modulate the inflammatory response in human 
leukocytes in vitro (100 μM – 1 mM, equivalent to 16.2-162 μg/mL)16, 21.  
In conclusion, oral administration of  GTS-21 in the maximum dose tested to be safe in 
humans does not appear to modulate the inflammatory response in vivo in man. This is 
likely caused by the high intersubject variability in GTS-21 plasma concentrations and 
relatively low median GTS-21 plasma concentrations achieved, because we did find 
correlations between higher plasma concentrations and lower inflammatory cytokine 
levels within the group of  GTS-21 treated subjects. Large groups would be needed to 
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definitively establish the anti-inflammatory effects of  GTS-21 in man using this dosage 
scheme. In view of  these findings, similar studies using higher doses or another route 
of  administration (e.g. intravenous) should be undertaken to determine the definitive 
potential of  GTS-21 to modulate the innate immune response in humans. Studies 
exploring the potential of  other selective α7nAChR agonists to modulate the innate 
immune response in humans are also warranted. Compounds such as AR-R17779 
and TC-7020 have shown promise in animal models of  inflammation, but have not 
been administered to humans up to now38-40. These drugs might have better PK 
properties and potency/efficacy compared with GTS-21, resulting in higher plasma 
concentrations and more pronounced α7nAChR stimulation.
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Abstract
Background A dysregulated inflammatory response is an important cause of  
morbidity and mortality in critically ill patients. Enteral administration of  lipid-
enriched nutrition was previously shown to attenuate inflammation and organ damage 
via a cholecystokinin-mediated vagovagal reflex in animal studies. The current proof-
of-principle study investigates the immunomodulatory potential of  enteral lipid- and 
protein-enriched (enriched) nutrition during experimental human endotoxemia.
Methods After an overnight fast, 18 healthy male subjects received an 
intravenous bolus of  Escherichia coli lipopolysaccharide (LPS; 2 ng/kg). Subjects in the 
fasted group (n = 6) were deprived of  food throughout the study, while subjects in the 
intervention groups were fed either enriched (n = 6) or isocaloric control nutrition (n 
= 6) via a nasojejunal tube, starting 1 hour prior to LPS administration until 6 hours 
afterwards. 
Results  LPS administration resulted in a marked inflammatory response. 
Continuous postpyloric administration of  nutrition increased plasma cholecystokinin 
levels. Enriched nutrition attenuated circulating levels of  the proinflammatory cytokines 
TNF-α and IL-6, and IL-1 receptor antagonist compared with control nutrition (all: 
p<0.01) and fasted subjects (all: p<0.05). Additionally, enriched nutrition augmented 
the anti-inflammatory response, reflected by increased IL-10 release compared with 
fasted subjects (p<0.0001). 
Conclusions The current study establishes the anti-inflammatory potential of  
enriched nutrition in humans. The instant anti-inflammatory effect of  enriched 
nutrition suggests that the beneficial effects are mediated via a cholecystokinin-
dependent vagovagal reflex. Enteral administration of  enriched nutrition is a 
promising intervention to modulate the immune response in the early course of  
systemic inflammation. 
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Introduction
Despite diagnostic and therapeutic advances in medical care, a dysregulated systemic 
inflammatory response remains a major complication in surgical, trauma and critically 
ill patients, which is associated with increased morbidity and mortality1, 2. Modulation 
of  the early excessive inflammatory response represents a potential therapeutic 
option to improve outcome3. Although experimental studies demonstrated promising 
results of  interventions aimed at inhibition of  single proinflammatory mediators, 
clinical implementation has failed to be successful4. Enhanced insight in disease 
pathology and development of  novel treatment modalities which broadly affect the 
inflammatory response are warranted to reduce morbidity and mortality5-7. Recently, 
enteral administration of  nutrients was shown to improve immune competence 
and clinical outcome in surgical and critically ill patients8-10. Although nutritional 
interventions are promising, the exact mechanisms behind the beneficial effects 
remain to be elucidated.
In the past two decades, the autonomic nervous system has been identified as a 
potent endogenous modulator of  the immune response7. Both microbial toxins and 
inflammatory cytokines are sensed by afferent vagal fibers, resulting in fever and a 
humoral anti-inflammatory response via the hypothalamic-pituitary-adrenal axis11. In 
turn, parasympathetic outflow suppresses release of  proinflammatory cytokines and 
enhances phagocytosis through binding of  acetylcholine to nicotinic acetylcholine 
receptors on inflammatory cells12, 13. Selective pharmacologic or electric stimulation 
of  this neuroimmune axis, called the cholinergic anti-inflammatory pathway, improves 
outcome in various inflammatory models14, 15. Our group demonstrated that this 
endogenous neuroimmune axis can be activated by short-term administration of  
enteral lipid-enriched nutrition16-18. The luminal presence of  lipid-enriched nutrition 
results in cholecystokinin (CCK) release, which activates CCK-receptors located on 
afferent vagal fibers19. Activation of  these receptors triggers a vagovagal reflex, that 
reduces systemic and organ-specific inflammation, and decreases intestinal damage 
via activation of  peripheral nicotinic receptors17, 18. 
A well-timed nutritional stimulation of  this potent gut-brain-immune axis could 
be a promising intervention to treat inflammatory conditions in the clinical setting. 
Therefore, the aim of  the current proof-of-principle study was to investigate the anti-
inflammatory potential of  a nutritional intervention, designed to result in a marked and 
prolonged CCK-release, in man. Based on observations that predominantly enteral 
lipids and proteins trigger CCK release20, continuous postpyloric administration of  a 
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lipid- and protein-enriched (enriched) nutrition was compared with an isocaloric low-
lipid and low-protein control nutrition and to fasting. The effect of  enriched nutrition 
on acute inflammation was studied utilizing the experimental human endotoxemia 
model21. Furthermore, the influence of  enriched nutrition on endotoxin-induced 
subclinical intestinal damage was investigated. 
Materials and methods
Subjects 
This study was registered at ClinicalTrail.gov (NCT01100996). After approval of  the 
ethics committee of  the Radboud University Nijmegen Medical Centre, 12 healthy 
male subjects gave written informed consent to participate in the experiments in 
accordance with the Declaration of  Helsinki. Samples of  fasted subjects (n = 6) were 
obtained from the placebo-group that participated in another double-blind LPS study 
(NCT00513110). There were no differences in subject characteristics (Table 1). All 
subjects tested negative for HIV and hepatitis B. The subjects did not have any febrile 
illness or used any medications in the two weeks preceding the study. 
Table 1     Subject characteristics
Data are represented as mean ± SEM; BMI, body mass index; TER, total energy requirement; NA, 
not applicable. 
Experimental human endotoxemia
Subjects were prehydrated with 1.5 L glucose 2.5%/NaCl 0.45% after which they 
received an intravenous bolus of  2 ng/kg body weight U.S. reference E. coli endotoxin 
(Escherichia coli O:113, Clinical Center Reference Endotoxin, National Institute of  
Health, Bethesda, MD) within one minute22. LPS-induced symptoms were rated using 
grades ranging from 0 (no symptoms) to 5 (most severe ever experienced), resulting in 
a cumulative sickness score23. Blood was drawn before the start of  postpyloric feeding 
and serially thereafter up to 24 hours after LPS administration (Figure 1). Routine 
hematology parameters were determined using flow cytometry (Sysmex XE-2100; 
Goffin Meyvis, Etten-Leur, the Netherlands). 
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Figure 1     Experimental design. Subjects are admitted to the intensive care unit (ICU) after an 
overnight fast. One hour prior to LPS administration, subjects are prehydrated and the continuous ad-
ministration of  enteral nutrition is started in the nutritional intervention groups, lasting until six hours 
after LPS administration. Blood is withdrawn at indicated time points during the experiment. Subjects 
leave the hospital 12 hours after intravenous administration of  LPS and return the day after for final 
blood sampling. 
Postpyloric feeding
On the experimental day, two groups received a nutritional intervention in a double-blind 
randomized fashion, while one group was fasted during the entire experiment (all groups: 
n=6). The nutritional intervention groups received continuous postpyloric infusion 
with a liquid, enriched or an isocaloric control enteral nutrition for 7 hours via a self-
advancing nasojejunal feeding tube (Tiger 2, Cook Medical, Bloomington, IN). No 
feeding was aspirated via nasogastric tube or regurgitated throughout the study. The 
rate of  feeding for each subject was based on their total energy requirement (TER). 
TER was calculated by multiplying basal metabolic rate of  each subject with their 
activity level (1.55 times for all subjects) using the Harris-Benedict equation (Table 1). 
Feeding composition and CCK measurement
The enriched nutrition contained 44 energy percent (en%) fat, 25en% protein and 
31en% carbohydrates. The protein fraction consisted of  intact casein, whey protein 
and soy protein hydrolysate. The control nutrition contained 20en% fat, 16en% protein 
and 64en% carbohydrates. Both the enriched and control nutrition provided 1 kcal/
ml. Systemic CCK levels were determined in plasma using a CCK-radioimmunoassay 
(Eurodiagnostica, Malmö, Sweden).
Determination of  plasma cytokines and subclinical intestinal damage 
TNF-α, IL-6, IL-10, and IL-1 receptor antagonist (IL-1RA) were measured 
batchwise using a multiplex Luminex Assay (Millipore, Billerica, MA). Intestinal- 
fatty acid binding protein (i-FABP) was determined in plasma using an in-house 
developed ELISA. 
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Statistical analysis
All values are depicted as mean ± SEM. Two-way analysis of  variance was used to 
detect differences between groups for serial data. Differences in serial data within 
groups were analyzed by one-way ANOVA with Bonferroni’s post-hoc test. Data 
were excluded from the analysis after being identified as significant outlier using the 
Grubb’s test (extreme studentized deviate method). A p-value less than 0.05 was 
considered statistically significant. 
Results
Hematologic and clinical response 
As summarized in Table 2, administration of  endotoxin resulted in changes in 
hematologic and clinical parameters in the fasted and nutritional intervention groups. 
In all groups, mean arterial blood pressure decreased from 90 minutes after LPS 
administration onwards (p < 0.001), while a compensatory rise in heart rate was 
observed (p < 0.001). Also, endotoxemia resulted in a rise in core body temperature 
(p < 0.001) and an initial fall followed by a rise in white blood cell count (p < 0.001) 
in both the fasted and nutritional intervention groups. The LPS-induced changes 
in hemodynamic parameters, body temperature and white blood cell count were 
not affected by enteral nutrition. Administration of  endotoxin resulted in flu-like 
symptoms such as headache, nausea, vomiting, backache, shivering and myalgia, 
which were expressed as sickness score. The sickness score of  all subjects peaked 
at 90 minutes following LPS administration. Administration of  enriched or control 
nutrition did not affect the sickness score compared with fasted subjects (p = 0.43 
and p = 0.28, respectively). 
Enteral feeding with enriched nutrition modulates the cytokine profile during experimental human 
endotoxemia
Intravenous administration of  LPS resulted in a marked proinflammatory response. 
The TNF-α values of  one subject in the enriched nutrition group were removed 
from the analysis after being identified as significant outliers. Treatment with enriched 
nutrition significantly attenuated TNF-α levels compared with fasted (p < 0.0001) and 
control nutrition (p < 0.05; Figure 2A). Enriched nutrition lowered peak TNF-α levels 
with 40 ± 8% compared with fasted subjects and 29 ± 10% compared with control 
nutrition. The control nutrition demonstrated a trend towards lower TNF-α plasma 
levels compared with fasted subjects (p = 0.06). Enriched nutrition significantly 
reduced IL-6 plasma concentrations during the endotoxemia protocol compared with 
control nutrition (p < 0.001) and fasting (p < 0.05. Figure 2B), whereas the control 
nutrition did not affect IL-6 compared with fasted subjects (p = 0.63). Administration 
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of  enriched nutrition attenuated peak levels of  IL-6 with 41 ± 9% compared with 
fasted subjects and 54 ± 7 % compared with control nutrition. Intravenous injection 
of  LPS is known to trigger a complex compensatory anti-inflammatory response. 
The specific IL-1 receptor antagonist, IL-1RA is released during inflammation and 
is thought to control the immune-modulating effects of  IL-1. Enriched nutrition 
decreased circulating IL-1RA during the experiment compared with control nutrition 
(p < 0.0001) and fasted (p < 0.0001; Figure 2C). Peak levels of  IL-1RA were 37 ± 8% 
lower in the enriched nutrition group compared with fasted subjects, and 25 ± 6% 
lower compared with control nutrition. The control nutrition did not affect IL-1RA 
levels compared with fasted. Continuous postpyloric infusion of  enriched nutrition 
resulted in elevated plasma concentrations of  IL-10 over time compared with fasted 
(p < 0.0001), whereas the control nutrition demonstrated a trend towards higher IL-
10 levels (p = 0.07; Figure 2D). Enriched nutrition enhanced peak levels of  IL-10 
with 231 ± 19% compared with fasted subjects and 130 ± 12% with control nutrition. 
Table 2     Hemodynamic parameters, blood leukocyte count and sickness score during human endotoxemia
T, time expressed in hours after lipopolysaccharide administration; MAP, mean arterial pressure; HR, 
heart rate; ND, not determined. Data expressed as mean ± SEM. p values are comparisons between 
groups over time and were determined by two-way repeated measures-analyses of  variance. 
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Figure 2     Enriched nutrition modulates the inflammatory response during endotoxemia. Mean plasma 
concentrations of  TNF-α (A), IL-6 (B), IL-1RA (C), and IL-10 (D) following intravenous LPS 
administration. Enriched nutrition attenuates TNF-α, IL-6 and IL-1RA levels compared with control 
nutrition (p < 0.05) and fasting (p < 0.0001). Administration of  the control product displays a trend 
towards lower TNF-α levels (p = 0.06). The enriched nutrition enhances IL-10 release (p < 0.0001 vs 
fasted), while a trend is observed with control nutrition (p = 0.07 vs fasted). 
Enterocyte damage remains unaffected by enteral nutrition
In all subjects, administration of  LPS resulted in a gradual increase in i-FABP plasma 
levels until 4 hours post-LPS, representing the occurrence of  enterocyte damage 
(Figure 3A). From 4 hours post-LPS to 8 hours, levels of  i-FABP in all groups returned 
to baseline. Fasted subjects and subjects receiving control nutrition displayed a more 
prominent increase in i-FABP levels during the experiment compared with subjects 
fed with enriched nutrition. Total i-FABP release tended to be lower for the enriched 
nutrition group compared with control nutrition and fasted subjects, although this did 
not reach statistical significance (Figure 3B). 
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Figure 3     Administration of  LPS results in sub-clinical intestinal damage. Intravenous adminis-
tration of  LPS results in a gradual increase of  plasma i-FABP levels in all groups (A). Subjects fed 
enriched nutrition display a smaller increase in circulating i-FABP levels (A-B), although this does not 
reach statistical significance. 
Figure 4     Postpyloric administration of  control or enriched nutrition increases plasma levels of  CCK. 
Continuous enteral administration of  both the control and enriched nutrition results in an increase in 
CCK plasma levels compared with fasted subjects. Both nutritional interventions demonstrate a slight 
decrease in CCK plasma levels at 4 hours following LPS administration. After cessation of  nutrient 
infusion, plasma CCK levels fall below detection level (A). There is no significant difference in total CCK 
release between control and enriched nutrition (B). ND, not detectable. 
Increased plasma CCK levels during administration of  enteral nutrition
In order to assess the effect of  continuous duodenal infusion on CCK release, plasma 
CCK levels were assessed on indicated time points (Figure 1). CCK levels increased 
from nondetectable values (< 0.3 pmol/L) before administration of  enteral nutrition 
(T = -1 hrs) to 2.3 ± 0.5 pmol/L at 1 hour after onset of  continuous administration 
of  enriched and control nutrition (T= 0; Figure 4A). Four hours after intravenous 
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LPS injection CCK plasma levels in the control group dropped (0.7 ± 0.2 pmol/L; 
p < 0.05) compared with the levels at t = 0. The drop in CCK levels tended to be 
smaller in the enriched group. There were no significant differences in total plasma 
CCK release between enriched and control nutrition (Figure 4B). CCK levels dropped 
to undetectable levels at 8 hours, after cessation of  the nutrient infusion. In fasted 
subjects, plasma CCK levels stayed below the detection level throughout the protocol.
Discussion
The present study is the first to investigate the immediate immunomodulatory effect 
of  continuous enteral administration of  nutrition enriched with lipids and protein in 
man. Our data reveal that enriched nutrition modulates the innate immune response 
during human endotoxemia, resulting in attenuated plasma levels of  TNF-α, IL-6, 
and IL-1RA, and elevated circulating IL-10, indicating a reduced proinflammatory 
response and an augmented anti-inflammatory response.
During the last decades, the catabolic state of  surgical and critically ill patients 
increasingly gained interest24, 25. The observed negative correlation between catabolism 
and clinical outcome resulted in more liberal nutritional regimes, such as reduced 
preoperative fasting and early administration of  enteral nutrition24. Implementation of  
these renewed nutritional support regimes reduced morbidity and length of  hospital 
stay9, 10. Although the exact mechanisms behind these beneficial effects are not well 
known, it is assumed that adequate nutritional support prevents immunodeficiency 
induced by caloric deficits26. In addition to caloric support, prolonged ingestion of  
nutrition enriched with intrinsic anti-inflammatory compounds, such as long-chain n-3 
polyunsaturated fatty acids and glutamine results in immune-modulating effects and 
improves outcome by influencing specific metabolic processes, including eicosanoid 
production, glutathione synthesis, and generation of  heat shock proteins27, 28. Our 
group has revealed a novel pathway in which enteral nutrition modulates the immune 
response via a fast-acting hard-wired pathway. Enteral lipid-enriched nutrition was 
shown to limit inflammation and reduce organ damage via a CCK-mediated activation 
of  the cholinergic anti-inflammatory pathway in several rodent models16-19, 29. Herein, 
we present the first evidence of  the effectiveness of  the nutritional anti-inflammatory 
mechanism in man.
Virtually every surgical, trauma, and ICU patient suffers from systemic inflammation. 
The complex interplay between pro- and anti-inflammatory mechanisms during 
such a systemic inflammatory response is still incompletely understood30. The 
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human endotoxemia model does not replicate these clinical conditions, but has been 
extensively employed to study the acute systemic inflammatory response in vivo21. 
Administration of  endotoxin affects various systemic physiological and metabolical 
processes in a manner similar to the early phase of  injury and infection, making it a 
suitable human model for proof-of-principle studies21. 
Excess release of  TNF-α is known to contribute to the development of  systemic 
inflammatory response syndrome, organ damage, and mortality in sepsis31. 
Furthermore, circulating levels of  TNF-α and IL-6 are correlated with the severity of  
sepsis in patients32. In line with our animal data16, 17, the current study demonstrates 
that enriched nutrition limits inflammation during human experimental endotoxemia 
by attenuating circulating levels of  TNF-α and IL-6. Moreover, the intervention 
with enriched nutrition resulted in decreased IL-1RA plasma levels. These data are 
conform previous reports, demonstrating that TNF-α and IL-6 enhance IL-1RA 
release during endotoxemia, while inhibition of  these cytokines lowers circulating IL-
1RA33, 34. In accordance, attenuation of  the inflammatory response using epinephrine 
or glucocorticoids downregulates IL-1RA and IL-1 plasma levels35, 36. In parallel with 
these reports, our findings that enriched nutrition not only decreases plasma levels 
of  TNF-α and IL-6, but also of  IL-1RA, reflect an overall reduced proinflammatory 
state. Interestingly, postpyloric administration of  enriched nutrition amplified the 
anti-inflammatory response to endotoxin, as evidenced by a pronounced increase in 
circulating IL-10 compared with fasted subjects. IL-10 is considered to be part of  
the host-protective mechanism that counterbalances the proinflammatory response 
during acute infection and inflammation36. Furthermore, administration of  IL-10 has 
been shown to reduce endotoxin-induced lethality in mice37. The beneficial effect of  
enriched nutrition on the immune response during human endotoxemia is in line with 
previous studies using well-known pharmacological agents, including epinephrine 
and glucocorticoids, which inhibit plasma levels of  proinflammatory cytokines and 
augment circulating IL-1036, 38. Together, these data indicate that enriched enteral 
nutrition is a promising and physiological intervention to control acute inflammation. 
Intestinal epithelial cell damage often accompanies sepsis, trauma, and major surgery 
and is related to the degree of  gastrointestinal hypoperfusion39-41. Additionally, 
intestinal compromise has been implicated in the development of  inflammatory 
complications following injury42. Here, we show that intravenous administration of  
LPS resulted in increased i-FABP levels. The rise in plasma i-FABP levels tended to 
be smaller in subjects treated with enriched nutrition compared with control nutrition 
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or fasted subjects, although this did not reach statistical significance. These data are 
supported by rodent studies demonstrating that lipid-enriched nutrition preserves 
intestinal integrity17, 19. The small increase in i-FABP plasma levels is likely attributable 
to the relative low dose of  LPS and limited hypoperfusion due to the prehydration 
protocol. Future studies are therefore needed to ascertain the gut-protective effect of  
enriched nutrition in man.
CCK-mediated activation of  vagal afferents plays a dominant role in nutrient-
induced digestive, metabolic, and immunologic feedback19, 43, 44. Intestinal release of  
CCK is predominantly triggered by the luminal presence of  lipid and protein20, 45, 
while termination of  nutrient exposure results in a rapid drop of  CCK levels (45). 
Taking these considerations into account, we chose to continuously administer 
nutrition enriched with lipids and proteins to induce a prolonged stimulation of  the 
CCK-mediated anti-inflammatory pathway. Our nutritional intervention resulted in 
detectable circulating CCK levels during the entire endotoxin-induced inflammatory 
response. The fact that bolus administration of  a lipid-rich milkshake containing 100 
g fat prior to endotoxin challenge failed to affect the immune response46, underlines 
the importance of  continuous nutrient administration. In comparison, continuous 
infusion of  enriched nutrition delivered approximately 60 g fat in total. Although 
enriched nutrition displayed a more powerful anti-inflammatory effect than control 
nutrition, significant differences in CCK levels could not be detected in plasma. This 
might be explained by the fact that circulating CCK levels do not reflect local intestinal 
concentrations and subsequent activation of  afferent vagal fibres in the gut. In this 
context, it is interesting that plasma concentrations of  exogenous CCK have to be at 
least 10-fold higher compared with postprandial CCK levels to obtain a similar satiety 
effect47. Future studies using specific CCK-1 receptor antagonists, which are currently 
not available, should specify the role of  local CCK levels. In addition, these studies 
should also focus on the role of  other intestinal peptides, including glucagon-like 
peptide 1 (GLP-1). Recently, our group implicated GLP-1 as co-stimulatory peptide 
of  the nutritional anti-inflammatory pathway in rodents, because administration 
of  GLP-1 receptor antagonists partially reduced the inhibitory effect of  lipid-rich 
nutrition on systemic inflammation48. 
In conclusion, the current proof-of-principle study demonstrates for the first time that: 
1) continuous administration of  enteral nutrition instantly modulates inflammation in 
man, and 2) enrichment of  the nutritional composition with lipid and protein enforces 
this anti-inflammatory potential. Our findings show that the anti-inflammatory 
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effects of  enriched nutrition previously observed in rodents also apply to the human 
situation. Taken together, the current study implicates continuous administration of  
enriched nutrition as a promising intervention to modulate inflammatory conditions 
in the clinical setting. 
Acknowledgements
The authors would like to thank Lucas van Eijk for help during the endotoxemia 
experiments and Trees Jansen for help with the cytokine measurements. This work 
was financially supported by DANONE Research Centre for Specialised Nutrition, 
Wageningen, the Netherlands. The funding sources had no involvement in study 
design and analysis or interpretation of  data. 
196
Chapter 9
References
1. Riedemann NC, Guo RF, Ward PA. Novel strategies for the treatment of  sepsis. Nat 
Med 2003; 9(5):517-524.
2. Yende S, D’Angelo G, Kellum JA, Weissfeld L, Fine J, Welch RD, Kong L, Carter M, 
Angus DC. Inflammatory markers at hospital discharge predict subsequent mortality 
after pneumonia and sepsis. Am J Respir Crit Care Med 2008; 177(11):1242-1247.
3. Osuchowski MF, Welch K, Siddiqui J, Remick DG. Circulating cytokine/inhibitor 
profiles reshape the understanding of  the SIRS/CARS continuum in sepsis and 
predict mortality. J Immunol 2006; 177(3):1967-1974.
4. Rice TW, Wheeler AP, Bernard GR, Vincent JL, Angus DC, Aikawa N, Demeyer 
I, Sainati S, Amlot N, Cao C, Ii M, Matsuda H, Mouri K, Cohen J. A randomized, 
double-blind, placebo-controlled trial of  TAK-242 for the treatment of  severe sepsis. 
Crit Care Med 2010; 38(8):1685-1694.
5. Cinel I, Opal SM. Molecular biology of  inflammation and sepsis: a primer. Crit Care 
Med 2009; 37(1):291-304.
6. Marshall JC, Charbonney E, Gonzalez PD. The immune system in critical illness. Clin 
Chest Med 2008; 29(4):605-16, vii.
7. Parrish WR, Gallowitsch-Puerta M, Czura CJ, Tracey KJ. Experimental therapeutic 
strategies for severe sepsis: mediators and mechanisms. Ann N Y Acad Sci 2008; 
1144():210-236.
8. Doig GS, Heighes PT, Simpson F, Sweetman EA, Davies AR. Early enteral nutrition, 
provided within 24 h of  injury or intensive care unit admission, significantly reduces 
mortality in critically ill patients: a meta-analysis of  randomised controlled trials. 
Intensive Care Med 2009; 35(12):2018-2027.
9. El Nakeeb A., Fikry A, El MT, Fouda E, Youssef  M, Ghazy H, Badr S, Khafagy W, 
Farid M. Early oral feeding in patients undergoing elective colonic anastomosis. Int J 
Surg 2009; 7(3):206-209.
10. Noblett SE, Watson DS, Huong H, Davison B, Hainsworth PJ, Horgan AF. Pre-
operative oral carbohydrate loading in colorectal surgery: a randomized controlled 
trial. Colorectal Dis 2006; 8(7):563-569.
11. Fleshner M, Goehler LE, Schwartz BA, McGorry M, Martin D, Maier SF, Watkins 
LR. Thermogenic and corticosterone responses to intravenous cytokines (IL-1beta 
and TNF-alpha) are attenuated by subdiaphragmatic vagotomy. J Neuroimmunol 
1998; 86(2):134-141.
12. Wang H, Yu M, Ochani M, Amella CA, Tanovic M, Susarla S, Li JH, Wang H, Yang 
H, Ulloa L, Al-Abed Y, Czura CJ, Tracey KJ. Nicotinic acetylcholine receptor alpha7 
subunit is an essential regulator of  inflammation. Nature 2003; 421(6921):384-388.
197
Lipid- and protein-enriched enteral nutrition limits inflammation in healthy volunteers
9
13. van der Zanden EP, Snoek SA, Heinsbroek SE, Stanisor OI, Verseijden C, 
Boeckxstaens GE, Peppelenbosch MP, Greaves DR, Gordon S, de Jonge WJ. 
Vagus nerve activity augments intestinal macrophage phagocytosis via nicotinic 
acetylcholine receptor alpha4beta2. Gastroenterology 2009; 137(3):1029-39, 1039.
14. Borovikova LV, Ivanova S, Zhang M, Yang H, Botchkina GI, Watkins LR, Wang H, 
Abumrad N, Eaton JW, Tracey KJ. Vagus nerve stimulation attenuates the systemic 
inflammatory response to endotoxin. Nature 2000; 405(6785):458-462.
15. Pavlov VA, Ochani M, Yang LH, Gallowitsch-Puerta M, Ochani K, Lin X, Levi J, 
Parrish WR, Rosas-Ballina M, Czura CJ, Larosa GJ, Miller EJ, Tracey KJ, Al-Abed Y. 
Selective alpha7-nicotinic acetylcholine receptor agonist GTS-21 improves survival in 
murine endotoxemia and severe sepsis. Crit Care Med 2007; 35(4):1139-1144.
16. de Haan JJ, Lubbers T, Hadfoune M, Luyer MD, Dejong CH, Buurman WA, Greve 
JW. Postshock intervention with high-lipid enteral nutrition reduces inflammation and 
tissue damage. Ann Surg 2008; 248(5):842-848.
17. Lubbers T, de Haan JJ, Luyer MD, Verbaeys I, Hadfoune M, Dejong CH, Buurman 
WA, Greve JW. Cholecystokinin/Cholecystokinin-1 receptor-mediated peripheral 
activation of  the afferent vagus by enteral nutrients attenuates inflammation in rats. 
Ann Surg 2010; 252(2):376-382.
18. Luyer MD, Greve JW, Hadfoune M, Jacobs JA, Dejong CH, Buurman WA. 
Nutritional stimulation of  cholecystokinin receptors inhibits inflammation via the 
vagus nerve. J Exp Med 2005; 202(8):1023-1029.
19. Lubbers T, de Haan JJ, Hadfoune M, Zhang Y, Luyer MD, Grundy D, Buurman WA, 
Greve JW. Lipid-enriched enteral nutrition controls the inflammatory response in 
murine Gram-negative sepsis. Crit Care Med 2010; 38(10):1996-2002.
20. Karhunen LJ, Juvonen KR, Huotari A, Purhonen AK, Herzig KH. Effect of  protein, 
fat, carbohydrate and fibre on gastrointestinal peptide release in humans. Regul Pept 
2008; 149(1-3):70-78.
21. Lowry SF. Human endotoxemia: a model for mechanistic insight and therapeutic 
targeting. Shock 2005; 24 Suppl 1():94-100.
22. Pickkers P, Dorresteijn MJ, Bouw MP, van der Hoeven JG, Smits P. In vivo evidence 
for nitric oxide-mediated calcium-activated potassium-channel activation during 
human endotoxemia. Circulation 2006; 114(5):414-421.
23. van Eijk LT, Dorresteijn MJ, Smits P, van der Hoeven JG, Netea MG, Pickkers P. 
Gender differences in the innate immune response and vascular reactivity following 
the administration of  endotoxin to human volunteers. Crit Care Med 2007; 
35(6):1464-1469.
24. Soreide E, Ljungqvist O. Modern preoperative fasting guidelines: a summary of  the 
present recommendations and remaining questions. Best Pract Res Clin Anaesthesiol 
2006; 20(3):483-491.
198
Chapter 9
25. van Ginhoven TM, Mitchell JR, Verweij M, Hoeijmakers JH, Ijzermans JN, de Bruin 
RW. The use of  preoperative nutritional interventions to protect against hepatic 
ischemia-reperfusion injury. Liver Transpl 2009; 15(10):1183-1191.
26. Kreymann KG, Berger MM, Deutz NE, Hiesmayr M, Jolliet P, Kazandjiev G, 
Nitenberg G, van den BG, Wernerman J, Ebner C, Hartl W, Heymann C, Spies C. 
ESPEN Guidelines on Enteral Nutrition: Intensive care. Clin Nutr 2006; 25(2):210-
223.
27. Calder PC. n-3 polyunsaturated fatty acids, inflammation, and inflammatory diseases. 
Am J Clin Nutr 2006; 83(6 Suppl):1505S-1519S.
28. Vermeulen MA, van de Poll MC, Ligthart-Melis GC, Dejong CH, van den Tol MP, 
Boelens PG, van Leeuwen PA. Specific amino acids in the critically ill patient--
exogenous glutamine/arginine: a common denominator? Crit Care Med 2007; 35(9 
Suppl):S568-S576.
29. Lubbers T, Luyer MD, de Haan JJ, Hadfoune M, Buurman WA, Greve JW. Lipid-rich 
enteral nutrition reduces postoperative ileus in rats via activation of  cholecystokinin-
receptors. Ann Surg 2009; 249(3):481-487.
30. Flohe SB, Flohe S, Schade FU. Invited review: deterioration of  the immune system 
after trauma: signals and cellular mechanisms. Innate Immun 2008; 14(6):333-344.
31. Abraham E, Laterre PF, Garbino J, Pingleton S, Butler T, Dugernier T, Margolis 
B, Kudsk K, Zimmerli W, Anderson P, Reynaert M, Lew D, Lesslauer W, Passe S, 
Cooper P, Burdeska A, Modi M, Leighton A, Salgo M, Van der AP. Lenercept (p55 
tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: 
a randomized, double-blind, placebo-controlled, multicenter phase III trial with 1,342 
patients. Crit Care Med 2001; 29(3):503-510.
32. Harbarth S, Holeckova K, Froidevaux C, Pittet D, Ricou B, Grau GE, Vadas L, Pugin 
J. Diagnostic value of  procalcitonin, interleukin-6, and interleukin-8 in critically ill 
patients admitted with suspected sepsis. Am J Respir Crit Care Med 2001; 164(3):396-
402.
33. Gabay C, Smith MF, Eidlen D, Arend WP. Interleukin 1 receptor antagonist (IL-1Ra) 
is an acute-phase protein. J Clin Invest 1997; 99(12):2930-2940.
34. van der Poll T, van Deventer SJ, ten CH, Levi M, ten Cate JW. Tumor necrosis factor 
is involved in the appearance of  interleukin-1 receptor antagonist in endotoxemia. J 
Infect Dis 1994; 169(3):665-667.
35. Arzt E, Sauer J, Pollmacher T, Labeur M, Holsboer F, Reul JM, Stalla GK. 
Glucocorticoids suppress interleukin-1 receptor antagonist synthesis following 
induction by endotoxin. Endocrinology 1994; 134(2):672-677.
36. van der Poll T, Coyle SM, Barbosa K, Braxton CC, Lowry SF. Epinephrine inhibits 
tumor necrosis factor-alpha and potentiates interleukin 10 production during human 
endotoxemia. J Clin Invest 1996; 97(3):713-719.
199
Lipid- and protein-enriched enteral nutrition limits inflammation in healthy volunteers
9
37. Howard M, Muchamuel T, Andrade S, Menon S. Interleukin 10 protects mice from 
lethal endotoxemia. J Exp Med 1993; 177(4):1205-1208.
38. de Kruif  MD, Lemaire LC, Giebelen IA, van Zoelen MA, Pater JM, van den Pangaart 
PS, Groot AP, de Vos AF, Elliott PJ, Meijers JC, Levi M, van der Poll T. Prednisolone 
dose-dependently influences inflammation and coagulation during human 
endotoxemia. J Immunol 2007; 178(3):1845-1851.
39. de Haan JJ, Lubbers T, Derikx JP, Relja B, Henrich D, Greve JW, Marzi I, Buurman 
WA. Rapid development of  intestinal cell damage following severe trauma: a 
prospective observational cohort study. Crit Care 2009; 13(3):R86.
40. Derikx JP, Poeze M, van Bijnen AA, Buurman WA, Heineman E. Evidence for 
intestinal and liver epithelial cell injury in the early phase of  sepsis. Shock 2007; 
28(5):544-548.
41. Derikx JP, van Waardenburg DA, Thuijls G, Willigers HM, Koenraads M, van Bijnen 
AA, Heineman E, Poeze M, Ambergen T, van OA, van Rhijn LW, Buurman WA. 
New Insight in Loss of  Gut Barrier during Major Non-Abdominal Surgery. PLoS 
ONE 2008; 3(12):e3954.
42. Fink MP, Delude RL. Epithelial barrier dysfunction: a unifying theme to explain the 
pathogenesis of  multiple organ dysfunction at the cellular level. Crit Care Clin 2005; 
21(2):177-196.
43. Chandra R, Liddle RA. Cholecystokinin. Curr Opin Endocrinol Diabetes Obes 2007; 
14(1):63-67.
44. Cheung GW, Kokorovic A, Lam CK, Chari M, Lam TK. Intestinal cholecystokinin 
controls glucose production through a neuronal network. Cell Metab 2009; 10(2):99-
109.
45. Pilichiewicz AN, Little TJ, Brennan IM, Meyer JH, Wishart JM, Otto B, 
Horowitz M, Feinle-Bisset C. Effects of  load, and duration, of  duodenal lipid on 
antropyloroduodenal motility, plasma CCK and PYY, and energy intake in healthy 
men. Am J Physiol Regul Integr Comp Physiol 2006; 290(3):R668-R677.
46. Harris HW, Johnson JA, Wigmore SJ. Endogenous lipoproteins impact the response 
to endotoxin in humans. Crit Care Med 2002; 30(1):23-31.
47. Reidelberger RD, Kalogeris TJ, Solomon TE. Plasma CCK levels after food intake 
and infusion of  CCK analogues that inhibit feeding in dogs. Am J Physiol 1989; 
256(5 Pt 2):R1148-R1154.
48. Lubbers T, de Haan JJ, Hadfoune M, Zabeau L, Tavernier J, Zhang Y, Grundy 
D, Greve JW, Buurman WA. Chylomicron formation and glucagon-like peptide 1 
receptor are involved in activation of  the nutritional anti-inflammatory pathway. J 
Nutr Biochem 2011; epub ahead of  print.
200
201
Chapter 10
The influence of  concentration/meditation on autonomic 
nervous system activity and the innate immune response: 
a case study
Matthijs Kox, Monique Stoffels, Sanne P. Smeekens, Nens van Alfen, 
Marc Gomes, Thijs  M.H. Eijsvogels, Maria T.E. Hopman, 
Johannes G. van der Hoeven, Mihai G. Netea, Peter Pickkers
Submitted
202
Chapter 10
Abstract 
Background  It might be possible to influence autonomic nervous system activity 
and the innate immune response through concentration/meditation techniques. A 
Dutch individual known as ‘the iceman’ holds several world records with regard to 
tolerating extreme cold, and claims he can influence his autonomic nervous system 
and thereby his innate immune response through a special concentration/meditation 
technique.
Methods We performed a case study of  the iceman. The subject’s ex 
vivo cytokine response (stimulation of  peripheral blood mononuclear cells with 
lipopolysaccharide [LPS]) was determined before and after an 80-minute full-body 
ice immersion during which the subject practiced his concentration/meditation 
technique. Furthermore, the subject’s in vivo inflammatory response was studied 
while practicing his concentration/mediation technique during experimental 
endotoxemia (i.v. administration of  2 ng/kg LPS). The results from the endotoxemia 
experiment were compared with a historical cohort of  112 subjects who participated 
in endotoxemia experiments in our institution. 
Results  The ex vivo pro- and anti-inflammatory cytokine response was greatly 
attenuated by concentration/meditation during ice immersion, accompanied by high 
levels of  cortisol. In the endotoxemia experiment, concentration/meditation resulted 
in increased circulating concentrations of  catecholamines, and plasma cortisol 
concentrations were higher than in any of  the previously studied subjects. The 
subject’s in vivo cytokine response and clinical symptoms following LPS administration 
were remarkably low compared with previously studied subjects.  
Conclusions The concentration/meditation technique employed by the iceman 
volunteer appears to evoke a controlled stress response. This response is characterized 
by sympathetic nervous system activation and subsequent catecholamine/cortisol 
release, which appears to attenuate the innate immune response. 
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Introduction 
The innate immune system embodies the first defence mechanism against invading 
pathogens1. While this system is crucial to our survival, an excessive inflammatory 
response, characterized by high levels of  inflammatory mediators and activated 
effector immune cells, can result in tissue damage and organ injury2. Examples of  
excessive or inappropriate inflammatory responses include sepsis and major trauma, 
as well as autoimmune disorders such as inflammatory bowel disease and rheumatoid 
arthritis3. In these conditions, limiting the innate immune response could reduce 
disease burden and improve outcome.  
It has become increasingly clear that the autonomic nervous system (ANS) can 
limit the innate immune response. It has long been known that the sympathetic 
nervous system can attenuate systemic inflammation directly via activation of  β2-
adrenoceptors by catecholamines4-6. In addition, as part of  a stress response, increased 
levels of  catecholamines are often accompanied by elevations in cortisol, a well-
known immunodepressant7-9. More recently, the parasympathetic nervous system has 
been shown to modulate innate immunity, as electrical stimulation of  the efferent 
vagus nerve greatly attenuates the inflammatory response in animal models10-12. 
The ANS is generally regarded as a system that cannot be willingly influenced. 
However, several recent investigations suggest that through certain concentration/
meditation techniques, it is possible to modulate autonomic activity. For instance, 
heart rate variability (HRV; a measure of  cardiac ANS activity) was shown to be 
remarkably different during meditation compared with resting conditions13. Other 
studies have reported increased parasympathetic activity (also measured by HRV) 
during Zen-meditation in healthy subjects14 and in subjects with coronary heart 
disease practicing transcendental meditation15. Furthermore, reduced sympathetic 
nervous system activation (measured by skin conductance level, SCL) was found after 
mindfulness-based stress-reduction (MBSR) in fibromyalgia patients16.
In light of  the effects of  the ANS on the innate immune system, it is conceivable that 
concentration/meditation techniques can influence inflammatory parameters17. There 
are a few reports that support the existence of  such a relation. For example, Guolin 
Qigong (a combination of  meditation, controlled breathing, and physical movement) 
reduced ex vivo inflammatory cytokine production by leukocytes18. Likewise, MBSR 
has been shown to result in decreased proinflammatory cytokine production in ex vivo 
stimulated leukocytes of  breast and prostate cancer patients19. 
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A Dutch individual known as ‘the iceman’20 holds several world records with regard 
to withstanding extreme cold, including the fastest half  marathon barefoot on ice/
snow21 and standing fully immersed in ice for 1 hour and 50 minutes. He claims to 
achieve these remarkable feats through a special concentration/meditation technique 
that he developed himself. He claims that, through this technique, he can influence 
his autonomic nervous system and also his immune response22. Herein, we describe 
a case study of  this man, focusing on the effects of  his concentration/meditation 
technique on autonomic nervous system parameters and the innate immune response, 
both ex vivo during ice immersion and in vivo during experimental human endotoxemia 
(lipopolysaccharide [LPS] administration). The experimental human endotoxemia 
model, a well-characterized standardized model to study the innate immune 
response23, has been operational at our institution for several years24-28. This allowed 
us to compare the response of  the iceman to a large group of  healthy volunteers who 
underwent the same endotoxemia protocol.
Materials and methods
Study subjects
The iceman is a healthy male, aged 51 years. The cytokine, hemodynamic, temperature, 
and illness score results from the endotoxemia experiment in the iceman (Clinical 
Trial Register number NCT01352871) were compared with a historical cohort of  112 
healthy male volunteers that participated in human endotoxemia trials in our institution 
(NCT00246714, NCT00513110, NCT00783068, NCT00785018, NCT00916448, 
NCT01349699,  NCT01091571). Demographic characteristics of  the iceman and 
the 112 previously studied subjects are listed in Table 1. Only subjects who, besides 
endotoxin, received placebo-treatment or an intervention that had no effect on the 
endotoxin-induced inflammatory response were included for comparison. Neither 
the iceman nor the 112 volunteers used any medication. Other exclusion criteria were: 
cardiovascular disease, a (family) history of  cerebrovascular disease, previous vagal 
collapse, hypertension (Riva Rocci (RR) systolic > 160 or RR diastolic > 90 mmHg), 
hypotension (RR systolic < 100 or RR diastolic < 50 mmHg), renal impairment 
(plasma creatinine > 120 µmol/l), liver enzyme abnormalities, and positive hepatitis 
or HIV serology. 
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Table 1     Demographic characteristics of  the iceman and the 112 healthy male 
volunteers previously studied used for comparison
Data are presented as mean ± SEM
 
Study protocols
We performed three distinct experiments on three separate days to study the effect 
of  concentration/meditation on the autonomic nervous system and innate immune 
response:
1) Concentration/meditation during ice immersion
Before ice immersion, a cannula was placed in the antecubital vein to permit blood 
withdrawal. Approximately 30 minutes after the iceman started practicing his 
concentration/meditation technique, an initial blood sample was obtained for cortisol 
determination and ex vivo stimulation experiments. Subsequently, iceman was fully 
immersed in ice (with the exception of  his head) for 80 minutes (starting at 2.45 PM). 
Throughout the ice immersion, he practiced his concentration/meditation technique. 
Immediately after cessation of  ice immersion (and the concentration/meditation 
period), only a very limited amount of  blood could be collected due to vasoconstriction 
(this was only sufficient for cortisol analysis). Therefore, he subsequently took a hot 
shower and blood was collected 30 minutes later for cortisol determination and ex vivo 
stimulation experiments.
2) Concentration/meditation without ice immersion
At 9.45 AM, a cannula was placed in the antecubital vein to permit blood withdrawal 
and infusion of  25 mL/hour 2.5% glucose/ 0.45% saline solution. Furthermore, 
a recorder for heart rate variability (HRV) registration and electroencephalography 
(EEG) electrodes were connected. EEG was performed to monitor vigilance and 
for signs of  drowsiness or sleep before, during, and after meditation. Heart rate was 
continuously monitored using a 3-lead ECG. Cuff  blood pressure and tympanic 
temperature was measured every 30 minutes. At 10.45 AM, a baseline blood sample 
was obtained and subsequently, the iceman started the sham concentration/meditation 
period during which he watched television. After 1.5 hours, a blood sample was 
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obtained and the iceman started his concentration/meditation technique. 1.5 hours 
later, the final blood sample was obtained. Blood was used for ex vivo stimulation 
experiments and cortisol and catecholamine determination.
3) Concentration/meditation during human endotoxemia
The study protocol was approved by the Ethics Committee of  the Radboud University 
Nijmegen Medical Centre and complies with the Declaration of  Helsinki, including 
current revisions and the Good Clinical Practice guidelines. The subject had not been 
exposed to ice-immersion for more than 6 weeks before the experiment and signed 
written informed consent. Screening of  the subject 14 days before the experiment 
revealed no abnormalities in medical history or upon physical examination. The 
subject refrained from food 12 hours before the start of  the experiment, and caffeine 
or alcohol containing substances 24 hours before the start of  the experiment. The 
experiment was performed at the research unit of  the intensive care department, with 
the subject in supine position. After local anaesthesia (lidocaine HCl 20 mg/ml) the 
radial artery was cannulated using a 20 Gauge arterial catheter and connected to an 
arterial pressure monitoring set. The arterial line was used for continuous monitoring 
of  blood pressure and blood sampling. A cannula was placed in the antecubital vein 
to permit infusion of  2.5% glucose/ 0.45% saline solution; the subject received 1.5 L 
during one hour starting one hour before endotoxin infusion (prehydration), followed 
by 150 ml/h until 6 hours after endotoxin infusion, and 75 ml/h until the end of  
the experiment. A recorder for HRV registration, muscle sympathetic nerve activity 
(MSNA) electrodes and EEG electrodes were connected. EEG was performed to 
assess for possible encephalopathy after LPS infusion and monitor vigilance and 
for signs of  drowsiness or sleep before, during, and after meditation. Tympanic 
temperature was measured every 30 minutes. Heart rate and respiratory rate were 
monitored by a 3-lead ECG. Blood pressure, heart rate, and respiratory rate data 
were stored every 30 seconds by a custom in-house developed data recording system 
(ICweb). Subjects were asked to score the severity of  the endotoxin-induced flulike 
symptoms (nausea, headache, shivering, muscle, and back pain) every 30 min up to 6 hrs 
after the administration of  endotoxin. Symptoms were scored on a scale ranging from 
0 (symptom not present) to 5 (worst ever experienced) and these scores were added, 
forming an arbitrary total symptom score. 30 minutes before LPS administration 
(T=-0.5 hrs), the subject started concentrating/meditating for 3 hours (until T=2.5 
hrs). The subject received U.S. Reference E. coli endotoxin (lipopolysaccharide; LPS 
derived from Escherichia coli O:113, Clinical Centre Reference Endotoxin, National 
Institute of  Health (NIH), Bethesda, MD). Endotoxin, supplied as a lyophilized 
powder, was reconstituted in 5 ml saline 0.9% for injection and vortex-mixed for at 
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least 10 minutes after reconstitution. The endotoxin solution was administered as an 
intravenous bolus injection at a dose of  2 ng/kg of  body weight at 10.50 AM.
The endotoxemia protocols for the 112 healthy volunteers to which the iceman 
was compared (historical cohort) were identical, with the exception of  practicing 
concentration/meditation. All of  these study protocols were approved by the Ethics 
Committee of  the Radboud University Nijmegen Medical Centre and comply with the 
Declaration of  Helsinki, including current revisions and the Good Clinical Practice 
guidelines. All volunteers signed written informed consent. The circadian variation in 
cortisol levels did not confound the comparison between the iceman and the historical 
cohort, because in all endotoxemia studies, LPS was administered between 10-11 AM. 
Ex vivo stimulation experiments
Peripheral blood mononuclear cells (PBMCs) were isolated using Ficoll-Paque 
Plus (GE Healthcare Bio-Sciences AB, Diegem, Belgium). Cells at a concentration 
of  5x106/mL in RPMI 1640 medium (Dutch modification; Invitrogen, Paisley, 
UK), supplemented with 1 mM sodium pyruvate, 2 mM L-Glutamine and 50 μg/
mL gentamicin, were incubated in round-bottom 96-wells plates at 37 °C and 5% 
CO2. After 24 hrs (for TNF-α and IL-6) or 60 hrs (for IL-10) of  incubation with 
LPS (10 ng/mL), supernatants were collected and stored at −80 °C until further 
analysis. For macrophage experiments, PBMCs at a concentration of  5x106/ml in the 
abovementioned RPMI 1640 medium, additionally containing 10% pooled human 
serum, were kept at 37 °C and 5% CO2. After 6 days of  incubation, cells were stimulated 
with LPS (10 ng/mL) for 24 hrs, after which supernatants were collected and stored 
at  −80 °C until further analysis. All stimulation experiments were performed in 
duplicate. LPS (E. Coli serotype 055:B5) was purchased from Sigma-Aldrich, and an 
additional purification step was performed as described previously29. 
Cortisol, catecholamine, and cytokine measurements
Cortisol levels were determined in EDTA plasma using a luminometric immunoassay 
on a random access analyzer (Architect® i System, Abbott, Illinois, USA). The cortisol 
response was compared with that of  a subgroup of  the aforementioned cohort of  
112 subjects in which cortisol was determined  (n=15, NCT00513110)30. Blood 
samples for catecholamine determination were collected into chilled lithium-heparin 
tubes and were immediately placed on ice. Plasma norepinephrine and epinephrine 
concentrations were measured using sensitive and specific high-performance liquid 
chromatography with fluorometric detection as described previously31. TNF-α, IL-6, 
and IL-10 concentrations in EDTA plasma obtained from the endotoxemia experiment 
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of  the iceman and the historical cohort were measured using a simultaneous Luminex 
assay according to the manufacturer’s instructions (Milliplex, Millipore, Billerica, MA, 
USA). Concentrations of  TNF-α, IL-6, and IL-10 in ex vivo stimulated cell culture 
supernatants were determined by commercial ELISA’s according to the manufacturer’s 
instructions (TNF-α: R&D systems, Minneapolis, MN, USA; IL-6 & IL-10: Pelikine 
Compact, Sanquin, Amsterdam, The Netherlands).
Electroencephalography (EEG) analysis
EEG was determined using a standard 21-lead recording with surface Ag/AgCl cup 
electrodes  as described previously9, 30. The full-length recording was analyzed visually 
by an experienced clinical neurophysiologist (NvA) and  scored using a five category 
classification system for septic encephalopathies. Additionally, EEG background 
activity was monitored during concentration/meditation and the presence of  
drowsiness or sleep was noted, as were signs of  shivering indicated by the presence 
of  tremorous muscle activity artifacts at both the scalp and chest electrodes. For 
further quantitative analysis at least once per 30 minutes a one-minute artefact-free 
raw EEG sample (10-second epoch) of  the subject lying awake with his eyes closed 
was selected.
Heart rate variability (HRV) analysis
Short-term HRV (5-min recordings) was measured in supine position and during qui-
et circumstances. A 3-lead ECG signal was obtained using a Medilog AR12 recorder 
(Huntleigh Healthcare, Cardiff, UK) and analyzed as described previously32. Normal-
ized units of  low and high frequency spectral power (LFnu and HFnu, representing 
sympathetic and parasympathetic modulation, respectively33) were calculated by divid-
ing LF or HF power by the sum of  LF and HF power. The HRV data of  the iceman 
was compared with a subgroup of  the aforementioned cohort of  112 subjects where 
HRV was measured (n=40, NCT00513110 and NCT00783068)32.
Muscle sympathetic nerve activity
Muscle sympathetic nerve activity (MSNA) was measured as described before34. How-
ever, the subject exhibited quite vigorous movement during the concentration/medi-
tation period, which led to dislocation of  the electrodes. Therefore, only a reliable 
baseline recording was obtained.
 
Data analysis and calculations
Analyses were performed using Graphpad Prism 5.0 (Graphpad Software, San Diego, 
CA, USA).
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Results
Experiment 1. Concentration/meditation during ice immersion 
Thirty minutes after the start of  concentration/meditation (just before ice-immersion), 
cortisol levels were already relatively high (0.69 μmol/L at 2.15 PM, which is above 
the reference limits for both 8 AM and 5 PM which are 0.55 and 0.38 μmol/L in 
our centre, respectively) and rose to slightly higher levels immediately after the end 
of  the ice immersion period (0.75 μmol/L at 4.05 PM). 30 Minutes later (4.35 PM), 
cortisol levels decreased to 0.53 μmol/L. LPS-induced cytokine production of  ex vivo 
stimulated peripheral blood mononuclear cells (PBMCs) obtained after ice immersion 
was greatly attenuated compared with PBMCs obtained before (Figure 1A). Both pro- 
(TNF-α and IL-6) and anti-inflammatory (IL-10) responses were equally affected. 
This effect was not only observed after stimulation with LPS, but also when PBMCs 
were stimulated with other (components of) heat-killed pathogens such as Candida 
albicans and Staphylococcus aureus (data not shown). Strikingly, in monocyte-derived 
macrophage cultures stimulated with LPS 6 days after the ice immersion, a similar 
pattern was observed (Figure 1B).
Figure 1     Production of   pro- (TNF-α and IL-6) and anti-inflammatory (IL-10) cytokines in 
peripheral blood mononuclear cells (A) and monocyte-derived macrophages (B) obtained before and after 
ice-immersion that were ex vivo stimulated with RPMI (control) or LPS (10 ng/mL) for 24 hours 
(TNF-α and IL-6) or 60 hours (IL-10). Macrophages were obtained by culturing monocytes for 6 days 
in the presence of  10% pooled human serum.
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Experiment 2. Concentration/meditation without ice immersion
To investigate whether the remarkable reduction in ex vivo cytokine production 
was an effect of  the subject’s concentration/meditation technique or a direct 
effect of  the cold exposure, we studied the subject while practicing his technique 
without exposure to ice. Cortisol and norepinephrine levels were not increased by 
concentration/meditation (cortisol: sham concentration/meditation: 0.39 μmol/L, 
concentration/meditation: 0.36 μmol/L; norepinephrine: sham concentration/
meditation: 2.12 nmol/L, concentration/meditation: 2.25  nmol/L). In contrast, 
the plasma epinephrine concentration during sham concentration/meditation was 
0.23 nmol/L (normal value: 0.2 nmol/L), and showed a pronounced rise after 
the concentration/meditation period to 0.36 nmol/L. HRV analysis revealed that, 
while total spectral power increased considerably during concentration/meditation 
compared with sham  (sham concentration/meditation: 2584 ms2; concentration/
meditation: 5798 ms2), no differences in cardiac autonomic balance were observed 
(sham concentration/meditation: LFnu 79%, HFnu 21%; concentration/mediation: 
LFnu: 77%, HFnu: 23%). The EEG recording showed normal background cortical 
activity during baseline and sham concentration/meditation (i.e. watching tv). After 
6 cycles of  concentration/meditation with hyperventilation the EEG background 
showed slight slowing that turned in to drowsiness after the 8th cycle, and a very 
short period of  stage II sleep before the subject was woken up by ambient noise. No 
abnormalities were found. Stimulation of  PBMCs or macrophages revealed no effects 
of  concentration/meditation on cytokine production ex vivo (data not shown). 
Experiment 3. Concentration/meditation during human endotoxemia
To determine the effects of  concentration/meditation on the inflammatory 
response in vivo, the subject participated in a human endotoxemia experiment while 
practicing his concentration/meditation technique for three hours starting 30 minutes 
before LPS administration (from T=-0.5 to T=2.5). MSNA before the start of  the 
concentration/meditation period was: total MSNA: 28.3 ± 2.1 bursts/min; frequency 
corrected MSNA: 47.5 ± 5.5 bursts/100 beats (mean ± SD), which is comparable to 
what was previously reported in subjects under resting conditions35. Figure 2 depicts 
the breathing and hemodynamic pattern during the first 30 minutes of  concentration/
meditation (T=-0.5 - T=0). The technique is characterized by cycles consisting of  a 
few minutes of  hyperventilation followed by breath holding for up to 1-2 minutes. 
30 Minutes after the start of  concentration/meditation (T=0), blood gas analysis 
revealed a distinct alkalosis in combination with a low pCO2 (Table 2), consistent with 
hyperventilation. This pattern was even more pronounced at T=1. After cessation of  
concentration/meditation, blood gas values gradually returned to normal. 
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Figure 2     Respiratory rate (A), heart rate (B) and mean arterial pressure (C) during the first 30 
minutes of  concentration/meditation (T=-0.5 – T=0).
Table 2      Iceman’s blood gas parameters during human endotoxemia
LPS administration in the iceman resulted in remarkably few symptoms, he only 
reported a mild headache for 10 minutes at T=1.5 (the time-point at which the 
symptom score normally peaks), yielding a symptom score of  1 compared with a 
symptom score of  6.6 ± 2.8 (mean ± SD) at T=1.5 in the 112 previously studied 
subjects. Of  note, only one out of  the 112 persons studied before exhibited an equally 
low symptom score. The LPS-induced rise in body temperature was comparable to 
that of  the 112 previously studied subjects (iceman: 1.3 oC; 112 subjects: 1.6 ± 0.6 oC 
[mean ± SD]). The LPS-induced decrease in mean arterial pressure and increase in 
heart rate was similar to that of  the historical cohort as well. Plasma norepinephrine 
levels peaked immediately after the start of  concentration/meditation and gradually 
returned to baseline levels (Figure 3A). Epinephrine showed a similar, but delayed 
pattern: levels started to rise at T=0 and peaked one hour after LPS administration 
(Figure 3A). Plasma cortisol levels at the time of  LPS administration were similar 
to those of  15 subjects (a subgroup from the historical cohort of  112 subjects) not 
practicing concentration/meditation (Figure 3B). However, the increase in cortisol 
after LPS administration was much more pronounced in the iceman compared with 
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the other subjects. The area under curve (AUC) of  the iceman’s cortisol time-course 
(only using time-points also measured in the previously studied subjects: T=0, T=2, 
T=4 and T=8) was outside the reference range (mean + 1.96*SD) of  the other 15 
subjects. 
Figure 3     Plasma levels of  catecholamines (A) and cortisol (B) during experimental human endotox-
emia. Cortisol data (mean ± SEM) of  15 previously studied subjects are shown for comparison.  
LPS-induced plasma levels of  inflammatory cytokines were remarkably low in the 
iceman (Figure 4). The AUCs of  the 112 subjects were ranked and the iceman’s AUC 
cytokine response lied within the 18th percentile for TNF-α, 5th percentile for IL-6 and 
13th percentile for IL-10. 
Besides an initial increase in total spectral power and SDNN (which is the time-domain 
correlate of  total spectral power), no clear-cut effects of  concentration/meditation 
on HRV indices were observed (SDNN and total spectral power depicted in Figure 
5). Furthermore, the common decrease in HRV indices following LPS administration 
was also present in the iceman and to a similar extent as in 40 previously studied 
subjects. 
The EEG showed normal cortical background activity at baseline, with an 
occipitoparietotemporal alpha rhythm of  8.8 - 9.3 Hz. During the first 4 hours of  the 
experiment, including baseline, LPS infusion, and meditation period afterwards, there 
were no signs of  encephalopathy, nor a drop in vigilance shown as either drowsiness 
or sleep. During the subjects’ meditation cycle short periods (10-15 s) of  focused 
attention were found in the EEG, reflected by a disappearance of  the occipitoparietal 
alpha rhythm and diffuse irregular beta frequencies associated with cognitive activity. 
Quantitative EEG showed no relevant changes during the sample periods.
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Figure 4
Plasma levels of  pro- (A: TNF-α 
and B: IL-6) and anti-inflamma-
tory (C: IL-10) cytokines during 
experimental human endotoxemia. 
Data (mean ± SEM) of  112 
previously studied subjects are 
shown for comparison.
Figure 5     Log SDNN (A) and total spectral power (B) heart rate variability indices during ex-
perimental human endotoxemia. Data (mean ± SEM) of  40 previously studied subjects are shown for 
comparison. 
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Discussion 
In the present study, we describe the effects of  a special concentration/meditation 
technique developed by an individual known as ‘the iceman’ on the autonomic nervous 
system and innate immune response. This individual holds several world records 
with regard to extreme tolerance to cold exposure. Concentration/meditation during 
ice immersion resulted in high cortisol levels and suppressed cytokine production 
ex vivo. Although elevated levels of  epinephrine were found during concentration/
meditation without ice immersion, no effects on norepinephrine, cortisol levels, or the 
ex vivo cytokine response were observed. Finally, we demonstrate that concentration/
meditation during experimental endotoxemia resulted in elevated levels of  (nor)
epinephrine and an amplified cortisol response, associated with a remarkably mild 
inflammatory response.
In the presence of  an exogenous stimulus (ice immersion and LPS administration), 
cortisol levels well above the reference values were observed upon concentration/
meditation. In the endotoxemia study, this was preceded by an increase in (nor)
epinephrine. These data indicate that the iceman’s concentration/meditation 
technique evokes a stress response characterized by activation of  the sympathetic 
nervous system and  hypothalamic-pituitary-adrenal (HPA) axis. Both catecholamines 
and cortisol are well-known immunosupressants; administration of  both of  these 
mediators has been shown to attenuate the inflammatory response in vivo in the human 
endotoxemia model4-8. Furthermore, in heart failure patients, plasma cortisol levels 
correlated negatively with ex vivo cytokine production36. Therefore, this concentration/
meditation-induced stress response might explain the observed immunosupression ex 
vivo in the ice immersion experiment and the remarkably mild inflammatory response 
in vivo during endotoxemia. 
Increased cortisol levels following LPS administration have been reported by 
ourselves30 and others7, 37. Cortisol was already elevated in the sample obtained after 
30 minutes of  concentration/meditation, but before ice immersion. While baseline 
cortisol levels in the endotoxemia experiment were comparable to those of  the young 
healthy volunteers that were previously studied, the LPS-induced increase was more 
pronounced than in any of  the subjects we have previously studied. The remarkable 
differences in the ex vivo cytokine responses between the leukocytes obtained before 
and after ice immersion may be explained by the fact that the leukocytes obtained 
after ice-immersion had been subjected to high cortisol and/or catecholamine 
levels for a prolonged period (>2 hours) compared with the cells obtained before. 
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Interestingly, macrophages cultured from monocytes derived after ice immersion 
that were stimulated with LPS 6 days later still showed a vastly attenuated cytokine 
response. It might be speculated that monocytes exposed to high concentrations of  
cortisol and/or catecholamines are deactivated for a prolonged period. Along these 
lines, it has been shown that short incubations with the corticosteroid dexamethasone 
have long-lasting effects in monocytes38.
In the endotoxemia experiment in the iceman, catecholamines levels peaked at the 
time of  endotoxin administration (norepinephrine) and 1 hour after endotoxin 
(epinephrine), thereafter declining to baseline or even below baseline levels. In 
contrast, others have demonstrated peak catecholamine levels 1.5 (norepinephrine) 
and 3 (epinephrine) hours following endotoxin administration35. This strengthens the 
notion that the concentration/meditation technique is responsible for this increase in 
(nor)epinephrine. The absence of  increased levels at 3 hours post-endotoxin might be 
the result of  the relatively mild inflammatory response in the iceman. 
The iceman reported exceptionally few symptoms during endotoxemia. However, 
the symptom score is a highly subjective parameter and the iceman may be used to 
extreme circumstances, which makes it difficult to compare these results to those of  
the previously studied healthy volunteers. Despite a very mild inflammatory response, 
the LPS-induced changes in heart rate, blood pressure, and temperature were 
comparable to those of  the previously studied subjects, which appears conflicting. 
However, we have recently shown that the cytokine response does not correlate with 
hemodynamic parameters, temperature, and illness score during endotoxemia26. 
Meditation is generally associated with reduction of  stress and catecholamine/
cortisol levels16, 19, 39-41. These discrepant results compared with our study might be 
explained by the fact that the other studies, in contrast to ours, have evaluated effects 
of  meditation in the long term (weeks to months). Furthermore, the concentration/
meditation technique practiced by the iceman is very different to those employed in 
other studies. This particular technique is not targeted at relaxation of  the body, but 
rather appears to activate it. This is supported by data from a previous report showing 
that the iceman’s oxygen consumption doubled during ice immersion42, indicating 
that practicing this technique results in increased metabolism. The increased energy 
expenditure (and therefore heat production) might play a role in the subject’s extreme 
tolerance towards cold; despite 80 minutes of  full-body ice immersion and significant 
heat loss through the skin, core body temperature was maintained42. Furthermore, 
216
Chapter 10
the iceman reported that ice-immersion results in significant weight-loss (personal 
communication). Signs of  increased energy expenditure were also apparent during the 
last hours of  the endotoxemia experiment; after cessation of  concentration/meditation 
the subject was noticeably tired and very hungry. Hyperventilation (followed by breath 
holding) is an obvious element of  the iceman’s concentration/meditation technique 
and might have direct effects on sympathetic nervous system activity and/or stress 
hormones. One study in healthy subjects found relatively large increases in (nor)
epinephrine, but only a marginal increase in cortisol immediately after 20 minutes of  
hyperventilation43. In another study, three minutes of  hyperventilation resulting in a 
pH of  7.65 increased cortisol levels 1.5-fold44. Interestingly, 3-minute hyperventilation 
followed by maximal voluntary breath holding resulted in an even more pronounced 
and longer-lasting increase in cortisol44. The remarkably low cytokine response is 
unlikely to result from the hyperventilation-induced low pCO2
 and high pH levels, 
because  hypocapnic alkalosis, as opposed to hypercapnic acidosis45, is not associated 
with anti-inflammatory effects.  
With respect to the subject’s particular concentration/meditation technique, our 
findings might better be compared with studies investigating the effects of  acute stress 
on the inflammatory response. Subjects exposed to a standardized laboratory stressor 
(Trier social stress test, TSST) displayed elevated levels of  cortisol40. Furthermore, 
it was recently reported that acute psychological stress results in increased levels of  
norepinephrine and cortisol accompanied by decreased TNF-α mRNA 46 and protein47 
expression in ex vivo LPS-stimulated leukocytes. In accordance, a very recent and 
remarkable study demonstrated a profound rise in catecholamines and cortisol during 
bungee-jumping, which was associated with significantly reduced cytokine production 
in ex vivo LPS-stimulated whole blood48. These results are in line with ours. In contrast 
to acute stressors, prolonged stress, such as in depression or post-traumatic stress 
syndrome, is associated with increased levels of  inflammatory cytokines49-51. A possible 
explanation for this might be the opposing effects of  short- and long-term exposure 
to catecholamines. While acute exposure to or infusion of  β-adrenergic agonists 
attenuates proinflammatory cytokine production in vitro52 and in vivo5, 6, prolonged 
exposure increases production of  these mediators in vitro52. In accordance, 24-hour 
norepinephrine infusion results in increased plasma concentrations of  proinflammatory 
mediators in rats53. Another explanation for increased cytokine levels upon long-term 
stress might be development of  glucocorticoid and/or catecholamine insensitivity 
due to receptor downregulation or desensitization. Loss of  leukocyte glucocorticoid 
receptors is well-described in patients with depression54, 55. Furthermore, sustained 
217
Effects of  concentration/meditation on autonomic activity and the immune response
10
heightened activation of  the sympathetic nervous system, reflected by high levels of  
circulating catecholamines, results in β-receptor downregulation and uncoupling in 
congestive heart failure patients56, 57.
We did find an increase in HRV total spectral power during concentration/meditation, 
which was not surprising in light of  the large fluctuations in heart rate during this 
period. However, we did not find evidence for increased sympathetic activity using 
HRV analysis. It has been reported that while certain HRV indices (in particular high 
frequency power) correlate well with parasympathetic modulation58, sympathetic 
correlates of  HRV are still disputed59. Therefore, HRV analysis might not be an 
appropriate tool to investigate sympathetic activity. Furthermore, HRV is known 
to be affected by breathing patterns/frequency60, therefore, the iceman’s extremely 
irregular breathing may have influenced the measurements. 
Our study has several limitations. First an foremost, we describe a set of  studies 
on a single subject making it impossible to determine a cause effects relationship 
between concentration/meditation and the autonomic nervous system and/or the 
innate immune response. Nevertheless, case reports with remarkable findings can 
yield valuable information61 and are important in hypothesis generation for further 
research. This study is further limited by the absence of  an additional endotoxemia 
experiment in which the iceman did not practice his concentration/meditation 
technique. This is rather a limitation of  the human endotoxemia model; our group 
has demonstrated that repeated LPS administrations result in the development of  
endotoxin tolerance26, 62, therefore, data from a cross-over experiment would be 
impossible to interpret. Finally, the iceman’s age is considerably higher than that of  
the 112 healthy volunteers used for comparison. This could have biased our results. 
However, a human endotoxemia study comparing a group with a median age of  24 
to a group with a median age of  66 revealed that ageing was associated with a slightly 
higher cytokine response to LPS63. Therefore, age appears not to explain the relatively 
low cytokine levels observed in the iceman.
In conclusion, the iceman’s autodidact concentration/meditation technique appears 
to result in a consciously controlled stress response, characterized by sympathetic 
nervous system activation and subsequent catecholamine/cortisol release. This 
response appears to attenuate the innate immune response. The iceman claims that 
he can teach others this technique within a relatively short time-frame (one week). 
Therefore, further investigations should establish whether the results obtained in the 
iceman can be reproduced in larger groups of  individuals.
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Abstract
Background HRV (heart rate variability) analysis is a widely employed method 
to assess cardiac autonomic nervous system activity. Accurate HRV measurement is 
critical to its value as a diagnostic and prognostic tool. Different breathing patterns 
may affect HRV, but results obtained under static conditions are conflicting. HRV 
indices decrease considerably during systemic inflammation evoked by experimental 
endotoxaemia, enabling the determination of  the effects of  different breathing 
patterns on HRV in a dynamic setting. We investigated the impact of  different breathing 
patterns on short-term HRV measurements during experimental  endotoxaemia. 
Furthermore, we assessed whether paced breathing improved HRV reproducibility.
Methods Twelve healthy male volunteers received an intravenous bolus 
(2 ng/kg of  body weight) of  endotoxin (LPS [lipopolysaccharide], derived from 
Escherichia coli O:113) on two occasions with an interval of  2 weeks (visits 1 and 2). 
Five-minute HRV recordings were performed just prior to LPS administration and 
hourly thereafter until 8 hours post-LPS. Three breathing protocols were employed 
every hour: 1) spontaneous breathing, 2) metronome-guided breathing at the subject’s 
normal respiratory rate (paced), and 3) metronome-guided breathing at 150% of  the 
subject’s normal respiratory rate (mild hyperventilation).
Results  LPS administration resulted in a sharp decrease of  all of  the HRV 
indices measured, which was similar during both LPS administrations. Neither 
paced breathing nor mild hyperventilation influenced HRV indices compared with 
spontaneous breathing. Paced breathing did not improve reproducibility, as it did 
not exert a significant effect on intra-subject coefficients of  variation and intra-class 
correlation coefficients (calculated between both visits).
Conclusions Over a wide range of  HRV magnitudes during experimental 
endotoxaemia, neither paced breathing nor mild hyperventilation affected HRV 
indices. Moreover, paced breathing did not result in a significant improvement in 
reproducibility. Therefore, employing a paced breathing protocol is not required to 
obtain valid HRV data during endotoxaemia.
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Introduction 
HRV (heart rate variability) analysis is a widely employed method to assess cardiac 
autonomic nervous system activity1. Owing to its noninvasive nature, HRV, and 
especially short-term HRV recordings (5 min), are easily obtainable from patients or 
healthy volunteers. Changes in HRV, in particular a reduction in HRV, are associated 
with increased mortality after myocardial infarction and heart failure2-5. In systemically 
inflamed critically ill patients, such as in sepsis, HRV is diminished and inversely 
correlated with disease severity6-9. Moreover, reduced HRV is a predictor of  MODS 
(multi-organ dysfunction syndrome) and death in these patients10, 11. Therefore, HRV 
analysis could represent a valuable diagnostic and prognostic tool.
Accurate measurements of  HRV are critical for its interpretation and clinical use. For 
example, it is well-documented that postural changes have a major impact on HRV12-14. 
Therefore, all HRV measurements within a study should be performed in the same 
position and data cannot be compared with subjects measured in another position. 
Less attention has been paid to effects of  different breathing patterns, although this 
is considered to have a significant impact on HRV. The parasympathetic component 
of  HRV (respiratory sinus arrhythmia, reflected by HF [high-frequency] power 
and r-MSSD [root-mean-square differences of  successive NN (normal-to-normal) 
intervals]) is thought to be predominantly mediated by respiration-induced blood 
pressure changes, which are sensed by carotid baroreceptors leading to (de)activation 
of  cardiac vagal fibres15, 16. An increased respiratory rate has been linked to a reduction 
in LF (low-frequency) and HF power17; however, increased HF and reduced LF power 
with increased breathing rate have also been reported18. Metronome-guided (paced) 
breathing appears to result in increased HF and reduced LF power compared with 
spontaneous breathing in some19, 20, but not all studies21. In addition, paced breathing 
may19, 22 or may not23, 24 increase HRV analysis reproducibility. These conflicting 
results indicate that the effects of  different breathing patterns on HRV are not well 
established yet.
To date, all studies investigating effects of  different breathing patterns on HRV 
have been performed under relatively static conditions, i.e. when HRV does not 
vary to a large extent. Experimental endotoxaemia (LPS [lipopolysaccharide] 
administration in healthy volunteers) is a well-characterized standardized model of  
systemic inflammation widely used to study the innate immune response in man25. 
HRV indices greatly fluctuate during experimental endotoxaemia26-29, which makes 
it a very suitable model to investigate the effects of  different breathing patterns on 
230
Chapter 11
HRV in a dynamic setting. Therefore, the aim of  our present study was to investigate 
whether paced breathing or mild hyperventilation affect short-term HRV indices 
during experimental endotoxaemia. Furthermore, because subjects in our study 
were administered endotoxin twice with an interval of  2 weeks, we assessed whether 
paced breathing improved HRV measurement reproducibility during experimental 
endotoxaemia.
Materials and methods
Subjects
Twelve healthy young male non-smoking volunteers were enrolled in a cross-over 
experimental endotoxaemia study (Clinical Trial Register number NCT00783068) in 
which they received LPS twice (LPS visits 1 & 2) with a mean interval of  14 days 
(range, 11-18 days). The study protocol was approved by the local ethics committee 
of  the Radboud University Nijmegen Medical Centre and is in accordance with the 
Declaration of  Helsinki (2000) of  the World Medical Association. Written informed 
consent was obtained from all study participants. The findings of  the physical 
examinations, electrocardiography, and routine laboratory studies on all the volunteers 
before the start of  the experiment showed normal results. Volunteers were not taking 
any prescription medications, and they were negative for hepatitis B surface antigen 
and HIV infection. 
Experimental endotoxaemia model
Subjects refrained from food 12 hours before the start of  the experiment, and 
from caffeine or alcohol containing substances 24 hours before the start of  the 
experiment. The experiments were performed at the research unit of  the intensive 
care department, with subjects in supine position. After local anaesthesia (lidocaine 
HCl 20 mg/ml), the radial artery was cannulated using a 20-Gauge arterial catheter 
(Angiocath, Becton Dickinson, Sandy UT, USA) and connected to an arterial pressure 
monitoring set (Edwards Lifesciences LLC, Irvine CA, USA), connected to a Phillips 
IntelliVue MP70 monitor (Philips Medical Systems, Eindhoven, The Netherlands). 
The arterial line was used for continuous monitoring of  blood pressure and blood 
sampling. A cannula was placed in the antecubital vein to permit infusion of  2.5% 
glucose/0.45% saline solution; subjects received a bolus of  1.5 litres during 1 hour 
before LPS infusion (prehydration), followed by 150 ml/h until 6 hours after LPS 
infusion and 75 ml/h until the end of  the experiment. Heart rate was continuously 
monitored using a three-lead ECG. Body temperature was measured every 30 minutes 
using an infrared tympanic thermometer (FirstTemp Genius, Sherwood Medical, 
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Crawley/Sussex, UK). Leukocyte counts were determined using flow cytometry 
(Sysmex XE-2100; Goffin Meyvis, Etten-Leur, the Netherlands). U.S. Reference 
Escherichia coli endotoxin (E. coli O:113, Clinical Center Reference Endotoxin, NIH 
[National Institute of  Health], Bethesda, MD) was used. Lot Ec-5 endotoxin, supplied 
as a lyophilized powder, was reconstituted in 5 ml saline 0.9% for injection and 
vortex-mixed for at least 10 minutes after reconstitution. The endotoxin solution was 
administered as an intravenous bolus injection at a dose of  2 ng/kg of  body weight.
HRV measurements
HRV was measured hourly by 5-min recordings starting just before LPS administration 
(T=0 or baseline) up to 8 hours after LPS administration. HRV was measured in supine 
position and in a quiet environment. HRV measurements were performed at the same 
time of  day during both visits (T=0 at 11 am). Each subject’s normal spontaneous 
breathing rate was determined in rest before LPS administration. We employed three 
breathing protocols, repeated every hour: 1) 5 minutes of  spontaneous breathing, 2) 
five minutes of  metronome-guided breathing at the subject’s spontaneous respiratory 
rate (paced) and 3) five minutes of  metronome-guided breathing at 150% of  the 
subject’s spontaneous respiratory rate (mild hyperventilation). A three-lead ECG 
signal was obtained using a Medilog AR12 recorder (Huntleigh Healthcare, Cardiff, 
UK). R-peak position was determined at a sample rate of  4096 Hz. HRV was analyzed 
using dedicated software (Medilog Darwin HRV, Huntleigh Healthcare, Cardiff, UK). 
In each 5-min recording, QRS complexes were detected, and only NN beat intervals 
were tabulated, yielding an interval tachogram (from which the mean heart rate was 
calculated). Recordings with artefacts such as extrasystolic or supraventricular beats, 
or other arrhythmias comprising more than 5% of  the total epoch were discarded. 
After linear detrending, power spectral density was determined by fast Fourier 
transformation of  interval tachograms using the Welch method and a FFT (fast 
Fourier transform) width of  1024. We chose to solely analyze ‘raw’ HRV indices, not 
calculated indices such as LF/HF, LFnu (LF power in normalized units) and HFnu 
(HF power in normalized units), because effects on calculated values are a direct 
consequence of  their impact on raw values and therefore do not provide additional 
information. We analyzed time domain indices SDNN (SD of  NN intervals) and 
r-MSSD, and frequency domain indices LF power, HF power and total power. VLF 
(very-LF) power (0.0033-0.04 Hz) was not analyzed because this parameter cannot 
be reliably obtained from 5-min recordings30. The HRV indices analyzed, their 
definitions, and their physiological correlates are listed in Table 1. 
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Table 1     HRV indices definitions and physiological correlates 
ms, milliseconds.
Calculations and statistical analysis
None of  the measured HRV indices was normally distributed (calculated using the 
Shapiro-Wilk test) and therefore they were log-transformed. Comparison of  the HRV 
indices between both LPS visits were made by repeated measures two-way ANOVA. 
For Bland-Altman analysis, paced breathing was designated as the gold standard31. 
The Grubbs test (extreme studentized deviate method) was performed to test for 
significant outliers. Percentage intraCVs (intra-subject coefficients of  variation) were 
calculated by the following formula: 100 X (standard deviation [visit 1, visit 2] / mean 
[visit1, visit 2]). We performed a power calculation to determine the power achieved 
in case of  actual intraCV differences of  1 and 2%. Using a SD of  4% 32, a sample 
size of  108 observations (12 subjects measured at nine time points), and a two-tailed 
α of  0.05, we would achieve a 73,1% power to detect an intraCV difference of  1%, 
and 99.9% to detect an intraCV difference of  2%. Percentage intraCVs between 
spontaneous and paced breathing were tested by paired, two-sided Student’s t-tests. 
A p-value <0.05 was considered significant. Statistical analysis was performed using 
Graphpad Prism 5 (Graphpad software, San Diego, CA, USA) and MedCalc 11.3.1.0 
(MedCalc software, Mariakerke, Belgium).
Results
Effects of  endotoxin administration on hemodynamic, clinical, haematological, and HRV parameters
LPS administration resulted in a typical changes in haemodynamic, clinical, and 
haematological parameters (data of  visit 1 depicted in Figure 1), as well as increased 
plasma levels of  pro- and anti-inflammatory cytokines (data not shown). 
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Figure 1     Haemodynamic, clinical, and haematological parameters during experimental endotox-
aemia. Values are mean ± SEM of  12 subjects during LPS visit 1. HR, heart rate; MAP, mean 
arterial pressure.
Endotoxaemia also resulted in a typical sharp decrease of  all HRV indices (data of  
spontaneously breathing subjects during visit 1 are depicted in Figure 2). There were 
no differences in the hemodynamic, clinical, haematological, and HRV responses to 
LPS between both visits (data not shown). 
Influence of  paced breathing on HRV during endotoxaemia
We constructed Bland-Altman plots of  the difference between spontaneous breathing 
vs. metronome-guided paced breathing at a subject’s normal respiratory rate (mean 
rate 11, range 8-15 breaths/min) against their average values from 0 to 8 hours post-
LPS administration (Figure 3A). All  indices displayed a symmetrical distribution 
around the zero line, indicating the absence of  a systematic error. The bias was not 
dependent on HRV magnitude which greatly decreased following LPS administration. 
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Influence of  mild hyperventilation on HRV during endotoxaemia
As depicted in Figure 3B, there was no difference in HRV indices between paced 
breathing at a subject’s normal respiratory rate compared with paced breathing at 
150% of  this rate (mean rate 17, range 12-22 breaths/min) during experimental 
endotoxaemia. Again, the bias was not dependent on HRV magnitude. In the subject 
with the lowest normal respiratory rate (8 breaths/min), a large increase in HF power 
was observed during mild hyperventilation (12 breaths/min; bias: 20.6%, significant 
outlier compared with the 11 other subjects whose mean bias was -3.2% with a range 
of  -11.6 to 3.6%).
Figure 2     HRV indices during experimental endotox-
aemia. Values are mean ± SEM of  12 subjects during 
LPS visit 1. ms indicates milliseconds. Log SDNN and 
r-MSSD are in ms; log LF, HF, and total are in ms2.
Effect of  paced breathing on HRV measurement 
reproducibility 
IntraCVs (calculated between visit 1 and 2) 
did not differ between paced and spontaneous 
breathing  (Table 2). Similarly, ICCs (intra-class 
correlation coefficients) of  paced and sponta-
neous breathing were not significantly different.
Discussion
In the present study, we investigated the effects 
of  different breathing patterns on short-term 
HRV and its reproducibility in a dynamic setting 
during experimental endotoxaemia in humans. 
Compared with spontaneous breathing, neither 
paced breathing nor mild hyperventilation af-
fected HRV indices significantly. Furthermore, 
paced breathing did not improve HRV repro-
ducibility.
To the best of  our knowledge, this is the first 
study assessing the effects of  different breath-
ing patterns on HRV during experimental endo-
toxaemia. The effects of  endotoxin administra-
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tion on HRV are well-established. Similar to other studies26-29, we observed a distinct 
decrease in all measured HRV indices. Consequently, the experimental endotoxaemia 
model uniquely allowed us to investigate the effects of  different breathing patterns 
on HRV and its reproducibility in a wide range of  HRV magnitudes, as opposed to 
previous studies that examined it during relatively static conditions17-19, 21-24, 32, 33. 
Figure 3     Bland-Altman plots of  A) the % bias (100*[spontaneous-paced]/average on the y-axis) 
of  HRV indices between spontaneous breathing and paced breathing against their average (x-axis) dur-
ing experimental endotoxaemia. B) the % bias (100*[hyperventilation-paced]/average on the y-axis) of  
HRV indices between paced breathing and paced breathing at 150% of  this rate against their average 
(x-axis) during experimental endotoxaemia.
Dotted lines indicate upper and lower 95% limits of  agreement. Data from 12 subjects who were admin-
istered LPS on two separate occasions (visit 1 and visit 2) with an interval of  two weeks are depicted. 
HRV indices (SDNN and r-MSSD in ms; LF, HF, and total power in ms2) were measured during 
spontaneous and paced breathing, and mild hyperventilation every hour starting at T=0 until T=8, 
yielding a total of  216 data points. Mean ± SD bias is shown in each panel.   
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Table 2     % intraCVs and intra-class correlation coefficients (ICC)  of  HRV indices between spon-
taneous and paced breathing during experimental endotoxaemia
Values of  12 subjects who were administered LPS on two separate occasions (visits 1 and 2) with an 
interval of  2 weeks are listed. HRV indices were measured during spontaneous and paced breathing 
every hour starting at T=0 until T=8, yielding a total of  108 paired observations from which ICCs and  
% intraCVs were calculated.
Our first objective was to investigate the effects of  different breathing patterns on 
HRV. We employed a paced breathing protocol in which subjects were paced at their 
normal respiratory rate, measured in rest before LPS administration. In all other 
investigations on the subject, a fixed respiratory rate of  12 or 15 breaths/min was 
employed19, 21, 32-34. Paced breathing has been shown to lead to an increased HF and 
a decreased LF power19, 32, 33, whereas others found no differences21, 34. The absence 
of  a significant bias during spontaneous breathing in our present study could result 
from the fact that subjects breathed extremely regularly during the spontaneous 
breathing measurements, implying that breathing patterns were virtually identical 
during spontaneous and paced breathing measurements. However, we did not find 
any differences when the subjects were paced at 150% of  their normal respiratory 
rate either. Interestingly, the only subject in whom a relatively large bias (increased 
HF power) was observed upon mild hyperventilation had a low spontaneous 
respiratory rate of  8 breaths/min. This observation can be explained by the fact 
that this subject’s respiratory rate corresponds to a frequency of  0.13 Hz, which 
is just outside of  the HF power spectrum (0.15-0.4 Hz), while all other subjects’ 
spontaneous breathing frequencies were within the HF band. Mild hyperventilation 
moved this subject’s breathing frequency well within the HF band (0.2 Hz). These 
findings are corroborated by a recent investigation in which subjects, as part of  a 
HRV biofeedback protocol, were paced at low respiratory frequencies outside the 
HF band (0.1 Hz) during endotoxaemia35. In these subjects, large differences in 
HRV parameters were found compared with subjects paced at 0.25 Hz. Effects of  
paced respiration (within the HF band) on HRV might also be observed in subjects 
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breathing spontaneously at frequencies above 0.4 Hz, which has been reported during 
experimental endotoxaemia26. However, we can only speculate on this, because we did 
not measure the spontaneous respiratory rate throughout the study protocol.
The second objective of  this study was to determine the effects of  paced breathing 
on HRV measurement reproducibility during repeated experimental endotoxaemia. 
There is a large body of  literature on the stability of  HRV over time and the effect 
of  paced breathing on it. Although the definition of  a categorical rating of  relative 
reproducibility based on ICC is still controversial, values found during spontaneous 
breathing in the present study can be considered moderate-to-good (0.69-0.83)22, 36, 
37. These results are in line with those found by others, using intervals between HRV 
measurements of  1 day22, 23, 5 days38, and 3 weeks24. Paced breathing did not result in 
significant reproducibility improvements. Our findings are in line with several other 
investigations, where either no differences or small nonsignificant ICC & intraCV 
improvements were found with measurement intervals of  1 day22, 23, 5 days38, 3 
weeks24, and two months33. In one small study, significantly reduced intraCVs were 
found for LF and HF power for paced breathing (12 breaths/min) compared with 
spontaneous breathing19. However, in that study, indices were not log-transformed, 
which is surprising in light of  the commonly described skewed distribution of  HRV 
indices22, 33, 38. By definition, skewed data results in incorrect and falsely high SD, which 
consequently overestimates the variation of  the measurements.
In the present study, we provide strong evidence for the lack of  an effect of  
paced breathing or mild hyperventilation on HRV in healthy subjects exposed to 
experimental endotoxaemia. It is not clear, however, whether our findings can be 
extrapolated to different patient groups, because several conditions might alter the 
relationship between respiration and HRV. For instance, hypertension and diabetes 
are associated with a decreased baroreflex sensitivity, which may significantly affect 
the influence of  respiration on the parasympathetic component of  HRV39, 40.
In conclusion, over a wide range of  HRV magnitudes during experimental 
endotoxaemia, paced breathing and mild hyperventilation did not affect HRV indices, 
provided that breathing frequencies lay within the HF band. Furthermore, paced 
breathing did not improve HRV measurement reproducibility. Therefore, employing a 
paced breathing protocol is not required to obtain valid HRV data during experimental 
endotoxaemia. In subjects whose respiratory frequency lies outside the HF band, 
paced breathing at frequencies within the HF band might be considered.
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Abstract
Background Endotoxin (lipopolysaccharide) tolerance is characterized by a 
transient refractory state to a subsequent lipopolysaccharide challenge. Following 
human endotoxemia, ex vivo tolerance of  circulating leukocytes to LPS resolves within 
24 hours. However, the duration of  in vivo tolerance, assumed to be primarily mediated 
by tissue-resident macrophages, is unknown. 
Methods We performed a clinical experimental study in 16 healthy male 
volunteers at an Intensive care research unit. To compare ex vivo and in vivo 
tolerance kinetics, whole blood from healthy volunteers was stimulated with 
lipopolysaccharide before, 4 hours after and 1, 2, 3, and 4 weeks following in vivo 
endotoxin (2 ng/kg; lipopolysaccharide derived from E coli O:113) administration. 
Furthermore, we compared the inflammatory response during two subsequent 
endotoxemia experiments in healthy volunteers with an interval of  two weeks. The 
cytokines TNF-α, IL-6, IL-10, IL-1RA, and TGF-β were measured.     
Results  Four hours after in vivo lipopolysaccharide administration, production 
of  TNF-α, IL-6, and IL-10, but not IL-1RA in ex vivo lipopolysaccharide-stimulated 
whole blood was diminished. Ex vivo lipopolysaccharide tolerance completely resolved 
within one week. In contrast, in vivo lipopolysaccharide tolerance was still apparent 
after two weeks. Compared with the first lipopolysaccharide administration, plasma 
peak levels of  TNF-α, IL-6, IL-10, IL-1RA, and TGF-β were attenuated by  46%, 
36%, 45%, 10%, and 14%, respectively (all p<0.05). 
Conclusions While ex vivo lipopolysaccharide tolerance quickly resolves, in vivo 
lipopolysaccharide tolerance persists for at least two weeks. These findings strengthen 
the notion that the in vivo response to lipopolysaccharide is mediated by tissue-
resident macrophages and that ex vivo stimulation does not accurately reflect the in 
vivo innate immune response. Intervention studies utilizing the human endotoxemia 
model should be performed using parallel groups rather than a cross-over design. 
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Introduction
Lipopolysaccharide (LPS) or endotoxin tolerance is characterized by a blunted 
inflammatory response to subsequent LPS challenges1. The most compelling 
evidence for this phenomenon has been established in mice, where pretreatment 
with a sublethal dose of  LPS prevented mortality induced by a normally lethal LPS 
challenge2. Clinically, the immune paralysis frequently observed in e.g. sepsis/trauma 
patients may be related to endotoxin tolerance and this hyporesponsive state observed 
after the initial hyperinflammatory phase may render them vulnerable for secondary 
infections3.
Endotoxin tolerance is commonly objectified by the measurement of  inflammatory 
cytokines following consecutive LPS incubations/administrations, and tolerance 
studies can be divided into three categories. First, in vitro models in which inflammatory 
cells pre-exposed to LPS display a diminished cytokine response to a subsequent 
LPS challenge (in vitro tolerance)4. Second, in vivo exposure to LPS followed within 
hours by ex vivo LPS restimulation of  circulating leucocytes harvested from the host 
show a diminished cytokine response (ex vivo tolerance)5-8.  Finally, subsequent in vivo 
LPS challenges result in a diminished in vivo cytokine response (in vivo tolerance)2, 9. 
Importantly, ex vivo tolerance may not correlate with the in vivo situation because the 
in vivo response to endotoxin is thought to be primarily mediated by tissue-resident 
cells and not by circulating leukocytes, as illustrated by elevated cytokine levels in LPS-
challenged neutropenic mice10.
Our group recently showed that LPS administrations for five consecutive days 
almost completely abolished pro- and anti-inflammatory cytokine release11. While the 
hyporesponsiveness of  ex vivo stimulated leukocytes from septic and trauma patients 
persists for several days to weeks, it is thought that in vivo tolerance after a single 
LPS challenge is shortlived and as such, pharmacological intervention trials during 
experimental human endotoxemia are frequently designed in a cross-over manner, 
using an interval of  1-2 weeks12-15. Also, hyporesponsiveness of  ex vivo stimulated 
leukocytes is generally accepted to reflect in vivo tolerance (and hence a subject’s 
immune status), thereby ignoring the role of  tissue resident cells such as macrophages, 
which play an important role in host defense. In this study, we compared the kinetics 
of  ex vivo and in vivo LPS tolerance in humans. We used inflammatory cytokine levels 
as the primary measure of  tolerance, but also investigated clinical parameters such as 
symptom score, hemodynamics, temperature response, and leukocyte counts. 
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Materials and methods
Subjects
Ex vivo endotoxin tolerance was studied in 4 healthy male nonsmoking volunteers who 
participated in a human endotoxemia trial in which volunteers were administered LPS 
once (Clinical Trial Register number NCT00513110). In vivo endotoxin tolerance was 
examined in 12 healthy male nonsmoking volunteers who participated in a crossover 
human endotoxemia study (Clinical Trial Register number NCT00783068) in which 
they received LPS twice (visit 1 & 2) with a mean interval of  14 days (range 11-18 days). 
The study protocols were approved by the local ethics committee of  the Radboud 
University Nijmegen Medical Centre. Written informed consent was obtained from 
all study participants. The findings of  the physical examinations, electrocardiography, 
and routine laboratory studies on all the volunteers before the start of  the experiment 
showed normal results. Volunteers were not taking any prescription medications, and 
they were negative for hepatitis B surface antigen and human immunodeficiency virus 
infection. 
Human endotoxemia model
Human endotoxemia protocols for the ex vivo and in vivo endotoxin tolerance 
studies were identical. Subjects refrained from food 12 hours before the start of  
the experiment, and caffeine or alcohol containing substances 24 hours before the 
start of  the experiment. The experiments were performed at the research unit of  
the intensive care department, with subjects in supine position. After local anesthesia 
(lidocaine HCl 20 mg/ml) the radial artery was cannulated using a 20 Gauge arterial 
catheter (Angiocath, Becton Dickinson, Sandy UT, USA) and connected to an arterial 
pressure monitoring set (Edwards Lifesciences LLC, Irvine CA, USA), connected 
to a Phillips IntelliVue MP70 monitor (Philips Medical Systems, Eindhoven, The 
Netherlands). The arterial line was used for continuous monitoring of  blood pressure 
and blood sampling. A cannula was placed in the antecubital vein to permit infusion 
of  2.5% glucose/ 0.45% saline solution; subjects received 1.5 L during one hour 
starting one hour before LPS infusion (prehydration), followed by 150 ml/h until 
6 hours after LPS infusion, and 75 ml/h until the end of  the experiment. Body 
temperature was measured every 30 minutes using an infrared tympanic thermometer 
(FirstTemp Genius, Sherwood Medical, Crawley/Sussex, UK). Heart rate was 
continuously monitored using a 3-lead electrocardiogram. Subjects were asked to 
score the severity of  the endotoxin-induced flulike symptoms (nausea, headache, 
shivering, muscle, and back pain) every 30 min up to 6 hrs after the administration of  
endotoxin. Symptoms were scored on a scale ranging from 0 (symptom not present) 
247
Differential ex vivo and in vivo endotoxin tolerance kinetics following human endotoxemia
12
to 5 (worst ever experienced) and these scores were added, forming an arbitrary total 
symptom score. U.S. Reference E. coli endotoxin (Escherichia coli O:113, Clinical Center 
Reference Endotoxin, National Institute of  Health [NIH], Bethesda, MD) was used. 
Ec-5 endotoxin, supplied as a lyophilized powder, was reconstituted in 5 mL saline 
0.9% for injection and vortex-mixed for at least 10 minutes after reconstitution. The 
endotoxin solution was administered as an intravenous bolus injection at a dose of  2 
ng/kg of  body weight. 
Whole blood stimulation
To investigate ex vivo endotoxin tolerance, blood of  4 subjects that received LPS in 
vivo was rechallenged with LPS ex vivo immediately after withdrawal. Arterial (day of  
LPS administration) or venous (1, 2, 3, and 4 weeks after human endotoxemia) blood 
was drawn into 5 mL lithium-heparin containing vacutainers (Vacutainer System, BD 
Biosciences). Whole blood was diluted 1:5 in RPMI and stimulated for 24 hours with 1 
ng/mL E. coli LPS (serotype O55:B5, Sigma-Aldrich, St Louis, MO, USA) or medium 
(control).  LPS was further purified as described previously16. After stimulation, whole 
blood cultures were centrifuged (14000 rpm, 5 min) after which supernatants were 
stored at -80 oC until assayed.
Cytokine measurements 
During human endotoxemia experiments, EDTA anticoagulated blood was collected 
from the arterial line and immediately centrifuged at 2000g for 10 minutes at 4 oC to 
obtain plasma. Concentrations of  TNF-α, IL-6, IL-10, and IL-1RA in plasma and 
whole blood stimulation supernatants were measured using a simultaneous Luminex 
Assay according to the manufacturer’s instructions (Bio-plex cytokine assay, BioRad, 
Hercules, CA, USA). Plasma levels of  TGF-β were determined by ELISA according 
to the manufacturer’s instructions (TGF-β1 Duoset, R&D systems, Minneapolis, MN, 
USA).
Calculations and statistical analysis
The Shapiro-Wilk test was used to test for normality. Whole blood stimulation cytokines 
were normalized for monocyte count as these are the main producers of  cytokines in 
whole blood stimulations17. Furthermore, cytokine production in unstimulated whole 
blood samples was subtracted from cytokine production in LPS-stimulated whole 
blood to correct for circulating cytokines and basal stimulation. Ex vivo tolerance data 
was analyzed using repeated measures one-way analysis of  variance with Dunnett’s 
Multiple Comparisons post-hoc test. To test for the presence of  in vivo tolerance, the 
response to the first and second in vivo LPS administration (cytokines, hemodynamic 
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data, temperature, leukocyte count, symptom score) were compared using repeated 
measures two-way analysis of  variance (interaction term). The % decreases in peak 
plasma cytokine levels between visit 1 and 2 for the different cytokines measured were 
compared using repeated measures one-way analysis of  variance with Newman-Keuls 
post-hoc test. Correlation between the decrease in peak cytokine levels during both 
LPS challenges and the interval between both challenges was tested using Pearson 
correlation coefficients. Data are expressed as mean ± SEM. A p-value of  less than 
0.05 was considered statistically significant.
Results
The ex vivo cytokine response following LPS administration is restored within one week
Ex vivo stimulation with LPS of  whole blood obtained from four LPS-challenged 
subjects demonstrated a significant reduction of  proinflammatory cytokines TNF-α 
and IL-6 4 hours after in vivo LPS administration, compared with stimulated blood 
drawn before LPS administration. Subsequent ex vivo whole blood stimulations after 
1, 2, 3, and 4 weeks showed that the ex vivo proinflammatory cytokine response was 
restored within one week (Figure 1, left panel). While the ex vivo IL-10 production 
was also attenuated 4 hours after in vivo LPS administration, one week later it was 
significantly higher compared with before the in vivo LPS challenge (Figure 1, right 
panel). Ex vivo production of  the anti-inflammatory cytokine IL-1RA was not 
impaired at any time point following LPS administration.
Figure 1 Proinflammatory (TNF-α and IL-6, left panel) and anti-inflammatory (IL-10 and 
IL-1RA, right panel) cytokine production in ex vivo LPS-stimulated whole blood of  subjects on the day 
of  LPS administration (T=0 and T=4 after LPS administration) and 4 weeks afterwards (W1-W4). 
Data are expressed as pg/1000 monocytes and as mean ± SEM of  four subjects. * indicates p<0.05 vs. 
T=0 (repeated measures one-way analysis of  variance with Dunnet’s Multiple Comparisons post-hoc test).
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Figure 2     Plasma concentrations (in pg/mL) 
of  cytokines (TNF-α, IL-6, IL-10, IL-RA, and 
TGF-β) during human endotoxemia of  subjects 
who were administered LPS on two separate occa-
sions (visits 1 and 2) with an interval of  approxi-
mately 2 weeks. Data are expressed as mean ± 
SEM of  12 subjects. p-values were calculated using 
repeated measures two-way analysis of  variance (in-
teraction term).
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Figure 3     Changes in mean arterial pressure (MAP, upper left panel), temperature (TEMP, up-
per right panel), heart rate (HR, lower left panel) and symptom score (lower right panel) during human 
endotoxemia of  subjects who were administered LPS on two separate occasions (visits 1 and 2) with an 
interval of  approximately 2 weeks. Data are expressed as mean ± SEM of  12 subjects. p-values were 
calculated using repeated measures two-way analysis of  variance (interaction term).
Table 1     Leukocyte counts (X 109) during human endotoxemia of  subjects who were administered 
LPS on two separate occasions (visits 1 and 2) with an interval of  approximately 2 weeks. 
Values are mean ± SEM of  12 subjects.
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The in vivo cytokine response following LPS administration is still impaired after 2 weeks
The first in vivo LPS administration (visit 1) resulted in a typical transient increase 
in plasma concentrations of  the proinflammatory cytokines TNF-α and IL-6 and 
the anti-inflammatory cytokines IL-10 and IL-1RA (Figure 2). TGF-β plasma 
levels only showed an increase 8 hours post-LPS (Figure 2). Compared with the 
first LPS administration, the second LPS administration led to an attenuation of  
peak plasma levels of  TNF-α, IL-6, and IL-10 by 46±10%, 36±9%, and 45±8%, 
respectively. Although statistically significant, peak levels of  IL-1RA and TGF-β 
were only attenuated by 10±7% and 14±6%, respectively. The attenuation in peak 
concentrations of  IL-1RA and TGF-β was significantly less pronounced than that 
of  the other cytokines measured (p<0.05). There was no correlation between the 
attenuation of  peak levels of  the various cytokines and the interval between the two 
LPS experiments (TNF-α: r=0.16; IL-6: r=0.06; IL-10: r=0.14, IL-1RA: r=-0.12, 
TGF-β: r=0.09). 
In contrast to the cytokine data, LPS-induced changes in mean arterial pressure, 
heart rate, temperature, and symptom score were similar during both endotoxemia 
experiments (Figure 3). Likewise, leukocyte counts did not differ between both visits 
(Table 1).  
Discussion
In the present study, we demonstrate that following a single in vivo LPS challenge, the 
ex vivo cytokine response to LPS is restored within one week, whereas attenuation of  
the in vivo cytokine response persists for at least two weeks. The attenuated cytokine 
response did not result in less pronounced clinical symptoms, hemodynamic changes, 
rise in temperature, and leukocyte counts. 
Reports on in vivo LPS tolerance in humans are scarce. In a previous study, 0.06 ng/
kg LPS (as opposed to 2 ng/kg in the present study) was administered twice with 
an interval of  two weeks. Although very low circulating cytokine levels were found, 
a small, but significant attenuation of  TNF-α, IL-6, and IL-1RA plasma levels was 
observed upon the second LPS administration18. Earlier work from our group has 
shown that after LPS administration for 5 consecutive days in healthy volunteers, the 
cytokine response is virtually nullified at day 511, 19, and similar results were observed 
in LPS-treated cancer patients20. 
Rapid reversal of  ex vivo endotoxin tolerance after a single in vivo LPS challenge has 
been demonstrated before by ourselves and others5, 6, 8. Ex vivo hyporesponsiveness 
was not restricted to LPS, but also observed using other Toll-like receptor stimuli, 
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indicating cross-tolerance5, 6. In line with these data, we confirm that the ex vivo TNF-α, 
IL-6 and IL-10  response is severely impaired 4 hours after LPS administration, but 
is restored after one week and remains unaltered in the following 3 weeks. Ex vivo 
hyporesponsiveness to LPS was not mediated by high levels of  circulating TGF-β, a 
well-described suppressor of  LPS-induced proinflammatory cytokine production21, 
because plasma TGF-β levels were not increased until 8 hours post-LPS. The limited 
duration of  ex vivo endotoxin tolerance after a single LPS administration might be 
due to the relatively short lifespan of  monocytes in the circulation. Especially during 
inflammation they leave the circulation and extravasate into tissues22, 23. Subsequently, 
the blood pool is replenished by ‘new’ monocytes originating from the bone marrow 
or from a splenic reservoir22-24. These new monocytes may not have been exposed to 
LPS and therefore appear not to have developed tolerance. In contrast to our data, 
the tolerant state of  ex vivo stimulated leukocytes of  septic or injured patients can 
persist for several weeks3, 25. The discrepancy in duration of  ex vivo tolerance between 
patients and human endotoxemia volunteers may be due to the fact that human 
disease states complicated by or induced by endotoxin are often episodic (multi-hit 
theory) or continuous. Repeated activation of  the immune system is likely to result 
in the development of  a more profound tolerance, both in vivo and ex vivo, compared 
with a single hit.
The difference between the ex vivo and in vivo LPS tolerance duration signifies the notion 
that the blood compartment does not contribute significantly to the in vivo cytokine 
response to LPS, and the fact that tissue-resident macrophages are its main source. 
This hypothesis is strengthened by several findings. First, our group has demonstrated 
that there exists no correlation between the ex vivo and in vivo inflammatory response 
to LPS, indicating that these responses are mediated by two different compartments26. 
Second, increased cytokine levels have been found in neutropenic mice and patients10, 
27, 28. Third, macrophages are unable to produce IL-1β in response to solely LPS29, 
whereas monocytes produce large amounts of  IL-1β upon LPS stimulation30. In the 
human endotoxemia model, IL-1β is barely detectable31, implicating a limited role for 
monocytes in the cytokine production to an in vivo LPS challenge. The turnover of  
tissue-resident macrophages is slow, which may explain the relatively lengthy refractory 
state after a single hit32. Furthermore, as our data indicate, the hyporesponsive state in 
vivo is not reflected by ex vivo cytokine production of  stimulated leukocytes. Therefore, 
conclusions regarding the immune status of  patients or subjects based on ex vivo 
stimulation experiments should be met with caution.
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Interestingly, tolerance was not observed in the production of  IL-1RA ex vivo, and 
only very moderately in vivo. In ex vivo stimulated whole blood of  patients with 
meningococcal infection, TNF-α, IL-1β, and IL-6 production is severely depressed 
at admission and gradually restores upon patient recovery, whereas this pattern is 
reversed for IL-RA production33. Furthermore, ex vivo LPS-stimulated leukocytes of  
septic shock patients produce significantly less amounts of  IL-1β compared with 
leukocytes obtained from control subjects, whereas IL-1RA production is unaltered34. 
It was demonstrated that while the LPS-induced increase in transcription of  IL-1β 
and IL-1RA is similarly attenuated in leukocytes of  septic patients, IL-1RA mRNA 
is more stable than IL-1β mRNA. As a result, the slowly decaying ‘pool’ of  IL-RA 
mRNA is still effectively translated upon LPS stimulation34. 
In contrast to the in vivo LPS tolerance measured by attenuated cytokine release, 
endotoxemia-induced changes in hemodynamics, temperature, leukocyte counts, and 
symptom score were not blunted during the second endotoxemia experiment. During 
LPS administrations for 5 consecutive days, cytokine levels were virtually nullified 
at day 5, whereas significant LPS-induced changes in temperature, heart rate, mean 
arterial pressure, and white blood cell counts persisted, albeit it to a lesser extent11. 
Therefore, it appears likely that mediators or processes other than the cytokines 
measured are responsible for generation of  these effects and that these do not become 
tolerant to LPS. The disparity between clinical symptoms and cytokine levels are of  
particular interest from a clinical point of  view. In a sepsis trial, patients are usually 
included when systemic inflammatory response syndrome criteria are present. If  the 
effects of, e.g., an anti-cytokine intervention are studied, our data illustrate that the 
target analyte cytokine of  interest may not be elevated in the presence of  systemic 
inflammatory response syndrome criteria. Therefore, evidence that the analyte target 
is present should be one of  the inclusion criteria prior to enrolment.
This study may also have important consequences for the design of  pharmacological 
intervention trials using the human endotoxemia model. Our data show that a cross-
over design with an interval of  1-2 weeks12-15 is importantly hindered by development 
of  in vivo LPS tolerance. At this moment it is unclear which wash-out period between 
LPS administrations is sufficient. As our data show, tolerance will be present within the 
2 weeks following the first LPS administration, whereas a diminished response to LPS 
due to antibody formation may occur at a later stage35. Therefore, we suggest to use 
parallel groups to investigate interventions aimed at modulation of  the inflammatory 
response during human endotoxemia.  
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Our study has several limitations. First, our study design has not permitted us to 
investigate the duration of  in vivo LPS tolerance. In order to determine this, multiple 
parallel groups of  healthy volunteers that are administered LPS on two separate 
occasions with different wash-out periods would be needed. Also, we cannot draw 
definitive conclusions regarding the tolerant state of  tissue-resident macrophages 
or mediators/mechanisms of  tolerance, such as the recently implicated role of  
IL-1 receptor-associated kinase-M (IRAK-M) and suppression of  tumorigenicity 2 
(ST2)8, 36, because it requires invasive procedures to harvest these cells.
In conclusion, our results imply that the in vivo response to LPS is mediated by tissue-
resident macrophages that remain tolerant for a much longer period than circulating 
leukocytes. Therefore, ex vivo stimulation of  circulating leukocytes, a frequently used 
method to investigate a subject’s or patient’s immune status, might not be indicative 
of  the in vivo innate immune response to a pathogenic stimulus. The disparity between 
cytokine levels and clinical symptoms may have implications for the design of  sepsis 
trials in which patients are often enrolled based on clinical symptoms. Finally, due to 
in vivo tolerance, intervention studies utilizing the human endotoxemia model should 
employ an unpaired parallel group design.
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Letter to the editor
Nitric oxide inhalation and glucocorticoids as combined 
treatment in human experimental endotoxemia: it takes 
not always two to tango
Jan C. Pompe, Matthijs Kox, Cornelia W. Hoedemaekers, 
Johannes G. van der Hoeven, Peter Pickkers
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Abstract original article
Nitric oxide inhalation and glucocorticoids as combined treatment in human 
experimental endotoxemia
Hållström L, Berghäll E, Frostell C, Sollevi A, Soop AL.
Critical Care Medicine 2008; 36(11):3043-7
Background Inhaled nitric oxide and glucocorticoids as a combination therapy 
may attenuate endotoxin-induced inflammatory responses in humans as indicated 
by levels of  cytokines and clinical signs. Because other authors have shown that 
combined inhaled nitric oxide and steroids improved the histologic damage both in 
pulmonary and systemic organs in a porcine endotoxin model, we examined if  an 
anti-inflammatory interaction could be demonstrated in humans.
Methods We performed a double-blind, crossover, placebo-controlled 
randomized study in fifteen healthy white volunteers (4 women, 11 men) at the 
intensive care unit of  a university hospital. Endotoxin (2 ng/kg) was administered 
intravenously. Thirty minutes thereafter the volunteers were given glucocorticoids 
(2 mg/kg) intravenously and inhaled nitric oxide 30 ppm or placebo (nitrogen) 
administered through a nasal cannula. Blood samples and clinical signs were collected 
before and up to 5.5 hrs after the endotoxin infusion.
Results  Following endotoxin body temperature and heart rate increased 
significantly compared with baseline. There were no differences observed between 
the treatments. Endotoxin challenge also markedly elevated the plasma levels of  
tumor necrosis factor-alpha, interleukin (IL)-6, IL-10, and IL1-ra concentrations 
during the study period. No difference between placebo/glucocorticoids and inhaled 
nitric oxide/glucocorticoids treatment was seen in the cytokine response.
Conclusions In a human experimental inflammatory model using endotoxin, 
inhaled nitric oxide and glucocorticoids in low doses given after the endotoxin 
challenge did not modify the inflammatory cascade as monitored in this study.
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To the editor
We read with interest the article by Hållström et al1 about the effects on the innate 
immune response of  inhaled nitric oxide (iNO) during experimental endotoxemia. 
All 15 volunteers received hydrocortisone 30 mins after the  endotoxin challenge. 
The study design was crossover, randomized, double-blind, and placebo-controlled 
regarding iNO. At least 3 to 4 wks elapsed between the experiments. This is the 
first study in healthy volunteers in which two potential immune modulating therapies 
are combined in the human endotoxin model and in our view, several issues 
concerning this complex study design and its subsequent influence on the results 
should be addressed. We recently performed a comparable trial in which we induced 
experimental human endotoxemia twice in 12 healthy male volunteers, in the presence 
or absence of  a pharmacological intervention or placebo. Similarly, this study was 
also performed in a crossover design, 10 to 18 days apart (mean, 14 days). After 
deblinding of  the study, however, we discovered an important tolerance effect of  the 
administration of  endotoxin, with a lower inflammatory response during the second 
visit regardless of  the pharmacological intervention (active or placebo). We would like 
to know whether such effects were also encountered during the study by Hållström 
et al. Previous crossover studies with the human endotoxin model generally chose a 
washout period of  2 wks on average2 or a washout period of  6 wks on average3 to 
avoid the potential effects of  lipopolysaccharide (LPS)-antibody formation. Why did 
they choose a washout period of  3 to 4 wks? 
Inhaled nitric oxide may modulate the acute neutrophilic inflammation of  the lung 
parenchyma and dysfunction of  the alveolar-capillary membrane that characterizes 
acute respiratory distress syndrome at several levels. Given the fact that inhaled 
nitric oxide is inactivated within seconds (by hemoglobin in  blood, by haptoglobin-
hemoglobin complexes in plasma, and by a reaction with heme ferrous iron and ferric 
iron that  forms nitrosyl-hemoglobin), the question is if  the very low concentrations of  
iNO can attenuate the (parenterally administrated) LPS-mediated cytokine production 
outside of  the lung. There is no human data that 30 ppm iNO in fact can attenuate the 
LPS-mediated cytokine production in the lung, which could be examined in humans 
with use of  LPS inhalation4. In addition, it is unclear to us why hydrocortisone was 
administered to all of  the volunteers. Why  examine the possible effect of  iNO during 
a suppressed innate immune response if  the effect of  iNO alone is questionable? It 
now remains possible that iNO in the absence of  steroid treatment may influence the 
LPS-induced response. Furthermore, in this protocol hydrocortisone was injected 30 
mins after endotoxin infusion as a bolus (2 mg/kg), while other studies that investigate 
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the immune modulating effects of  glucocorticoids in the human endotoxin model use 
pretreatment with continuous infusion of  hydrocortisone during a period of  at least 
6 hrs before endotoxin infusion5. It is unclear if  and to what extent hydrocortisone 
administration 30 mins after the induction of  endotoxemia will influence the innate 
immune response, given that no control group for the steroid treatment was tested. 
In our view, time control experiments in which LPS is administrated twice to 
volunteers without another  pharmacological intervention are needed to demonstrate 
the presence of  absence of  time-related effects on the innate immune response of  
LPS. In addition, we feel it is preferable to study one pharmacological intervention 
at the time or to use four study groups (both iNO and cortisone randomized) if  
combined effects need to be established. 
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In this thesis, we describe preclinical, translational and clinical studies investigating 
the interplay between the autonomic nervous system (ANS) and the innate immune 
response. We focused on the effects of  the parasympathetic nervous system, the 
so-called cholinergic anti-inflammatory pathway, because this is a relatively newly 
discovered pathway and its mechanisms and effects have been sparsely studied, 
especially in humans. 
Chapter 1 is a short introduction on the ANS and innate immunity, but mainly focuses 
on the links between these two systems. In the last decades, the ANS has been identified 
as a regulator of  the innate immune system. At first, it was shown that the afferent 
vagus nerve can detect inflammation in organs and relay this information to the brain, 
resulting in fever, cortisol release, and increased efferent vagus nerve activity. In the 
1990s, it was shown that the efferent sympathetic nervous system can limit the innate 
immune response via catecholamines acting on β-receptors. This was confirmed in 
humans in vivo: administration of  epinephrine resulted in decreased production of  
proinflammatory cytokines and increased production of  anti-inflammatory mediators 
during human endotoxemia1. In 2000, Tracey and colleagues identified the cholinergic 
anti-inflammatory pathway, in which efferent vagus nerve activity limits the immune 
response via binding of  acetylcholine to the α7nAChR receptor on macrophages2, 3. 
Part one: Autonomic nervous system – innate immune interactions in human 
health and disease
In the first part of  this thesis, we investigated the interplay between the ANS and the 
innate immune response, both in patients and healthy volunteers. 
In chapter 2a, we postulated the hypothesis that increased vagus nerve activity results in 
the observed immune paralysis in traumatic brain injury patients. These patients often 
suffer from a hyporeactive innate immune system, making them more susceptible for 
infections4, 5. Furthermore, in traumatic brain injury patients, increased vagus nerve 
activity, measured by heart rate variability (HRV), is reported6, 7. We linked these two 
observations, suggesting that the observed immune paralysis results from persistent 
increased vagus nerve activity and subsequent excessive dampening of  the innate 
immune response through the cholinergic anti-inflammatory pathway. We proposed 
that the increased intracranial pressure, often observed in brain injury patients, is 
the major contributor to the increased activity of  the vagus nerve. Pressure-induced 
compression of  the brainstem might lead to vigorous firing of  the dorsal motor 
nucleus in the medulla oblongata, the centre where the vagus nerve originates. This is 
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supported by findings of  increased vagus nerve activity in subarachnoid haemorrhage 
patients, which often exhibit high intracranial pressures8, and animal experiments, 
where vagal activity increased relative to the increase in intracranial pressure induced 
by inflating a subdural balloon9.
In the previous chapter, we proposed a relation between increased intracranial pressure, 
vagus nerve activity, and the innate immune response in subarachnoid haemorrhage 
patients. With regard to this relation, in chapter 2b, we commented on an article 
describing the relationship between sympathetic nervous system activity, measured by 
norepinephrine spillover, and circulating inflammatory cytokines in ICU patients with 
subarachnoid haemorrhage10. The authors found increased norepinephrine spillover 
and increased levels of  plasma cytokines, but no quantitative correlation between 
these parameters. We put forward that measuring circulating cytokines might not 
properly reflect a patient’s innate immune status as these cytokines could merely result 
from the initial insult and not provide information on the immune system’s capacity 
to respond to a stimulus. We stated that measuring the inflammatory response of  
ex vivo stimulated leukocytes might be a better option. Furthermore, we proposed 
to the authors that, with regard to the cholinergic anti-inflammatory pathway, not 
only sympathetic, but also parasympathetic parameters should be assessed when 
investigating inflammatory parameters in patients with subarachnoid haemorrhage. 
Nicotine is a non-specific agonist of  the α7nAChR. Therefore, the cholinergic anti-
inflammatory pathway might be activated by nicotine administration in patients. 
In chapter 2c, we discussed an article reporting increased mortality in critically ill 
patients receiving nicotine-replacement therapy11. We speculated that nicotine might 
have suppressed the innate immune response in these patients to the point of  immune 
paralysis, putting them at a higher risk of  acquiring concomitant infections leading 
to worse outcome. This is supported by the fact that in the nicotine-treated group, 
8% of  the patients died of  infections compared with 2% in patients not treated with 
nicotine11. Unfortunately, infection incidence was not reported. 
In chapter 3, we investigated the hypothesis described in chapter 2a. To this end, we 
studied the relationship between ANS activity and the innate immune response in 
intensive care patients with neurological damage in the first 4 days after admission. 
ANS activity was measured by HRV and the immune response was assessed by cytokine 
production in ex vivo stimulated leukocytes as well as levels of  plasma cytokines. We 
demonstrated a significant inverse correlation of  HFnu (a HRV parameter reflecting 
vagus nerve activity) and ex vivo stimulated TNF-α production. These results suggest 
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that vagus nerve activity attenuates cytokine production by circulating leukocytes. 
To further investigate effects of  intracranial pressure on vagus nerve activity and 
the innate immune response in brain injury, we compared patients with conditions 
associated with high (intracranial haemorrhage) and low (subarachnoid haemorrhage 
with an extraventricular drain) intracranial pressure. Ex vivo stimulated cytokine 
production was significantly lower in patients with intracranial haemorrhage compared 
with subarachnoid haemorrhage. Furthermore, within the intracranial haemorrhage 
group, there was a strong significant inverse correlation between HFnu and plasma 
levels of  TNF-α. The fact that patients with intracranial haemorrhage exhibited the 
most pronounced immune paralysis suggests intracranial pressure-induced activation 
of  the vagus nerve and subsequent dampening of  the innate immune response.
In chapter 4, the relationship between cardiac ANS activity, measured by HRV, and 
the innate immune response in a large group of  healthy volunteers during human 
endotoxemia was examined. It is conceivable that a subject’s basal vagus nerve or 
sympathetic activity would correlate with the inflammatory response. Therefore, we 
first set out to determine whether baseline HRV parameters, determined before LPS 
administration, predicted a subject’s subsequent plasma cytokine response to LPS 
in this controlled model of  the innate immune response. We found no correlations 
between any of  the HRV parameters and plasma cytokines. Upon LPS administration, 
HRV parameters decreased considerably. We investigated whether the extent of  LPS-
induced HRV changes correlated with the magnitude of  the plasma cytokine response. 
Again, no relation was found. Further evidence for the lack of  a relation between 
the plasma cytokine response and HRV alterations was obtained from experiments 
where healthy volunteers received LPS twice with an interval of  two weeks. Due to 
endotoxin tolerance, the plasma cytokine response to LPS was roughly halved upon 
the second LPS administration, however, HRV changes were identical. These findings 
suggest that cardiac ANS activity may not be representative for ANS outflow to other 
organs involved in the inflammatory response and indicates that changes in HRV are 
not a reliable surrogate measure for the extent of  the inflammatory response during 
human endotoxemia.
Part two: Limiting the innate immune response through the cholinergic anti-
inflammatory pathway; in vitro, animal, and human studies
In the second part of  this thesis, we focused on the effects of  stimulation of  the 
cholinergic anti-inflammatory pathway. We investigated this in animals, using models 
of  ventilator-induced lung injury (VILI), and in humans, both in vitro using primary 
human leukocytes and in vivo during experimental human endotoxemia. 
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In chapter 5, we investigated the effects of  stimulation and ablation of  the cholinergic 
anti-inflammatory pathway on VILI. Mechanical ventilation is a life-saving therapy, 
that at the same time can induce lung injury. Activation of  the innate immune system 
by mechanical ventilation, so-called biotrauma, has been shown to play a detrimental 
role in the pathogenesis of  VILI12, 13. Patients with underlying inflammatory processes, 
which is common in the ICU, have an increased risk of  developing VILI14. We 
investigated the effects of  stimulation of  the cholinergic anti-inflammatory pathway 
by electrical vagus nerve stimulation and ablation of  this pathway by vagotomy in 
a rat two-hit VILI model: LPS administration followed by mechanical ventilation. 
We performed vagus nerve stimulation or vagotomy after LPS administration but 
before the start of  mechanical ventilation. We chose this time-point to simulate a 
patient with systemic inflammation admitted to the ICU for initiation of  mechanical 
ventilation. We demonstrated that mechanical ventilation with high (15 mL/kg), 
but not low (8 mL/kg), tidal volumes potentiates the LPS-induced inflammatory 
response in the lungs. Vagotomy resulted in elevated levels of  pulmonary cytokines 
and reduced oxygenation in spontaneously breathing animals, but did not further 
enhance the inflammatory response in LPS-treated mechanically ventilated rats. 
Vagus nerve stimulation did not affect the inflammatory response during spontaneous 
breathing and mechanical ventilation. These results suggest that delayed stimulation 
of  the cholinergic anti-inflammatory pathway has no beneficial effects on pulmonary 
inflammation and questions the clinical applicability of  stimulation of  this pathway 
in systemically inflamed patients admitted to the ICU where mechanical ventilation 
is initiated.
In chapter 6, we explored the anti-inflammatory effects and underlying mechanisms 
of  α7nAChR stimulation on primary human leukocytes. We demonstrated that 
both the non-specific α7nAChR agonist nicotine and the specific agonist GTS-21 
dose-dependently inhibited proinflammatory cytokine release by human leukocytes 
stimulated with various Toll-like receptor agonists. GTS-21 was more potent and 
efficacious than nicotine. Furthermore, we revealed that the anti-inflammatory effects 
of  GTS-21 are mediated at the transcriptional level as it prevented upregulation of  
cytokine mRNA levels. Finally, qPCR array data and experiments using the JAK2 
inhibitor AG490 indicated that the effects of  GTS-21 involve activation of  the JAK2-
STAT3 pathway. These data demonstrate that GTS-21 has potent anti-inflammatory 
effects on human innate immune cells and that these effects are transcriptionally 
mediated.
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The anti-inflammatory potential of  GTS-21 was further examined in chapter 7, 
where we investigated its effects in a murine VILI model. Furthermore, the effects 
of  acetylcholinesterase inhibition with neostigmine, which improved outcome 
in murine sepsis15, and nAChR blockade with mecamylamine, which worsened 
murine pancreatitis16, were explored. Mice were ventilated with a clinically relevant 
tidal volume of  8 mL/kg for 4 hours, which resulted in a pulmonary and systemic 
inflammatory response. Pre-treatment with GTS-21 attenuated pulmonary and 
systemic TNF-α at the transcriptional level, and lowered the arterial-alveolar gradient, 
indicating improved gas exchange. Furthermore, GTS-21 inhibited TNF-α mRNA 
expression and production in isolated alveolar macrophages. Neither neostigmine, 
nor mecamylamine affected inflammatory or respiratory parameters. This study 
demonstrates that selective α7nAChR stimulation can limit VILI elicited by mechanical 
ventilation using clinically relevant ventilator settings. The absence of  effects of  
neostigmine and mecamylamine may be related to the fact that the relatively mild 
inflammatory response induced by mechanical ventilation is not severe enough to 
endogenously activate the cholinergic anti-inflammatory pathway.
After the encouraging effects of  GTS-21 in vitro and in mice, it remained to be 
determined whether this compound could limit the innate immune response in 
humans in vivo as well. To this end, in chapter 8, we performed a double blind placebo-
controlled pilot study to investigate the effects of  GTS-21 on the innate immune 
response in healthy volunteers during experimental endotoxemia. Subjects received 
GTS-21 or placebo orally during 3 days before endotoxin administration, and on 
the day of  the human endotoxemia experiment. We found no differences in plasma 
cytokine levels between the GTS-21 and the placebo groups. This may be caused by 
the fact that plasma concentrations of  GTS-21 were relatively low and highly variable 
between subjects. However, within the GTS-21-treated group, higher GTS-21 plasma 
concentrations correlated with lower levels of  TNF-α, IL-6, and IL-1RA, but not IL-
10. The correlation between higher plasma levels of  GTS-21 and lower concentrations 
of  inflammatory cytokines suggest that, at higher concentrations, GTS-21 can limit 
the innate immune response in humans in vivo.
Apart from GTS-21, we also studied another means of  activating the cholinergic anti-
inflammatory pathway in humans. In chapter 9, we investigated a novel gut-brain-
immune axis in healthy volunteers during experimental endotoxemia. Recent animal 
studies have revealed that the cholinergic anti-inflammatory pathway can be activated 
by short-term enteral administration of  lipid-enriched nutrition devoid of  intrinsic 
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anti-inflammatory properties17-19. The luminal presence of  lipid-enriched nutrition 
results in cholecystokinin (CCK) release, which activates CCK-receptors located 
on afferent vagal fibers20. Activation of  these CCK receptors triggers a vagovagal 
reflex, that reduces the innate immune response via the cholinergic anti-inflammatory 
pathway. In our study, subjects received either lipid- and protein-enriched or isocaloric 
control nutrition via nasojejunal tube. A third group of  subjects was fasted throughout 
the study. Administration of  lipid- and protein-enriched nutrition significantly 
attenuated plasma levels of  the proinflammatory cytokines TNF-α, IL-6 and IL-
1RA compared with control nutrition and fasting. Furthermore, enriched nutrition 
significantly augmented release of  the anti-inflammatory cytokine increased IL-10 
compared with fasted subjects. These results indicate that enteral administration of  
protein- and lipid-enriched nutrition can activate the cholinergic anti-inflammatory 
pathway in humans, resulting in attenuation of  the innate immune response. 
In the last chapter of  part two, chapter 10, we investigated whether the ANS, and 
through it, the innate immune response, can be influenced through concentration/
meditation. We describe a case study of  a Dutch individual known as ‘the iceman’. This 
individual holds several world records with regard to withstanding extreme cold. He 
claims to achieve these remarkable feats through a special autodidact concentration/
meditation technique through which, he claims, he influences his ANS and also 
his immune response. We demonstrated that 80 minutes of  ice-immersion (during 
which the iceman practiced his concentration/meditation technique) resulted in high 
levels of  cortisol and a large reduction of  cytokine production in ex vivo stimulated 
leukocytes. We also performed a human endotoxemia experiment in this individual 
while he practiced his concentration/meditation technique. We found elevated levels 
of  catecholamines after initiating concentration/meditation, and the increase in plasma 
cortisol level was higher than in any of  the previously studied healthy volunteers 
during endotoxemia. Moreover, the LPS-induced plasma cytokine response and 
symptoms were remarkably mild in comparison to a large group of  previously studied 
subjects. In conclusion, these results suggest that, through concentration/meditation, 
this individual can elicit a consciously controlled stress response, characterized by 
sympathetic nervous system activation and subsequent catecholamine/cortisol 
release which dampens the innate immune response. Moreover, this study implies that 
the ANS might be consciously influenced through special concentration/meditation 
techniques.
270
Chapter 13
Part three: Methodological considerations 
The use of  various measurement techniques and experimental models inevitably leads 
to various interesting findings concerning these techniques and models. In the third 
part of  this thesis, we describe methodological considerations regarding HRV and the 
human endotoxemia model. 
In chapter 11, we investigated the influence of  different breathing patterns on HRV 
and its reproducibility in healthy subjects during human endotoxemia. Different 
breathing patterns might influence HRV, but results from previous studies are 
conflicting and have all been obtained under static conditions, when HRV does 
not vary to a great extent. As we have shown in chapter 4, HRV parameters greatly 
fluctuate as a result of  the systemic inflammatory response to endotoxin. This makes 
the human endotoxemia model ideal to investigate the effects of  different breathing 
patterns on HRV in a dynamic setting. We demonstrated that, over a wide range 
of  HRV magnitudes, neither paced breathing nor mild hyperventilation influenced 
any of  the HRV parameters compared with spontaneous breathing. Furthermore, 
paced breathing did not improve HRV measurement reproducibility. We concluded 
that a paced breathing protocol is not required to obtain valid HRV data during 
endotoxemia. 
Our research group has previously shown that repeated endotoxin administration 
results in endotoxin tolerance, characterized by a blunted inflammatory response 
to LPS challenges, both in vivo and ex vivo21, 22. However, while pharmacological 
intervention trials during experimental human endotoxemia are frequently performed 
in a cross-over manner using an interval of  1-2 weeks23-26, it is unknown for how 
long the refractory state that may lead to carry-over effects persists. In chapter 12a, 
we describe the kinetics of  endotoxin tolerance in human volunteers, both ex vivo 
and in vivo. We demonstrate that following endotoxin administration in vivo, the ex 
vivo response of  circulating leukocytes to LPS is restored within a week. However, 
two weeks after endotoxin administration, the in vivo cytokine response to a second 
endotoxin challenge is still severely suppressed. These findings imply that the in vivo 
response to LPS is mediated by tissue-resident macrophages and that ex vivo stimulation 
does not accurately reflect the in vivo innate immune response. Furthermore, this study 
implicates that intervention studies utilizing the human endotoxemia model should be 
performed using parallel groups rather than a cross-over design.
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In light of  the findings reported in chapter 12a, in chapter 12b we commented on 
an experimental human endotoxemia study employing a cross-over design with a 
washout period of  3-4 weeks27. We speculate that this washout period might have 
been too short and tolerance may still be present, hampering clear interpretation 
of  the data. The authors replied that, upon reviewing their data, a tolerance effect 
was indeed found, but this did not affect the conclusions of  this particular study. 
Furthermore, they stated that in another study, using a washout period of  6 weeks, no 
tolerance effects were observed28.
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General discussion
A well-functioning innate immune system protects us from invading pathogens. Upon 
recognition of  microorganisms, the production of  proinflammatory cytokines, such 
as TNF-α and IL-6, by cells of  the innate immune system is one of  the initial steps in 
the orchestration of  an inflammatory response aimed to clear the body of  invaders. 
However, as Shakespeare already knew: ‘too much of  a good thing can be bad for 
you’1. Overproduction of  proinflammatory cytokines can lead to a hyperinflammatory 
state that can have devastating effects on organs. The innate immune system therefore 
is a double-edged sword: it is essential to our survival, but excessive or persistent 
activation of  this system may be harmful. It has become clear that the autonomic 
nervous system (ANS) can limit the innate immune response, which might represent 
new treatment options to counteract excessive inflammation. 
In this final chapter, we discuss the findings described in this thesis, also in light 
of  recent studies in the field that were performed during the conduct of  our own 
research. Furthermore, we draw conclusions and present future perspectives.
Autonomic nervous system – innate immune interactions in human health and 
disease 
In the first part of  this thesis, we demonstrated that ANS activity, measured by HRV 
analysis, does not correlate with the innate immune response or vice-versa in healthy 
subjects during human endotoxemia. However, we did find evidence in support of  
the cholinergic anti-inflammatory pathway in patients with brain injury. 
It is still unclear whether vagal input to the heart (which is reflected by HRV) reflects 
vagal input to other organs involved in the innate immune response. This has, to the best 
of  our knowledge, never been studied. However, in case of  the sympathetic nervous 
system, several studies are in support of  a differentiated output. In animals, systemic 
inflammation was found to be associated with increased sympathetic nerve activity 
to the spleen and adrenals, but decreased outflow in other sympathetic branches2, 3. 
A recent study examined different measures of  sympathetic nervous system activity 
during human endotoxemia: muscle sympathetic nerve activity (MSNA) and plasma 
catecholamines4. While MSNA was depressed, circulating catecholamine levels were 
elevated. HRV analysis, as demonstrated by ourselves and others5, shows sympathetic 
predominance after LPS administration, which is in accordance with elevated 
catecholamine levels. These results suggest that the autonomic nervous system 
represents a highly differentiated system and outflow is organ-specific. Moreover, it 
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was shown that, at least in animals, the cholinergic anti-inflammatory pathway can be 
activated by electrical charges below the threshold required to influence heart rate, 
making it undetectable by HRV6. Taken together, these findings demonstrate that 
several limitations inherent to HRV limit its use in investigation of  the cholinergic 
anti-inflammatory pathway in humans. Nevertheless, in critically ill patients, relations 
between HRV and the immune response were found by us and others7. It might be 
speculated that the differentiation of  autonomic outflow observed in healthy subjects 
is (partly) lost in critical illness and/or brain injury. Such a phenomenon is known to 
occur during vasovagal syncope, when effects of  increased vagal outflow are observed 
on all organs innervated. If  the loss of  differentiation is indeed dependent on illness 
severity, the absence of  a relation between HRV and the immune response in healthy 
subjects during human endotoxemia may not be surprising, because this model of  
inflammation is relatively mild. 
Based on our observational study, we cannot draw definitive conclusions regarding 
our hypothesis that persistent activation of  the cholinergic anti-inflammatory 
pathway accounts for the immune paralysis observed in patients with brain injury, as 
we did not find increased vagus nerve HRV parameters in these patients. However, 
in agreement with our hypothesis, the largest suppression of  ex vivo stimulated 
cytokines was found in the group of  patients with intracranial haemorrhage, a 
condition associated with increased intracranial pressure. Of  interest, in a very 
recent investigation, nonsurviving subarachnoid haemorrhage patients exhibited 
significantly higher levels of  parasympathetic activity (measured by HRV) compared 
with survivors8. Unfortunately, the cause of  death was not reported. It is conceivable 
that the infection prevalence was higher in the nonsurvivors due to the observed 
increased vagus nerve activity and that this contributed to the increased mortality. 
However, the worse outcome might also be a direct result of  increased intracranial 
pressure, of  which the high parasympathetic activity in these patients is indicative. 
In conclusion, several lines of  evidence suggest that the cholinergic anti-inflammatory 
pathway may play a detrimental role in different conditions in critically ill patients. 
However, the highly heterogeneous patient population and the only currently available 
method to assess vagus nerve activity, HRV, does not allow us to draw definitive 
conclusions regarding the involvement of  this pathway.
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Limiting the innate immune response through the cholinergic anti-
inflammatory pathway
In the second part of  this thesis, we demonstrated that pharmacological stimulation 
of  the cholinergic anti-inflammatory pathway by the selective α7nAChR agonist GTS-
21 before the start of  mechanical ventilation limits VILI in mice. However, delayed 
stimulation of  the pathway by electrical vagus nerve stimulation did not attenuate 
VILI in a second-hit model in rats. Furthermore, we showed that GTS-21 has potent 
anti-inflammatory effects in human leukocytes, but its potential to limit the innate 
immune response in vivo in humans appears to be hampered by its pharmacokinetic 
properties upon oral administration. We further demonstrated a novel gut-brain-
immune axis in humans, in which enteral lipid- and protein-enriched nutrition limits 
the immune response, supposedly via CCK-mediated activation of  the cholinergic 
anti-inflammatory pathway. Finally, we described a case study of  a remarkable 
individual, the iceman, who appears to be able to consciously influence his autonomic 
nervous system and thereby his innate immune response. 
While we confirmed previous findings demonstrating that vagotomy amplifies 
pulmonary inflammation9, we did not corroborate the anti-inflammatory effects 
of  vagus nerve stimulation9 in a second hit model of  VILI. This might result from 
differences in the first hit employed. We used LPS administration, whereas in the 
other study hemorrhagic shock preceded mechanical ventilation. Furthermore, 
we performed vagus nerve stimulation at a clinically relevant time point: after the 
first hit. In the other study, stimulation was performed twice: before haemorrhagic 
shock as well as before the start of  mechanical ventilation. The lack of  an effect in 
our study could therefore result from the timing of  stimulation, as the vast majority 
of  studies on vagus nerve stimulation in models of  inflammation that have shown 
beneficial results have performed stimulation before or simultaneously with the insult6, 
9-17. We know of  only two other investigations that assessed delayed stimulation of  the 
cholinergic anti-inflammatory pathway18, 19. In one study, the effects of  administration 
of  the acetylcholinesterase inhibitor physostigmine was evaluated in a cecal ligation 
and puncture (CLP) model, a widely used model to mimic polymicrobial sepsis18. 
While administration of  physostigmine simultaneous with CLP induction attenuated 
inflammation and septic shock, administration 6 hours after CLP induction conferred 
no protective effects18. In contrast, the other study did report beneficial effects of  
administration of  nicotine 24 hours after induction of  CLP19. These conflicting results 
indicate that further studies are required to establish whether delayed stimulation of  
the cholinergic anti-inflammatory pathway has beneficial effects. This is an important 
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question, because it defines the clinical applicability of  this pathway in ICU patients, 
in which pretreatment is often not possible.
It was recently demonstrated that pre-treatment with CNI-1493, a centrally acting 
drug that increases vagus nerve activity, reduced VILI induced by injurious mechanical 
ventilation (20 mL/kg, no PEEP) in mice9. We expanded on these findings by 
demonstrating that pre-treatment with GTS-21 attenuates VILI induced by mechanical 
ventilation with clinically relevant ‘protective’ ventilator settings (8 mL/kg, 1.5 
cmH2O PEEP). Our findings suggest that real lung-protective mechanical ventilation 
does not exist, at least not using tidal volumes that maintain normocapnia. Specific 
pharmacological stimulation of  the α7nAChR might have therapeutic potential to 
limit the mechanical ventilation-induced inflammatory response.
The effects of  GTS-21 on human leukocytes presented in this thesis have recently 
been replicated by others that demonstrated identical results20. Interestingly, we could 
not block GTS-21 effects with antagonists of  the α7nAChR. This may implicate 
the involvement of  other receptors in the anti-inflammatory effects of  GTS-21. 
While the α7nAChR is widely regarded as the receptor responsible for the anti-
inflammatory effects of  the vagus nerve, several recent studies have implicated 
roles for other nAChRs. For instance, nicotine’s effects on phagocytosis in murine 
peritoneal macrophages were blocked by an antagonist of  the α4/β2 nAChR, but not 
by α7nAChR antagonists21. Furthermore, nicotine was recently found to inhibit LPS-
induced increases in serum TNF-α levels in both wild-type and α7nAChR knockout 
mice22. An alternative explanation involves differences between the α7nAChR in 
excitable cells such as neurons, and non-excitable cells such as macrophages and 
monocytes. For example, while T-cells express an essentially identical transcript for 
the α7nAChR subunit as neuronal cells, they do not form functional ligand-gated ion 
channels23. In this study, α7nAChR specific antagonists MLA and α-bungarotoxin also 
failed to inhibit nicotine-induced effects23. This might be due to other pharmacological 
properties of  the α7nAChR in these cells. Along these lines, it was shown that 
primary human leukocytes24, 25 as well as several monocytic cell lines25 do not express 
the normal α7 subunit, but an α7 duplicate nicotinic acetylcholine receptor-related 
protein (dupα7) which lacks the α-bungarotoxin binding site24, 26. The activation of  the 
JAK2-STAT3 pathway downstream of  α7nAChR activation has been demonstrated 
before in murine peritoneal macrophages12. Our study confirms these findings 
in primary human leukocytes. In contrast, it was recently reported that GTS-21 and 
nicotine decreased IL-6-induced JAK2-STAT3 activation in endothelial cells. This can 
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be explained by the fact that the effects of  activation of  the JAK2-STAT3 pathway 
are highly dependent on the stimulus and the cell type used; in endothelial27 cells and 
hepatocytes28 it exerts proinflammatory effects, whereas it attenuates the inflammatory 
response in macrophages28, 29. The disparate effects in different cell types as well and 
the fact that the JAK2-STAT3 pathway is involved in the response to various other 
stimuli/processes30 prevents it from being a specific marker for α7nAChR activation.
Oral administration of  GTS-21 did not attenuate the innate immune response 
during human endotoxemia. However, the significant inverse correlations between 
the plasma concentrations of  GTS-21 and plasma cytokines within the GTS-21 
treated group strongly suggest that the absence of  a group effect was due to low 
GTS-21 plasma concentrations. We used the maximum dose that has been tested 
safe in humans31, but this still resulted in relatively low plasma concentrations. The 
highest plasma concentration we found was approximately 0.5 μM, which is below the 
concentration range that was shown by us to be effective in attenuating the cytokine 
response in leukocytes in vitro (1-100 μM). Nevertheless, the inverse correlations 
between GTS-21 concentrations and plasma cytokine levels suggest that this drug may 
be able to modulate the innate immune response in humans in vivo. The only other 
report on pharmacological stimulation of  the cholinergic anti-inflammatory pathway 
in humans describes the effects of  transdermal nicotine administration during human 
endotoxemia32. Nicotine exerted no effects on proinflammatory cytokines, but it 
potentiated plasma levels of  the anti-inflammatory cytokine IL-10. Similar to our 
study, the absence of  an effect on proinflammation was likely due to the low plasma 
levels of  nicotine achieved. Furthermore, the authors speculated that the increase in 
IL-10 might result from increased cortisol levels found in the nicotine-treated group 
rather than a direct effect of  α7nAChR stimulation, because glucocorticosteroids 
have been shown to enhance IL-10 production during human endotoxemia33, 34. 
We demonstrated remarkable anti-inflammatory effects of  enteral administration of  
lipid- and protein-enriched nutrition during human endotoxemia. We hereby present, 
for the first time, human in vivo evidence for a recently described gut-brain-immune 
axis. Nutritional stimulation of  the cholinergic anti-inflammatory pathway had, up till 
now, only been investigated in animal models35-37. In these studies, it was shown that 
vagotomy, as well as nAChR and CCK receptor antagonists, inactivate this pathway. 
In addition, a recent study demonstrated that mesenteric afferent vagus nerve firing 
significantly increased in response to lipid-enriched nutrition36. These findings have 
led to the characterization of  a gut-brain-immune axis in which lipid-rich nutrition 
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results in intestinal release of  CCK, which activates vagal afferents, resulting in a 
vago-vagal reflex that limits the immune response via activation of  nAChRs on 
immune cells. Animal studies revealed that low-lipid nutrition also dampens the 
innate immune response compared with fasted animals, albeit to a lesser extent than 
enriched nutrition36, which we confirm in our human study. However, we must remain 
cautious in our conclusions, as the role of  the vagus nerve was not assessed in our 
study. It is interesting to discuss our findings in light of  the superior effects of  early 
enteral versus parenteral nutrition on outcome in critically ill patients38-41, of  which 
the mechanisms are largely unknown. The gut-brain-immune axis could play a role 
in this observed difference, as parenteral nutrition does not lead to CCK release 
in the intestine and activation of  this pathway, while enteral nutrition does. In this 
respect, attenuation of  excessive inflammation by activation of  the cholinergic anti-
inflammatory pathway might contribute to the better outcome associated with early 
enteral nutrition. The fact that early (< 24 hour) administration of  enteral nutrition is 
associated with better outcome than late38, 42, 43 is in support of  the notion that limiting 
the innate immune response in the initial phase of  ICU admission might be beneficial, 
while it might have detrimental effects in the later phase.
The ANS is regarded as a system that we cannot consciously influence. However, 
several recent investigations suggest that through certain concentration/meditation 
techniques, it is possible to modulate autonomic activity44-47. In light of  the 
immunomodulatory effect of  the ANS, it is conceivable that by influencing the ANS, 
the innate immune system can also be modulated. We set out to investigate this in 
the iceman, and demonstrated remarkable results of  a concentration/meditation 
technique that appears to activate the stress response and thereby the sympathetic 
nervous system, resulting in suppression of  the innate immune response. However, it 
is important to emphasize that a set of  experiments on a single subject does not enable 
us to demonstrate a cause-effect relationship between concentration/meditation, the 
autonomic nervous system, and the innate immune response. It was not possible to 
repeat the experimental endotoxemia study in the same subject without concentration/
meditation because of  the development of  endotoxin tolerance (this thesis and 48). 
Nevertheless, case studies with remarkable findings can yield valuable information 
and are important in hypothesis generation for further research. 
In conclusion, stimulation of  the cholinergic anti-inflammatory pathway can exert 
beneficial effects in VILI, but the timing of  stimulation of  this pathway is crucial, 
which might limit its clinical applicability. Our studies further indicate that stimulation 
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of  the cholinergic anti-inflammatory pathway is a feasible option to limit the innate 
immune response in humans, either via nutritional stimulation or via α7nAChR 
agonists. However, the only currently available specific agonist in humans, GTS-
21, has unfavourable pharmacokinetic properties. Concentration/meditation might 
represent a novel method to consciously activate the sympathetic nervous system and 
thereby attenuate the innate immune response, but further studies are necessary to 
confirm this single observation.
 
Methodological considerations
In the final part of  this thesis, we demonstrated that different breathing patterns do 
not affect HRV parameters or reproducibility over a wide range of  HRV magnitudes 
during human endotoxemia. Lastly, we demonstrated discrepant kinetics of  endotoxin 
tolerance in vivo and ex vivo.
Paced breathing did not affect HRV parameters. This confirms the validity of  the HRV 
data obtained in the spontaneously breathing healthy subjects presented in this thesis. 
Hyperventilation did not affect HRV indices as well. This was surprising, because 
the parasympathetic component of  HRV (respiratory sinus arrhythmia) is thought to 
be predominantly mediated by respiration-induced blood pressure changes which are 
sensed by carotid baroreceptors, leading to (de)activation of  cardiac vagal fibres49, 50. 
Interestingly, in one subject, a relatively large bias (an increase in HF power, a measure 
of  vagus nerve activity) was observed upon mild hyperventilation. This subject had a 
very low spontaneous respiratory rate (8 breaths/min), corresponding to a frequency 
of  0.13 Hz, just outside of  the HF power spectrum (0.15-0.4 Hz). Hyperventilation 
moved this subject’s breathing frequency within the HF band, leading to the observed 
increase in HF power. In conclusion, HRV measurements in spontaneously breathing 
subjects yield valid and reproducible HRV data provided that the subjects respiratory 
rate lies within the HF frequency band (9-24 breaths/min).
The observed differential ex vivo and in vivo endotoxin tolerance kinetics following 
human endotoxemia teaches us various things. The fact that ex vivo endotoxin tolerance 
quickly subsides, while the in vivo response to endotoxin is still severely impaired two 
weeks later indicates that the blood compartment does not contribute significantly to 
the in vivo cytokine response to LPS, and that tissue-resident macrophages are its main 
source. This is supported by previous data from our group demonstrating that there 
exists no correlation between the ex vivo and in vivo inflammatory response to LPS51. 
This is an important observation, because in many studies, a subject’s or patient’s 
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LPS-stimulated leukocyte response ex vivo is used as a measure of  the immune status 
in vivo. Our data indicate that, while a patient’s or subject’s ex vivo response might 
be normal, the in vivo response to a pathogenic stimulus, vital in host defence, may 
still be severely impaired. It is also important to mention that endotoxemia-induced 
changes in hemodynamics, temperature, leukocyte counts and symptom score were 
similar during both endotoxemia experiments. These responses were apparently not 
subject to tolerance. This disparity between clinical symptoms and cytokine levels are 
of  particular interest from a clinical point of  view. In a clinical sepsis trial, patients are 
usually included when SIRS criteria are present. If  the effects of, e.g. an anti-cytokine 
intervention are studied, our data illustrate that the target cytokine of  interest may not 
be elevated in the presence of  SIRS criteria. Therefore, in our view, evidence that the 
target analyte is present should be one of  the inclusion criteria prior to enrolment. 
Furthermore, our data have important implications for the design of  pharmacological 
intervention trials using the human endotoxemia model. We show that a washout of  
2 weeks is not enough and the author’s response in chapter 12a indicates that 4 weeks 
is not enough as well. They state that 6 weeks is an appropriate window, but by then, 
antibodies to LPS may have been formed. We therefore recommend to refrain from 
cross-over designs but use parallel groups instead in trials using the experimental 
endotoxemia model. 
284
Chapter 14
Future perspectives
Investigation of  the cholinergic anti-inflammatory pathway is seriously hindered by 
the lack of  a proper readout for vagus nerve activity or activation of  the α7nAChR. 
The only available method to determine vagus nerve activity in humans in vivo is HRV, 
and we and others52 debate its value. In addition and to the best of  our knowledge, 
there are no measures of  specific activation of  the α7nAChR on immune cells, such as 
mRNA or protein expression patterns. This makes it difficult to assess the beneficial 
or pathological role of  this pathway in health and disease. Therefore, novel techniques 
to measure vagus nerve activity or α7nAChR activation are highly warranted.
Given the difficulties outlined above, the role of  intracranial pressure on vagus nerve 
activity and the immune response should perhaps also be investigated using animal 
models of  increased intracranial pressure53-56. In these models, electrophysiological 
recordings57 of  efferent vagus nerve discharges can shed light on the effects of  
increased intracranial pressure on vagus nerve activity. These experiments can also be 
combined with an inflammatory challenge (LPS or live bacterial sepsis) to investigate 
the effects of  intracranial pressure-induced vagus nerve activity on the innate immune 
response. Moreover, an electrophysiological approach can elucidate organ-specific 
outflow and allow for comparison with vagal HRV parameters, which can be obtained 
in animals as well58, 59.
The only two studies to date on the effects of  stimulation of  the cholinergic anti-
inflammatory pathway in single hit VILI models (our study and 9) are promising. 
Therefore, it could represent a novel therapeutic option to limit mechanical 
ventilation-induced pulmonary inflammation in previously healthy lungs, for instance 
in mechanical ventilation during elective surgery. Limiting the first mechanical 
ventilation-induced hit might reduce the risk of  complications in the later phase. 
For example, inflammation of  the lungs can spread systemically and lead to multiple 
organ dysfunction syndrome (MODS)60. 
We did not demonstrate that pharmacological stimulation of  the cholinergic anti-
inflammatory pathway with GTS-21 attenuated the innate immune response during 
human endotoxemia. Nevertheless, with regard to the low plasma levels of  GTS-
21 (relative to the concentrations needed to attenuate the inflammatory response in 
vitro), and the observed correlations between higher GTS-21 plasma concentrations 
and lower cytokine levels in the in vivo study, we feel that selective pharmacological 
stimulation of  the cholinergic anti-inflammatory pathway might have therapeutic 
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potential. In case of  GTS-21, higher dosages or other routes (parenteral) of  
administration should be evaluated. Furthermore, the therapeutic potential of  other 
specific α7nAChR agonists such as AR-R17779, CAP55, PNU-282987 in humans 
should be explored if  or when they are safe and suitable for human use. 
Furthermore, alternative means of  stimulation of  the cholinergic anti-inflammatory 
pathway should be investigated in humans. We have shown that lipid- and protein-
enriched nutrition greatly limits the innate immune response during human 
endotoxemia, supposedly via CCK-mediated activation of  the cholinergic anti-
inflammatory pathway. This mechanism should be further expanded on using specific 
CCK receptor antagonists, which are currently not available for human use. On the 
effector side, studies with mecamylamine, a nAChR antagonist used for the treatment 
of  hypertension and in smoking cessation, could establish the role of  nAChRs. 
Besides nutritional or pharmacological activation of  this pathway, other means, such 
as transcutaneous vagus nerve stimulation should be evaluated. This technique is 
feasible in humans61 and has recently been shown to be equally effective in limiting 
the innate immune response as electrical vagus nerve stimulation in mice6. 
The lack of  an effect in our second-hit VILI model questions the clinical applicability 
of  stimulation of  the cholinergic anti-inflammatory pathway in critically ill patients 
with an already present systemic inflammatory process, such as in sepsis. Given the 
scarcity of  studies on the effects of  delayed stimulation of  the cholinergic anti-
inflammatory pathway, further preclinical investigations should be performed before a 
translation to the clinic is in sight. However, in patients where pretreatment is feasible, 
such as the inflammatory response caused by major elective surgery, therapies based 
on stimulation of  the cholinergic pathway might be introduced earlier in the clinical 
setting. Stimulation of  this pathway may also be of  benefit in autoimmune diseases 
where timing of  treatment is not as vital. The clinical translation of  therapies based 
on stimulation of  the cholinergic anti-inflammatory pathway may therefore turn out 
to be analogous to that of  the many therapies aimed to limit the innate immune 
response in sepsis that also showed great promise in animal models. While these 
treatments have ultimately failed in the treatment of  sepsis, they are very effective in 
the treatment of  autoimmune diseases such as rheumatoid arthritis. Such a role for 
therapies based on stimulation of  the cholinergic anti-inflammatory pathway is supported 
by the promising results recently obtained in animal models of  rheumatoid arthritis62, 
63. The first study investigating the effects of  electrical vagus nerve stimulation in 
rheumatoid arthritis patients is currently being performed in Amsterdam.  
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The effects of  the iceman’s concentration/meditation technique on the sympathetic 
nervous system and innate immune response are remarkable. However, as we already 
pointed out, we describe a study in just one individual. The iceman claims that he can 
teach others his technique within a short time frame. We are currently investigating 
the possibilities to perform a study to reproduce these findings in a larger group of  
individuals. 
Finally, while the long-lasting in vivo tolerance that we demonstrated in this thesis 
prohibits the use of  a superior cross-over design in pharmacological intervention 
trials using the human endotoxemia model, it provides a novel tool to study effects of  
therapeutic modalities aimed to stimulate the immune response and reverse immune 
paralysis in humans in vivo, currently a hot topic in the sepsis literature64. The persisting 
hyporesponsive state provides an ample window for administration of  drugs. This 
study has thereby opened the way for translational research into immunostimulatory 
therapies that are currently conducted in our department. A more nuanced evaluation 
of  the sepsis patient may eventually result in tailor-made therapies to modulate the 
innate immune response: inhibition in patients suffering from hyperinflammation and 
stimulation in immune paralyzed patients. This could prove to be the way to go for 
the treatment of  sepsis patients and presents an exciting challenge for future research.
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Een goed functionerend aangeboren immuunsysteem beschermt het lichaam tegen 
ziekteverwekkende micro-organismen zoals bacteriën en virussen. Na herkenning van 
micro-organismen door receptoren, met name de Toll-like receptoren, aanwezig op 
cellen van het aangeboren immuunsysteem produceren deze cellen ontstekingseiwitten, 
ook wel cytokinen genoemd. Deze cytokinen, zoals tumour necrosis factor-α (TNF-α) 
en interleukine-6 (IL-6), zijn belangrijk voor het genereren van een effectieve 
immuunrespons, ook wel ontstekings/inflammatoire respons genoemd, met als doel 
de micro-organismen op te ruimen. Echter, zoals Shakespeare al zei: ‘teveel van 
iets goeds kan slecht voor je zijn’. Teveel of  persisterende productie van cytokinen, 
zoals bijvoorbeeld bij sepsis, en onnodige activatie van het immuunsysteem zoals bij 
autoimmuunziekten, kan leiden tot een hyperinflammatoire status, waardoor organen 
schade kunnen ondervinden. Het aangeboren immuunsysteem heeft daarom twee 
gezichten: enerzijds is het essentieel voor onze afweer en overleving, terwijl anderzijds 
over- of  langdurige activatie van dit systeem schade veroorzaakt bij de gastheer. 
Uit recent onderzoek is gebleken dat het autonome zenuwstelsel het aangeboren 
immuunsysteem kan remmen. De bestaande gedachte dat een ontstekingsreactie 
niet door het brein beïnvloed kon worden blijkt onjuist. Dit mechanisme wordt tot 
op heden niet benut om ziektebeelden geassocieerd met overmatige inflammatie te 
behandelen, maar biedt daar wel mogelijkheden toe. Het autonome zenuwstelsel bestaat 
uit twee delen: het sympathische zenuwstelsel en het parasympathische zenuwstelsel, 
het laatste vrijwel geheel bestaand uit de nervus vagus (de 10e hersenzenuw). Het 
autonome zenuwstelsel beïnvloedt nagenoeg alle organen in het lichaam.
Dit proefschrift bevat preklinische, translationele en klinische studies gericht op 
de interactie tussen het autonome zenuwstelsel en de aangeboren immuunrespons. 
We hebben ons voornamelijk gericht op de effecten van de nervus vagus op het 
immuunsysteem, de zogenaamde ‘cholinerge anti-inflammatoire pathway’. Deze 
pathway is recent ontdekt en de onderliggende mechanismen en effecten van de 
beïnvloeding van deze pathway zijn, vooral bij de mens, nog nauwelijks onderzocht. 
Hoofdstuk 1 geeft een korte introductie op het autonome zenuwstelsel, het 
aangeboren immuunsysteem en de interactie tussen beide systemen. Eerder is 
aangetoond dat de afferente tak van de nervus vagus, van organen naar het brein, 
een ontsteking in perifere organen kan detecteren en zo het brein kan informeren, 
hetgeen resulteert in koorts, productie van cortisol en verhoogde activiteit van de 
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efferente nervus vagus, van het brein naar de organen. In de jaren negentig van de 
vorige eeuw is ontdekt dat efferente activiteit van het sympathische zenuwstelsel 
de immuunrespons remt door effecten van catecholamines, de neurotransmitters 
van het sympathisch zenuwstelsel, op β-receptoren. Deze resultaten zijn bevestigd 
bij mensen in vivo, in het gehele lichaam, dus niet in geïsoleerde cellen of  weefsels 
in het laboratorium. Middels intraveneuze toediening van lipopolysaccharide, LPS, 
een bestanddeel van de celwand van een Gram negatieve bacterie is het mogelijk de 
aangeboren immuunrespons bij de mens op te wekken en te onderzoeken. Dit wordt 
experimentele endotoxinemie genoemd. Toediening van de catecholamine adrenaline 
leidt tot verminderde productie van cytokinen tijdens experimentele endotoxinemie 
in gezonde vrijwilligers. In 2000 is door Tracey en collega’s de cholinerge anti-
inflammatoire pathway bij dieren beschreven. Stimulatie van de efferente nervus 
vagus remt de aangeboren immuunrespons, via binding van acetylcholine, de vagale 
neurotransmitter, aan de α7 nicotinerge acetycholine receptor (α7nAChR) op cellen 
van het aangeboren immuunsysteem, zoals macrofagen. Remming van de efferente 
nervus vagus heeft het tegenovergestelde effect. Hoe belangrijk de rol van deze 
pathway bij de mens is, is niet bekend.
Deel 1: Interacties tussen het autonome zenuwstelsel en het aangeboren 
immuunsysteem
Het eerste deel van dit proefschrift beschrijft onderzoek naar de interactie tussen 
het autonome zenuwstelsel en het aangeboren immuunsysteem. We onderzochten dit 
zowel bij gezonde vrijwilligers als bij patiënten met hersenletsel. 
In hoofdstuk 2a postuleren we de hypothese dat verhoogde activiteit van de 
nervus vagus een rol speelt in het optreden van immuunparalyse bij patiënten 
met traumatisch hersenletsel. Deze patiënten hebben vaak een verminderd 
functionerend immuunsysteem, ook wel immuunparalyse genoemd, met als gevolg 
verhoogde vatbaarheid voor infecties. Bij deze patiënten met hersenletsel is tevens 
verhoogde activiteit van de nervus vagus aangetoond, gemeten door middel van 
hartritmevariabiliteit (HRV). We koppelen deze twee observaties aan elkaar: we 
stellen dat de immuunparalyse bij deze patiënten veroorzaakt kan worden door 
(langdurig) verhoogde activiteit van de nervus vagus, resulterend in een remming van 
de immuunrespons via de cholinerge anti-inflammatoire pathway. We veronderstellen 
verder dat verhoogde intracraniële druk (hersendruk), vaak voorkomend bij patiënten 
met hersenletsel, een belangrijke rol speelt in de verhoogde activiteit van de nervus 
vagus. Deze druk kan leiden tot compressie van de hersenstam met als gevolg verhoogde 
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activiteit van de dorsale motor nucleus in de medulla oblongata, het centrum waar de 
nervus vagus ontspringt. Dit wordt ondersteund door bevindingen van verhoogde 
activiteit van de nervus vagus in patiënten met subarachnoïdale bloedingen, een 
aandoening die vaak gepaard gaat met hoge intracraniële drukken. Verder is middels 
dierexperimenteel onderzoek waarbij de intracraniële druk kunstmatig wordt verhoogd 
door het opblazen van een subdurale ballon aangetoond dat de stijging in activiteit 
van de nervus vagus correleert met de stijging van de intracraniële druk.
In het voorgaande hoofdstuk veronderstellen we een relatie tussen verhoogde 
intracraniële druk, activiteit van de nervus vagus en de aangeboren immuunrespons 
bij patiënten met een subarachnoïdale bloeding. Met het oog op deze relatie 
becommentariëren we in hoofdstuk 2b een artikel waarin de relatie tussen de 
activiteit van het sympathisch zenuwstelsel, gemeten door noradrenaline spillover, en 
circulerende cytokinen bij intensive care patiënten met een subarachnoïdale bloeding 
wordt beschreven. De auteurs tonen verhoogde noradrenaline spillover en verhoogde 
concentraties van cytokinen in het bloed aan bij deze patiënten, maar vinden geen 
kwantitatieve correlatie tussen deze twee. We stellen dat het meten van cytokinen in het 
bloed wellicht geen goede maat is van de status van het aangeboren immuunsysteem 
van patiënten, omdat de productie van deze cytokinen waarschijnlijk slechts het 
gevolg is van het initiële insult en niet weergeeft in hoeverre het immuunsysteem 
nog in staat is om te reageren op een volgende infectie door een bacterie of  een 
virus. Meten van de immuunrespons van ex vivo, dat wil zeggen buiten het lichaam 
in het laboratorium, gestimuleerde leukocyten geeft in dit geval een beter beeld van 
de status van het aangeboren immuunsysteem. Daarnaast stellen we voor dat het 
interessant is om, met het oog op de cholinerge anti-inflammatoire pathway, naast 
parameters van het sympathische zenuwstelsel, ook die van het parasympathische 
zenuwstelsel te bepalen bij onderzoek naar het immuunsysteem bij patiënten met een 
subarachnoïdale bloeding. 
Nicotine is een aspecifieke agonist van de α7nAChR. Daarom kan de cholinerge 
anti-inflammatoire pathway mogelijk geactiveerd worden door behandeling van 
patiënten met nicotine. In hoofdstuk 2c becommentariëren we een artikel waarin 
verhoogde mortaliteit wordt gerapporteerd bij intensive care patiënten die behandeld 
zijn met nicotine vervangingstherapie. We speculeren dat nicotine de aangeboren 
immuunrespons onderdrukt bij deze patiënten, waardoor ze via de cholinerge anti-
inflammatoire pathway immuunparalytisch worden. De daaruit volgende verhoogde 
vatbaarheid voor infecties kan bijgedragen hebben aan de verhoogde kans op overlijden 
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van deze patiënten. Dit wordt ondersteund door de bevinding dat 8% van de groep 
patiënten die behandeld werden met nicotine overleed aan infecties vergeleken met 
2% in de groep patiënten die niet behandeld werden met nicotine. Helaas wordt de 
infectie-incidentie niet vermeld in het artikel. 
In hoofdstuk 3 wordt onze hypothese uit hoofdstuk 2a onderzocht. In deze studie 
hebben we de relatie onderzocht tussen de activiteit van het autonome zenuwstelsel 
en de aangeboren immuunrespons bij intensive care patiënten met hersenschade 
tijdens de eerste vier dagen na opname. De activiteit van het autonome zenuwstelsel 
werd gemeten door middel van HRV en de immuunrespons door middel van 
zowel cytokineproductie van ex vivo gestimuleerde leukocyten als concentraties van 
cytokinen in het bloed. We vonden een significante correlatie tussen hogere niveaus 
van HFnu, een HRV parameter die correspondeert met activiteit van de nervus vagus, 
en lagere ex vivo gestimuleerde TNF-α productie. Om de invloed van intracraniële 
druk op de activiteit van de nervus vagus en de aangeboren immuunrespons verder te 
onderzoeken hebben we patiëntgroepen vergeleken met verschillende aandoeningen, 
geassocieerd enerzijds met hoge intracraniële druk (intracraniële bloeding) en 
anderzijds met normale intracraniële druk (subarachnoïdale bloeding met een 
extraventriculaire drain). De ex vivo gestimuleerde cytokineproductie was significant 
lager bij patiënten met een intracraniële bloeding vergeleken met patiënten met een 
subarachnoïdale bloeding. Daarnaast was er een sterke correlatie tussen hogere niveaus 
van HFnu en lagere concentraties van TNF-α in het bloed in de groep patiënten met 
een intracraniële bloeding. 
Deze resultaten suggereren een verband tussen hoge intracraniële druk, verhoogde 
activiteit van de nervus vagus en remming van de immuunrespons en dus een rol voor 
de cholinerge anti-inflammatoire pathway bij de mens. 
Hoofdstuk 4 beschrijft de relatie tussen activiteit van het autonome zenuwstelsel, 
gemeten door middel van HRV, en de aangeboren immuunrespons bij een grote groep 
gezonde vrijwilligers die deelnamen aan experimentele endotoxinemie studies. Om te 
bepalen of  de basale activiteit van de nervus vagus of  het sympathisch zenuwstelsel 
de mate van de aangeboren immuunrespons voorspelt, onderzochten we of  baseline 
HRV parameters, bepaald vóór LPS toediening, correleerden met concentraties van 
cytokinen in het bloed na LPS toediening. We vonden geen enkele correlatie tussen HRV 
parameters en cytokinen in het bloed. Na LPS toediening daalden HRV parameters 
aanzienlijk. Daarom onderzochten we vervolgens of  de activatie van het aangeboren 
immuunsysteem het autonome zenuwstelsel beïnvloedt. Wederom toonden we geen 
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relatie aan. Het ontbreken van een relatie tussen concentraties van plasma cytokinen 
en HRV veranderingen bleek verder uit experimenten waarbij gezonde vrijwilligers 
tweemaal LPS toegediend kregen met een interval van twee weken. Als gevolg van 
endotoxine-tolerantie waren de cytokineconcentraties in het bloed ongeveer half  zo 
hoog na de tweede LPS toediening vergeleken met de eerste LPS toediening. Echter, 
de HRV veranderingen waren identiek na beide LPS toedieningen, hetgeen aantoont 
dat er geen directe relatie is tussen de concentratie cytokinen in het bloed en de HRV 
veranderingen.
Onze bevindingen wijzen er enerzijds op dat de vagale activiteit, gemeten op het hart 
door middel van HRV, niet de mate van de ontstekingsrespons op LPS voorspelt. 
Anderzijds tonen onze resultaten aan dat de mate van de ontstekingsreactie niet 
gerelateerd is aan de veranderingen in HRV.
Deel twee: remmen van de aangeboren immuunrespons door middel van de 
cholinerge anti-inflammatoire pathway; in vitro, bij proefdieren en bij de mens.
Het tweede deel van dit proefschrift is gericht op de effecten van stimulatie van de 
cholinerge anti-inflammatoire pathway. We onderzochten dit bij proefdieren, met 
behulp van muis- en ratmodellen van beademingsgeïnduceerde longschade, en bij 
de mens, zowel in vitro bij leukocyten van de mens en in vivo tijdens experimentele 
endotoxinemie.
In hoofdstuk 5 beschrijven we de effecten van stimulatie en het uitschakelen van 
de cholinerge anti-inflammatoire pathway op beademingsgeïnduceerde longschade. 
Mechanische beademing is een levensreddende ingreep, maar kan ook longschade 
veroorzaken. Deze schade wordt mede veroorzaakt door activatie van het aangeboren 
immuunsysteem door de mechanische beademing met positieve druk, zogenaamd 
biotrauma. Een onderliggend ontstekingsproces, dat vaak aanwezig is bij intensive care 
patiënten, geeft een verhoogd risico op beademingsgeïnduceerde longschade. In onze 
studie stimuleerden we de cholinerge anti-inflammatoire pathway door elektrische 
stimulatie van de nervus vagus met een elektrode in de hals. Het uitschakelen van 
deze pathway werd bereikt door de nervus vagus door te snijden (vagotomie). We 
onderzochten de effecten van deze behandelingen in de volgorde die in de kliniek 
ook vaak voorkomt: eerst een inflammatoire respons, bijvoorbeeld door een infectie, 
gevolgd door beademing. We stimuleerden de nervus vagus of  voerden de vagotomie 
uit na LPS toediening, maar vóór het starten van de beademing. Voor dit tijdspunt 
werd gekozen om een patiënt met systemische (in het gehele lichaam) ontsteking te 
simuleren die op de intensive care is gebracht voor beademing. Beademing met een 
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hoog (15 ml/kg), maar niet met een laag (8 ml/kg) teugvolume versterkte de LPS-
geïnduceerde ontstekingsreactie in de longen. Vagotomie resulteerde in verhoogde 
concentraties van cytokinen in de long en verminderde zuurstofspanning in het bloed 
bij spontaan ademende dieren, maar leidde niet tot verdere verergering van de LPS-
geïnduceerde ontstekingsreactie in beademde ratten. Stimulatie van de nervus vagus 
had geen invloed op de ontstekingsreactie in zowel spontaan ademende als beademde 
dieren. 
Deze resultaten suggereren dat, in aanwezigheid van een onderliggend 
ontstekingsproces, stimulatie van de cholinerge anti-inflammatoire pathway geen 
gunstige effecten meer heeft op beademingsgeïnduceerde longschade. Dit roept 
twijfels op over het klinisch nut van stimulatie van deze pathway bij patiënten met een 
onderliggend systemisch ontstekingsproces die op de intensive care worden gebracht 
voor beademing.
Hoofdstuk 6 beschrijft de ontstekingsremmende effecten en onderliggende 
mechanismen van α7nAChR stimulatie in leukocyten van de mens. Zowel de 
niet-specifieke α7nAChR agonist nicotine als de specifieke agonist GTS-21 
remde dosisafhankelijk de cytokineproductie in leukocyten gestimuleerd met 
verschillende Toll-like receptor agonisten. GTS-21 was effectiever dan nicotine. 
De ontstekingsremmende effecten van GTS-21 werden gereguleerd op het 
transcriptionele niveau, dat wil zeggen dat GTS-21 de afschrijving van cytokinegenen 
(mRNA expressie) remde. Tenslotte, uit qPCR array data en experimenten met de 
JAK2 remmer AG490 bleek dat de effecten van GTS-21 waarschijnlijk via de JAK2-
STAT3 pathway verlopen.
Onze data tonen aan dat GTS-21 sterke ontstekingsremmende effecten op primaire 
menselijke cellen van het aangeboren immuunsysteem en dat deze effecten op het 
transcriptionele niveau gereguleerd zijn.
In hoofdstuk 7 beschrijven we de ontstekingsremmende effecten van GTS-21 in een 
muismodel van beademingsgeïnduceerde longschade. Daarnaast onderzochten we de 
effecten van zowel neostigmine, een medicijn dat acetylcholine concentraties verhoogt 
en in eerder onderzoek effectief  is gebleken in de behandeling van sepsis bij muizen, 
als de effecten van het blokkeren van nAChRs door middel van mecamylamine, een 
medicijn dat in eerder onderzoek pancreatitis in muizen bleek te verergeren. In onze 
studie werden muizen beademd met een klinisch relevant teugvolume van 8 ml/kg 
gedurende 4 uur, wat resulteerde in een ontstekingsreactie, zowel in de longen als in 
het bloed. Behandeling met GTS-21 voor de start van beademing verminderde de 
300
Chapter 15
concentraties van TNF-α in de longen en in het bloed en verlaagde de arteriële-alveolaire 
gradiënt, hetgeen een verbeterde longfunctie aanduidt. Verder remde GTS-21 TNF-α 
mRNA expressie en productie in geïsoleerde alveolaire macrofagen. Neostigmine en 
mecamylamine lieten geen effecten zien op ontstekings- of  respiratoire parameters. 
Onze studie toont aan dat selectieve farmacologische stimulatie van de α7nAChR 
longschade, geïnduceerd door beademing met klinisch relevante beademingsinstellingen, 
kan remmen. Een verklaring voor het feit dat neostigmine en mecamylamine geen 
effecten laten zien, kan zijn dat de relatief  milde ontstekingsreactie in ons model 
niet ernstig genoeg is voor endogene activatie van de cholinerge anti-inflammatoire 
pathway.
Na de bemoedigende resultaten met GTS-21 in onze vorige studies in vitro en 
bij muizen, hebben we onderzocht of  deze stof  ook in staat is de aangeboren 
immuunrespons bij de mens in vivo te remmen. Daartoe hebben we in hoofdstuk 8 een 
dubbelblinde placebo-gecontroleerde pilot-studie uitgevoerd bij gezonde vrijwilligers 
tijdens experimentele endotoxinemie. In onze studie slikten proefpersonen GTS-21 
of  een placebo gedurende 3 dagen vóór, en op de dag van endotoxine-toediening. 
We vonden geen verschillen in cytokineconcentraties in het bloed tussen de groep 
proefpersonen behandeld met GTS-21 en de groep behandeld met placebo. Dit 
kan te wijten zijn aan de relatief  lage, en de, tussen de proefpersonen, zeer variabele 
concentraties van GTS-21 in het bloed. Echter, binnen de groep proefpersonen die 
behandeld waren met GTS-21 correleerden hogere GTS-21 plasmaconcentraties met 
lagere plasmaconcentraties van de cytokinen TNF-α, IL-6 en IL-1RA. 
De correlatie tussen hogere plasmaspiegels van GTS-21 en lagere concentraties 
van cytokinen suggereren dat GTS-21, in hogere concentraties, de aangeboren 
immuunrespons bij de mens in vivo kan remmen.
Naast GTS-21 hebben we ook andere methoden onderzocht om de cholinerge anti-
inflammatoire pathway in de mens te activeren. Hoofdstuk 9 beschrijft onderzoek 
naar een nieuwe darm-hersen-immuun pathway bij gezonde vrijwilligers tijdens 
experimentele endotoxinemie. Uit eerdere dierstudies is gebleken dat de cholinerge 
anti-inflammatoire pathway kan worden geactiveerd door enterale toediening van 
vetverrijkte voeding. Vetverrijkte voeding resulteert in cholecystokinine (CCK) release 
in de darm, wat lokaal in de darm CCK-receptoren op afferente vagale vezels activeert. 
Activatie van deze receptoren leidt tot een vagovagale reflex die de aangeboren 
immuunrespons remt via de cholinerge anti-inflammatoire pathway. In ons onderzoek 
kregen proefpersonen vet- en eiwitverrijkte voeding of  isocalorische controle 
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voeding toegediend via een nasojejunale sonde. Een derde groep proefpersonen 
vastte gedurende de studie. Toediening van vet- en eiwitverrijkte voeding resulteerde 
in lagere concentraties van de cytokinen TNF-α, IL-6 en IL-1RA in het bloed 
vergeleken met controle voeding en vasten. Bovendien was de concentratie van de 
ontstekingsremmende stof  IL-10 verhoogd in de groep behandeld met eiwit- en 
vetverrijkte voeding vergeleken bij de gevaste proefpersonen. 
Deze resultaten geven aan dat enterale toediening van vet- en eiwitverrijkte voeding de 
cholinerge anti-inflammatoire pathway kan activeren in de mens en zo de aangeboren 
immuunrespons kan remmen.
In het laatste hoofdstuk van deel twee, hoofdstuk 10, hebben we onderzocht of  
het autonome zenuwstelsel, en daardoor de aangeboren immuunrespons, kan worden 
beïnvloed door concentratie/meditatie. We beschrijven een case-study van een individu 
bekend als ‘the iceman’. Deze man heeft diverse uitzonderlijke prestaties op zijn naam 
staan met betrekking tot extreme koudetolerantie. Hij beweert dat hij deze opmerkelijke 
prestaties bereikt door middel van een speciale concentratie/meditatie techniek, die 
hij zichzelf  heeft aangeleerd. Hij claimt verder dat hij middels deze techniek zijn 
autonome zenuwstelsel en daardoor zijn immuunrespons kan beïnvloeden. In onze 
studie resulteerde tachtig minuten lang zitten in een bak met ijs, waarin ‘the iceman’ 
zijn concentratie/meditatie techniek beoefende, in hoge concentraties van plasma 
cortisol en remming van de cytokineproductie in ex vivo gestimuleerde leukocyten. 
Ook hebben we een endotoxinemie-experiment uitgevoerd bij deze persoon, terwijl 
hij zijn concentratie/ meditatie techniek beoefende. Na het starten van concentratie/
meditatie vonden we verhoogde concentraties van catecholamines in het bloed en 
de toename van cortisol in het bloed van ‘the iceman’ was hoger dan dat van alle 
eerder onderzochte gezonde vrijwilligers tijdens endotoxinemie. Bovendien waren 
de symptomen na LPS-toediening bij ‘the iceman’ opvallend mild in vergelijking 
met een grote groep proefpersonen die we eerder hebben onderzocht gedurende 
endotoxinemie en lagen de gemeten piekconcentraties van de cytokinen in het bloed 
op 1/3 tot 1/2 van de gemiddelden van de groep proefpersonen die we eerder 
gemeten hebben. 
Deze resultaten suggereren dat the iceman, door concentratie/meditatie, een 
gecontroleerde stressreactie kan opwekken, die gekenmerkt wordt door activering 
van het sympathische zenuwstelsel en de daarop volgende catecholamine- en 
cortisolproductie die vervolgens de aangeboren immuunrespons remt. Bovendien 
impliceert deze studie dat het autonome zenuwstelsel bewust kan worden beïnvloed 
door middel van concentratie/meditatie technieken.
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Deel drie: studies met betrekking tot de gebruikte methoden in dit proefschrift 
Het gebruik van verschillende meettechnieken en experimentele modellen leidt 
onvermijdelijk tot allerlei interessante bevindingen over deze technieken en modellen. 
In het derde deel van dit proefschrift beschrijven we studies met betrekking tot HRV-
analyse en het experimentele endotoxinemiemodel.
In hoofdstuk 11 hebben we de invloed van verschillende ademhalingspatronen op 
HRV parameters onderzocht, evenals de reproduceerbaarheid van HRV parameters, 
bij gezonde proefpersonen tijdens experimentele endotoxinemie. Verschillende 
ademhalingspatronen zouden van invloed kunnen zijn op HRV. Resultaten uit 
eerdere studies spreken elkaar echter tegen. Deze studies zijn allemaal uitgevoerd 
onder statische omstandigheden, waarin HRV niet in grote mate varieert. In 
hoofdstuk 4 hebben we laten zien dat HRV parameters sterk variëren als gevolg 
van de ontstekingsrespons geïnduceerd door toediening van LPS. Dit maakte het 
voor ons mogelijk om de effecten van verschillende ademhalingspatronen op HRV 
te onderzoeken in een dynamische setting. Gestuurde ademhaling, dat wil zeggen 
ademen op het ritme van een metronoom, of  milde hyperventilatie hadden geen 
invloed op HRV vergeleken met spontane ademhaling. Bovendien verbeterde 
gestuurde ademhaling de reproduceerbaarheid van HRV metingen niet.
Onze data laten zien dat gestuurde ademhaling niet noodzakelijk om valide HRV data 
te verkrijgen.
Onze onderzoeksgroep heeft al eerder aangetoond dat herhaalde toediening van LPS 
leidt tot endotoxine-tolerantie, gekenmerkt door een verminderde respons op LPS, 
zowel in vivo als ex vivo. Farmacologische interventiestudies, die gebruik maken van 
het experimentele endotoxinemie model, worden vaak uitgevoerd in een cross-over 
wijze met een interval van één à twee weken. Het is echter niet bekend hoe lang 
de staat van endotoxine-tolerantie, die kan leiden tot carry-over effecten, aanhoudt. 
In hoofdstuk 12a wordt de kinetiek van endotoxine-tolerantie beschreven, zowel ex 
vivo en in vivo. Na toediening van LPS in vivo herstelde binnen een week de initieel 
gedempte ex vivo gestimuleerde cytokineproductie van leukocyten uit het bloed van 
de vrijwilligers die LPS toegediend hadden gekregen. Twee weken na toediening van 
LPS was de in vivo productie van cytokinen na een tweede LPS toediening echter nog 
altijd sterk onderdrukt. Opvallend genoeg waren de veranderingen in hemodynamiek, 
lichaamstemperatuur, leukocytenaantal en symptomen vergelijkbaar na beide LPS-
toedieningen; hier werd, in tegenstelling tot de cytokineproductie, geen tolerantie 
gezien.
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Deze bevindingen geven aan dat circulerende immuuncellen niet de belangrijkste bron 
zijn van cytokineproductie na LPS toediening, maar dat deze cytokinen waarschijnlijk 
hoofdzakelijk worden geproduceerd door weefselmacrofagen. Verder wijzen onze 
resultaten erop dat ex vivo stimulatie van leukocyten de status van de aangeboren 
immuunrespons in vivo niet goed weergeeft. Tenslotte impliceren de resultaten 
van dit onderzoek dat interventiestudies die gebruik maken van het experimentele 
endotoxinemiemodel moeten worden uitgevoerd met parallelle groepen in plaats van 
een cross-over design, omdat de endotoxine-tolerantie die ontstaat de interpretatie 
van de effecten van de farmacologische interventie bemoeilijkt.
Gezien de bevindingen van hoofdstuk 12a hebben we in hoofdstuk 12b een artikel 
becommentarieerd waarin een experimentele endotoxinemiestudie beschreven wordt 
die gebruik maakt van een cross-over design met een periode van drie à vier weken 
tussen de twee LPS toedieningen. We opperen dat deze wash-out periode te kort 
is, waardoor endotoxine-tolerantie nog steeds aanwezig kan zijn. Dit belemmert de 
interpretatie van de studiegegevens. De auteurs antwoordden dat ze, na een herziening 
van hun gegevens, inderdaad een tolerantie-effect vonden. Dit had echter volgens hen 
geen invloed op de conclusies van dit specifieke onderzoek. 
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Algehele conclusies en toekomstperspectieven
In het eerste deel van dit proefschrift hebben we aangetoond dat activiteit van de 
nervus vagus of  het sympathisch zenuwstelsel, gemeten met HRV, niet correleert 
met de aangeboren immuunrespons of  vice-versa in gezonde vrijwilligers. We hebben 
echter wel correlaties gevonden tussen HRV parameters die de activiteit van de nervus 
vagus weergeven en parameters van het aangeboren immuunsysteem bij patiënten 
met hersenletsel. Dit suggereert dat de cholinerge anti-inflammatoire pathway bij de 
zieke mens wel een rol speelt. Echter, op basis van deze observationele studie kunnen 
we geen definitieve conclusies trekken met betrekking tot onze hypothese dat de 
immuunparalyse bij deze patiënten veroorzaakt wordt door activatie van de cholinerge 
anti-inflammatoire pathway, mede omdat we geen verhoging hebben gevonden van de 
HRV parameters die de activiteit van de nervus vagus weergeven bij deze patiënten. 
In overeenstemming met onze hypothese vonden we wel de grootste onderdrukking 
van ex vivo cytokineproductie in de groep patiënten met een intracraniële bloeding, 
een aandoening geassocieerd met een verhoogde intracraniële druk. Helaas wordt 
onderzoek naar de cholinerge anti-inflammatoire pathway in de mens nog in grote 
mate beperkt door het ontbreken van een goede uitleesmaat voor activiteit van 
de nervus vagus of  activatie van de α7nAChR. De enige beschikbare methode is 
HRV, een methode waarvan de betrouwbaarheid betwist wordt. HRV weerspiegelt 
namelijk slechts de effecten van de nervus vagus op het hart en het is onduidelijk 
of  deze activiteit ook de effecten weergeeft van de nervus vagus op andere organen 
betrokken bij de aangeboren immuunrespons. Dit is, voor zover ons bekend, nog 
nooit onderzocht. Er zijn echter wel een aantal studies die laten zien dat de outflow 
van het sympathische zenuwstelsel verschillend is per orgaan, hetgeen suggereert dat 
het autonome zenuwstelsel een sterk gedifferentieerd systeem is. Bovendien is bij 
proefdieren aangetoond dat de cholinerge anti-inflammatoire pathway geactiveerd 
kan worden door elektrische stimulatie met een intensiteit die onder het niveau 
ligt dat nodig is voor beïnvloeding van de hartslag, waardoor het mogelijk niet te 
detecteren is met HRV. Deze bevindingen tonen aan dat HRV een aantal inherente 
beperkingen heeft, die onderzoek naar de cholinerge anti-inflammatoire pathway 
bij de mens belemmeren. Niettemin vinden wij en anderen correlaties tussen HRV 
en de immuunrespons bij ernstig zieke patiënten. Een mogelijke verklaring voor dit 
fenomeen is dat differentiatie van de outflow van het autonome zenuwstelsel wel 
aanwezig is bij gezonde proefpersonen, maar dat deze, deels, verloren gaat bij ernstige 
ziekte en/of  hersenletsel. Als het verlies van differentiatie inderdaad afhankelijk 
is van de ernst van de ziekte, is het ontbreken van correlaties tussen HRV en de 
immuunrespons bij gezonde proefpersonen tijdens experimentele endotoxinemie niet 
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opmerkelijk, aangezien dit model relatief  mild is. 
Gezien de problemen inherent aan HRV zijn nieuwe technieken om de activiteit 
van de nervus vagus of  α7nAChR activatie te bepalen zeer gewenst voor toekomstig 
onderzoek naar de cholinerge anti-inflammatoire pathway. Verder moet de rol van 
intracraniële druk op de activiteit van de nervus vagus en de immuunrespons wellicht 
ook worden onderzocht met behulp van diermodellen waarin de intracraniële druk 
kunstmatig verhoogd wordt. In deze modellen kunnen elektrofysiologische metingen 
van de efferente nervus vagus, dat wil zeggen directe zenuwmetingen met behulp van 
elektrodes, de effecten van verhoogde intracraniële druk op de activiteit van de nervus 
vagus definitief  vaststellen. Deze experimenten kunnen worden gecombineerd met 
een ontstekingsstimulus (LPS of  bacteriële sepsis) om de effecten van de nervus 
vagus op de aangeboren immuunrespons te onderzoeken. Bovendien kan door 
elektrofysiologische zenuwmetingen orgaanspecifieke outflow bepaald worden en 
kan een vergelijking worden gemaakt met HRV parameters die de activiteit van de 
nervus vagus weergeven.
In het tweede deel van dit proefschrift hebben we aangetoond dat farmacologische 
stimulatie van de cholinerge anti-inflammatoire pathway door de selectieve α7nAChR 
agonist GTS-21, toegediend vóór de start van beademing, beademingsgeïnduceerde 
longschade bij muizen beperkt. Elektrische stimulatie van de nervus vagus, uitgevoerd 
na LPS toediening maar vóór de start van beademing, had geen gunstige effecten in 
ratten. Dit zou het gevolg kunnen zijn van de timing; zoals gezegd stimuleerden wij de 
zenuw tussen twee ontstekingsprikkels (LPS en beademing) in, terwijl in de overgrote 
meerderheid van studies waarin positieve effecten gevonden werden, de zenuw 
gestimuleerd werd vóór, of  gelijktijdig met het insult. We hebben verder laten zien dat 
GTS-21 sterke ontstekingsremmende effecten op leukocyten van de mens in vitro heeft. 
Helaas konden we geen ontstekingsremmende effecten van GTS-21 bij mensen in vivo 
aantonen. Dit is hoogstwaarschijnlijk te wijten aan de lage plasmaconcentraties van 
GTS-21 die bereikt werden na orale toediening van de maximaal toegestane dosering. 
Deze concentraties zijn namelijk lager dan de concentraties die ontstekingsremmende 
effecten in vitro lieten zien. We vonden wel omgekeerde correlaties tussen hogere 
bloedspiegels van GTS-21 en lagere concentraties van cytokinen in het bloed. Helaas 
konden we geen hogere doseringen van GTS-21 gebruiken, omdat de door ons 
gebruikte dosering de hoogste is die tot nu toe bij mensen veilig is gebleken. De 
gevonden correlaties suggereren wel dat farmacologische stimulatie van de cholinergic 
anti-inflammatoire pathway met specifieke agonisten de aangeboren immuunrespons 
in de mens kan remmen. Ook beschrijven we voor de eerste keer een nieuwe darm-
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hersen-immuun pathway bij de mens, waarin enterale toediening van eiwit- en 
vetverrijkte voeding de aangeboren immuunrespons remt via CCK-gemedieerde 
activatie van de cholinerge anti-inflammatoire pathway. Deze pathway was tot op 
heden alleen bij dieren onderzocht. Buiten het feit dat dit mechanisme een nieuwe 
therapie kan opleveren om overmatige ontsteking te remmen, zijn onze bevindingen 
interessant in het licht van de superieure effecten van vroeg enteraal versus parenteraal 
voeden op de prognose van intensive care patiënten. De mechanismen hierachter zijn 
namelijk grotendeels onbekend. Mogelijk speelt de darm-hersen-immuun pathway 
hierin een rol, omdat, in tegenstelling tot enterale voeding, parenterale voeding niet 
leidt tot het vrijkomen van CCK in de darm en activatie van deze pathway, omdat 
er simpelweg geen voeding in de darm komt. Het is mogelijk dat de activatie van 
deze pathway door enterale voeding overmatige ontsteking kan remmen en daardoor 
kan bijdragen aan een betere prognose van deze patiënten. In het laatste hoofdstuk 
van deel twee presenteren we resultaten die suggereren dat ‘the iceman’, via zijn 
concentratie/meditatie techniek, bewust invloed kan uitoefenen op zijn autonome 
zenuwstelsel en daardoor op zijn aangeboren immuunrespons. Het is echter belangrijk 
om te benadrukken dat een serie experimenten bij één proefpersoon geen oorzaak-
gevolg relatie tussen de concentratie/meditatie techniek, het autonome zenuwstelsel, 
en de aangeboren immuunrespons aan kan tonen, maar de bevindingen zijn wel 
opmerkelijk genoeg om vervolgonderzoek bij groepen proefpersonen na te streven. 
Met het oog op de toekomst blijkt uit het tweede deel van dit proefschrift dat stimulatie 
van de cholinerge anti-inflammatoire pathway een mogelijke nieuwe therapie is om 
overmatige ontsteking te verminderen bij de mens. In het geval van GTS-21 zouden 
hogere doseringen, als deze veilig zijn, of  andere routes, bijvoorbeeld intraveneus, 
moeten worden geëvalueerd. Bovendien moet het therapeutisch potentieel van 
andere specifieke α7nAChR agonisten bij de mens worden onderzocht wanneer ze 
veilig en geschikt zijn gebleken voor gebruik in de mens. Ook zouden alternatieve 
manieren van stimulatie van de cholinerge anti-inflammatoire pathway, zoals de door 
ons onderzochte darm-hersen-immuun pathway, verder moeten worden uitgediept. 
Naast activatie van de cholinerge anti-inflammatoire pathway door voeding of  
farmaca kunnen ook andere methoden, zoals transcutane stimulatie van de nervus 
vagus stimulatie, worden geëvalueerd. Deze techniek is haalbaar bij de mens en non-
invasief. Onlangs is bij proefdieren aangetoond dat het even effectief  kan zijn in 
het remmen van de aangeboren immuunrespons als elektrische stimulatie van de 
nervus vagus. Beïnvloeding van het autonome zenuwstelsel en de immuunrespons 
door concentratie/meditatie behoeft onderzoek bij grotere groepen om de door 
ons gevonden effecten definitief  vast te kunnen stellen. ‘The iceman’ zegt dat hij 
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anderen zijn techniek binnen een kort tijdsbestek kan aanleren. We onderzoeken 
momenteel de mogelijkheden voor een  studie met een groep proefpersonen, getraind 
door ‘the iceman’ om onze bevindingen te reproduceren. Een belangrijke uitdaging 
voor toekomstig onderzoek is om vast te stellen of  stimulatie van de cholinerge 
anti-inflammatoire pathway in geval van een reeds aanwezig ontstekingsproces 
gunstige effecten heeft. Dit is een belangrijke vraag, omdat het in grote mate het 
klinisch nut van stimulatie van deze pathway bij intensive care patiënten bepaalt. De 
meerderheid van deze patiënten arriveert namelijk op de intensive care met een reeds 
aanwezig ontstekingsproces, waardoor voorbehandeling vaak niet mogelijk is. Echter, 
bij patiënten waarbij voorbehandeling wel haalbaar is, zoals bij een grote electieve 
operatie die een ontstekingsreactie veroorzaakt en waarbij de patiënt beademd moet 
gaan worden, hetgeen kan leiden tot verdere longschade, kunnen therapieën gebaseerd 
op stimulatie van de cholinerge anti-inflammatoire pathway wellicht eerder hun weg 
vinden naar de kliniek. Stimulatie van deze pathway kan ook van nut zijn bij auto-
immuunziekten, waar de timing van de behandeling minder stringent is. Het pad van 
preklinisch onderzoek naar de kliniek voor therapieën gebaseerd op stimulatie van de 
cholinerge anti-inflammatoire pathway kan derhalve wel eens analoog blijken te zijn 
aan dat van de vele ontstekingsremmende therapieën die initieel ontwikkeld zijn voor 
de behandeling van sepsis, maar thans vooral toegepast worden bij patiënten met auto-
immuunziekten. Deze veelbelovende therapieën bij proefdiermodellen van sepsis, 
bleken uiteindelijk niet effectief  te zijn bij de behandeling van septische patiënten. 
Niettemin worden deze therapieën nu in grote mate gebruikt voor de behandeling van 
auto-immuunziekten zoals reumatoïde artritis, waarin ze wel erg effectief  zijn. Een 
dergelijke toekomst voor therapieën gebaseerd op stimulatie van de cholinerge anti-
inflammatoire pathway wordt ondersteund door veelbelovende resultaten onlangs 
verkregen in verscheidene proefdierstudies naar reumatoïde artritis. In Amsterdam 
loopt momenteel het eerste onderzoek waarin onderzocht wordt of  elektrische 
stimulatie van de nervus vagus de ziekteactiviteit bij reumapatiënten vermindert.
In het laatste deel van dit proefschrift hebben we aangetoond dat verschillende 
ademhalingspatronen niet van invloed zijn op HRV parameters en reproduceerbaarheid 
tijdens experimentele endotoxinemie. We laten verder zien dat de ademhalingsfrequentie 
van proefpersonen/patiënten binnen de HF-frequentieband (9-24 ademhalingen/
minuut) moet liggen voor een goede beoordeling van de HRV parameters die correleren 
met nervus vagus activiteit. Onze studie bevestigt de validiteit van de HRV data van 
gezonde vrijwilligers eerder beschreven dit proefschrift. In het laatste hoofdstuk van 
dit proefschrift tonen we aan dat de kinetiek van in vivo en ex vivo endotoxine-tolerantie 
verschillend is. Het feit dat ex vivo endotoxine-tolerantie snel afnam, terwijl de in vivo 
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respons op LPS na twee weken nog steeds ernstig verlaagd was, geeft aan dat het 
bloedcompartiment geen significante bijdrage heeft aan de in vivo cytokineproductie 
op LPS-toediening. Waarschijnlijk zijn de weefselmacrofagen de belangrijkste bron 
van de cytokinen in het bloed na LPS-toediening. Dit is een belangrijke constatering, 
omdat in veel studies de cytokineproductie van ex vivo gestimuleerde leukocyten 
wordt gebruikt als een maatstaf  voor de immuunstatus van een patiënt. Onze 
resultaten tonen aan dat, terwijl de ex vivo gestimuleerde cytokineproductie normaal 
is, de in vivo respons op een ontstekingsstimulus, van vitaal belang voor de afweer 
tegen bacteriën of  virussen, nog steeds ernstig verminderd kan zijn. Een andere 
interessante bevinding van onze studie is dat LPS-geïnduceerde veranderingen in 
hemodynamiek, lichaamstemperatuur, leukocytenaantal en symptomen vergelijkbaar 
zijn na beide LPS-toedieningen. Het verschil tussen deze symptomen en plasma 
cytokineconcentraties is van belang vanuit een klinisch oogpunt. In een klinische 
sepsisstudie worden patiënten namelijk meestal geïncludeerd op basis van systemic 
inflammatory response syndrome (SIRS) criteria, waarna ze behandeld worden met 
bijvoorbeeld een antilichaam tegen een cytokine. Onze data laten echter zien dat, 
hoewel een patiënt wellicht klinisch een ernstige ontstekingsreactie heeft (meer dan 
twee SIRS criteria), het cytokine waartegen het antilichaam gericht is, wellicht helemaal 
niet of  niet meer verhoogd is. In onze ogen moet daarom eerst bewijs worden 
geleverd dat de cytokine, waartegen het antilichaam gericht is, verhoogd aanwezig is, 
voordat de patiënt geïncludeerd wordt. Onze data hebben ook belangrijke implicaties 
voor het design van farmacologische interventiestudies die gebruik maken van het 
experimentele endotoxinemiemodel. Deze data laten namelijk zien dat een wash-out 
periode van twee weken niet genoeg is. In plaats van een cross-over design raden wij 
daarom aan om parallelle groepen te gebruiken in studies die gebruik maken van het 
experimentele endotoxinemiemodel. 
Tenslotte, met het oog op de toekomst, maakt ons onderzoek duidelijk dat langdurige 
in vivo tolerantie het gebruik van het superieure cross-over design beperkt, maar dat 
het wel nieuwe mogelijkheden biedt om het effect van medicijnen te onderzoeken 
die gericht zijn op het stimuleren van de aangeboren immuunrespons en daarmee 
het behandelen van immuunparalyse bij de mens in vivo. Dit is momenteel een hot 
topic in de sepsisliteratuur. Ons onderzoek heeft daarmee de weg vrijgemaakt voor 
translationeel onderzoek naar immunostimulerende therapieën, wat momenteel ook 
wordt uitgevoerd op onze afdeling. De toekomst voor de behandeling van sepsis 
ligt wellicht in op maat gemaakte therapieën met betrekking tot modulatie van de 
aangeboren immuunrespons: remming bij patiënten die lijden aan hyperinflammatie 
en stimulatie bij patiënten met tekenen van immuunparalyse. Voor toekomstig 
onderzoek naar de behandeling van sepsis ligt hier een grote uitdaging
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Zo, het zit erop! Ruim vier jaar promotieonderzoek doen is een avontuur met 
alles erop en eraan: successen en tegenslagen, blijdschap en frustratie. En hoewel 
de resultaten van een studie of  het al dan niet geaccepteerd worden van een artikel 
zeker van belang zijn, staat het leerproces voor mij toch voorop. Kennis vergaren, 
vaardigheden opdoen, onderzoek opzetten, zelfstandig beslissingen nemen en, heel 
belangrijk, jezelf  leren kennen. De afgelopen jaren heb ik dus vooral heel veel geleerd, 
en ook nog op een leuke manier! Op deze periode zal ik daarom altijd met veel plezier 
terugkijken. En hoewel het soms een eenzame bezigheid kan zijn, is promoveren 
toch echt een team effort! Velen hebben bijgedragen aan de totstandkoming van dit 
proefschrift. In deze epiloog, tevens het meest, of  vaak zelfs enige, gelezen deel van 
een proefschrift, wil ik enkele mensen in het bijzonder bedanken.
 
Allereerst professor Pickkers, beste Peter, wat heb ik het getroffen met jou als 
promotor! Naast het feit dat je een begenadigd onderzoeker bent, bezit je in extremis 
de gave om mensen te motiveren, mijns inziens de belangrijkste eigenschap voor een 
(co)promotor. Jij wist altijd weer de positieve punten te benadrukken en in op het 
eerste gezicht waardeloze resultaten toch lichtpuntjes te ontwaren. Ook je grenzeloos 
optimisme wat betreft de uiteindelijke acceptatie van artikelen na een revisie (kat in 
het bakkie!) is aanstekelijk, en klopt bijna altijd ;). Verder zag je altijd kans om op 
korte termijn een gaatje vrij te maken voor een overleg en heb je mijn manuscripten 
supersnel bekeken en gecorrigeerd, met als tegenprestatie het regelen van een 
Nintendo-spelletje voor Marc of  een computerklusje :). De iceman rollercoaster-ride 
die we samen beleefd hebben was een onvergetelijke ervaring, we voelden ons echt 
even BN’ers! Naast het werk ben je ook gewoon een ontzettend fijne vent en heb ik 
grote bewondering voor de wijze waarop jij werk en privé in balans houdt. Ik hoop 
dat we nog lang mogen samenwerken!
Dr. Hoedemaekers, beste Astrid, ook jou ben ik veel dank verschuldigd. Jij hebt alle 
eigenschappen die een goed onderzoeker en copromotor moet hebben, enthousiast, 
gedreven, kritisch en bovenal met kennis van zaken. Je hebt me wel eens moeten 
afremmen als ik in mijn enthousiasme iets te kort door de bocht wilde, wat, na een extra 
experiment of  verdere zoektocht in de literatuur, altijd een significante verbetering 
van het artikel opleverde. Ook bij jou kon ik altijd binnenlopen en je expertise op 
het gebied van de neuro-IC patiënt is van grote waarde geweest bij de vorming van 
de hypothese van verhoogde vagusactiviteit bij deze patiënten en de daaropvolgende 
klinische studie. En je had gelijk: het kump good!
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Professor van der Hoeven, beste Hans, ik heb zelden zo’n inspirerend persoon als 
jou ontmoet. Je bent onbetwist hét gezicht van de IC, die zowel boven als tussen de 
vele medewerkers staat, een eigenschap waarvoor ik veel bewondering heb. Verder 
bewaakte je als promotor de grote lijn van mijn project en gaf  een bezoek aan je 
kamer om de laatste resultaten van beademde muizen of  ratten te bespreken altijd 
weer richting en inspiratie voor nieuwe experimenten. Ik ben je zeer dankbaar voor 
het vertrouwen wat je me gegeven hebt en ook voor de toekomst in me stelt. Ik vind 
het geweldig dat ik onderzoek op de IC kan blijven doen!
Beste Jan, we zijn samen aan dit promotietraject begonnen maar door verschillende 
omstandigheden is het bij jou (nog) niet zo gelopen als je wellicht voor je had gezien. 
Toch hebben we samen veel gelachen tijdens de uitvoer van de LPS-GTS-21 studie en 
op congressen. Ik wens je heel veel geluk voor de toekomst.
Professor van Vugt, dank voor het vertrouwen wat u in me stelde door me aan te 
nemen op dit project.
Het dierexperimentele werk in dit proefschrift is uitgevoerd op het laboratorium 
Anesthesiologie in het dierenlab. Een aantal mensen van deze afdeling wil ik hierbij 
bedanken. Professor Scheffer, beste Gert-Jan, ik ben zeer dankbaar dat ik gebruik 
heb kunnen maken van jullie mooie lab en geweldige medewerkers. Daar gaan we 
in de toekomst nog veel plezier aan beleven! Ik ben blij dat u mij het vertrouwen 
hebt gegeven het onderzoek in dit laboratorium te gaan coördineren. Ook van de 
afdeling Anesthesiologie: Michiel, je bent een ontzettend fijne, down-to-earth, 
pragmatische kerel. Het gebruiken van GTS-21 in ‘jouw’ muismodel heeft een mooie 
publicatie opgeleverd. Ik heb alle vertrouwen in onze samenwerking in de toekomst. 
De geweldige medewerkers van het lab waar ik net aan refereerde zijn natuurlijk 
Francien en Ilona. Jullie ooghandcoördinatie grenst aan het onmogelijke! Zonder 
jullie microchirurgische vaardigheden waren de dierexperimentele studies uit dit 
proefschrift er nooit gekomen. Ik kijk uit naar de toekomstige samenwerking en dan 
vooral naar de gezellige koffiepraat (moet de labjas nu aan of  uit?) over alle dingen die 
niets met onderzoek te maken hebben! In dit kader wil ik ook Daphne en Debby van 
het dierenlab bedanken, hoewel ik jullie vaak door elkaar heb gehaald hebben jullie 
me enorm uit de brand geholpen met de goedkeuring van vele last-minute ingediende 
werkprotocollen.
311
Dankwoord
Alle medewerkers van het laboratorium algemene interne geneeskunde, bedankt 
voor jullie gastvrijheid, hulp en gezelligheid. Ik wil een paar mensen in het bijzonder 
bedanken. Dr. Joosten, beste Leo, bedankt dat ik al mijn in vitro experimenten en 
assays op ‘jouw’ lab interne heb kunnen doen, en wat is het mooi geworden na de 
verhuizing! Trees, dank voor de vele cytokine analyses en voor het wegwijs maken op 
het lab. Liesbeth, sorry dat ik de radiozender altijd veranderde op het lab, en bedankt 
voor de ELISA adviezen. Anneke en Johanna, dank voor de hulp bij mijn eerste 
stappen op het qPCR pad. Ineke, bedankt voor de muis-cytokinebepalingen. Cor, 
bedankt voor het gezellige gekeuvel en het feit dat je zo’n beetje het hele Radboud 
kent zodat je altijd wel ergens een stofje of  apparaat weet te ritselen.
Professor Netea, beste Mihai, bedankt voor je bijdrage aan de artikelen, het feit dat 
je altijd tijd weet vrij te maken voor een overleg en je bereidheid om als voorzitter van 
mijn manuscriptcommissie op te treden. Je bent een inspirerend wetenschapper. 
Richard, Luminex-god, dank voor alle hulp, zelfs nadat ik met een spierhomogenaat 
die machine van 100000 euro wekenlang buiten dienst heb gesteld ;). Beste Renoud, 
onze gezamenlijke experimenten hebben niet zoveel opgeleverd, maar ik heb er wel 
veel van opgestoken. Op onze lunches waarin we de PhD blues uitwisselden, of  de 
volgende borrelafspraak planden, kijk ik ook met veel plezier terug, succes met de 
laatste loodjes!
Alle (overige) mede-auteurs, bedankt voor jullie inspanningen en input. Een paar 
mensen wil ik in het bijzonder bedankten. Ten eerste Tim en Jacco uit Maastricht, 
wat hebben we geknald voor de LPS-voedingstudie! Maar het was het waard. Als het 
artikel geplaatst is gaan we een biertje drinken. Beste Stan, hopelijk gaan we nog vele 
studies samen doen, succes met het vervolg van je promotie. Sanne en Monique, 
terwijl ik gezellig met iceman Wim aan het keuvelen was, zaten jullie in het lab te 
zwoegen met de verkregen cellen, dank! Jeroen van Velzen, jouw flowcytometrie 
expertise was van groot belang voor het in vitro GTS-21 artikel. Jeroen van der 
Laak, zonder jouw slimme software en microscoop-skills was leukocyten tellen (nog) 
minder leuk geweest. Nens, je enthousiasme is aanstekelijk en je hebt een leek als ik 
het EEG-abracadabra toch enigszins duidelijk kunnen maken.    
Ik wil ook de instrumentele dienst, en in het bijzonder Joris en Wim Kleinhans en 
Geert Toenders, bedanken voor het last-minute regelen, repareren of  fabriceren van 
oscilloscopen, monitoren, electrodes, kabels, standaarden etc. voor mijn experimenten.
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De studenten die de afgelopen jaren bij me stage hebben gelopen en zo een bijdrage 
aan dit proefschrift hebben geleverd mogen natuurlijk niet ontbreken! Leonie, Marije, 
Esther, Maarten van den Berg, Maarten Vrouwenvelder, Sanneke, Ebru, Sara 
en Rebecca, bedankt voor het vele werk wat jullie verzet hebben!
Wie ook zeker niet mogen ontbreken zijn de researchverpleegkundigen van de 
Research-IC: Hetty, Aarnout en Marieke en secretaresse Yvonne. Bedankt voor 
de inclusie van patiënten, assistentie bij LPS experimenten, bestellingen en vooral de 
gezelligheid tijdens de lunches. En natuurlijk wil ik hierbij ook Tijn, de pater familias 
van de research-IC, noemen. Of  het nu ging over de opzet van patiëntenstudies, 
administratie rondom studenten, regelen van inzet van researchverpleegkundigen, of, 
zeer belangrijk, PSV, je stond altijd klaar, bedankt! 
Op deze plaats wil ik ook de andere medewerkers van de IC, zoals de secretaresses, 
verpleegkundigen, stafleden en fellows bedanken voor alle hulp en adviezen. Jullie 
dragen er allemaal aan bij dat de IC een superleuke werkomgeving is.   
Professor Grundy from the Department of  Biomedical Science of  the University 
of  Sheffield, thank you for having me over to learn about electrophysiological 
measurements of  the vagus nerve. I would also like to thank Professor Tracey from 
the Laboratory of  Biomedical Sciences of  the Feinstein Institute of  Medical Research 
in New York. It was inspiring to learn how to stimulate the vagus nerve at the lab 
where the cholinergic anti-inflammatory pathway was discovered.
The foundations for this PhD were unquestionably laid at St. Mary’s Hospital in 
London. Under the supervision of  Professor Hughes I first learned about LPS and 
its inflammatory and vasodilatory effects. Dear Alun, thank you for this invaluable 
experience!
Een van de belangrijkste voorwaarden voor een succesvol promotietraject is plezier 
in je werk. Dit wordt in grote mate bepaald door je naaste collega’s. Daarom wil ik 
mijn collega-promovendi van de IC, oftewel mijn kamergenoten, heel erg bedanken. 
Ten eerste Mark, alias Boogaard (sorry, het moest gewoon), we hebben vooral 
veel gelachen, maar je was tevens een grote steun voor me als het even tegenzat. 
Ontzettend bedankt voor beide en voor al die keren dat ik in je wiel heb mogen 
hangen zonder over te nemen! Jonne, matlabkoning en wielrenfenomeen, serieus als 
het moet maar erg gezellig als het kan, hou dat vast! Ook bedankt voor de scripts die 
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mijn data-analyse significant versneld hebben. Lucas, de Bear Grylls van onze kamer, 
bij -20 graden buiten in een slaapzak liggen is geen sinecure, net als de fabelachtige 
correlaties die jij uit je data weet te toveren! Dank voor de fijne gesprekken over van 
alles en nog wat en je hulp bij onder meer de LPS-voeding en iceman studie! Mirrin, 
voor advies over wat dan ook kon ik altijd bij jou terecht! Je prettige drukheid is 
onmisbaar op de kamer, bedankt! Benno, ook jij bedankt voor de matlab scripts die 
het leven vergemakkelijken! Verder moeten we die wielrentocht naar Enschede met 
bijbehorende stapavond maar weer eens snel herhalen, al wordt het nu waarschijnlijk 
een ‘iets’ korter ritje naar Arnhem, in ieder geval een stuk beter op mijn fietstalent 
toegespitst! Tenslotte Kim en Jenneke, wat ben ik blij met twee van zulke enthousiaste, 
intelligente en leuke nieuwe promovendi. We gaan de komende jaren mooi onderzoek 
doen!
Een andere collega, één kamer verder en al gepromoveerd, Suzanne, jij hebt het 
allemaal al eens meegemaakt, dank voor al je wijze raad. We gaan er in de nieuwbouw 
een gezellige kamer van maken.
Naast het werk aan dit proefschrift heb ik natuurlijk gelukkig ook heel veel andere 
leuke dingen beleefd de afgelopen jaren, waarvan ik velen heb kunnen delen met 
mijn lieve vrienden en vriendinnen. Dank voor al de mooie momenten, steun en 
hoognodige relativering. Een speciale vermelding voor de guys en girls van OMG 
FUST, de GNK/BMW vrienden van het eerste uur; wat is het toch top om al zo lang 
zo veel lol te hebben samen. 
Dan mijn paranimfen, Bart en Bart. Supermooi dat jullie vandaag aan mijn zijde staan! 
Bart Ramakers, ik schrijf  dit nu op een volle en gezellige promovendikamer maar 
nog niet zo lang geleden zaten we hier met zijn tweeën. Maar toen was het niet minder 
gezellig! Het praten over de nieuwe aankopen van PSV, klussen in huis en de aankoop 
van nieuwe apparaten zoals televisies en telefoons was altijd prima te combineren 
met het onderzoek. Het happy hardcore uurtje of  Iron Maiden’s Fear of  the Dark op 
vrijdagmiddag deed ons beiden lonken naar de stafborrel en na telefonisch overleg 
met de baas (Elke bedankt!) kon er ook nog vaak een bezoek aan de Aesculaaf  vanaf. 
Verder is je geordendheid (er was een ‘klein’ verschil tussen jouw en mijn bureau) 
en delegeerkunst ongeëvenaard. Bart, je bent een ontzettend fijne kerel en naast je 
bijdrage aan verschillende studies in dit proefschrift wil ik je vooral enorm bedanken 
voor de dosis plezier die je in mijn werkdagen hebt gebracht. 
En dan die andere Bart, Bart Voet, maatje, wat is het toch fijn om jou als beste 
vriend te hebben! Met jou kan ik alles bespreken, al hebben we het over de inhoud 
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van dit boekje (gelukkig) zelden gehad ;). Maar wat ik ook soms denk of  zeg, jij vindt 
niets gek en hebt altijd een zinnig antwoord wat me weer aan het denken zet of  de 
zaken relativeert. Je energie is jaloersmakend onuitputtelijk, ik hoop er nog lang van 
te genieten, bedankt voor alles!
Toon en Diny, bedankt voor de steun en de ongelooflijke gastvrijheid. Ik voel me 
perfect thuis bij jullie! Frank en Maike, dank voor de oprechte interesse. Oma, 
prachtig dat je er weer bij kunt zijn, op naar 26 mei! Justus, broer, heb ik toch eindelijk 
een titel die jij niet hebt ;). Hoewel je zelf  niet zo van medische zaken (lees: bloedige 
operaties op tv) houdt, informeerden jij en Marit vaak naar wat ik nu weer aan het 
doen was in Nijmegen. Vooral de verhalen over dierexperimenten spraken erg tot de 
verbeelding! Dank voor de interesse en natuurlijk ook voor alle leuke momenten die 
niets met dit boekje te maken hebben. Lieve Feline, mocht je geïnteresseerd zijn, ik 
leg het je ooit graag allemaal uit.
Lieve pa en ma, jullie hebben me meegegeven dat hard werken loont, maar zeker ook 
dat er meer is in het leven dan dat. Mijn keuzes hebben jullie altijd onvoorwaardelijk 
gesteund en jullie hebben nooit druk op me gelegd. Ik ben jullie hier heel erg dankbaar 
voor. Pa, bedankt voor het maken van de prachtige kaft en het corrigeren van de 
Nederlandse teksten in dit boekje, ik heb geleerd dat Nederlands in de wetenschap 
soms een moeilijkere taal is dan Engels. Ik kijk uit naar jouw boekje! 
Lieve Petri, jouw bijdrage aan dit boekje is niet in woorden uit te drukken. Wij zijn 
1 boom.
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